In	O
the	O
PPI	O
network	O
,	O
2	O
clusters	O
of	O
VTE	O
genes	O
,	O
including	O
ribosomal	O
protein	O
family	O
genes	O
and	O
NADH	O
family	O
-	O
ubiquinol	O
-	O
cytochrome	O
genes	O
,	O
were	O
identified	O
,	O
such	O
as	O
ribosomal	O
protein	O
L9	O
(	O
RPL9	O
)	O
,	O
RPL5	O
,	O
RPS20	O
,	O
RPL23	O
,	O
and	O
tumor	S-Phenotype
protein	O
p53	O
(	O
TP53	O
)	O
.The	O
nod	O
-	O
like	O
receptor	O
signaling	O
pathway	O
,	O
ribosomal	O
protein	O
family	O
genes	O
,	O
such	O
as	O
RPL9	O
,	O
RPL5	O
,	O
RPS20	O
,	O
and	O
RPL23	O
,	O
and	O
DEG	O
of	O
TP53	O
may	O
have	O
the	O
potential	O
to	O
be	O
used	O
as	O
targets	O
for	O
diagnosis	O
and	O
treatment	O
of	O
VTE	O

We	O
have	O
revealed	O
significant	O
association	O
of	O
FGFR2	O
and	O
MAP3K1	O
polymorphisms	O
with	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

With	O
reduced	O
YAP	O
expression	O
using	O
shRNA	O
or	O
YAP	O
inhibitors	O
,	O
TKI	O
-	O
resistant	O
cells	O
become	O
TKI	O
-	O
sensitive	O
.	O

SLC39A4	O
silencing	O
by	O
lentivirus	O
-	O
mediated	O
shRNA	O
blocked	O
human	O
lung	B-Phenotype
cancer	E-Phenotype
cell	O
epithelial	O
-	O
mesenchymal	O
transition	O
and	O
metastasis	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
respectively	O
.	O

The	O
incidence	O
of	O
thyroid	B-Phenotype
cancer	E-Phenotype
has	O
increased	O
the	O
past	O
few	O
decades	O
,	O
the	O
most	O
frequent	O
type	O
has	O
been	O
identified	O
to	O
be	O
the	O
papillary	B-Phenotype
thyroid	I-Phenotype
carcinoma	E-Phenotype
(	O
PTC	O	S-Phenotype
)	O
.	O

ERCC1	O
rs3212986	O
were	O
related	O
with	O
the	O
increased	O
risk	O
of	O
ovarian	B-Phenotype
cancer	E-Phenotype
under	O
recessive	O
model	O
(	O
adjusted	O
OR	O
=	O
2.40	O
,	O
95	O
%	O
CI	O
=	O
1.30	O
-	O
4.44	O
,	O
liP=0.005	O
)	O
.	O

HtrA1	O
is	O
a	O
serine	O
protease	O
suggested	O
to	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
various	O
diseases	O
,	O
including	O
age	O
-	O
related	O
macular	B-Phenotype
degeneration	E-Phenotype
and	O
osteoarthritis	S-Phenotype
,	O
by	O
modulating	O
extracellular	O
matrix	O
or	O
cell	O
surface	O
proteins	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
prostate	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
LNCaP	O
and	O
LAPC4	O
display	O
markedly	O
different	O
sensitivity	O
to	O
docetaxel	O
with	O
AR	O
activation	O
,	O
and	O
RNA	O
-	O
seq	O
analysis	O
of	O
these	O
cell	O
lines	O
identified	O
KDM5D	O
(	O
lysine	O
-	O
specific	O
demethylase	O
5D	O
)	O
encoded	O
on	O
the	O
Y	O
chromosome	O
as	O
a	O
potential	O
mediator	O
of	O
this	O
sensitivity	O
.	O

Our	O
study	O
therefore	O
identifies	O
POPDC1	O
as	O
a	O
disease	O
gene	O
causing	O
a	O
very	O
rare	O
autosomal	B-Phenotype
recessive	I-Phenotype
cardiac	I-Phenotype
arrhythmia	E-Phenotype
and	O
LGMD	O
,	O
expanding	O
the	O
genetic	O
causes	O
of	O
this	O
heterogeneous	S-Phenotype
group	O
of	O
inherited	O
rare	O
diseases	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
NIBP	O
on	O
chemotherapy	O
resistance	O
of	O
gastric	B-Phenotype
cancer	E-Phenotype
(	O
GC	S-Phenotype
)	O
and	O
to	O
research	O
the	O
mechanisms	O
of	O
Ginkgo	O
biloba	O
extract	O
761	O
(	O
EGb	O
761R	O
)	O
on	O
reversing	O
chemoresistence	O
which	O
has	O
been	O
confirmed	O
in	O
our	O
previous	O
study	O
.	O

BCOR	O
immunoexpression	O
was	O
studied	O
in	O
these	O
tumors	S-Phenotype
and	O
their	O
morphologic	O
mimics	O
to	O
assess	O
its	O
diagnostic	O
utility	O
.	O

Although	O
genes	O
that	O
are	O
essential	O
for	O
cortical	O
developmental	O
expansion	O
have	O
been	O
identified	O
from	O
the	O
genetics	O
of	O
human	O
primary	B-Phenotype
microcephaly	E-Phenotype
(	O
a	B-Phenotype
disorder	I-Phenotype
associated	I-Phenotype
with	I-Phenotype
reduced	I-Phenotype
brain	I-Phenotype
size	I-Phenotype
and	I-Phenotype
intellectual	I-Phenotype
disability	E-Phenotype
)	O
lsup1	O
/	O
sup	O
,	O
studies	O
of	O
these	O
genes	O
in	O
mice	O
,	O
which	O
have	O
a	O
smooth	O
cortex	O
that	O
is	O
one	O
thousand	O
times	O
smaller	O
than	O
the	O
cortex	O
of	O
humans	O
,	O
have	O
provided	O
limited	O
insight	O
.	O

No	O
pathogenic	O
mutations	O
were	O
detected	O
in	O
PAX6	O
,	O
FOXC1	O
or	O
PITX2	O
in	O
the	O
only	O
patient	O
with	O
a	B-Phenotype
sporadic	I-Phenotype
form	I-Phenotype
of	I-Phenotype
aniridia‑like	I-Phenotype
phenotype	E-Phenotype
,	O
confirming	O
the	O
genetic	O
heterogeneity	S-Phenotype
associated	O
with	O
this	O
disease	O
.	O

The	O
present	O
study	O
focuses	O
on	O
replicating	O
the	O
analyses	O
completed	O
by	O
Ji	O
et	O
al	O
to	O
identify	O
effects	O
of	O
rare	O
variants	O
in	O
the	O
population	O
-	O
based	O
Atherosclerosis	S-Phenotype
Risk	O
in	O
Communities	O
(	O
ARIC	O
)	O
study.We	O
attempted	O
to	O
replicate	O
the	O
findings	O
by	O
Ji	O
et	O
al	O
by	O
applying	O
their	O
criteria	O
to	O
identify	O
putative	O
loss	O
-	O
of	O
-	O
function	O
variants	O
with	O
allele	O
frequency	O
AAAA0.001	O
and	O
complete	O
conservation	O
across	O
a	O
set	O
of	O
orthologs	O
,	O
to	O
exome	O
sequencing	O
data	O
from	O
7444	O
European	O
ancestry	O
participants	O
of	O
the	O
ARIC	O
study.Although	O
we	O
failed	O
to	O
replicate	O
the	O
previous	O
findings	O
when	O
applying	O
their	O
methods	O
to	O
the	O
ARIC	O
study	O
data	O
,	O
we	O
observed	O
a	O
similar	O
effect	O
when	O
we	O
restricted	O
analyses	O
to	O
the	O
subset	O
of	O
variants	O
they	O
observed.These	O
results	O
simultaneously	O
support	O
the	O
utility	O
of	O
exome	O
sequencing	O
data	O
for	O
studying	O
extremely	O
rare	O
coding	O
variants	O
in	O
hypertension	S-Phenotype
and	O
underscore	O
the	O
need	O
for	O
improved	O
filtering	O
methods	O
for	O
identifying	O
functional	O
variants	O
in	O
human	O
sequences	O

Correlation	O
analysis	O
showed	O
that	O
PSAT1	O
expression	O
positively	O
correlated	O
with	O
the	O
levels	O
of	O
phosphorylated	O
GSK	O
-	O
3β	O
,	O
cyclin	O
D1	O
and	O
phosphorylated	O
Rb	O
in	O
NSCLC	O
primary	O
tumors	S-Phenotype
.	O

Finally	O
,	O
we	O
will	O
discuss	O
the	O
impact	O
of	O
faulty	O
DPC	O
repair	O
on	O
disease	O
and	O
cancer	S-Phenotype
therapy	O

Here	O
,	O
we	O
report	O
that	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
tissue	O
samples	O
and	O
breast	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
,	O
GPT2	O
expression	O
level	O
was	O
markedly	O
elevated	O
and	O
correlated	O
with	O
the	O
pathological	O
grades	O
of	O
breast	B-Phenotype
cancers	E-Phenotype
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
expression	O
and	O
functional	O
significance	O
of	O
KLF9	O
in	O
vitro	O
,	O
by	O
assessing	O
the	O
expression	O
of	O
KLF9	O
in	O
pancreatic	B-Phenotype
cancer	E-Phenotype
tissue	O
samples	O
and	O
its	O
association	O
with	O
the	O
total	O
survival	O
of	O
patients	O
and	O
clinicopathological	O
data	O
.	O

Fully	O
activated	O
YAP	O
is	O
required	O
to	O
support	O
the	O
growth	O
in	O
CDK8	O
-	O
knockout	O
colon	B-Phenotype
cancer	E-Phenotype
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Existing	O
research	O
points	O
to	O
the	O
potential	O
use	O
of	O
various	O
Eph	O
/	O
ephrin	O
members	O
as	O
biomarkers	O
for	O
assessing	O
prognosis	O
and	O
selecting	O
the	O
most	O
suitable	O
therapeutic	O
strategies	O
in	O
variable	O
clinical	O
scenarios	O
,	O
also	O
for	O
overcoming	O
drug	B-Phenotype
resistance	E-Phenotype
,	O
in	O
the	O
era	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
heterogeneity	O

Finally	O
,	O
we	O
show	O
that	O
a	O
combination	O
of	O
2	O
miRNAs	O
(	O
miR	O
-	O
190b	O
and	O
miR	O
-	O
516a	O
-	O
5p	O
)	O
exhibiting	O
altered	O
expression	O
in	O
TamR	O
cell	O
lines	O
were	O
predictive	O
of	O
treatment	O
outcome	O
in	O
a	O
cohort	O
of	O
ER+	O
breast	B-Phenotype
cancer	E-Phenotype
patients	O
receiving	O
adjuvant	O
tamoxifen	O
mono	O
-	O
therapy	O
.	O

CHK1	O
,	O
both	O
at	O
the	O
mRNA	O
and	O
protein	O
level	O
,	O
is	O
highly	O
expressed	O
in	O
medulloblastoma	S-Phenotype
and	O
elevated	O
CHK1	O
expression	O
in	O
Group3	O
medulloblastoma	S-Phenotype
is	O
an	O
adverse	O
prognostic	O
marker	O
.	O

Further	O
mechanistic	O
studies	O
showed	O
that	O
ADAMTS18	O
suppressed	O
epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
,	O
further	O
inhibited	O
migration	O
and	O
invasion	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Sonic	O
hedgehog	O
(	O
SHH	O
)	O
signaling	O
is	O
an	O
important	O
promotor	O
of	O
desmoplasia	O
,	O
a	O
critical	O
feature	O
in	O
pancreatic	B-Phenotype
cancer	E-Phenotype
stromal	O
reactions	O
involving	O
the	O
activation	O
of	O
pancreatic	O
stellate	O
cells	O
(	O
PSCs	O
)	O
.	O

Besides	O
the	O
hallmark	O
features	O
,	O
this	O
patient	O
also	O
presents	O
problems	O
not	O
previously	O
associated	O
with	O
RIN2	O
syndrome	O
,	O
including	O
cervical	B-Phenotype
vertebral	I-Phenotype
fusion	E-Phenotype
,	O
mild	B-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
,	O
and	O
colonic	B-Phenotype
fibrosis	E-Phenotype
.	O

Lentivirus	O
-	O
mediated	O
knockdown	O
of	O
STX3	O
represses	O
in	O
vitro	O
proliferation	O
and	O
colony	O
formation	O
and	O
in	O
vivo	O
growth	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
whereas	O
STX3	O
overexpression	O
promotes	O
the	O
growth	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Mutations	O
in	O
CNNM2	O
were	O
shown	O
to	O
cause	O
hypomagnesemia	S-Phenotype
,	O
seizures	S-Phenotype
and	O
intellectual	B-Phenotype
disability	E-Phenotype
.	O

SPG56	O
is	O
a	O
rare	O
autosomal	B-Phenotype
recessive	E-Phenotype
early	O
onset	O
complicated	O
form	O
of	O
HSP	O
caused	O
by	O
mutations	O
in	O
CYP2U1	O
.	O

The	O
nucleotide	O
degrading	O
enzyme	O
gene	O
RNASEH2A	O
(	O
ribonuclease	O
H2	O
subunit	O
A	O
)	O
has	O
been	O
found	O
to	O
be	O
overexpressed	O
in	O
cancers	S-Phenotype
.	O

The	O
expression	O
of	O
the	O
ID2	O
,	O
PRELP	O
and	O
SMOC2	O
genes	O
was	O
compared	O
between	O
the	O
endometrium	O
of	O
women	O
without	O
endometriosis	S-Phenotype
in	O
the	O
proliferative	O
phase	O
of	O
their	O
menstrual	O
cycle	O
and	O
the	O
eutopic	O
and	O
ectopic	O
endometrium	O
of	O
women	O
with	O
endometriosis	S-Phenotype
in	O
the	O
proliferative	O
phase	O
.	O

Furthermore	O
,	O
we	O
identified	O
the	O
activity	O
of	O
nitric	O
oxide	O
synthase	O
2	O
(	O
NOS2	O
,	O
also	O
known	O
as	O
iNOS	O
)	O
originating	O
from	O
the	O
glioma	S-Phenotype
cells	O
as	O
a	O
driving	O
stimulus	O
in	O
the	O
control	O
of	O
microglial	O
caspase	O
-	O
3	O
activity	O
.	O

TNM	O
staging	O
,	O
tumor	S-Phenotype
location	O
and	O
subsequent	O
chemotherapy	O
were	O
also	O
prognostic	O
factors	O
in	O
these	O
patients	O
.	O

Our	O
data	O
unveiled	O
a	O
previously	O
unknown	O
mechanism	O
in	O
the	O
regulation	O
of	O
adipocyte	O
insulin	O
signaling	O
by	O
Fam13a	O
and	O
identified	O
its	O
significant	O
role	O
in	O
systemic	O
metabolic	O
homeostasis	O
,	O
shedding	O
light	O
on	O
Fam13a	O
as	O
a	O
pharmacotherapeutic	O
target	O
to	O
treat	O
obesity	S-Phenotype
-	O
related	O
metabolic	O
disorders	O

Application	O
of	O
a	O
PIEZO1	O
agonist	O
Yoda1	O
effectively	O
induced	O
Ca2+	O
response	O
and	O
cation	O
channel	O
currents	O
in	O
PIEZO1	O
-	O
expressing	O
HEK	O
(	O
HEK	O
-	O
Piezo1	O
)	O
cells	O
and	O
synovial	B-Phenotype
sarcoma	E-Phenotype
SW982	O
(	O
SW982	O
)	O
cells	O
.	O

Primary	B-Phenotype
ciliary	I-Phenotype
dyskinesia	E-Phenotype
(	O
PCD	S-Phenotype
)	O
can	O
manifest	O
in	O
the	O
neonatal	O
period	O
with	O
severe	O
respiratory	B-Phenotype
distress	E-Phenotype
.	O

The	O
expression	O
levels	O
of	O
the	O
up	O
-	O
regulated	O
genes	O
(	O
NAT1	O
,	O
BBS1	O
and	O
PH	O
-	O
4	O
)	O
were	O
also	O
found	O
to	O
be	O
correlated	O
to	O
epithelial	O
to	O
mesenchymal	O
transition	O
status	O
of	O
the	O
tumour	S-Phenotype
.	O

Fundus	O
imaging	O
demonstrated	O
that	O
R172W	O
mice	O
developed	O
severe	O
clinical	O
signs	O
of	O
disease	O
nearly	O
identical	O
to	O
those	O
seen	O
in	O
human	O
MD	O
patients	O
,	O
including	O
retinal	B-Phenotype
degeneration	E-Phenotype
,	O
retinal	B-Phenotype
pigment	I-Phenotype
epithlium	I-Phenotype
(	I-Phenotype
RPE	I-Phenotype
)	I-Phenotype
defects	E-Phenotype
and	O
loss	B-Phenotype
of	I-Phenotype
the	I-Phenotype
choriocapillaris	E-Phenotype
.	O

Notably	O
,	O
a	O
significant	O
difference	O
in	O
the	O
distribution	O
of	O
the	O
AG	O
genotype	O
and	O
the	O
minor	O
allele	O
A	O
of	O
FSHB	O
rs11031006	O
SNP	O
was	O
found	O
between	O
the	O
endometriosis	S-Phenotype
patients	O
and	O
controls	O
.	O

Oropharyngeal	B-Phenotype
cancer	E-Phenotype
associations	O
were	O
limited	O
to	O
the	O
human	O
leukocyte	O
antigen	O
(	O
HLA	O
)	O
region	O
,	O
and	O
classical	O
HLA	O
allele	O
imputation	O
showed	O
a	O
protective	O
association	O
with	O
the	O
class	O
II	O
haplotype	O
HLA	O
-	O
DRB1	O
*	O
1301	O
-	O
HLA	O
-	O
DQA1	O
*	O
0103	O
-	O
HLA	O
-	O
DQB1	O
*	O
0603	O
(	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
0.59	O
,	O
P	O
=	O
2.7	O
x	O
10	O
-	O
9	O
)	O
.	O

Primary	B-Phenotype
ciliary	I-Phenotype
dyskinesia	E-Phenotype
(	O
PCD	S-Phenotype
)	O
is	O
a	O
genetically	O
heterogeneous	S-Phenotype
,	O
autosomal	O
-	O
recessive	O
disorder	O
,	O
characterized	O
by	O
oto	B-Phenotype
-	I-Phenotype
sino	I-Phenotype
-	I-Phenotype
pulmonary	I-Phenotype
disease	E-Phenotype
and	O
situs	B-Phenotype
abnormalities	E-Phenotype
.	O

Our	O
findings	O
suggested	O
that	O
WDR34	O
inhibits	O
OSCC	O
progression	O
and	O
might	O
be	O
a	O
potential	O
tumor	S-Phenotype
-	O
suppressor	O
molecule	O
in	O
OSCCs	O

Additionally	O
,	O
decreased	O
SPRY4	O
-	O
IT1	O
contributed	O
to	O
tumor	S-Phenotype
suppressive	O
effect	O
through	O
attenuating	O
cell	O
growth	O
,	O
clonogenic	O
ability	O
and	O
facilitating	O
apoptosis	O
via	O
Bcl	O
-	O
2	O
/	O
caspase	O
-	O
3	O
pathway	O
in	O
PANC1	O
and	O
Capan	O
-	O
2	O
cells	O
.	O

In	O
conclusion	O
,	O
we	O
provide	O
evidence	O
that	O
HSPB8	O
promotes	O
cancer	S-Phenotype
cell	O
growth	O
by	O
activating	O
the	O
ERK	O
-	O
CREB	O
pathway	O
and	O
may	O
serve	O
as	O
a	O
potential	O
prognostic	O
factor	O
in	O
GC	O
patients	O

LMO1	O
is	O
a	O
high	O
-	O
risk	O
neuroblastoma	S-Phenotype
susceptibility	O
gene	O
,	O
but	O
how	O
LMO1	O
cooperates	O
with	O
MYCN	O
in	O
neuroblastoma	S-Phenotype
tumorigenesis	O
is	O
unclear	O
.	O

Moreover	O
,	O
we	O
show	O
that	O
most	O
SCLC	O
tumors	S-Phenotype
can	O
be	O
classified	O
into	O
one	O
of	O
three	O
lineages	O
based	O
on	O
the	O
expression	O
of	O
POU2F3	O
,	O
ASCL1	O
,	O
or	O
NEUROD1	O
.	O

In	O
two	O
large	O
Turkish	O
consanguineous	O
families	O
,	O
a	O
locus	O
for	O
autosomal	B-Phenotype
recessive	I-Phenotype
nonsyndromic	I-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
(	O
ARNSHL	S-Phenotype
)	O
was	O
mapped	O
to	O
chromosome	O
6p21.3	O
by	O
genome	O
-	O
wide	O
linkage	O
analysis	O
in	O
an	O
interval	O
overlapping	O
with	O
the	O
loci	O
DFNB53	O
(	O
COL11A2	O
)	O
,	O
DFNB66	O
,	O
and	O
DFNB67	O
.	O

CD31	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
were	O
stained	O
to	O
reflect	O
tumor	S-Phenotype
angiogenesis	O
in	O
67	O
CC	O
tissues	O
.	O

Consistent	O
with	O
this	O
pattern	O
of	O
activity	O
,	O
polr1c	O
and	O
polr1d	O
homozygous	O
mutant	O
zebrafish	O
exhibit	O
cartilage	O
hypoplasia	O
and	O
cranioskeletal	O
anomalies	S-Phenotype
characteristic	O
of	O
humans	O
with	O
Treacher	B-Phenotype
Collins	I-Phenotype
syndrome	E-Phenotype
.	O

We	O
further	O
show	O
that	O
p53R2	O
is	O
important	O
for	O
oncogenic	O
growth	O
,	O
migration	O
and	O
invasion	O
in	O
cervical	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Altogether	O
,	O
these	O
data	O
indicate	O
that	O
the	O
NIBP	O
-	O
regulated	O
NF	O
-	O
kB	O
signaling	O
pathway	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
chemoresistance	O
of	O
gastric	B-Phenotype
cancer	E-Phenotype
by	O
promoting	O
CD133	O
-	O
induced	O
EMT	O

Germline	O
DCC	O
mutations	O
disrupt	O
the	O
development	O
of	O
predominantly	O
commissural	O
tracts	O
in	O
the	O
central	S-Phenotype
nervous	O
system	O
(	O
CNS	O
)	O
and	O
cause	O
a	B-Phenotype
spectrum	I-Phenotype
of	I-Phenotype
neurological	I-Phenotype
disorders	E-Phenotype
.	O

We	O
analyzed	O
the	O
expression	O
of	O
STX3	O
in	O
148	O
patients	O
with	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

In	O
a	O
family	O
with	O
post	B-Phenotype
-	I-Phenotype
lingual	I-Phenotype
progressive	I-Phenotype
non	I-Phenotype
-	I-Phenotype
syndromic	I-Phenotype
deafness	E-Phenotype
,	O
whole	O
-	O
exome	O
sequencing	O
of	O
genomic	O
DNA	O
from	O
five	O
hearing	O
-	O
impaired	O
relatives	O
revealed	O
a	O
single	O
variant	O
,	O
p.Gly488Glu	O
(	O
rs145970949	O
:	O
GAAAAA	O
)	O
in	O
MYO3A	O
,	O
co	O
-	O
segregating	O
with	O
HL	O
as	O
an	O
autosomal	O
dominant	O
trait	O
.	O

Biallelic	O
mutations	O
in	O
NDUFAF6	O
have	O
been	O
identified	O
as	O
responsible	O
for	O
cases	O
of	O
autosomal	B-Phenotype
recessive	I-Phenotype
Leigh	I-Phenotype
syndrome	E-Phenotype
associated	O
with	O
mitochondrial	B-Phenotype
complex	I-Phenotype
I	I-Phenotype
deficiency	E-Phenotype
.	O

Conclusion	O
While	O
novel	O
diagnostic	O
tumour	S-Phenotype
markers	O
are	O
urgently	O
needed	O
,	O
the	O
examined	O
potential	O
tumour	S-Phenotype
markers	O
,	O
with	O
the	O
exception	O
of	O
PIVKAII	O
seem	O
to	O
be	O
inadequate	O
for	O
diagnosing	O
HCC	O
in	O
ALC	O
.	O

No	O
differences	O
were	O
found	O
in	O
age	O
,	O
sex	O
,	O
mean	O
arterial	O
pressure	O
,	O
heart	O
rate	O
,	O
HDL	O
,	O
cirrhosis	S-Phenotype
etiology	O
,	O
degree	O
of	O
alcohol	O
consumption	O
,	O
encephalopathy	S-Phenotype
,	O
variceal	O
bleeding	O
history	O
,	O
or	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
between	O
patients	O
with	O
or	O
without	O
adrenal	B-Phenotype
insufficiency	E-Phenotype
.	O

The	O
paper	O
reviews	O
the	O
data	O
concerning	O
the	O
appearance	O
of	O
ectopic	O
FSHR	O
in	O
particular	O
human	O
neoplasms	S-Phenotype
.	O

Finally	O
,	O
we	O
established	O
a	O
causal	O
link	O
between	O
PFN1	O
and	O
BRCA1	O
-	O
induced	O
changes	O
in	O
cell	O
migration	O
thus	O
uncovering	O
a	O
novel	O
mechanistic	O
basis	O
for	O
BRCA1	O
-	O
dependent	O
regulation	O
of	O
ovarian	B-Phenotype
cancer	E-Phenotype
cell	O
migration	O
.	O

Here	O
,	O
we	O
determine	O
that	O
non	O
-	O
canonical	O
IKKα	O
-	O
RelB	O
pathway	O
activation	O
of	O
KRAS	O
-	O
mutant	O
tumor	S-Phenotype
cells	O
mediates	O
MPE	O
development	O
and	O
this	O
is	O
fueled	O
by	O
host	O
-	O
provided	O
interleukin	O
IL	O
-	O
1β	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
protumoral	O
property	S-Phenotype
of	O
TAMs	O
is	O
induced	O
by	O
the	O
hypoxia	S-Phenotype
-	O
triggered	O
FoxO1	O
deficiency	O
,	O
which	O
could	O
be	O
a	O
potential	O
target	O
of	O
novel	O
anti	O
-	O
tumor	S-Phenotype
therapies	O

3	B-Phenotype
-	I-Phenotype
Methylglutaconic	I-Phenotype
aciduria	E-Phenotype
is	O
associated	O
with	O
variants	O
in	O
genes	O
encoding	O
mitochondrial	S-Phenotype
inner	O
membrane	O
organizing	O
determinants	O
,	O
including	O
TAZ	O
,	O
DNAJC19	O
,	O
SERAC1	O
and	O
QIL1	O
/	O
MIC13	O

Non	B-Phenotype
-	I-Phenotype
invasive	I-Phenotype
follicular	I-Phenotype
thyroid	I-Phenotype
neoplasm	E-Phenotype
with	O
papillary	O
-	O
like	O
nuclear	O
features	O
(	O
NIFTP	O
)	O
is	O
an	B-Phenotype
indolent	I-Phenotype
thyroid	I-Phenotype
tumor	E-Phenotype
characterized	O
by	O
frequent	O
RAS	O
mutations	O
and	O
an	O
absence	O
of	O
the	O
BRAF	O
V600E	O
mutation	O
commonly	O
seen	O
in	O
classical	O
papillary	B-Phenotype
thyroid	I-Phenotype
carcinoma	E-Phenotype
(	O
cPTC	O
)	O
.	O

An	O
array	O
of	O
tumor	S-Phenotype
syndromes	O
caused	O
by	O
complex	O
II	O
-	O
associated	O
gene	O
mutations	O
,	O
in	O
both	O
succinate	O
dehydrogenase	O
and	O
associated	O
accessory	O
factor	O
genes	O
(	O
SDHA	O
,	O
SDHB	O
,	O
SDHC	O
,	O
SDHD	O
,	O
SDHAF1	O
,	O
SDHAF2	O
)	O
,	O
have	O
been	O
identified	O
over	O
the	O
last	O
12	O
years	O
and	O
include	O
hereditary	O
paraganglioma	S-Phenotype
-	O
pheochromocytomas	S-Phenotype
,	O
a	O
diverse	O
group	O
of	O
renal	B-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
,	O
and	O
a	O
specific	O
subtype	O
of	O
gastrointestinal	B-Phenotype
stromal	I-Phenotype
tumors	E-Phenotype
(	O
GIST	S-Phenotype
)	O
.	O

Misregulation	O
of	O
MID1	O
expression	O
is	O
associated	O
with	O
various	O
diseases	O
including	O
midline	B-Phenotype
malformation	I-Phenotype
syndromes	E-Phenotype
,	O
cancer	S-Phenotype
and	O
neurodegenerative	B-Phenotype
diseases	E-Phenotype
.	O

E168d2	O
mice	O
carry	O
a	O
frameshift	O
mutation	O
in	O
the	O
CRX	O
activation	O
domain	O
,	O
Glu168del2	O
,	O
which	O
is	O
associated	O
with	O
severe	S-Phenotype
dominant	O
CoRD	O
or	O
LCA	O
in	O
humans	O
.	O

In	O
humans	O
,	O
PNKP	O
mutations	O
underlie	O
the	O
neurological	O
disease	O
known	O
as	O
MCSZ	O
,	O
but	O
these	O
individuals	O
are	O
not	O
predisposed	O
for	O
cancer	S-Phenotype
,	O
implying	O
effective	O
alternative	O
repair	O
pathways	O
in	O
dividing	O
cells	O
.	O

Overexpression	O
of	O
Nanos3	O
induces	O
epithelial	O
-	O
mesenchymal	O
transition	O
in	O
lung	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
partly	O
by	O
repressing	O
E	O
-	O
cadherin	O
.	O

Furthermore	O
,	O
we	O
identified	O
specific	O
variants	O
of	O
DTC	O
that	O
have	O
different	O
effects	O
according	O
to	O
cancer	S-Phenotype
type	O
or	O
ethnicity	O
.	O

Transplantation	O
of	O
rod	O
photoreceptors	O
,	O
derived	O
either	O
from	O
neonatal	O
retinae	O
or	O
pluripotent	O
stem	O
cells	O
(	O
PSCs	O
)	O
,	O
can	O
restore	O
rod	O
-	O
mediated	O
visual	O
function	O
in	O
murine	O
models	O
of	O
inherited	O
blindness	S-Phenotype
.	O

Here	O
,	O
we	O
show	O
that	O
biallelic	O
liDicer1	O
/	O
i	O
deletion	O
with	O
liaP2	O
-	O
Cre	O
/	O
i	O
drives	O
aggressive	O
and	O
metastatic	B-Phenotype
angiosarcoma	E-Phenotype
independent	O
of	O
other	O
genetically	O
engineered	O
oncogenes	O
or	O
tumor	S-Phenotype
suppressor	O
loss	O
.	O

We	O
performed	O
permutation	O
-	O
based	O
analysis	O
to	O
test	O
for	O
overall	O
enrichment	O
of	O
these	O
510	O
genes	O
carrying	O
these	O
548	O
variants	O
with	O
genes	O
mutated	O
in	O
Kallmann	O
syndrome	O
and	O
with	O
a	O
control	O
set	O
of	O
genes	O
mutated	O
in	O
hypogonadotrophic	B-Phenotype
hypogonadism	E-Phenotype
without	O
anosmia	S-Phenotype
.	O

Encapsulation	O
of	O
mirin	O
in	O
nanoparticles	O
allowed	O
its	O
use	O
on	O
MYCN	O
-	O
amplified	O
neuroblastoma	S-Phenotype
xenografts	O
in	O
vivo	O
,	O
which	O
resulted	O
in	O
a	O
sharp	O
impairment	O
of	O
tumor	S-Phenotype
growth	O
,	O
associated	O
with	O
DDR	O
activation	O
,	O
p53	O
accumulation	O
,	O
and	O
cell	O
death	O
.	O

Gene	O
mutations	O
in	O
the	O
IGF1	O
and	O
IGF2	O
genes	O
have	O
been	O
described	O
in	O
patients	O
presenting	O
intrauterine	B-Phenotype
growth	I-Phenotype
retardation	E-Phenotype
and	O
postnatal	O
short	B-Phenotype
stature	E-Phenotype
.	O

These	O
results	O
support	O
a	O
clinical	O
study	O
for	O
the	O
safety	O
and	O
anti	O
-	O
tumor	S-Phenotype
immune	O
responses	O
with	O
combination	O
therapy	O
of	O
IL	O
PV	O
-	O
10	O
and	O
PD	O
-	O
1	O
/	O
PD	O
-	O
L1	O
blockade	O

To	O
reveal	O
novel	O
molecular	O
factors	O
behind	O
the	O
development	O
of	O
salivary	B-Phenotype
gland	I-Phenotype
cancer	E-Phenotype
,	O
we	O
performed	O
gene	O
expression	O
analyses	O
from	O
Smgb	O
-	O
Tag	O
mouse	O
salivary	O
gland	O
samples	O
.	O

The	O
oncogenicity	O
induced	O
by	O
low	O
HOXB1	O
expression	O
was	O
prevented	O
by	O
an	O
miR	O
-	O
3175	O
inhibitor	O
in	O
glioma	S-Phenotype
cells	O
.	O

However	O
,	O
activated	O
T	O
cells	O
and	O
B	O
cells	O
secrete	O
pro	O
-	O
osteoclastogenic	O
factors	O
including	O
receptor	O
activator	O
of	O
Nuclear	O
factor	O
-	O
kappaB	O
(	O
NF	O
-	O
kB	O
)	O
ligand	O
(	O
RANKL	O
)	O
,	O
Interleukin	O
(	O
IL	O
)	O
-	O
17A	O
,	O
and	O
tumor	S-Phenotype
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
α	O
promoting	O
bone	O
loss	O
in	O
inflammatory	O
states	O
such	O
as	O
rheumatoid	B-Phenotype
arthritis	E-Phenotype
.	O

Clinical	O
studies	O
have	O
also	O
revealed	O
that	O
ZIC1	O
gain	O
of	O
function	O
mutations	O
contribute	O
to	O
coronal	B-Phenotype
craniosynostosis	E-Phenotype
,	O
a	O
rare	O
skull	O
malformation	O
.	O

As	O
a	O
reason	O
why	O
the	O
present	O
case	O
showed	O
lethal	O
phenotype	O
despite	O
the	O
in	O
-	O
frame	O
deletion	O
mutation	O
,	O
rapid	O
degradation	O
of	O
neo	O
-	O
synthesized	O
α6	O
protein	O
and	O
/	O
or	O
impaired	O
transport	O
of	O
integrin	O
were	O
suggested	O
from	O
previous	O
reports	O
,	O
and	O
the	O
lack	O
of	O
localization	O
of	O
integrin	O
α6β4	O
to	O
the	O
epidermal	O
basement	O
membrane	O
resulted	O
in	O
skin	B-Phenotype
fragility	E-Phenotype
.	O

The	O
generated	O
Tprn	O
-	O
null	O
mice	O
are	O
ideal	O
models	O
of	O
human	O
hereditary	O
deafness	S-Phenotype
DFNB79	O

De	O
novo	O
missense	O
and	O
frameshift	O
mutations	O
and	O
deletions	O
involving	O
TBL1XR1	O
have	O
been	O
described	O
in	O
patients	O
with	O
intellectual	B-Phenotype
disability	E-Phenotype
and	O
autism	S-Phenotype
,	O
but	O
without	O
any	O
of	O
the	O
dysmorphic	O
findings	O
or	O
malformations	O
associated	O
with	O
Pierpont	O
syndrome	O
,	O
implying	O
a	O
mutation	O
-	O
specific	O
mechanism	O
for	O
the	O
pathogenicity	O
of	O
p.Tyr446Cys	O
.	O

BACKGROUND	O
HSP60	O
-	O
related	O
immunological	O
activities	O
are	O
found	O
in	O
normal	O
-	O
pressure	O
glaucoma	S-Phenotype
(	O
NPG	O
)	O
patients	O
,	O
in	O
whom	O
an	O
elevated	B-Phenotype
intraocular	I-Phenotype
pressure	E-Phenotype
(	O
IOP	S-Phenotype
)	O
found	O
in	O
primary	O
open	O
-	O
angle	O
glaucoma	S-Phenotype
(	O
POAG	O
)	O
is	O
not	O
observed	O
.	O

Many	O
cancer	S-Phenotype
cell	O
lines	O
derived	O
from	O
hematopoietic	O
and	O
lymphoid	O
lineages	O
are	O
sensitive	O
to	O
indisulam	O
,	O
and	O
their	O
sensitivity	O
correlates	O
with	O
DCAF15	O
expression	O
levels	O
.	O

Anti	O
-	O
PUF60	O
antibodies	O
were	O
also	O
observed	O
in	O
systemic	B-Phenotype
lupus	I-Phenotype
erythematosus	E-Phenotype
(	O
SLE	S-Phenotype
)	O
,	O
rheumatoid	B-Phenotype
arthritis	E-Phenotype
(	O
RA	S-Phenotype
)	O
,	O
and	O
Sjögren	B-Phenotype
's	I-Phenotype
syndrome	E-Phenotype
(	O
SS	S-Phenotype
)	O
patients	O
at	O
a	O
positive	O
rate	O
of	O
17.3	O
,	O
14.5	O
,	O
and	O
10.1	O
%	O
respectively	O
.	O

Since	O
RAPSN	O
-	O
associated	O
limb	O
-	O
girdle	O
type	O
CMS	O
was	O
only	O
manifested	O
in	O
AK9	O
homozygous	O
variant	O
carriers	O
,	O
the	O
disease	O
phenotype	O
was	O
of	O
digenic	B-Phenotype
inheritance	E-Phenotype
,	O
and	O
was	O
determined	O
by	O
the	O
novel	O
disease	O
modifier	O
AK9	O
which	O
provides	O
NTPs	O
for	O
N	O
-	O
glycosylation	O
.	O

Loss	O
of	O
GLIS3	O
function	O
in	O
humans	O
and	O
mice	O
leads	O
to	O
the	O
development	O
of	O
several	O
pathologies	O
,	O
including	O
neonatal	B-Phenotype
diabetes	E-Phenotype
and	O
congenital	B-Phenotype
hypothyroidism	E-Phenotype
,	O
polycystic	B-Phenotype
kidney	I-Phenotype
disease	E-Phenotype
,	O
and	O
infertility	S-Phenotype
.	O

Three	O
loci	O
with	O
high	O
mutation	O
frequencies	O
,	O
the	O
138665410	O
FOXL2	O
gene	O
variant	O
,	O
the	O
23862952	O
MYH6	O
gene	O
variant	O
,	O
and	O
the	O
71098693	O
HYDIN	O
gene	O
variant	O
were	O
found	O
to	O
be	O
significantly	O
associated	O
with	O
sporadic	S-Phenotype
ASD	O
(	O
PAAAA0.05	O
)	O
;	O
variants	O
in	O
FOXL2	O
and	O
MYH6	O
were	O
found	O
in	O
patients	O
with	O
isolated	O
,	O
sporadic	O
ASD	O
(	O
PAAAA5×10^	O
-	O
4	O
)	O
.	O

The	O
main	O
clinical	O
feature	O
was	O
similar	O
to	O
Lichtenstein	O
-	O
Knorr	O
syndrome	O
but	O
deafness	S-Phenotype
may	O
not	O
be	O
an	O
essential	O
phenotypic	O
feature	O
of	O
SLC9A1	O
mutation	O
.	O

Here	O
we	O
report	O
a	O
consanguineous	O
Arab	O
family	O
from	O
Qatar	O
with	O
three	O
children	O
having	O
an	O
early	O
lethal	O
form	O
of	O
arthrogryposis	S-Phenotype
multiplex	O
congenita	O
and	O
a	O
novel	O
frameshift	O
mutation	O
in	O
CNTNAP1	O
.	O

Consistent	O
with	O
this	O
result	O
,	O
mutations	O
in	O
the	O
CNTNAP2	O
gene	O
coding	O
for	O
CASPR2	O
in	O
human	O
have	O
been	O
identified	O
in	O
neurodevelopmental	O
disorders	O
such	O
as	O
autism	S-Phenotype
,	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
and	O
epilepsy	S-Phenotype
.	O

Primary	O
hyperoxaluria	S-Phenotype
(	O
PH	O
)	O
is	O
a	O
very	O
rare	O
genetic	O
disorder	O
;	O
it	O
is	O
characterized	O
by	O
total	O
or	O
partial	O
deficiency	O
of	O
the	O
enzymes	O
related	O
to	O
the	O
metabolism	O
of	O
glyoxylate	O
,	O
with	O
an	O
overproduction	O
of	O
calcium	O
oxalate	O
that	O
is	O
deposited	O
in	O
different	O
organs	O
,	O
mainly	O
the	O
kidney	O
,	O
leading	O
to	O
recurrent	O
lithiasis	O
,	O
nephrocalcinosis	S-Phenotype
and	O
end	B-Phenotype
stage	I-Phenotype
renal	I-Phenotype
disease	E-Phenotype
(	O
ESRD	S-Phenotype
)	O
.	O

Loss	O
of	O
GLIS3	O
function	O
in	O
humans	O
and	O
mice	O
leads	O
to	O
the	O
development	O
of	O
several	O
pathologies	O
,	O
including	O
neonatal	B-Phenotype
diabetes	E-Phenotype
and	O
congenital	B-Phenotype
hypothyroidism	E-Phenotype
,	O
polycystic	B-Phenotype
kidney	I-Phenotype
disease	E-Phenotype
,	O
and	O
infertility	S-Phenotype
.	O

Here	O
we	O
report	O
that	O
RANK	O
-	O
c	O
transcript	O
is	O
expressed	O
in	O
3.2	O
%	O
of	O
cases	O
in	O
The	O
Cancer	S-Phenotype
Genome	O
Atlas	O
breast	B-Phenotype
cancer	E-Phenotype
cohort	O
evenly	O
between	O
ER	O
-	O
positive	O
and	O
ER	O
-	O
negative	O
cases	O
.	O

Pure	O
hair	O
and	O
nail	B-Phenotype
ectodermal	I-Phenotype
dysplasia	I-Phenotype
9	E-Phenotype
(	O
ECTD	B-Phenotype
-	I-Phenotype
9	E-Phenotype
)	O
is	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
genetic	O
disease	O
caused	O
by	O
mutation	O
of	O
HOXC13	O
and	O
is	O
characterized	O
by	O
hypotrichosis	S-Phenotype
and	O
nail	B-Phenotype
dystrophy	E-Phenotype
in	O
humans	O
.	O

We	O
find	O
that	O
lung	O
squamous	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
SQCC	S-Phenotype
)	O
,	O
which	O
accounts	O
for	O
~20	O
%	O
of	O
lung	B-Phenotype
cancer	E-Phenotype
,	O
exhibits	O
increased	O
expression	O
of	O
the	O
PI3K	O
subunit	O
PIK3R2	O
,	O
which	O
is	O
at	O
low	O
expression	O
levels	O
in	O
normal	O
tissues	O
.	O

Cilia	O
play	O
essential	O
roles	O
in	O
normal	O
human	O
development	O
and	O
health	O
;	O
cilia	O
dysfunction	O
results	O
in	O
diseases	O
such	O
as	O
primary	B-Phenotype
ciliary	I-Phenotype
dyskinesia	E-Phenotype
(	O
PCD	S-Phenotype
)	O
.	O

These	O
studies	O
illustrate	O
that	O
Dicer1	O
can	O
function	O
as	O
a	O
traditional	O
loss	O
-	O
of	O
-	O
function	O
tumor	S-Phenotype
suppressor	O
gene	O
,	O
and	O
they	O
provide	O
a	O
fully	O
penetrant	O
animal	O
model	O
for	O
the	O
study	O
of	O
angiosarcoma	S-Phenotype
development	O
and	O
metastasis	O
.	O

Since	O
then	O
,	O
a	O
number	O
of	O
novel	O
,	O
small	O
-	O
molecule	O
inhibitors	O
directed	O
against	O
the	O
ALK	O
receptor	O
have	O
demonstrated	O
superiority	O
over	O
standard	O
chemotherapies	O
in	O
the	O
treatment	O
of	O
ALK	O
rearrangement	O
-	O
positive	O
lung	B-Phenotype
cancer	E-Phenotype
.	O

Five	O
tag	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
of	O
liKCNQ5	O
/	O
i	O
were	O
genotyped	O
,	O
and	O
association	O
testing	O
with	O
high	B-Phenotype
myopia	E-Phenotype
was	O
conducted	O
using	O
logistic	O
regression	O
analysis	O
adjusted	O
for	O
sex	O
and	O
age	O
to	O
give	O
liP	O
/	O
isubasym	O
/	O
sub	O
values	O
,	O
and	O
multiple	O
comparisons	O
were	O
corrected	O
by	O
permutation	O
test	O
to	O
give	O
liP	O
/	O
isubemp	O
/	O
sub	O
values	O
.	O

OGFOD1	O
knockdown	O
in	O
MDA	O
-	O
MB	O
-	O
231	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
significantly	O
impeded	O
cell	O
proliferation	O
and	O
resulted	O
in	O
the	O
accumulation	O
of	O
G1	O
and	O
G2	O
/	O
M	O
cells	O
by	O
decreasing	O
the	O
mRNA	O
levels	O
of	O
G1	O
/	O
S	O
transition	O
-	O
and	O
G2	O
/	O
M	O
-	O
related	O
transcription	O
factors	O
and	O
their	O
target	O
genes	O
.	O

Here	O
we	O
investigated	O
methylation	O
of	O
the	O
Cripto	O
promoter	O
in	O
mouse	O
germ	O
cells	O
and	O
human	O
germ	O
cell	O
cancer	S-Phenotype
and	O
correlated	O
this	O
with	O
the	O
level	O
of	O
CRIPTO	O
protein	O
expression	O
.	O

Deafness	S-Phenotype
genes	O
,	O
which	O
harbor	O
pathogenic	O
mutations	O
that	O
have	O
been	O
identified	O
in	O
families	O
with	O
hereditary	B-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
,	O
are	O
commonly	O
expressed	O
in	O
the	O
auditory	O
end	O
organ	O
or	O
the	O
cochlea	O
and	O
may	O
contribute	O
to	O
normal	O
hearing	O
function	O
,	O
yet	O
some	O
of	O
the	O
mouse	O
models	O
carrying	O
these	O
mutations	O
fail	O
to	O
recapitulate	O
the	O
hearing	B-Phenotype
loss	E-Phenotype
phenotype	O
.	O

Up	O
to	O
half	O
of	O
patients	O
with	O
PC	O
/	O
PGL	O
and	O
renal	B-Phenotype
neoplasia	E-Phenotype
had	O
VHL	O
syndrome	O
,	O
SDH	O
deficiency	O
,	O
or	O
alterations	O
in	O
TMEM127	O
.	O

Spinocerebellar	B-Phenotype
ataxia	I-Phenotype
type	I-Phenotype
8	E-Phenotype
(	O
SCA8	S-Phenotype
)	O
is	O
a	O
progressive	O
neurological	O
disorder	O
caused	O
by	O
the	O
expanded	O
repeat	O
CTA	O
/	O
CTG	O
of	O
two	O
overlapping	O
genes	O
,	O
ATXN8OS	O
and	O
ATXN8	O
,	O
expressed	O
bidirectionally	O
.	O

Furthermore	O
,	O
parallel	O
immunohistochemical	O
analysis	O
of	O
three	O
PP2A	O
inhibitors	O
demonstrated	O
that	O
two	O
PP2A	O
inhibitors	O
,	O
CIP2A	O
and	O
SET	O
,	O
are	O
highly	O
expressed	O
in	O
both	O
dysplastic	S-Phenotype
and	O
adenocarcinomatous	B-Phenotype
tumors	E-Phenotype
of	O
the	O
Smgb	O
-	O
Tag	O
mice	O
.	O

Mutations	O
in	O
eight	O
of	O
them	O
(	O
PDSS1	O
,	O
PDSS2	O
,	O
COQ2	O
,	O
COQ4	O
,	O
COQ6	O
,	O
ADCK3	O
,	O
ADCK4	O
,	O
and	O
COQ9	O
)	O
cause	O
primary	O
CoQ	O
(	O
10	O
)	O
deficiency	O
,	O
a	O
heterogeneous	S-Phenotype
group	O
of	O
disorders	O
with	O
variable	O
age	O
of	O
onset	O
(	O
from	O
birth	O
to	O
the	O
seventh	O
decade	O
)	O
and	O
associated	O
clinical	O
phenotypes	O
,	O
ranging	O
from	O
a	O
fatal	O
multisystem	O
disease	O
to	O
isolated	O
steroid	B-Phenotype
resistant	I-Phenotype
nephrotic	I-Phenotype
syndrome	E-Phenotype
(	O
SRNS	S-Phenotype
)	O
or	O
isolated	B-Phenotype
central	I-Phenotype
nervous	I-Phenotype
system	I-Phenotype
disease	E-Phenotype
.	O

We	O
will	O
also	O 
discuss	O
emerging	O
paradigms	O
of	O
the	O
molecular	O
and	O
cellular	O
pathophysiology	O
of	O
disease	O
-	O
causing	O
ephrinB2	O
-	O
EphB4	O
-	O
RASA1	O
mutations	O
,	O
including	O
the	O
potential	O
role	O
of	O
somatic	B-Phenotype
mosaicism	E-Phenotype
.	O

The	O
locus	O
lies	O
within	O
a	O
region	O
containing	O
TFAP2A	O
,	O
which	O
encodes	O
a	O
transcriptional	O
activation	O
protein	O
that	O
interacts	O
with	O
several	O
tumor	S-Phenotype
suppressor	O
genes	O
.	O

We	O
determined	O
that	O
LDHA	O
was	O
over	O
-	O
expressed	O
in	O
GBC	O
tumor	S-Phenotype
tissues	O
compared	O
with	O
normal	O
tissues	O
,	O
which	O
was	O
also	O
an	O
independent	O
prognostic	O
factor	O
for	O
the	O
overall	O
survival	O
of	O
GBC	O
patients	O
by	O
tissue	O
microarrays	O
analysis	O
.	O

Our	O
patient	O
had	O
all	O
the	O
major	O
characteristic	O
features	O
consistent	O
with	O
Ellis	O
-	O
van	O
Creveld	O
syndrome	O
including	O
post	B-Phenotype
-	I-Phenotype
axial	I-Phenotype
polydactyly	E-Phenotype
,	O
teeth	B-Phenotype
and	I-Phenotype
nail	I-Phenotype
abnormalities	E-Phenotype
,	O
congenital	B-Phenotype
heart	I-Phenotype
defect	E-Phenotype
and	O
skeletal	B-Phenotype
dysplasia	E-Phenotype
.	O

CMG2	O
mRNA	O
was	O
measured	O
in	O
121	O
tumor	S-Phenotype
samples	O
of	O
soft	B-Phenotype
tissue	I-Phenotype
sarcoma	E-Phenotype
patients	O
using	O
quantitative	O
real	O
-	O
time	O
PCR	O
.	O

Next	O
-	O
generation	O
sequencing	O
(	O
NGS	O
)	O
of	O
the	O
genetic	O
information	O
of	O
cancer	S-Phenotype
cells	O
has	O
revolutionized	O
the	O
field	O
of	O
cancer	S-Phenotype
biology	O
,	O
including	O
prostate	B-Phenotype
cancer	E-Phenotype
(	O
PCa	S-Phenotype
)	O
.	O

Finally	O
,	O
in	O
colon	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
we	O
prove	O
that	O
the	O
FZD4	O
/	O
PI3K	O
axis	O
elicited	O
by	O
FzM1.8	O
preserves	O
stemness	O
and	O
promotes	O
proliferation	O
of	O
undifferentiated	O
cells	O

These	O
studies	O
highlight	O
the	O
conserved	O
role	O
for	O
Hmx1	O
in	O
BA2	O
-	O
derived	O
tissues	O
and	O
provide	O
an	O
entry	O
point	O
for	O
improved	O
understanding	O
of	O
the	O
causes	O
of	O
the	O
frequent	O
lateral	B-Phenotype
facial	I-Phenotype
birth	I-Phenotype
defects	E-Phenotype
in	O
humans	O

A	O
GARP	O
complex	O
mutation	O
analogous	O
to	O
a	O
VPS53	O
allele	O
causing	O
progressive	B-Phenotype
cerebello	I-Phenotype
-	I-Phenotype
cerebral	I-Phenotype
atrophy	I-Phenotype
type	I-Phenotype
2	E-Phenotype
(	O
PCCA2	S-Phenotype
)	O
in	O
humans	O
exhibits	O
similar	O
,	O
albeit	O
weaker	O
,	O
phenotypes	O
in	O
yeast	O
,	O
providing	O
mechanistic	O
insights	O
into	O
disease	O
pathogenesis	O
.	O

Therefore	O
,	O
PYCR1	O
might	O
serve	O
as	O
a	O
prognostic	O
biomaker	O
for	O
either	O
ER	O
-	O
positive	O
or	O
ER	O
-	O
negative	O
breast	B-Phenotype
cancer	E-Phenotype
subtypes	O
and	O
can	O
also	O
be	O
a	O
potential	O
target	O
for	O
breast	B-Phenotype
cancer	E-Phenotype
therapy	O

All	O
these	O
findings	O
implied	O
the	O
important	O
roles	O
of	O
FBP1	O
expression	O
in	O
lung	B-Phenotype
cancer	E-Phenotype
development	O
and	O
progression	O
and	O
the	O
potential	O
use	O
of	O
the	O
methylation	O
status	O
detected	O
in	O
FBP1	O
promoter	O
region	O
as	O
a	O
novel	O
predictor	O
for	O
prognosis	O
and	O
therapeutic	O
target	O
for	O
NSCLC	O
patients	O

The	O
patient	O
carried	O
GLRB	O
gene	O
mutations	O
found	O
by	O
genetic	O
analysis	O
,	O
and	O
was	O
finally	O
diagnosed	O
with	O
hyperekplexia	S-Phenotype
.	O

In	O
an	O
in	O
vivo	O
model	O
,	O
downregulation	O
of	O
PSMB8	O
suppressed	O
tumor	S-Phenotype
growth	O
.	O

In	O
summary	O
,	O
our	O
results	O
reveal	O
that	O
rare	O
loss	O
-	O
of	O
-	O
function	O
variants	O
in	O
GABRA3	O
increase	O
the	O
risk	O
for	O
a	O
varying	O
combination	O
of	O
epilepsy	S-Phenotype
,	O
intellectual	B-Phenotype
disability	E-Phenotype
/	O
developmental	B-Phenotype
delay	E-Phenotype
and	O
dysmorphic	O
features	O
,	O
presenting	O
in	O
some	O
pedigrees	O
with	O
an	O
X	O
-	O
linked	O
inheritance	O
pattern	O

This	O
is	O
especially	O
relevant	O
in	O
the	O
context	O
of	O
the	O
aerobic	O
glycolysis	O
,	O
also	O
known	O
as	O
the	O
Warburg	O
effect	O
,	O
which	O
is	O
a	O
hallmark	O
in	O
many	O
types	O
of	O
cancer	S-Phenotype
,	O
and	O
MPC	O
loss	O
of	O
function	O
promotes	O
cancer	S-Phenotype
growth	O
.	O

In	O
conclusion	O
,	O
exosomal	O
ZIP4	O
promotes	O
cancer	S-Phenotype
growth	O
and	O
is	O
a	O
novel	O
diagnostic	O
biomarker	O
for	O
pancreatic	B-Phenotype
cancer	E-Phenotype

Notably	O
,	O
shRNA	O
-	O
mediated	O
knockdown	O
of	O
PLD2	O
suppressed	O
the	O
growth	O
and	O
invasion	O
of	O
tumors	S-Phenotype
in	O
nude	O
mouse	O
xenograft	O
models	O
.	O

4B	O
,	O
P	O
=	O
.000	O
)	O
.Hyper	O
expression	O
of	O
MTBP	O
maybe	O
an	O
adverse	O
event	O
for	O
the	O
survival	O
of	O
some	O
cancer	S-Phenotype
patients	O
,	O
especially	O
in	O
glioblastoma	S-Phenotype
,	O
kidney	B-Phenotype
cancer	E-Phenotype
,	O
and	O
lung	B-Phenotype
cancer	E-Phenotype
patients	O
,	O
which	O
has	O
been	O
verified	O
in	O
112	O
lung	B-Phenotype
cancer	E-Phenotype
patients	O
with	O
MTBP	O
status	O

Using	O
exome	O
sequencing	O
,	O
we	O
identified	O
dominant	O
mutations	O
in	O
DNM1L	O
on	O
chromosome	O
12p11.21	O
in	O
three	O
large	O
families	O
with	O
isolated	B-Phenotype
optic	I-Phenotype
atrophy	E-Phenotype
,	O
including	O
the	O
two	O
families	O
that	O
defined	O
the	O
OPA5	O
locus	O
on	O
chromosome	O
19q12.1	O
-	O
13.1	O
,	O
the	O
existence	O
of	O
which	O
is	O
denied	O
by	O
the	O
present	O
study	O
.	O

The	O
musculo	O
-	O
aponeurotic	O
fibrosarcoma	S-Phenotype
oncogene	O
homolog	O
B	O
(	O
MAFB	O
)	O
significantly	O
enhanced	O
the	O
activation	O
of	O
the	O
TFPI2	O
promoter	O
via	O
RARAAAAAalpha	O
;	O
while	O
MAFF	O
inhibited	O
it	O
.	O

Family	O
-	O
based	O
studies	O
have	O
recently	O
led	O
to	O
the	O
identification	O
of	O
the	O
MIR184	O
gene	O
for	O
keratoconus	S-Phenotype
with	O
cataract	S-Phenotype
and	O
to	O
the	O
DOCK9	O
gene	O
in	O
a	O
family	O
with	O
isolated	B-Phenotype
keratoconus	E-Phenotype
.	O

Overall	O
,	O
our	O
findings	O
identify	O
PRSS56	O
as	O
a	O
potential	O
therapeutic	O
target	O
for	O
modulating	O
ocular	O
growth	O
aimed	O
at	O
preventing	O
or	O
slowing	O
down	O
myopia	S-Phenotype
,	O
which	O
is	O
reaching	O
epidemic	O
proportions	O

The	O
regulation	O
of	O
the	O
post	O
-	O
mitotic	O
neural	O
survival	O
activity	O
of	O
TLE1	O
depends	O
critically	O
on	O
an	O
interaction	O
with	O
FOXG1	O
,	O
a	O
gene	O
shown	O
to	O
be	O
involved	O
in	O
a	O
postnatal	B-Phenotype
microcephaly	E-Phenotype
syndrome	O
.	O

Reported	O
susceptibility	O
SNPs	O
for	O
narcolepsy	S-Phenotype
in	O
the	O
Japanese	O
population	O
,	O
CPT1B	O
(	O
carnitine	O
palmitoyltransferase	O
1B	O
)	O
,	O
TRA	O
@	O
(	O
T	O
-	O
cell	O
receptor	O
alpha	O
)	O
and	O
P2RY11	O
(	O
purinergic	O
receptor	O
P2Y	O
,	O
G	O
-	O
protein	O
coupled	O
,	O
11	O
)	O
,	O
were	O
found	O
to	O
explain	O
0.8	O
%	O
of	O
narcolepsy	S-Phenotype
onset	O
(	O
Psubwhole	O
genome	O
without	O
HLA	O
-	O
DQB1	O
*	O
06:02	O
/	O
sub=9.74	O
×	O
10sup	O
-	O
2	O
/	O
sup	O
)	O
.	O

Experimentally	O
,	O
we	O
found	O
that	O
reducing	O
expression	O
of	O
SCRIB	O
by	O
short	O
-	O
hairpin	O
RNAs	O
(	O
shRNAs	O
)	O
reduces	O
the	O
growth	O
of	O
human	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
in	O
xenograft	O
assays	O
.	O

We	O
have	O
previously	O
identified	O
a	O
role	O
for	O
the	O
secreted	O
serine	O
protease	O
PRSS56	O
in	O
ocular	O
size	O
determination	O
and	O
PRSS56	O
variants	O
have	O
been	O
implicated	O
in	O
the	O
etiology	O
of	O
both	O
hyperopia	S-Phenotype
and	O
myopia	S-Phenotype
,	O
highlighting	O
its	O
importance	O
in	O
refractive	O
development	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
explore	O
whether	O
any	O
reproductive	O
factor	O
is	O
potentially	O
related	O
to	O
heart	B-Phenotype
failure	E-Phenotype
in	O
women	O
,	O
based	O
on	O
genetic	O
similarities	O
.	O

To	O
investigate	O
SCRIB	O
-	O
associated	O
proteins	O
that	O
might	O
participate	O
in	O
the	O
responses	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
to	O
altered	O
levels	O
of	O
SCRIB	O
,	O
we	O
used	O
mass	O
spectrometry	O
and	O
confocal	O
microscopy	O
.	O

Ectopically	O
injected	O
human	O
cancer	S-Phenotype
cell	O
lines	O
develop	O
into	O
tumors	S-Phenotype
in	O
SCID	O
pigs	O
,	O
thus	O
providing	O
a	O
human	O
-	O
sized	O
liin	O
vivo	O
model	O
for	O
evaluating	O
imaging	O
methods	O
to	O
improve	O
cancer	S-Phenotype
detection	O
and	O
therapeutic	O
research	O
and	O
development	O
.	O

In	O
total	O
sixteen	O
genomic	O
regions	O
have	O
been	O
associated	O
with	O
POAG	O
(	O
including	O
the	O
normal	O
tension	O
glaucoma	S-Phenotype
(	O
NTG	O
)	O
subgroup	O
)	O
,	O
8	O
with	O
PACG	O
and	O
2	O
with	O
XFS	O
.	O

Here	O
,	O
we	O
review	O
these	O
cellular	O
and	O
molecular	O
mechanisms	O
of	O
global	O
cerebral	B-Phenotype
edema	E-Phenotype
formation	O
in	O
aSAH	O
.	O

We	O
now	O
investigated	O
23	O
Japanese	O
sporPHP1B	O
cases	O
,	O
who	O
presented	O
with	O
hypocalcemia	S-Phenotype
,	O
hyperphosphatemia	S-Phenotype
,	O
elevated	O
PTH	O
levels	O
,	O
and	O
occasionally	O
with	O
TSH	O
elevations	O
and	O
mild	O
AHO	O
features	O
.	O

Targeted	O
exome	O
sequencing	O
identified	O
biallelic	O
mutations	O
in	O
WDR19	O
,	O
encoding	O
an	O
IFT	O
-	O
A	O
subunit	O
previously	O
associated	O
with	O
MZSDS	O
-	O
related	O
chondrodysplasia	S-Phenotype
,	O
Jeune	B-Phenotype
asphyxiating	I-Phenotype
thoracic	I-Phenotype
dysplasia	E-Phenotype
and	O
cranioectodermal	B-Phenotype
dysplasia	E-Phenotype
,	O
linked	O
to	O
primary	O
cilia	O
dysfunction	O
,	O
and	O
in	O
TEKT1	O
which	O
encodes	O
tektin	O
-	O
1	O
an	O
uncharacterized	O
member	O
of	O
the	O
tektin	O
family	O
,	O
mutations	O
of	O
which	O
may	O
cause	O
ciliary	B-Phenotype
dyskinesia	E-Phenotype
.	O

Mutations	O
in	O
MYH7	O
are	O
associated	O
with	O
not	O
only	O
skeletal	O
muscle	O
diseases	O
,	O
such	O
as	O
Laing	O
distal	S-Phenotype
myopathy	S-Phenotype
and	O
myosin	O
storage	O
myopathy	S-Phenotype
,	O
but	O
also	O
hypertrophic	B-Phenotype
cardiomyopathy	E-Phenotype
.	O

In	O
the	O
last	O
10	O
years	O
,	O
the	O
primary	O
cilia	O
machinery	O
has	O
been	O
implicated	O
in	O
more	O
than	O
a	O
dozen	O
disorders	O
united	O
as	O
ciliopathies	O
,	O
including	O
skeletal	B-Phenotype
dysplasias	E-Phenotype
,	O
such	O
as	O
Jeune	B-Phenotype
syndrome	E-Phenotype
and	O
short	B-Phenotype
rib	I-Phenotype
-	I-Phenotype
polydactyly	I-Phenotype
type	I-Phenotype
III	E-Phenotype
.	O

YY1	O
expression	O
is	O
associated	O
with	O
that	O
of	O
cancer	S-Phenotype
stem	O
cell	O
markers	O
SOX2	O
,	O
BMI1	O
and	O
OCT4	O
across	O
many	O
cancers	S-Phenotype
suggesting	O
multidynamic	O
regulatory	O
control	O
and	O
groups	O
of	O
cancers	S-Phenotype
with	O
distinct	O
molecular	O
signatures	O
.	O

Immunoperoxidase	O
levels	O
in	O
the	O
tumor	S-Phenotype
were	O
positive	O
for	O
factor	O
VIII	O
and	O
CD31	O
and	O
negative	O
for	O
S100	O
,	O
protein	O
Melan	O
-	O
A	O
,	O
CD34	O
,	O
synaptophysin	O
,	O
chromogranin	O
,	O
desmin	O
,	O
muscle	O
specific	O
actin	O
,	O
ETFA	O
(	O
EMA	O
)	O
,	O
KRT20	O
(	O
CK20	O
)	O
,	O
CDX2	O
,	O
TTF1	O
,	O
LNPEP	O
(	O
PLAP	O
)	O
,	O
inhibin	O
,	O
?	O

Bcl2	O
-	O
associated	O
athanogene	O
3	O
(	O
BAG3	O
)	O
mutations	O
have	O
been	O
reported	O
to	O
cause	O
the	O
myofibrillar	B-Phenotype
myopathy	E-Phenotype
(	O
MFM	S-Phenotype
)	O
which	O
shows	O
progressive	O
limb	B-Phenotype
muscle	I-Phenotype
weakness	E-Phenotype
,	O
respiratory	B-Phenotype
failure	E-Phenotype
,	O
and	O
cardiomyopathy	S-Phenotype
.	O

Previous	O
studies	O
have	O
shown	O
that	O
ANXA11	O
participates	O
in	O
many	O
cellular	O
functions	O
and	O
has	O
significant	O
influence	O
on	O
ovarian	B-Phenotype
,	I-Phenotype
breast	I-Phenotype
,	I-Phenotype
liver	I-Phenotype
,	I-Phenotype
and	I-Phenotype
colorectal	I-Phenotype
cancer	E-Phenotype
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
current	O
data	O
on	O
the	O
functioning	O
of	O
the	O
FGFR	O
family	O
proteins	O
in	O
both	O
normal	O
and	O
cancer	S-Phenotype
cells	O
,	O
mutations	O
in	O
the	O
FGFR1	O
-	O
4	O
genes	O
,	O
and	O
mechanisms	O
underlying	O
their	O
oncogenic	O
potential	O
,	O
which	O
might	O
be	O
interesting	O
to	O
a	O
broad	O
range	O
of	O
scientists	O
searching	O
for	O
specific	O
tumor	S-Phenotype
markers	O
and	O
targeted	O
anti	O
-	O
cancer	S-Phenotype
drugs	O

We	O
provide	O
the	O
first	O
evidence	O
for	O
miRNA	O
controlling	O
retrograde	O
signaling	O
,	O
demonstrating	O
its	O
epigenetic	O
regulation	O
and	O
its	O
role	O
in	O
breast	B-Phenotype
tumorigenesis	E-Phenotype

In	O
summary	O
,	O
these	O
data	O
suggested	O
an	O
important	O
role	O
of	O
BKCa	O
in	O
proliferation	O
and	O
migration	O
of	O
endometrial	O
cancer	S-Phenotype
HEC	O
-	O
1	O
-	O
B	O
cells	O
.	O

The	O
present	O
study	O
investigated	O
the	O
association	O
between	O
Gremlin	O
1	O
and	O
SHH	O
,	O
and	O
the	O
effect	O
of	O
Gremlin	O
1	O
in	O
pancreatic	B-Phenotype
cancer	E-Phenotype
.	O

Ellis	O
-	O
van	O
Creveld	O
syndrome	O
is	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
skeletal	B-Phenotype
dysplasia	E-Phenotype
primarily	O
characterized	O
by	O
the	O
features	O
such	O
as	O
disproportionate	B-Phenotype
dwarfism	E-Phenotype
,	O
short	B-Phenotype
ribs	E-Phenotype
,	O
short	B-Phenotype
limbs	E-Phenotype
,	O
dysplastic	B-Phenotype
nails	E-Phenotype
,	O
cardiovascular	B-Phenotype
malformations	E-Phenotype
,	O
post	B-Phenotype
-	I-Phenotype
axial	I-Phenotype
polydactyly	E-Phenotype
(	O
PAP	S-Phenotype
)	O
(	O
bilateral	O
)	O
of	O
hands	O
and	O
feet	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
quantitative	O
proteomic	O
analyses	O
to	O
compare	O
a	O
highly	O
metastatic	O
cancer	S-Phenotype
cell	O
line	O
and	O
a	O
parental	O
breast	B-Phenotype
cancer	E-Phenotype
cell	O
line	O
;	O
and	O
observed	O
that	O
NDUFB9	O
,	O
an	O
accessory	O
subunit	O
of	O
the	O
mitochondrial	O
membrane	O
respiratory	O
chain	O
NADH	O
dehydrogenase	O
(	O
complex	O
I	O
)	O
,	O
was	O
down	O
-	O
regulated	O
in	O
highly	O
metastatic	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Here	O
,	O
we	O
report	O
that	O
these	O
defects	O
can	O
occur	O
independently	O
of	O
albinism	S-Phenotype
in	O
people	O
with	O
recessive	O
mutations	O
in	O
the	O
putative	O
glutamine	O
transporter	O
gene	O
SLC38A8	O
.	O

Thus	O
,	O
our	O
study	O
considerably	O
extends	O
the	O
picture	O
of	O
pathways	O
involved	O
in	O
molecular	O
pathogenesis	O
of	O
T	O
-	O
PLL	O
and	O
identifies	O
the	O
tumor	S-Phenotype
suppressor	O
gene	O
SAMHD1	O
with	O
~20	O
%	O
of	O
T	O
-	O
PLL	O
affected	O
by	O
destructive	O
lesions	O
likely	O
as	O
major	O
player	O
in	O
T	O
-	O
PLL	O
pathogenesis	O

The	O
APOL1	O
G1	O
polymorphism	O
,	O
an	O
identified	O
risk	O
factor	O
for	O
non	O
-	O
diabetic	O
renal	O
disease	O
,	O
was	O
associated	O
with	O
albuminuria	S-Phenotype
.	O

PITPNM3	O
,	O
known	O
as	O
a	O
human	O
homologue	O
of	O
the	O
Drosophila	O
retinal	B-Phenotype
degeneration	I-Phenotype
B	E-Phenotype
(	O
rdgB	S-Phenotype
)	O
,	O
lacks	O
the	O
N	O
-	O
terminal	O
PIT	O
domain	O
needed	O
for	O
transport	O
of	O
phospholipids	O
,	O
renewal	O
of	O
photoreceptors	O
membrane	O
and	O
providing	O
the	O
electroretinogram	O
(	O
ERG	O
)	O
response	O
to	O
light	O
.	O

Mutations	O
affecting	O
human	O
COG1	O
,	O
COG2	O
and	O
COG4	O
-	O
COG8	O
cause	O
monogenic	O
forms	O
of	O
inherited	O
,	O
autosomal	B-Phenotype
recessive	E-Phenotype
CDGs	O
.	O

Among	O
others	O
,	O
an	O
immature	O
subpopulation	O
of	O
self	O
-	O
renewing	O
and	O
therapy	O
-	O
resistant	O
tumor	S-Phenotype
cells	O
-	O
often	O
referred	O
to	O
as	O
glioblastoma	S-Phenotype
stem	O
-	O
like	O
cells	O
(	O
GSCs	O
)	O
-	O
has	O
been	O
shown	O
to	O
contribute	O
to	O
disease	O
recurrence	O
.	O

Furthermore	O
,	O
double	O
-	O
labeling	O
immunofluorescence	O
results	O
showed	O
that	O
NasubV	O
/	O
sub1.3	O
/	O
NasubV	O
/	O
sub1.6	O
and	O
CaM	O
co	O
-	O
localization	O
was	O
significantly	O
increased	O
in	O
the	O
tumor	S-Phenotype
group	O
compared	O
to	O
control	O
tissue	O
.	O

Although	O
clustering	O
of	O
missense	O
mutations	O
is	O
often	O
regarded	O
as	O
a	O
hallmark	O
of	O
oncoproteins	O
,	O
we	O
observed	O
that	O
a	O
number	O
of	O
tumor	S-Phenotype
suppressors	O
,	O
including	O
FBXW7	O
,	O
VHL	O
,	O
and	O
STK11	O
,	O
also	O
showed	O
such	O
clustering	O
.	O

Recently	O
,	O
hepaCAM	O
was	O
reported	O
to	O
be	O
implicated	O
in	O
cancer	S-Phenotype
development	O
,	O
and	O
many	O
researchers	O
investigated	O
its	O
biological	O
function	O
in	O
the	O
tumorigenesis	S-Phenotype
of	O
various	O
cancers	S-Phenotype
.	O

Consistently	O
,	O
SALL2	O
deficiency	O
associates	O
with	O
neural	B-Phenotype
tube	I-Phenotype
defects	E-Phenotype
and	O
coloboma	S-Phenotype
,	O
a	O
congenital	B-Phenotype
eye	I-Phenotype
disease	E-Phenotype
.	O

Specifically	O
,	O
Nrf2	O
plays	O
an	O
indispensable	O
role	O
in	O
NSCLC	O
cell	O
sensitivity	O
to	O
platinum	O
-	O
based	O
treatments	O
and	O
we	O
found	O
that	O
combination	O
of	O
CP	O
-	O
673451	O
and	O
cisplatin	O
produced	O
a	O
synergistic	O
anticancer	O
effect	S-Phenotype
and	O
substantial	O
ROS	O
production	O
in	O
vitro	O
.	O

We	O
report	O
the	O
genetic	O
and	O
functional	O
characterization	O
of	O
4	O
FRMPD4	O
deleterious	O
mutations	O
that	O
cause	O
a	O
new	O
X	O
-	O
linked	O
intellectual	B-Phenotype
disability	E-Phenotype
(	O
ID	S-Phenotype
)	O
syndrome	O
.	O

Meanwhile	O
,	O
the	O
expression	O
of	O
PTPN3	O
was	O
found	O
to	O
be	O
regulated	O
by	O
miR	O
-	O
199	O
in	O
resistant	O
ovarian	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

The	O
clinical	O
presentation	O
of	O
both	O
patients	O
was	O
initially	O
thought	O
to	O
be	O
suggestive	O
of	O
Lin	O
-	O
Gettig	O
syndrome	O
(	O
LGS	O
)	O
,	O
a	O
multiple	O
malformation	O
syndrome	O
associated	O
with	O
craniosynostosis	S-Phenotype
that	O
was	O
initially	O
reported	O
in	O
two	O
brothers	O
in	O
1990	O
,	O
with	O
a	O
third	O
patient	O
reported	O
in	O
2003	O
.	O

Our	O
experiments	O
demonstrate	O
that	O
these	O
mutations	O
in	O
CPA6	O
are	O
deleterious	O
and	O
provide	O
further	O
evidence	O
for	O
the	O
involvement	O
of	O
CPA6	O
mutations	O
in	O
the	O
predisposition	O
for	O
several	O
types	O
of	O
epilepsy	S-Phenotype
.	O

In	O
humans	O
,	O
exons	O
5	O
-	O
10	O
in	O
CHRNA7	O
are	O
duplicated	O
and	O
fused	O
to	O
the	O
FAM7A	O
genetic	O
element	O
,	O
giving	O
rise	O
to	O
the	O
hybrid	O
gene	O
CHRFAM7A	O
Its	O
product	O
,	O
dupa7	O
,	O
is	O
a	O
truncated	O
subunit	O
lacking	O
part	O
of	O
the	O
N	O
-	O
terminal	O
extracellular	O
ligand	O
-	O
binding	O
domain	O
and	O
is	O
associated	O
with	O
neurological	O
disorders	O
,	O
including	O
schizophrenia	S-Phenotype
,	O
and	O
immunomodulation	O
.	O

This	O
is	O
consistent	O
with	O
previous	O
studies	O
reporting	O
arthrogryposis	S-Phenotype
in	O
Lgi4	O
-	O
deficient	O
mice	O
due	O
to	O
peripheral	B-Phenotype
hypomyelination	E-Phenotype
.	O

ADAMTS18	O
dysregulation	O
plays	O
an	O
important	O
role	O
in	O
many	O
disease	O
processes	O
including	O
cancer	S-Phenotype
.	O

In	O
2007	O
,	O
FTO	O
(	O
fat	O
mass	O
and	O
obesity	S-Phenotype
associated	O
)	O
was	O
the	O
first	O
gene	O
identified	O
through	O
a	O
genome	O
-	O
wide	O
association	O
study	O
(	O
GWAS	O
)	O
associated	O
with	O
obesity	S-Phenotype
in	O
humans	O
.	O

One	O
clue	O
to	O
this	O
relationship	O
has	O
come	O
from	O
the	O
elucidation	O
of	O
the	O
hereditary	O
kidney	B-Phenotype
cancer	E-Phenotype
gene	O
,	O
TRC8	O
,	O
which	O
functions	O
partly	O
to	O
degrade	O
key	O
regulators	O
of	O
endogenous	O
cholesterol	O
and	O
lipid	O
biosynthesis	O
.	O

Clinical	O
presentation	O
of	O
COX	O
deficiency	O
is	O
heterogeneous	S-Phenotype
ranging	O
from	O
mild	O
to	O
severe	O
neuromuscular	O
diseases	O
.	O

We	O
report	O
ten	O
new	O
patients	O
from	O
eight	O
unrelated	O
kindreds	O
with	O
DGKE	O
nephropathy	S-Phenotype
.	O

AL	O
mice	O
showed	O
a	O
diabetes	O
prevalence	O
of	O
43	O
%	O
,	O
whereas	O
mice	O
under	O
CR	O
and	O
IF	O
were	O
completely	O
protected	O
against	O
hyperglycemia	S-Phenotype
.	O

Our	O
results	O
suggest	O
that	O
F	O
-	O
actin	O
regulators	O
LIMK	O
/	O
cofilin	O
pathway	O
and	O
SSH1	O
are	O
associated	O
with	O
CRC	O
progression	O
and	O
chemoresistance	O
representing	O
promising	O
tumor	S-Phenotype
biomarkers	O
and	O
therapeutic	O
targets	O
in	O
CRC	O

FOXRED1	O
encodes	O
a	O
complex	O
I	O
-	O
specific	O
assembly	O
factor	O
and	O
mutations	O
in	O
this	O
gene	O
result	O
in	O
complex	O
I	O
deficiency	O
,	O
infantile	B-Phenotype
onset	E-Phenotype
encephalomyopathy	S-Phenotype
and	O
Leigh	B-Phenotype
syndrome	E-Phenotype
.	O

We	O
discover	O
that	O
proline	O
catabolism	O
via	O
proline	O
dehydrogenase	O
(	O
Prodh	O
)	O
supports	O
growth	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
in	O
3D	O
culture	O
.	O

Here	O
,	O
we	O
report	O
a	O
novel	O
hemizygous	O
transition	O
c.975GAAAAA	O
(	O
p.Trp325	O
*	O
)	O
in	O
POU3F4	O
gene	O
(	O
Xq21	O
)	O
found	O
in	O
two	O
deaf	O
half	O
-	O
brothers	O
from	O
one	O
Yakut	O
family	O
(	O
Eastern	O
Siberia	O
,	O
Russia	O
)	O
with	O
identical	O
inner	B-Phenotype
ear	I-Phenotype
abnormalities	E-Phenotype
(	O
AAAAAAcorkscrewAAAAAA	O
cochlea	O
with	O
an	O
absence	O
of	O
modiolus	O
)	O
specific	O
to	O
X	O
-	O
linked	O
deafness	S-Phenotype
-	O
2	O
(	O
DFNX2	O
)	O
.	O

Increasing	O
attention	O
has	O
been	O
paid	O
to	O
the	O
roles	O
of	O
microRNAs	O
(	O
miRs	O
)	O
in	O
the	O
pathogenesis	O
of	O
cardiovascular	B-Phenotype
disease	E-Phenotype
,	O
including	O
miR	O
-	O
1	O
and	O
miR	O
-	O
133	O
(	O
in	O
the	O
electrophysiological	O
response	O
)	O
,	O
and	O
miR	O
-	O
34a	O
(	O
in	O
cardiac	O
fibrosis	O
)	O
.	O

Participants	O
were	O
assessed	O
for	O
cognitive	O
performance	O
(	O
Cogstate	O
battery	O
)	O
,	O
dietary	O
selenium	O
intake	O
(	O
two	O
24	O
-	O
h	O
food	O
recalls	O
)	O
,	O
plasma	O
selenium	O
concentration	O
,	O
inflammatory	O
markers	O
(	O
interleukin	O
(	O
IL	O
)	O
-	O
6	O
,	O
-	O
8	O
,	O
-	O
10	O
,	O
tumor	S-Phenotype
necrosis	O
factor	O
-	O
alpha	O
and	O
adiponectin	O
)	O
and	O
neurotrophic	O
factors	O
(	O
brain	O
-	O
derived	O
neurotrophic	O
factor	O
,	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
insulin	O
-	O
like	O
growth	O
factor	O
1	O
)	O
.	O

Also	O
,	O
the	O
generated	O
CIB2	O
-	O
/	O
-	O
mice	O
display	O
an	O
early	O
onset	O
profound	S-Phenotype
deafness	S-Phenotype
and	O
have	O
normal	O
balance	O
and	O
retinal	O
functions	O
.	O

Further	O
,	O
the	O
function	O
of	O
HOXA11	O
in	O
breast	O
tumorigenesis	S-Phenotype
was	O
analyzed	O
by	O
cell	O
proliferation	O
and	O
migration	O
assays	O
.	O

ADAMTS18	O
was	O
reduced	O
in	O
primary	O
breast	B-Phenotype
tumor	E-Phenotype
tissues	O
as	O
compared	O
with	O
their	O
adjacent	O
noncancer	O
tissues	S-Phenotype
.	O

Blocking	O
the	O
expression	O
of	O
PAK1	O
,	O
DIAPH2	O
,	O
and	O
RDX	O
significantly	O
inhibits	O
breast	B-Phenotype
cancer	E-Phenotype
cell	O
migration	O
induced	O
by	O
let	O
-	O
7b	O
repression	O
.	O

The	O
individuals	O
with	O
PARS2	O
and	O
NARS2	O
mutations	O
,	O
we	O
have	O
reported	O
here	O
demonstrate	O
similar	O
neurological	O
features	O
as	O
those	O
previously	O
reported	O
,	O
with	O
diversity	O
in	O
clinical	O
presentation	O
such	O
as	O
hearing	B-Phenotype
loss	E-Phenotype
and	O
seizure	S-Phenotype
type	O
.	O

Specifically	O
,	O
LRIG1	O
has	O
been	O
identified	O
as	O
a	O
tumor	S-Phenotype
suppressor	O
in	O
human	O
cancers	S-Phenotype
.	O

In	O
human	O
,	O
PDC	O
deficiency	O
leads	O
to	O
severe	O
neurodevelopmental	B-Phenotype
delay	E-Phenotype
and	O
progressive	B-Phenotype
neurodegeneration	E-Phenotype
.	O

A	O
germline	O
c.339_340delAG	O
variant	O
predicted	O
to	O
cause	O
premature	O
termination	O
of	O
the	O
protein	O
after	O
57	O
alternative	O
amino	O
acid	O
residues	O
was	O
identified	O
in	O
3	O
/	O
860	O
families	O
who	O
tested	O
negative	O
for	O
BRCA1	O
and	O
BRCA2	O
mutations	O
and	O
in	O
1	O
/	O
84	O
sporadic	S-Phenotype
breast	B-Phenotype
cancer	E-Phenotype
cases	O
.	O

Here	O
,	O
we	O
are	O
elucidating	O
the	O
mechanism	O
of	O
a	O
heritable	O
CCT5	O
subunit	O
mutation	O
that	O
causes	O
profound	S-Phenotype
neuropathy	S-Phenotype
in	O
humans	O
.	O

The	O
pathogenesis	O
of	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
is	O
poorly	O
understood	O
,	O
but	O
recent	O
advances	O
in	O
genomics	O
have	O
increased	O
our	O
understanding	O
of	O
the	O
mechanisms	O
by	O
which	O
hepatitis	S-Phenotype
B	O
virus	O
,	O
hepatitis	S-Phenotype
C	O
virus	O
,	O
alcohol	O
,	O
fatty	B-Phenotype
liver	E-Phenotype
disease	O
,	O
and	O
other	O
environmental	O
factors	O
,	O
such	O
as	O
aflatoxin	O
,	O
cause	O
liver	B-Phenotype
cancer	E-Phenotype
.	O

CDK5RAP2	O
gene	O
encodes	O
a	O
centrosomal	O
protein	O
,	O
highly	O
expressed	O
in	O
fetal	O
brain	O
and	O
essentially	O
indispensable	O
for	O
its	O
normal	O
development	O
,	O
as	O
biallelic	O
mutations	O
in	O
it	O
lead	O
to	O
primary	B-Phenotype
microcephaly	E-Phenotype
(	O
MCPH	S-Phenotype
)	O
.	O

Our	O
findings	O
provide	O
exploratory	O
evidence	O
for	O
hypermethylation	O
of	O
the	O
key	O
tumour	S-Phenotype
suppressor	O
gene	O
APC	O
being	O
implicated	O
in	O
smoking	O
-	O
associated	O
colorectal	O
carcinogenesis	O
.	O

MATERIAL	O
AND	O
METHODS	O
The	O
expression	O
of	O
ALG3	O
in	O
breast	B-Phenotype
carcinoma	E-Phenotype
tissues	O
was	O
determined	O
by	O
immunochemistry	O
.	O

Meckel	O
syndrome	O
(	O
MKS	O
)	O
is	O
an	O
embryonic	O
lethal	O
,	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
polycystic	B-Phenotype
kidney	I-Phenotype
disease	E-Phenotype
,	O
central	B-Phenotype
nervous	I-Phenotype
system	I-Phenotype
defects	E-Phenotype
,	O
polydactyly	S-Phenotype
and	O
liver	B-Phenotype
fibrosis	E-Phenotype
.	O

The	O
ichthyosis	S-Phenotype
genetic	O
panel	O
showed	O
mutations	O
in	O
the	O
ABCA12	O
gene	O
resulting	O
in	O
the	O
lamellar	O
ichthyosis	S-Phenotype
phenotype	O
of	O
ARCI	O
.	O

Detection	O
of	O
key	O
protein	O
expression	O
in	O
EMT	O
by	O
Western	O
blot	O
displayed	O
that	O
the	O
expression	O
of	O
E	O
-	O
cadherin	O
was	O
negatively	O
associated	O
with	O
Twist2	O
in	O
glioma	S-Phenotype
(	O
lir	O
/	O
i=	O
-	O
0.972	O
,	O
liP	O
/	O
iAAAA0.01	O
)	O
.	O

We	O
examined	O
47628	O
SNPs	O
in	O
61	O
mTOR	O
pathway	O
genes	O
in	O
the	O
genome	O
wide	O
association	O
study	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
in	O
the	O
African	O
Diaspora	O
study	O
(	O
The	O
Root	O
consortium	O
)	O
,	O
which	O
included	O
3686	O
participants	O
(	O
1657	O
cases	O
)	O
.	O

If	O
a	O
gonad	O
in	O
a	O
patient	O
who	O
has	O
a	O
disorder	O
of	O
sex	O
development	O
contains	O
germ	O
cells	O
with	O
delayed	O
maturation	O
,	O
and	O
also	O
harbours	O
the	O
TSPY1	O
gene	O
,	O
the	O
cells	O
can	O
undergo	O
transformation	O
to	O
classical	O
gonadoblastoma	S-Phenotype
.	O

Fragile	O
X	O
syndrome	O
(	O
FXS	O
)	O
,	O
the	O
leading	O
cause	O
of	O
inherited	O
forms	O
of	O
mental	B-Phenotype
retardation	E-Phenotype
and	O
autism	S-Phenotype
,	O
is	O
caused	O
by	O
the	O
transcriptional	O
silencing	O
of	O
fmr1	O
encoding	O
the	O
fragile	O
X	O
mental	B-Phenotype
retardation	E-Phenotype
protein	O
(	O
FMRP	O
)	O
.	O

Affected	O
patients	O
suffer	O
from	O
a	O
progressive	O
movement	B-Phenotype
disorder	E-Phenotype
including	O
chorea	S-Phenotype
,	O
parkinsonism	S-Phenotype
,	O
dystonia	S-Phenotype
,	O
tongue	B-Phenotype
protrusion	E-Phenotype
,	O
dysarthria	S-Phenotype
,	O
dysphagia	S-Phenotype
,	O
tongue	B-Phenotype
and	I-Phenotype
lip	I-Phenotype
biting	E-Phenotype
,	O
gait	B-Phenotype
impairment	E-Phenotype
,	O
progressive	O
distal	B-Phenotype
muscle	I-Phenotype
wasting	E-Phenotype
,	O
weakness	S-Phenotype
,	O
epileptic	B-Phenotype
seizures	E-Phenotype
,	O
cognitive	B-Phenotype
impairment	E-Phenotype
,	O
and	O
behavioral	B-Phenotype
changes	E-Phenotype
.	O

Shared	O
facial	O
features	O
are	O
a	O
broad	B-Phenotype
and	I-Phenotype
wide	I-Phenotype
forehead	E-Phenotype
,	O
similar	B-Phenotype
shape	I-Phenotype
of	I-Phenotype
the	I-Phenotype
eyes	I-Phenotype
with	I-Phenotype
long	I-Phenotype
palpebral	I-Phenotype
fissures	E-Phenotype
,	O
a	O
bulbous	B-Phenotype
tip	I-Phenotype
of	I-Phenotype
the	I-Phenotype
nose	E-Phenotype
and	O
thick	B-Phenotype
lips	E-Phenotype
.	O

We	O
evaluated	O
use	O
of	O
multi	O
-	O
site	O
FISH	O
in	O
the	O
diagnosis	O
of	O
acral	S-Phenotype
melanoma	S-Phenotype
in	O
a	O
series	O
of	O
82	B-Phenotype
acral	I-Phenotype
melanocytic	I-Phenotype
tumours	E-Phenotype
.	O

Keratitis	B-Phenotype
-	I-Phenotype
ichthyosis	I-Phenotype
-	I-Phenotype
deafness	E-Phenotype
(	O
KID	S-Phenotype
)	O
syndrome	O
is	O
a	O
rare	O
genodermatosis	O
that	O
typically	O
results	O
from	O
mutations	O
of	O
the	O
GJB2	O
gene	O
or	O
,	O
less	O
commonly	O
,	O
the	O
GJB6	O
gene	O
.	O

To	O
understand	O
the	O
importance	O
of	O
chr11q22.3	O
-	O
23.2	O
region	O
in	O
the	O
development	O
of	O
cervical	B-Phenotype
cancer	E-Phenotype
,	O
we	O
have	O
studied	O
the	O
genetic	O
and	O
epigenetic	O
alterations	O
of	O
the	O
candidate	O
genes	O
ATM	O
,	O
PPP2R1B	O
,	O
SDHD	O
and	O
CADM1	O
in	O
cervical	B-Phenotype
intraepithelial	I-Phenotype
neoplasia	E-Phenotype
(	O
CIN	S-Phenotype
)	O
and	O
cervical	B-Phenotype
carcinoma	E-Phenotype
(	O
CACX	S-Phenotype
)	O
samples	O
.	O

Our	O
results	O
indicate	O
that	O
MAGEL2	O
mutations	O
cause	O
multiple	O
congenital	O
anomalies	O
and	O
intellectual	B-Phenotype
disability	E-Phenotype
accompanied	O
by	O
arthrogryposis	B-Phenotype
multiplex	I-Phenotype
congenita	E-Phenotype
and	O
various	O
endocrinologic	O
abnormalities	O
,	O
supporting	O
that	O
the	O
view	O
that	O
clinical	O
phenotypes	O
of	O
MAGEL2	O
mutations	O
are	O
variable	O

TAF12	O
,	O
NFYC	O
,	O
and	O
RAD54L	O
co	O
-	O
located	O
on	O
human	O
chromosome	O
1p32	O
-	O
35.3	O
and	O
mouse	O
chromosome	O
4qD1	O
-	O
D3	O
were	O
identified	O
as	O
oncogenes	O
that	O
are	O
gained	O
in	O
tumors	S-Phenotype
in	O
both	O
species	O
and	O
required	O
for	O
disease	O
initiation	O
and	O
progression	O
.	O

In	O
128	O
female	O
patients	O
of	O
the	O
recruited	O
UCC	O
cohort	O
,	O
patients	O
who	O
carried	O
at	O
least	O
one	O
deletion	O
allele	O
of	O
liDRD2	O
/	O
i	O
rs1799732	O
showed	O
a	O
higher	O
incidence	O
of	O
having	O
an	O
invasive	O
stage	O
(	O
AOR=2.585	O
,	O
95	O
%	O
CI	O
:	O
1.066~6.264	O
,	O
lip	O
/	O
i=0.032	O
)	O
and	O
a	O
large	O
tumor	S-Phenotype
(	O
AOR=2.778	O
,	O
95	O
%	O
CI	O
:	O
1.146~6.735	O
,	O
lip	O
/	O
i=0.021	O
)	O
.	O

Here	O
,	O
we	O
hypothesize	O
that	O
PYCR1	O
might	O
be	O
a	O
novel	O
prognostic	O
biomarker	O
and	O
therapeutic	O
target	O
for	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

Instead	O
,	O
biallelic	O
mutations	O
have	O
been	O
associated	O
with	O
afibrinogenemia	S-Phenotype
/	O
severe	O
hypofibrinogenemia	S-Phenotype
,	O
i.e.	O
,	O
the	O
severest	O
forms	O
of	O
fibrinogen	O
deficiency	O
,	O
affecting	O
approximately	O
1	O
-	O
2	O
cases	O
per	O
million	O
people	O
.	O

The	O
expression	O
of	O
uncarboxylated	O
MGP	O
(	O
ucMGP	O
)	O
,	O
carboxylated	O
MGP	O
(	O
cMGP	O
)	O
,	O
matrix	O
metalloproteinase	O
(	O
MMP	O
)	O
-	O
13	O
,	O
collagen	O
type	O
X	O
,	O
collagen	O
type	O
II	O
,	O
tumor	S-Phenotype
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
a	O
and	O
interleukin	O
(	O
IL	O
)	O
-	O
1b	O
were	O
detected	O
by	O
ELISA	O
,	O
immunohistochemistry	O
,	O
reverse	O
transcription	O
-	O
quantitative	O
polymerase	O
chain	O
reaction	O
and	O
western	O
blotting	O
.	O

Collectively	O
,	O
our	O
data	O
illustrate	O
that	O
persistent	O
Hh	O
signaling	O
in	O
the	O
palatal	O
epithelium	O
contributes	O
to	O
the	O
etiology	O
and	O
pathogenesis	O
of	O
submucous	O
cleft	B-Phenotype
palate	E-Phenotype
through	O
its	O
interaction	O
with	O
a	O
p63	O
/	O
Irf6	O
-	O
dependent	O
biological	O
regulatory	O
loop	O
and	O
through	O
a	O
p63	O
-	O
induced	O
cell	O
adhesion	O
network	O

Bartter	O
syndrome	O
type	O
IV	O
,	O
characterized	O
by	O
salt	O
-	O
losing	O
nephropathies	S-Phenotype
and	O
sensorineural	B-Phenotype
deafness	E-Phenotype
,	O
is	O
caused	O
by	O
mutations	O
of	O
BSND	O
or	O
simultaneous	O
mutations	O
of	O
both	O
CLCNKA	O
and	O
CLCNKB	O
.	O

IgA	O
-	O
dominant	O
nephritis	S-Phenotype
,	O
endocarditis	S-Phenotype
-	O
associated	O
nephritis	S-Phenotype
and	O
shunt	O
nephritis	S-Phenotype
are	O
special	O
sub	O
-	O
subtypes	O
of	O
PIGN	O
.	O

Depending	O
on	O
the	O
tumor	S-Phenotype
cell	O
type	O
,	O
knockdown	O
of	O
TNFAIP8	O
was	O
found	O
to	O
be	O
associated	O
with	O
increased	O
mRNA	O
expression	O
of	O
several	O
antiproliferative	O
and	O
apoptotic	O
genes	O
(	O
e.g.	O
,	O
IL	O
-	O
24	O
,	O
FAT3	O
,	O
LPHN2	O
,	O
EPHA3	O
)	O
and	O
fatty	O
acid	O
oxidation	O
gene	O
ACADL	O
,	O
and	O
decreased	O
mRNA	O
levels	O
of	O
oncogenes	O
(	O
e.g.	O
,	O
NFAT5	O
,	O
MALAT1	O
,	O
MET	O
,	O
FOXA1	O
,	O
KRAS	O
,	O
S100P	O
,	O
OSTF1	O
)	O
and	O
glutamate	O
transporter	O
gene	O
SLC1A1	O
.	O

Immune	O
checkpoint	O
blockade	O
(	O
ICB	O
)	O
using	O
anti	O
-	O
CTLA4	O
and	O
anti	O
-	O
PD1	O
has	O
drawn	O
considerable	O
attention	O
towards	O
co	O
-	O
signaling	O
receptors	O
in	O
tumor	S-Phenotype
immunology	O
and	O
created	O
renewed	O
interest	O
in	O
studying	O
other	O
co	O
-	O
signaling	O
receptors	O
,	O
which	O
until	O
recently	O
have	O
not	O
been	O
as	O
well	O
studied	O
.	O

A	O
heterozygous	O
mutation	O
in	O
the	O
Wolfram	O
syndrome	O
type	O
1	O
gene	O
(	O
WFS1	O
)	O
causes	O
autosomal	B-Phenotype
dominant	I-Phenotype
nonsyndromic	I-Phenotype
hereditary	I-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
,	O
DFNA6	O
/	O
14	O
/	O
38	O
,	O
or	O
Wolfram	O
-	O
like	O
syndrome	O
.	O

Meanwhile	O
,	O
curcumin	O
treatments	O
considerably	O
increased	O
the	O
expression	O
of	O
AKR1C2	O
in	O
prostate	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
,	O
supporting	O
the	O
decrease	O
of	O
dihydrotestosterone	O
.	O

CDK8	O
knockout	O
phenocopied	O
Zyxin	O
knockdown	O
in	O
colon	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
while	O
ectopic	O
expression	O
of	O
CDK8	O
substantially	O
restored	O
the	O
tumorigenic	S-Phenotype
defects	O
of	O
Zyxin	O
-	O
depletion	O
cells	O
.	O

Mutations	O
in	O
the	O
D40	O
/	O
KNL1	O
/	O
CASC5	O
gene	O
,	O
which	O
was	O
initially	O
characterized	O
as	O
a	O
gene	O
involved	O
in	O
chromosomal	O
translocation	O
in	O
leukemia	S-Phenotype
and	O
as	O
a	O
member	O
of	O
the	O
cancer	S-Phenotype
/	O
testis	O
gene	O
family	O
,	O
was	O
later	O
found	O
to	O
encode	O
a	O
kinetochore	O
protein	O
essential	O
for	O
mitotic	O
cell	O
division	O
and	O
to	O
cause	O
MCPH4	O
.	O

Anaplastic	B-Phenotype
thyroid	I-Phenotype
cancer	E-Phenotype
(	O
ATC	S-Phenotype
)	O
is	O
associated	O
with	O
poor	O
prognosis	O
and	O
is	O
often	O
untreatable	O
.	O

Whole	O
exome	O
sequencing	O
in	O
triple	O
negative	O
breast	B-Phenotype
cancer	E-Phenotype
cases	O
(	O
n	O
=	O
8	O
)	O
and	O
targeted	O
sequencing	O
in	O
healthy	O
controls	O
(	O
n	O
=	O
48	O
)	O
revealed	O
BRIP1	O
rs552752779	O
(	O
MAF	O
:	O
75	O
%	O
vs.	O
6.25	O
%	O
,	O
OR	O
45.00	O
,	O
95	O
%	O
CI	O
9.43	O
-	O
243.32	O
)	O
,	O
ERBB2	O
rs527779103	O
(	O
MAF	O
:	O
62.5	O
%	O
vs.	O
7.29	O
%	O
,	O
OR	O
21.19	O
,	O
95	O
%	O
CI	O
5.11	O
-	O
94.32	O
)	O
,	O
ERCC2	O
rs121913016	O
(	O
MAF	O
:	O
56.25	O
%	O
vs.	O
7.29	O
%	O
,	O
OR	O
16.34	O
,	O
95	O
%	O
CI	O
4.02	O
-	O
70.41	O
)	O
,	O
MSH6	O
rs2020912	O
(	O
MAF	O
:	O
56.25	O
%	O
vs.	O
1.04	O
%	O
,	O
OR	O
122.13	O
,	O
95	O
%	O
CI	O
12.29	O
-	O
2985.48	O
)	O
as	O
risk	O
factors	O
for	O
triple	O
negative	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

TNFAIP8	O
-	O
centric	O
molecules	O
were	O
found	O
to	O
be	O
predominately	O
implicated	O
in	O
the	O
hypoxia	S-Phenotype
-	O
inducible	O
factor	O
-	O
1α	O
(	O
HIF	O
-	O
1α	O
)	O
signaling	O
pathway	O
,	O
and	O
cancer	S-Phenotype
and	O
development	O
signaling	O
networks	O
.	O

Patients	O
with	O
adult	O
-	O
onset	O
NCL	O
may	O
present	O
with	O
slowly	O
progressive	B-Phenotype
ataxia	E-Phenotype
,	O
persistent	O
photosensitivity	S-Phenotype
,	O
and	O
seizures	S-Phenotype
without	O
dementia	S-Phenotype
or	O
extrapyramidal	O
findings	O
.	O

Intragenic	O
mutations	O
of	O
the	O
UBE2A	O
gene	O
,	O
as	O
well	O
as	O
larger	O
deletions	O
of	O
Xq24	O
encompassing	O
UBE2A	O
have	O
in	O
recent	O
years	O
been	O
associated	O
with	O
a	O
syndromic	O
form	O
of	O
X	O
-	O
linked	O
intellectual	B-Phenotype
disability	E-Phenotype
called	O
UBE2A	O
deficiency	O
syndrome	O
or	O
X	O
-	O
linked	O
intellectual	B-Phenotype
disability	E-Phenotype
type	O
Nascimento	O
(	O
OMIM	O
#	O
300860	O
)	O
.	O

Pain	S-Phenotype
scores	O
correlated	O
with	O
total	O
body	O
tumor	S-Phenotype
volume	O
(	O
rho	O
=	O
0.32471	O
,	O
P	O
=	O
.0499	O
)	O
,	O
but	O
not	O
with	O
number	O
of	O
tumors	S-Phenotype
(	O
rho	O
=	O
0.23065	O
,	O
P	O
=	O
.1696	O
)	O
.We	O
found	O
no	O
significant	O
difference	O
in	O
quantitative	O
tumor	S-Phenotype
burden	O
between	O
mutational	O
groups	O
,	O
but	O
spinal	B-Phenotype
schwannomas	E-Phenotype
were	O
more	O
common	O
in	O
LZTR1	O
-	O
mutant	O
patients	O
.	O

Our	O
findings	O
highlight	O
the	O
importance	O
of	O
ARHGEF9	O
integrity	O
and	O
suggest	O
further	O
research	O
on	O
its	O
correlation	O
with	O
autism	S-Phenotype
and	O
neurobehavioral	O
problems	O

Our	O
analyses	O
identified	O
15	O
CpG	O
sites	O
within	O
the	O
APC	O
1A	O
promoter	O
that	O
were	O
significantly	O
hypermethylated	O
and	O
14	O
CpG	O
loci	O
within	O
the	O
NFATC1	O
gene	O
body	O
that	O
were	O
significantly	O
hypomethylated	O
(	O
pLIS	O
AAAA	O
1	O
×	O
10	O
-	O
5	O
)	O
in	O
the	O
tumours	S-Phenotype
of	O
active	O
smokers	O
.	O

Our	O
study	O
revealed	O
that	O
the	O
expression	O
of	O
WD	O
repeat	O
containing	O
antisense	O
to	O
P53	O
(	O
WRAP53	O
)	O
is	O
higher	O
in	O
lung	O
-	O
adenocarcinoma	O
specimens	O
than	O
in	O
specimens	O
from	O
adjacent	O
non	O
-	O
tumor	S-Phenotype
tissues	O
.	O

The	O
relationship	O
between	O
the	O
altered	O
expression	O
of	O
MACC1	O
,	O
c	O
-	O
MET	O
,	O
and	O
NM23	O
-	O
H1	O
and	O
pathological	O
microenvironmental	O
features	O
,	O
including	O
the	O
presence	O
of	O
tumor	S-Phenotype
budding	O
and	O
desmoplasia	O
,	O
were	O
assessed	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
expression	O
of	O
XIAP	O
and	O
p62	O
,	O
two	O
critical	O
mediators	O
of	O
autophagy	O
,	O
in	O
breast	B-Phenotype
and	I-Phenotype
colon	I-Phenotype
cancer	E-Phenotype
.	O

Pathogenic	O
sequence	O
variants	O
in	O
the	O
Sorting	O
Nexin	O
10	O
(	O
SNX10	O
)	O
gene	O
have	O
been	O
associated	O
with	O
autosomal	B-Phenotype
recessive	I-Phenotype
osteopetrosis	E-Phenotype
(	O
ARO	S-Phenotype
)	O
in	O
human	O
.	O

This	O
case	O
suggested	O
a	O
broad	O
phenotypic	O
spectrum	O
arises	O
from	O
SZT2	O
mutations	O
,	O
forming	O
a	O
continuum	O
from	O
epileptic	B-Phenotype
encephalopathy	E-Phenotype
and	O
severe	O
developmental	B-Phenotype
delay	E-Phenotype
to	O
mild	O
intellectual	B-Phenotype
disability	E-Phenotype
without	O
epilepsy	S-Phenotype
.	O

Protein	O
kinase	O
A	O
(	O
PKA	O
)	O
signaling	O
pathway	O
including	O
AKAP12	O
,	O
RDX	O
,	O
and	O
RAB13	O
genes	O
were	O
identified	O
as	O
potential	O
mechanisms	O
for	O
the	O
activity	O
of	O
garlic	O
extract	O
in	O
cancer	S-Phenotype
prevention	O
.	O

Our	O
findings	O
expand	O
the	O
clinical	O
phenotype	O
and	O
further	O
demonstrate	O
the	O
clinical	O
heterogeneity	S-Phenotype
related	O
to	O
PTRH2	O
variants	O

The	O
primary	O
objective	O
of	O
the	O
study	O
was	O
to	O
estimate	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
and	O
/	O
or	O
recommended	O
phase	O
II	O
dose	O
(	O
RP2D	O
)	O
of	O
oral	O
alpelisib	O
in	O
patients	O
with	O
advanced	O
solid	O
tumors	S-Phenotype
who	O
had	O
progressed	O
despite	O
standard	O
therapy	O
.	O

Finally	O
,	O
further	O
analysis	O
of	O
the	O
TCGA	O
data	O
demonstrated	O
SASS6	O
upregulation	O
in	O
a	O
modest	O
manner	O
in	O
8	O
of	O
11	O
cancer	S-Phenotype
types	O
other	O
than	O
colon	B-Phenotype
cancer	E-Phenotype
,	O
and	O
SASS6	O
upregulation	O
was	O
found	O
to	O
be	O
associated	O
with	O
a	O
poor	O
survival	O
outcome	O
in	O
patients	O
with	O
kidney	O
renal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
and	O
lung	B-Phenotype
adenocarcinoma	E-Phenotype
.	O

Complex	O
recessive	O
spastic	B-Phenotype
paraplegias	E-Phenotype
have	O
in	O
the	O
past	O
been	O
frequently	O
associated	O
with	O
mutations	O
in	O
SPG11	O
(	O
spatacsin	O
)	O
,	O
ZFYVE26	O
/	O
SPG15	O
,	O
SPG7	O
(	O
paraplegin	O
)	O
and	O
a	O
handful	O
of	O
other	O
rare	O
genes	O
,	O
but	O
many	O
cases	O
remain	O
genetically	O
undefined	O
.	O

The	O
proteomic	O
data	O
suggested	O
that	O
Danu	O
-	O
regulated	O
RPL15	O
signaling	O
might	O
contribute	O
to	O
the	O
cancer	S-Phenotype
cell	O
killing	O
effect	O
.	O

A	O
homozygous	O
mutation	O
of	O
SERPINB6	O
,	O
a	O
gene	O
encoding	O
an	O
intracellular	O
protease	O
inhibitor	O
,	O
has	O
recently	O
been	O
associated	O
with	O
post	O
-	O
lingual	O
,	O
autosomal	O
-	O
recessive	O
,	O
nonsyndromic	O
hearing	B-Phenotype
loss	E-Phenotype
in	O
humans	O
(	O
DFNB91	O
)	O
.	O

In	O
humans	O
,	O
heterozygous	O
mutations	O
in	O
NKX2.5	O
result	O
in	O
congenital	B-Phenotype
heart	I-Phenotype
defects	E-Phenotype
(	O
CHDs	S-Phenotype
)	O
.	O

Epidemiology	O
studies	O
also	O
showed	O
a	O
strong	O
association	O
of	O
FTO	O
SNPs	O
and	O
overweight	S-Phenotype
/	O
obesity	S-Phenotype
with	O
increased	O
risk	O
of	O
various	O
types	O
of	O
cancers	S-Phenotype
.	O

Moreover	O
,	O
the	O
overexpression	O
of	O
NIBP	O
was	O
closely	O
related	O
to	O
tumor	S-Phenotype
differentiation	O
,	O
depth	O
of	O
invasion	O
,	O
clinical	O
stage	O
and	O
lymphatic	O
metastasis	O
in	O
gastric	B-Phenotype
cancer	E-Phenotype
.	O

They	O
also	O
provide	O
the	O
proof	O
-	O
of	O
-	O
concept	O
that	O
expression	O
of	O
the	O
neuropathy	S-Phenotype
-	O
associated	O
MTMR2	O
gene	O
improves	O
the	O
MTM1	O
-	O
associated	O
myopathy	S-Phenotype
,	O
thus	O
identifying	O
MTMR2	O
as	O
a	O
novel	O
therapeutic	O
target	O
for	O
myotubular	O
myopathy	S-Phenotype

Induction	O
of	O
p53	O
by	O
5	O
-	O
Aza	O
-	O
dC	O
was	O
tested	O
in	O
vitro	O
using	O
cancer	S-Phenotype
cells	O
.	O

Agonistic	O
antibodies	O
,	O
which	O
bind	O
specifically	O
to	O
death	O
receptor	O
5	O
(	O
DR5	O
)	O
,	O
can	O
trigger	O
apoptosis	O
in	O
tumor	S-Phenotype
cells	O
through	O
the	O
extrinsic	O
pathway	O
.	O

We	O
extended	O
our	O
findings	O
to	O
BRAF	O
WT	O
tumor	S-Phenotype
cell	O
lines	O
that	O
are	O
intrinsically	O
resistant	O
to	O
vemurafenib	O
and	O
dabrafenib	O
.	O

CONCLUSIONS	O
High	O
expression	O
of	O
CCDC34	O
is	O
an	O
independent	O
unfavorable	O
prognostic	O
parameter	O
for	O
OS	O
and	O
DFS	O
of	O
CC	O
patients	O
,	O
which	O
was	O
strongly	O
associated	O
with	O
tumor	S-Phenotype
angiogenesis	O

Mutations	O
within	O
this	O
gene	O
are	O
responsible	O
for	O
kinesigenic	O
paroxysmal	B-Phenotype
dyskinesias	E-Phenotype
(	O
PKD	S-Phenotype
)	O
as	O
well	O
as	O
for	O
benign	B-Phenotype
familial	I-Phenotype
infantile	I-Phenotype
epilepsy	E-Phenotype
(	O
BFIE	S-Phenotype
)	O
,	O
a	O
disease	O
associating	O
infantile	B-Phenotype
convulsions	I-Phenotype
and	I-Phenotype
choreoathetosis	E-Phenotype
(	O
ICCA	S-Phenotype
)	O
,	O
a	O
form	O
of	O
familial	B-Phenotype
hemiplegic	I-Phenotype
migraine	E-Phenotype
(	O
FHM	B-Phenotype
type	I-Phenotype
4	E-Phenotype
)	O
,	O
paroxysmal	B-Phenotype
benign	I-Phenotype
torticollis	I-Phenotype
of	I-Phenotype
childhood	E-Phenotype
,	O
and	O
episodic	B-Phenotype
ataxia	E-Phenotype
.	O

Image	O
degradation	O
by	O
loss	O
of	O
higher	O
spatial	O
frequencies	O
causes	O
form	B-Phenotype
-	I-Phenotype
deprivation	I-Phenotype
myopia	E-Phenotype
(	O
FDM	S-Phenotype
)	O
in	O
humans	O
and	O
animals	O
,	O
and	O
cyclical	O
illumination	O
(	O
flicker	O
)	O
at	O
certain	O
frequencies	O
may	O
prevent	O
FDM	S-Phenotype
.	O

Rac1	O
hyperactivation	O
is	O
common	O
in	O
human	O
cancer	S-Phenotype
and	O
could	O
be	O
the	O
consequence	O
of	O
overexpression	O
,	O
abnormal	O
upstream	O
inputs	O
,	O
deregulated	O
degradation	O
,	O
and	O
/	O
or	O
anomalous	O
intracellular	O
localization	O
.	O

Five	O
HGCAs	O
harbored	O
either	O
mono	O
-	O
allelic	O
(	O
four	O
HGCAs	O
)	O
or	O
bi	O
-	O
allelic	O
(	O
one	O
HGCA	O
)	O
SMAD4	O
mutation	O
or	O
18q	O
loss	O
that	O
had	O
been	O
known	O
as	O
early	O
carcinoma	S-Phenotype
-	O
specific	O
changes	O
.	O

Cox	O
multifactor	O
regression	O
analysis	O
revealed	O
that	O
age	O
,	O
histology	O
and	O
MYCN	O
status	O
had	O
significant	O
prognostic	O
effect	O
on	O
event	O
-	O
free	O
survival	O
(	O
EFS	O
)	O
rate	O
for	O
neuroblastoma	S-Phenotype
patients	O
underwent	O
surgical	O
treatment.In	O
our	O
study	O
,	O
we	O
identified	O
a	O
series	O
of	O
prognostic	O
factors	O
including	O
age	O
,	O
histology	O
,	O
and	O
MYCN	O
status	O
predicting	O
the	O
prognosis	O
of	O
neuroblastoma	S-Phenotype
patients	O
after	O
surgical	O
treatment	O

This	O
study	O
investigated	O
the	O
roles	O
of	O
YAP	O
in	O
TKI	O
-	O
resistant	O
lung	B-Phenotype
adenocarcinoma	E-Phenotype
.	O

The	O
tumor	S-Phenotype
cells	O
resembled	O
pro	O
-	O
B	O
cells	O
,	O
and	O
were	O
CD19+IgM	O
-	O
IgD	O
-	O
CD93+CD43+CD21	O
-	O
CD23	O
-	O
VpreB+CXCR4+	O
Consistent	O
with	O
the	O
pro	O
-	O
B	O
-	O
cell	O
stage	O
of	O
B	O
-	O
cell	O
development	O
,	O
microarray	O
analysis	O
revealed	O
enrichment	O
of	O
transcripts	O
,	O
including	O
Rag1	O
,	O
Rag2	O
,	O
CD93	O
,	O
Vpreb1	O
,	O
Vpreb3	O
,	O
and	O
Igll1	O
We	O
confirmed	O
RAG1	O
expression	O
in	O
Tg26	O
tumors	S-Phenotype
,	O
and	O
hypothesized	O
that	O
HIV	O
-	O
1	O
matrix	O
protein	O
p17	O
may	O
directly	O
induce	O
RAG1	O
in	O
B	O
cells	O
.	O

The	O
results	O
show	O
that	O
LEPREL1	O
plays	O
an	O
important	O
role	O
in	O
eye	O
development	O
and	O
homozygous	O
loss	O
-	O
of	O
-	O
function	O
mutation	O
of	O
this	O
gene	O
can	O
cause	O
severely	O
high	B-Phenotype
myopia	E-Phenotype
and	O
early	O
-	O
onset	O
cataract	S-Phenotype
.	O

Sonic	O
Hedgehog	O
(	O
SHH	O
)	O
signaling	O
at	O
primary	O
cilia	O
drives	O
the	O
proliferation	O
and	O
progression	O
of	O
a	O
subset	O
of	O
medulloblastomas	S-Phenotype
,	O
the	O
most	O
common	O
malignant	O
paediatric	O
brain	B-Phenotype
tumor	E-Phenotype
.	O

This	O
rare	O
condition	O
is	O
characterized	O
by	O
bilateral	B-Phenotype
choanal	I-Phenotype
atresia	E-Phenotype
,	O
hearing	B-Phenotype
loss	E-Phenotype
,	O
cleft	B-Phenotype
lip	I-Phenotype
and	I-Phenotype
/	I-Phenotype
or	I-Phenotype
palate	E-Phenotype
,	O
and	O
other	O
craniofacial	O
dysmorphisms	O
.	O

Morpholino	O
-	O
based	O
knockdown	O
of	O
a	O
zebrafish	O
PYCR2	O
ortholog	O
,	O
pycr1b	O
,	O
recapitulated	O
the	O
human	O
microcephaly	S-Phenotype
phenotype	O
,	O
which	O
was	O
rescued	O
by	O
wild	O
-	O
type	O
human	O
PYCR2	O
mRNA	O
,	O
but	O
not	O
by	O
mutant	O
mRNAs	O
,	O
further	O
supporting	O
the	O
pathogenicity	O
of	O
the	O
identified	O
variants	O
.	O

A	O
plethora	S-Phenotype
of	O
human	O
diseases	O
are	O
associated	O
with	O
mutations	O
in	O
the	O
genes	O
encoding	O
human	O
SLC26	O
transporters	O
,	O
including	O
chondrodysplasias	O
with	O
varying	O
severity	O
in	O
SLC26A2	O
(	O
~50	O
mutations	O
,	O
27	O
point	O
mutations	O
)	O
,	O
congenital	O
chloride	O
-	O
losing	O
diarrhea	S-Phenotype
in	O
SLC26A3	O
(	O
~70	O
mutations	O
,	O
31	O
point	O
mutations	O
)	O
and	O
Pendred	O
Syndrome	O
or	O
deafness	S-Phenotype
autosomal	B-Phenotype
recessive	E-Phenotype
type	O
4	O
in	O
SLC26A4	O
(	O
~500	O
mutations	O
,	O
203	O
point	O
mutations	O
)	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
documented	O
case	O
of	O
synchronous	O
colon	O
and	O
prostate	B-Phenotype
cancers	E-Phenotype
,	O
with	O
isolated	O
PMS2	O
loss	O
present	O
in	O
the	O
colon	B-Phenotype
cancer	E-Phenotype
while	O
intact	O
DNA	O
mismatch	O
repair	O
(	O
MMR	O
)	O
protein	O
expressions	O
present	O
in	O
the	O
prostate	B-Phenotype
cancer	E-Phenotype
,	O
in	O
the	O
English	O
literature	O
.	O

Taken	O
together	O
,	O
we	O
firstly	O
revealed	O
that	O
quercetin	O
suppressed	O
the	O
progression	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
by	O
inhibiting	O
cell	O
mobility	O
and	O
glycolysis	O
through	O
Akt	O
-	O
mTOR	O
pathway	O
mediated	O
autophagy	O
induction	O
and	O
may	O
provide	O
a	O
potential	O
therapeutic	O
target	O
for	O
breast	B-Phenotype
cancer	E-Phenotype
treatment	O

In	O
summary	O
,	O
we	O
show	O
that	O
variants	O
in	O
EXOSC9	O
result	O
in	O
a	O
neurological	O
syndrome	O
combining	O
cerebellar	B-Phenotype
atrophy	E-Phenotype
and	O
spinal	B-Phenotype
motoneuronopathy	E-Phenotype
,	O
thus	O
expanding	O
the	O
list	O
of	O
human	O
exosomopathies	O

Thirteen	O
patients	O
with	O
GRM1	O
-	O
positive	O
tumors	S-Phenotype
were	O
enrolled	O
.	O

This	O
paper	O
shows	O
the	O
significant	O
difference	O
in	O
distribution	O
of	O
CRYGB	O
promoter	O
(	O
G	O
(	O
-	O
47	O
)	O
-	O
-	O
AAAAA	O
)	O
genotypes	O
in	O
patients	O
with	O
cataract	S-Phenotype
compared	O
to	O
the	O
control	O
group	O
.	O

germline	O
mutations	O
in	O
CHEK2	O
gene	O
(	O
c.1100delC	O
,	O
R145W	O
and	O
I157T	O
)	O
in	O
breast	B-Phenotype
cancers	E-Phenotype
in	O
Rwanda	O
.	O

We	O
recently	O
described	O
a	O
novel	O
role	O
for	O
A20	O
in	O
regulating	O
the	O
wnt	O
-	O
beta	O
-	O
catenin	O
signaling	O
pathway	O
and	O
suppressing	O
colonic	B-Phenotype
tumor	E-Phenotype
development	O
in	O
mice	O
.	O

In	O
contrast	O
,	O
SDH	O
and	O
FH	O
act	O
as	O
tumor	S-Phenotype
suppressors	O
and	O
genomic	O
inactivation	O
results	O
in	O
succinate	O
and	O
fumarate	O
accumulation	O
,	O
respectively	O
.	O

Primary	B-Phenotype
hyperoxaluria	I-Phenotype
type	I-Phenotype
1	E-Phenotype
(	O
PH1	S-Phenotype
)	O
is	O
a	O
rare	O
but	O
devastating	O
autosomal	B-Phenotype
recessive	E-Phenotype
inherited	O
disease	O
caused	O
by	O
mutations	O
in	O
gene	O
AGXT	O
.	O

When	O
we	O
generated	O
tricellulin	O
-	O
knockout	O
mice	O
(	O
Tric	O
(	O
-	O
/	O
-	O
)	O
)	O
,	O
we	O
found	O
an	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
rapidly	I-Phenotype
progressive	I-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
associated	O
with	O
the	O
degeneration	O
of	O
hair	O
cells	O
(	O
HCs	O
)	O
;	O
however	O
,	O
their	O
body	O
size	O
and	O
overall	O
appearance	O
were	O
normal	O
.	O

An	O
inverse	O
correlation	O
between	O
the	O
expression	O
levels	O
of	O
human	O
Nanos1	O
and	O
Nanos3	O
and	O
E	O
-	O
cadherin	O
was	O
observed	O
in	O
several	O
cancer	S-Phenotype
cell	O
lines	O
.	O

Here	O
we	O
investigated	O
that	O
abnormal	O
branched	O
-	O
chain	O
amino	O
acids	O
catabolism	O
in	O
colorectal	B-Phenotype
cancer	E-Phenotype
is	O
a	O
result	O
of	O
the	O
disease	O
process	O
,	O
with	O
no	O
role	O
in	O
disease	O
initiation	O
;	O
BCKDK	O
is	O
widely	O
expressed	O
in	O
colorectal	B-Phenotype
cancer	E-Phenotype
patients	O
,	O
and	O
those	O
patients	O
that	O
express	O
higher	O
levels	O
of	O
BCKDK	O
have	O
shorter	O
survival	O
times	O
than	O
those	O
with	O
lower	O
levels	O
;	O
BCKDK	O
promotes	O
cell	O
transformation	O
or	O
colorectal	B-Phenotype
cancer	E-Phenotype
ex	O
vivo	O
or	O
in	O
vivo	O
.	O

MALT1	O
mediates	O
activation	O
of	O
several	O
immune	O
cell	O
types	O
and	O
is	O
involved	O
in	O
the	O
proliferation	O
and	O
survival	O
of	O
cancer	S-Phenotype
cells	O
.	O

Furthermore	O
,	O
silencing	O
KIF2A	O
inhibited	O
cell	O
proliferation	O
and	O
induced	O
apoptosis	O
in	O
lung	B-Phenotype
adenocarcinoma	E-Phenotype
(	O
LUAD	S-Phenotype
)	O
cells	O
.	O

Our	O
results	O
highlight	O
the	O
impact	O
of	O
age	O
,	O
BMI	O
and	O
HbA1c	O
on	O
epigenetic	O
variation	O
of	O
candidate	O
genes	O
for	O
obesity	S-Phenotype
,	O
type	B-Phenotype
2	I-Phenotype
diabetes	E-Phenotype
and	O
cancer	S-Phenotype
in	O
human	O
adipose	O
tissue	O
.	O

Here	O
,	O
we	O
found	O
that	O
15	O
-	O
PGDH	O
expression	O
was	O
inversely	O
correlated	O
with	O
ALDH1	O
,	O
an	O
important	O
cancer	S-Phenotype
stem	O
cell	O
-	O
associated	O
marker	O
indicative	O
of	O
poor	O
prognosis	O
in	O
humans	O
.	O

All	O
intraductal	B-Phenotype
tubulopapillary	I-Phenotype
neoplasms	E-Phenotype
revealed	O
the	O
characteristic	O
histologic	O
(	O
cellular	O
intraductal	O
nodules	O
of	O
back	O
-	O
to	O
-	O
back	O
tubular	O
glands	O
lined	O
by	O
predominantly	O
cuboidal	O
cells	O
with	O
atypical	O
nuclei	O
and	O
no	O
obvious	O
intracellular	O
mucin	O
)	O
and	O
immunohistochemical	O
(	O
immunolabeled	O
with	O
MUC1	O
and	O
MUC6	O
but	O
were	O
negative	O
for	O
MUC2	O
and	O
MUC5AC	O
)	O
features	O
.	O

Our	O
exome	O
analysis	O
indicated	O
the	O
proband	O
as	O
a	O
compound	O
heterozygote	O
for	O
two	O
missense	O
variants	O
in	O
the	O
TECPR2	O
gene	O
according	O
to	O
a	O
recessive	O
mode	B-Phenotype
of	I-Phenotype
inheritance	E-Phenotype
.	O

Congenital	O
disorders	O
of	O
glycosylation	O
,	O
including	O
SLC35A3	O
-	O
CDG	O
,	O
can	O
present	O
as	O
a	O
wide	O
phenotypic	O
spectrum	O
,	O
including	O
skeletal	B-Phenotype
dysplasia	E-Phenotype
.	O

Therefore	O
,	O
our	O
findings	O
established	O
a	O
tumor	S-Phenotype
-	O
suppressive	O
role	O
for	O
miR	O
-	O
873	O
in	O
the	O
inhibition	O
of	O
CRC	O
progression	O
,	O
which	O
may	O
be	O
employed	O
as	O
a	O
novel	O
prognostic	O
marker	O
and	O
as	O
an	O
effective	O
therapeutic	O
target	O
for	O
CRC	O

Together	O
,	O
these	O
observations	O
suggest	O
that	O
Zyxin	O
promotes	O
colon	B-Phenotype
cancer	E-Phenotype
tumorigenesis	S-Phenotype
in	O
a	O
mitotic	O
-	O
phosphorylation	O
-	O
dependent	O
manner	O
and	O
through	O
CDK8	O
-	O
mediated	O
YAP	O
activation	O

Bidirectional	O
sequencing	O
of	O
exons	O
of	O
ATAD1	O
,	O
the	O
gene	O
encoding	O
Thorase	O
,	O
in	O
a	O
cohort	O
of	O
patients	O
with	O
schizophrenia	S-Phenotype
and	O
healthy	O
controls	O
revealed	O
rare	O
Thorase	O
variants	O
.	O

Despite	O
significant	O
progress	O
in	O
our	O
understanding	O
of	O
hereditary	B-Phenotype
neurodegenerative	I-Phenotype
diseases	E-Phenotype
,	O
the	O
list	O
of	O
genes	O
associated	O
with	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
dementia	E-Phenotype
is	O
not	O
yet	O
complete	O
.	O

Serendipitously	O
,	O
we	O
found	O
that	O
overexpression	O
of	O
Twist1	O
in	O
mouse	O
muscle	O
progenitor	O
cells	O
,	O
either	O
constitutively	O
during	O
development	O
or	O
inducibly	O
in	O
adult	O
animals	O
,	O
caused	O
severe	O
muscle	B-Phenotype
atrophy	E-Phenotype
with	O
features	O
reminiscent	O
of	O
cachexia	S-Phenotype
.	O

Since	O
it	O
is	O
known	O
that	O
the	O
native	O
protein	O
,	O
BMP	O
-	O
9	O
,	O
can	O
act	O
in	O
synergy	O
with	O
other	O
growth	O
factors	O
in	O
the	O
context	O
of	O
AD	O
,	O
here	O
we	O
study	O
the	O
potential	O
synergistic	O
effect	O
of	O
various	O
combinations	O
of	O
SpBMP	O
-	O
9	O
with	O
bFGF	O
,	O
EGF	O
,	O
IGF	O
-	O
2	O
or	O
NGF	O
on	O
the	O
cholinergic	O
differentiation	O
of	O
human	O
neuroblastoma	S-Phenotype
cells	O
SH	O
-	O
SY5Y	O
.	O

These	O
results	O
reveal	O
that	O
the	O
severity	O
of	O
NDE1	O
-	O
associated	O
microcephaly	S-Phenotype
results	O
not	O
from	O
defects	O
in	O
mitosis	O
,	O
but	O
rather	O
the	O
inability	O
of	O
neural	O
progenitors	O
to	O
ever	O
reach	O
this	O
stage	O

Human	O
placenta	O
-	O
derived	O
mesenchymal	O
stem	O
cell	O
(	O
hPMSC	O
)	O
transplantation	O
has	O
a	O
potential	O
to	O
restore	O
ovarian	O
dysfunction	O
associated	O
with	O
premature	B-Phenotype
ovarian	I-Phenotype
failure	E-Phenotype
(	O
POF	S-Phenotype
)	O
,	O
while	O
the	O
exact	O
function	O
of	O
the	O
Treg	O
cells	O
in	O
the	O
transplantation	O
still	O
needs	O
to	O
be	O
further	O
investigated	O
.	O

The	O
Cripto	O
-	O
1	O
(	O
CR	O
-	O
1	O
)	O
derived	O
EGF	O
-	O
CFC	O
family	O
was	O
overexpressed	O
in	O
tumor	S-Phenotype
development	O
enhancing	O
proliferation	O
,	O
epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
and	O
migration	O
of	O
tumor	S-Phenotype
cells	O
.	O

cDNA	O
-	O
encoded	O
FLAG	O
-	O
tagged	O
human	O
wildtype	O
ATP6V0A2	O
(	O
lia	O
/	O
i2	O
)	O
and	O
ATP6V0A4	O
(	O
lia	O
/	O
i4	O
)	O
subunits	O
and	O
their	O
mutants	O
,	O
lia	O
/	O
i2supP405L	O
/	O
sup	O
(	O
causing	O
cutis	B-Phenotype
laxa	E-Phenotype
)	O
,	O
and	O
lia	O
/	O
i4supR449H	O
/	O
sup	O
and	O
lia	O
/	O
i4supG820R	O
/	O
sup	O
(	O
causing	O
renal	B-Phenotype
tubular	I-Phenotype
acidosis	E-Phenotype
,	O
dRTA	O
)	O
,	O
were	O
transiently	O
expressed	O
in	O
HEK	O
293	O
cells	O
.	O

Expression	O
levels	O
of	O
miR	O
-	O
145	O
-	O
5p	O
and	O
miR	O
-	O
145	O
-	O
3p	O
were	O
markedly	O
reduced	O
in	O
cancer	S-Phenotype
tissues	O
,	O
and	O
ectopic	O
expression	O
of	O
these	O
miRNAs	O
inhibited	O
cancer	S-Phenotype
cell	O
aggressiveness	S-Phenotype
,	O
suggesting	O
that	O
both	O
miR	O
-	O
145	O
-	O
3p	O
as	O
well	O
as	O
miR	O
-	O
145	O
-	O
5p	O
acted	O
as	O
antitumor	O
miRNAs	S-Phenotype
.	O

Some	O
of	O
these	O
differences	O
(	O
CRYBB2	O
and	O
PSPH	O
)	O
may	O
exist	O
from	O
the	O
earliest	O
stages	O
of	O
tumor	S-Phenotype
development	O
,	O
or	O
may	O
even	O
precede	O
malignancy	O

However	O
,	O
BMP	O
-	O
9	O
is	O
a	O
big	O
protein	O
expensive	O
to	O
produce	O
that	O
can	O
hardly	O
access	O
the	O
central	S-Phenotype
nervous	O
system	O
.	O

However	O
,	O
the	O
functional	O
role	O
of	O
NSUN2	O
,	O
mechanism	O
of	O
NSUN2	O
overexpression	O
and	O
its	O
association	O
with	O
clinicopathologic	O
features	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
remain	O
unclear	O
.	O

In	O
conclusion	O
,	O
our	O
research	O
results	O
strongly	O
recommend	O
combination	O
analysis	O
of	O
cytoplasmic	O
and	O
nuclear	O
girdin	O
for	O
a	O
precise	O
prognostic	O
prediction	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

We	O
herein	O
report	O
an	O
infant	O
with	O
feeding	B-Phenotype
difficulty	E-Phenotype
,	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
hypotonia	S-Phenotype
,	O
and	O
dysmorphic	O
features	O
including	O
small	B-Phenotype
palpebral	I-Phenotype
fissures	E-Phenotype
,	O
telecanthus	S-Phenotype
,	O
sparse	B-Phenotype
hair	E-Phenotype
and	O
eyebrow	S-Phenotype
,	O
cup	B-Phenotype
-	I-Phenotype
shaped	I-Phenotype
ears	E-Phenotype
,	O
and	O
clinodactyly	S-Phenotype
.	O

Immunohistochemically	O
,	O
the	O
tumor	S-Phenotype
cells	O
were	O
positive	O
for	O
S	O
-	O
100	O
protein	O
(	O
4	O
/	O
4	O
)	O
,	O
SOX10	O
(	O
3	O
/	O
4	O
)	O
,	O
Langerin	O
/	O
CD207	O
(	O
4	O
/	O
4	O
)	O
,	O
CD1a	O
(	O
3	O
/	O
4	O
)	O
,	O
CD68	O
(	O
3	O
/	O
4	O
)	O
,	O
CD163	O
(	O
3	O
/	O
4	O
)	O
,	O
and	O
INI	O
-	O
1	O
(	O
4	O
/	O
4	O
)	O
.	O

A	O
previous	O
study	O
recently	O
described	O
two	O
consanguineous	O
families	O
in	O
which	O
homozygous	O
mutations	O
of	O
MCM9	O
were	O
responsible	O
for	O
POI	O
and	O
short	B-Phenotype
stature	E-Phenotype
.	O

We	O
aimed	O
to	O
identify	O
the	O
genetic	O
cause	O
of	O
the	O
devastating	O
neurodegenerative	B-Phenotype
disease	E-Phenotype
amyotrophic	B-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
(	O
ALS	S-Phenotype
)	O
in	O
a	O
German	O
family	O
with	O
two	O
affected	O
individuals	O
,	O
and	O
to	O
assess	O
the	O
prevalence	O
of	O
variants	O
in	O
the	O
identified	O
risk	O
gene	O
,	O
FIG4	O
,	O
in	O
a	O
central	O
European	O
ALS	O
cohort	O
.	O

Silencing	O
of	O
PTPN3	O
restored	O
sensitivity	O
to	O
cisplatin	O
and	O
doxorubicin	O
in	O
resistant	O
ovarian	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

The	O
number	O
of	O
PtdIns	O
(	O
3,4,5	O
)	O
Psub3	O
/	O
sub	O
/	O
pAKT	O
/	O
pGSK3β	O
-	O
positive	O
cilia	O
was	O
increased	O
in	O
cultured	O
Inpp5e	O
-	O
null	O
tumor	S-Phenotype
cells	O
relative	O
to	O
controls	O
.	O

Our	O
results	O
demonstrated	O
that	O
SelM	O
may	O
have	O
an	O
important	O
role	O
in	O
protecting	O
against	O
oxidative	O
damage	O
in	O
the	O
brain	O
of	O
chicken	O
,	O
which	O
might	O
shed	O
light	O
on	O
the	O
role	O
of	O
SelM	O
in	O
human	O
neurodegenerative	B-Phenotype
disease	E-Phenotype
.	O

In	O
fact	O
,	O
abnormal	O
activation	O
of	O
liGFI1B	O
/	O
i	O
and	O
liGFI1	O
/	O
i	O
has	O
been	O
related	O
to	O
human	O
medulloblastoma	S-Phenotype
and	O
is	O
also	O
likely	O
to	O
be	O
relevant	O
in	O
blood	O
malignancies	O
.	O

We	O
hope	O
that	O
our	O
study	O
will	O
stimulate	O
further	O
studies	O
and	O
a	O
new	O
targeted	O
therapy	O
and	O
early	O
medical	O
intervention	O
for	O
YAP	O
/	O
TAZ	O
could	O
be	O
a	O
useful	O
option	O
for	O
breast	B-Phenotype
cancer	E-Phenotype
cases	O
complicated	O
with	O
LKB1	O
deficiency	O

Restitution	O
of	O
ZBTB18	O
expression	O
reverses	O
the	O
phenotype	O
and	O
impairs	O
tumor	S-Phenotype
-	O
forming	O
ability	O
.	O

Results	O
Clinical	O
evaluations	O
suggested	O
autosomal	B-Phenotype
recessive	E-Phenotype
nonsyndromic	O
HL	O
.	O

Mutations	O
in	O
three	O
subunits	O
(	O
DRC1	O
,	O
DRC2	O
/	O
CCDC65	O
,	O
DRC4	O
/	O
GAS8	O
)	O
have	O
been	O
linked	O
to	O
defects	O
in	O
ciliary	O
motility	O
in	O
humans	O
and	O
lead	O
to	O
a	O
ciliopathy	O
known	O
as	O
primary	B-Phenotype
ciliary	I-Phenotype
dyskinesia	E-Phenotype
(	O
PCD	S-Phenotype
)	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
results	O
obtained	O
from	O
our	O
previously	O
published	O
methylation	O
array	O
were	O
analyzed	O
and	O
10	O
candidate	O
genes	O
involved	O
in	O
DNA	O
repair	O
[	O
protein	O
phosphatase	O
4	O
catalytic	O
subunit	O
(	O
PPP4C	O
)	O
]	O
,	O
apoptosis	O
[	O
runt	O
related	O
transcription	O
factor	O
3	O
(	O
RUNX3	O
)	O
,	O
interferon	O
regulatory	O
factor	O
4	O
(	O
IRF4	O
)	O
,	O
ubiquitin	O
C	O
-	O
terminal	O
hydrolase	O
L1	O
(	O
UCHL1	O
)	O
and	O
tumor	S-Phenotype
protein	O
p53	O
inducible	O
protein	O
3	O
(	O
TP53I3	O
)	O
]	O
,	O
cell	O
proliferation	O
[	O
cyclin	O
D2	O
(	O
CCND2	O
)	O
and	O
Ras	O
association	O
domain	O
family	O
member	O
1	O
(	O
RASSF1	O
)	O
]	O
,	O
drug	O
metabolism	O
[	O
aldehyde	O
dehydrogenase	O
1	O
family	O
member	O
A3	O
(	O
ALDH1A3	O
)	O
and	O
solute	O
carrier	O
family	O
29	O
member	O
1	O
(	O
SLC29A1	O
)	O
]	O
and	O
angiogenesis	O
[	O
human	O
immunodeficiency	S-Phenotype
virus	O
-	O
1	O
tat	O
interactive	O
protein	O
2	O
(	O
HTATIP2	O
)	O
]	O
were	O
selected	O
for	O
quantification	O
of	O
their	O
methylation	O
levels	O
in	O
54	O
CCA	O
and	O
19	O
adjacent	O
normal	O
tissues	O
using	O
methylation	O
-	O
sensitive	O
high	O
-	O
resolution	O
melting	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
assess	O
the	O
prevalence	O
of	O
central	S-Phenotype
neurological	O
manifestations	O
in	O
ANT1	O
mitochondrial	O
disease	O

First	O
-	O
line	O
IVF	O
is	O
a	O
good	O
option	O
in	O
case	O
of	O
no	O
operated	O
deeply	O
infiltrating	O
endometriosis	S-Phenotype
associated	O
infertility	S-Phenotype
.	O

We	O
previously	O
demonstrated	O
that	O
phospho	O
-	O
mTOR	O
expression	O
is	O
associated	O
with	O
tumor	S-Phenotype
aggressiveness	S-Phenotype
,	O
therapy	O
resistance	O
,	O
and	O
lower	O
mRNA	O
expression	O
of	O
SLC5A5	O
in	O
papillary	B-Phenotype
thyroid	I-Phenotype
carcinoma	E-Phenotype
(	O
PTC	S-Phenotype
)	O
,	O
while	O
phospho	O
-	O
S6	O
(	O
mTORC1	O
effector	O
)	O
expression	O
was	O
associated	O
with	O
less	O
aggressive	O
clinicopathological	O
features	O
.	O

In	O
the	O
largest	O
study	O
of	O
hybrid	O
LGFMS	O
-	O
SEF	O
tumors	S-Phenotype
to	O
date	O
,	O
all	O
cases	O
exhibited	O
FUS	O
rearrangements	O
,	O
a	O
similar	O
genetic	O
profile	O
to	O
LGFMS	O
.	O

This	O
study	O
determined	O
the	O
association	O
of	O
ERCC1	O
expression	O
with	O
survivin	O
expression	O
,	O
clinicopathological	O
characteristics	O
,	O
and	O
survival	O
of	O
esophageal	B-Phenotype
squamous	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
ESCC	S-Phenotype
)	O
patients	O
after	O
postoperative	O
concurrent	O
chemoradiotherapy.Tissue	O
specimens	O
from	O
102	O
resected	O
ESCC	O
patients	O
were	O
acquired	O
for	O
immunohistochemical	O
analysis	O
of	O
ERCC1	O
and	O
survivin	O
protein	O
expression.ERCC1	O
expression	O
was	O
detected	O
in	O
62.7	O
%	O
of	O
ESCC	O
tissues	O
and	O
in	O
9.8	O
%	O
of	O
normal	O
squamous	O
epithelium	O
tissues	O
(	O
P	O
AAAA	O
.01	O
)	O
,	O
while	O
survivin	O
expression	O
was	O
detected	O
in	O
60.8	O
%	O
of	O
ESCC	O
tissues	O
and	O
in	O
19.6	O
%	O
of	O
normal	O
squamous	O
epithelia	O
(	O
P	O
AAAA	O
.01	O
)	O
.	O

In	O
humans	O
,	O
liNF2	O
/	O
i	O
is	O
the	O
gene	O
responsible	O
for	O
the	O
disease	O
neurofibromatosis	S-Phenotype
type	O
II	O
,	O
which	O
results	O
in	O
the	O
development	O
of	O
brain	B-Phenotype
tumors	E-Phenotype
,	O
including	O
acoustic	B-Phenotype
neurinoma	E-Phenotype
and	O
meningioma	S-Phenotype
.	O

In	O
search	O
of	O
novel	O
germline	O
alterations	O
predisposing	O
to	O
tumors	S-Phenotype
,	O
in	O
particular	O
to	O
gliomas	S-Phenotype
,	O
we	O
studied	O
a	O
family	O
with	O
two	O
brothers	O
affected	O
by	O
anaplastic	B-Phenotype
gliomas	E-Phenotype
,	O
and	O
their	O
father	O
and	O
paternal	O
great	O
-	O
uncle	O
diagnosed	O
with	O
prostate	B-Phenotype
carcinoma	E-Phenotype
.	O

Likely	O
haploinsufficiency	O
of	O
one	O
or	O
several	O
of	O
the	O
19	O
genes	O
in	O
the	O
common	O
deleted	O
interval	O
(	O
ACTN1	O
,	O
DCAF5	O
,	O
EXD2	O
,	O
GALNTL1	O
,	O
ERH	O
,	O
SLC39A9	O
,	O
PLEKHD1	O
,	O
CCDC177	O
,	O
KIAA0247	O
,	O
LOC100289511	O
,	O
SRSF5	O
,	O
SLC10A1	O
,	O
SMOC1	O
,	O
SLC8A3	O
,	O
ADAM21P1	O
,	O
COX16	O
,	O
SYNJ2BP	O
,	O
SYNJ2BP	O
-	O
COX16	O
,	O
ADAM21	O
)	O
was	O
responsible	O
for	O
these	O
manifestations	O
,	O
but	O
apart	O
from	O
SMOC1	O
,	O
mutations	O
in	O
which	O
cause	O
autosomal	B-Phenotype
recessive	I-Phenotype
Waardenburg	I-Phenotype
anophthalmia	E-Phenotype
syndrome	O
,	O
and	O
ACTN1	O
,	O
mutations	O
in	O
which	O
are	O
associated	O
with	O
congenital	B-Phenotype
macrothrombocytopenia	E-Phenotype
,	O
no	O
disease	O
associations	O
have	O
so	O
far	O
been	O
reported	O
for	O
the	O
other	O
genes	O
.	O

Animal	O
models	O
of	O
viral	O
-	O
associated	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	O
)	O
disruption	O
and	O
experimental	O
cerebral	O
malaria	O
(	O
ECM	O
)	O
have	O
identified	O
perforin	O
as	O
critical	O
for	O
inducing	O
pathologic	O
central	S-Phenotype
nervous	O
system	O
CNS	O
vascular	O
permeability	O
.	O

In	O
A549	O
lung	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
which	O
endogenously	O
express	O
CXCR1	O
,	O
the	O
depletion	O
of	O
REEP5	O
and	O
REEP6	O
significantly	O
reduced	O
growth	O
and	O
invasion	O
by	O
downregulating	O
IL	O
-	O
8	O
-	O
stimulated	O
ERK	O
phosphorylation	O
,	O
actin	O
polymerization	O
and	O
the	O
expression	O
of	O
genes	O
related	O
to	O
metastasis	O
.	O

NKX2.5	O
-	O
R142C	O
is	O
a	O
mutation	O
that	O
was	O
reported	O
to	O
be	O
associated	O
with	O
atrial	B-Phenotype
septal	I-Phenotype
defect	E-Phenotype
(	O
ASD	S-Phenotype
)	O
and	O
atrioventricular	B-Phenotype
(	I-Phenotype
AV	I-Phenotype
)	I-Phenotype
block	E-Phenotype
in	O
13	O
-	O
patients	O
from	O
one	O
family	O
.	O

Biallelic	O
mutations	O
in	O
the	O
GPD1	O
gene	O
cause	O
a	O
rare	O
autosomal	B-Phenotype
recessive	E-Phenotype
inherited	O
disease	O
known	O
as	O
transient	B-Phenotype
infantile	I-Phenotype
hypertriglyceridemia	E-Phenotype
(	O
OMIM	O
#	O
614480	O
)	O
.	O

Interestingly	O
,	O
FIGNL1	O
is	O
recruited	O
to	O
sites	O
of	O
DNA	O
damage	O
in	O
a	O
manner	O
that	O
is	O
independent	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
2	O
,	O
early	O
onset	O
,	O
RAD51	O
,	O
and	O
probably	O
,	O
RAD51	O
paralogs	O
.	O

And	O
left	O
hallux	O
moved	O
involuntarily	O
toward	O
the	O
top	O
surface	O
of	O
the	O
foot	O
at	O
rest	O
,	O
that	O
is	O
dystonia	S-Phenotype
.	O

We	O
evaluated	O
MYO1A	O
variants	O
from	O
a	O
cohort	O
of	O
951	O
individuals	O
with	O
exome	O
sequencing	O
who	O
were	O
not	O
ascertained	O
for	O
hearing	B-Phenotype
loss	E-Phenotype
.	O

Here	O
,	O
we	O
show	O
that	O
fine	O
-	O
mapping	O
of	O
pancreatic	B-Phenotype
and	I-Phenotype
testicular	I-Phenotype
cancer	E-Phenotype
GWAS	O
within	O
one	O
of	O
these	O
loci	O
(	O
Region	O
2	O
in	O
CLPTM1L	O
)	O
focuses	O
the	O
signal	O
to	O
nine	O
highly	O
correlated	O
SNPs	O
.	O

Placental	O
mRNA	O
abundance	O
for	O
the	O
folate	O
receptor	O
alpha	O
(	O
liFOLR1	O
/	O
i	O
)	O
was	O
reduced	O
with	O
obesity	S-Phenotype
,	O
whilst	O
liDNMT1	O
/	O
i	O
was	O
increased	O
with	O
raised	O
BMI	O
,	O
responses	O
that	O
were	O
unaffected	O
by	O
GD	O
.	O

Surprisingly	O
,	O
we	O
detected	O
no	O
ADAM2	O
,	O
CALR3	O
and	O
SAGE1	O
in	O
the	O
67	O
lung	B-Phenotype
cancers	E-Phenotype
(	O
mainly	O
non	O
-	O
small	B-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
)	O
and	O
189	O
breast	B-Phenotype
cancers	E-Phenotype
,	O
while	O
MAGE	O
-	O
A	O
proteins	O
were	O
present	O
in	O
15	O
%	O
and	O
7	O
-	O
16	O
%	O
of	O
these	O
tumor	S-Phenotype
types	O
,	O
respectively	O
.	O

Here	O
,	O
we	O
assessed	O
the	O
effect	O
of	O
paired	O
tumor	S-Phenotype
-	O
associated	O
and	O
normal	O
lung	O
tissue	O
mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
on	O
the	O
growth	O
and	O
dissemination	O
of	O
primary	O
human	O
lung	O
carcinoma	S-Phenotype
cells	O
isolated	O
from	O
the	O
same	O
patients	O
.	O

The	O
authors	O
report	O
here	O
a	O
brief	O
summary	O
of	O
findings	O
from	O
12	O
lines	O
of	O
genetically	O
engineered	O
mice	O
that	O
presented	O
with	O
autosomal	B-Phenotype
recessive	I-Phenotype
congenital	I-Phenotype
hydrocephalus	E-Phenotype
.	O

The	O
SPG11	O
gene	O
was	O
first	O
analysed	O
,	O
revealing	O
homozygous	O
or	O
compound	O
heterozygous	O
mutations	O
in	O
30	O
/	O
97	O
(	O
30.9	O
%	O
)	O
of	O
probands	O
,	O
the	O
largest	O
SPG11	O
series	O
reported	O
to	O
date	O
,	O
and	O
by	O
far	O
the	O
most	O
common	O
cause	O
of	O
complex	O
spastic	B-Phenotype
paraplegia	E-Phenotype
in	O
the	O
UK	O
,	O
with	O
severe	O
and	O
progressive	O
clinical	O
features	O
and	O
other	O
neurological	O
manifestations	O
,	O
linked	O
with	O
magnetic	O
resonance	O
imaging	O
defects	O
.	O

GFAT1	O
was	O
identified	O
as	O
an	O
independent	O
prognosticator	O
for	O
OS	O
,	O
and	O
combining	O
GFAT1	O
expression	O
with	O
pTNM	O
stage	O
generated	O
a	O
predictive	O
nomogram	O
,	O
which	O
showed	O
better	O
prognostic	O
efficiency	O
for	O
OS	O
in	O
patients	O
with	O
pancreatic	B-Phenotype
cancer	E-Phenotype
.	O

Although	O
CHH	O
and	O
other	O
skeletal	B-Phenotype
dysplasias	E-Phenotype
caused	O
by	O
mutations	O
in	O
RMRP	O
or	O
POP1	O
are	O
commonly	O
cited	O
as	O
ribosomal	O
biogenesis	O
disorders	O
,	O
recent	O
studies	O
question	O
this	O
assumption	O
.	O

Missense	O
mutations	O
that	O
disrupt	O
the	O
RING	O
domain	O
of	O
the	O
tumor	S-Phenotype
suppressor	O
gene	O
BRCA1	O
lead	O
to	O
increased	O
risk	O
of	O
breast	B-Phenotype
and	I-Phenotype
ovarian	I-Phenotype
cancer	E-Phenotype
.	O

Our	O
findings	O
suggest	O
a	O
wide	O
allelic	O
heterogeneity	S-Phenotype
in	O
Mexican	O
MPSII	O
patients	O
;	O
DNA	O
microarray	O
analysis	O
contributes	O
to	O
further	O
delineation	O
of	O
the	O
resulting	O
phenotype	O
for	O
IDS	O
and	O
neighboring	O
loci	O
deletions	O

Moreover	O
,	O
we	O
found	O
ITGA3	O
expression	O
correlated	O
with	O
several	O
clinicopathological	O
features	O
,	O
including	O
tumor	S-Phenotype
size	O
,	O
lymph	O
node	O
metastasis	O
,	O
and	O
the	O
TNM	O
stage	O
.	O

Cold	B-Phenotype
-	I-Phenotype
induced	I-Phenotype
sweating	I-Phenotype
syndrome	E-Phenotype
(	O
CISS	S-Phenotype
)	O
is	O
a	O
rare	O
autosomal	B-Phenotype
recessive	E-Phenotype
disease	O
due	O
to	O
mutation	O
in	O
the	O
Cytokine	O
receptor	O
-	O
like	O
factor	O
1	O
(	O
CRLF1	O
)	O
.	O

Moreover	O
,	O
we	O
confirmed	O
that	O
knockdown	O
of	O
LDHA	O
could	O
inhibit	O
tumor	S-Phenotype
growth	O
in	O
vivo	O
.	O

X	B-Phenotype
-	I-Phenotype
inactive	I-Phenotype
specific	I-Phenotype
transcript	E-Phenotype
(	O
XIST	S-Phenotype
)	O
,	O
premature	B-Phenotype
ovarian	I-Phenotype
failure	I-Phenotype
1B	E-Phenotype
(	O
POF1B	S-Phenotype
)	O
and	O
calmin	S-Phenotype
(	O
CLMN	S-Phenotype
)	O
were	O
identified	O
in	O
the	O
DEmRNA	O
-	O
DElncRNA	O
co	O
-	O
expression	O
network	O
.	O

Ltd	O
)	O
,	O
a	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
(	O
VEGFR	O
-	O
2	O
)	O
tyrosine	O
kinase	O
inhibitor	O
,	O
has	O
been	O
proven	O
to	O
be	O
safe	O
and	O
to	O
significantly	O
prolong	O
survival	O
in	O
advanced	O
chemotherapy	O
-	O
refractory	O
gastric	B-Phenotype
cancer	E-Phenotype
.	O

On	O
the	O
other	O
hand	O
,	O
miR	O
-	O
34a	O
inhibitor	O
could	O
partly	O
counter	O
the	O
anticancer	O
effect	S-Phenotype
of	O
luteolin	O
.	O

In	O
the	O
present	O
study	O
,	O
a	O
differential	O
cytotoxicity	O
screen	O
of	O
hormone	O
-	O
resistant	O
prostate	B-Phenotype
cancer	E-Phenotype
LNCaP	O
-	O
hr	O
cells	O
and	O
the	O
parental	O
LNCaP	O
-	O
FGC	O
cells	O
against	O
normal	O
MRC5	O
fibroblast	O
cells	O
,	O
identified	O
a	O
small	O
molecule	O
compound	O
,	O
Aristeromycin	O
(	O
a	O
derivative	O
of	O
3	O
-	O
deazaneplanocin	O
A	O
(	O
DZNeP	O
)	O
)	O
.	O

Downregulation	O
of	O
α	O
-	O
actinin	O
-	O
1	O
in	O
E	O
-	O
cadherin	O
expressing	O
basal	O
-	O
like	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
demonstrate	O
that	O
α	O
-	O
actinin	O
-	O
1	O
-	O
assembled	O
actin	O
fibers	O
destabilize	O
E	O
-	O
cadherin	O
-	O
based	O
adhesions	O
.	O

In	O
addition	O
,	O
polymorphisms	O
in	O
apoptosis	O
-	O
related	O
genes	O
such	O
as	O
RNF7	O
,	O
TULP1	O
,	O
and	O
MERTK	O
are	O
associated	O
with	O
fibrosis	O
progression	O
,	O
and	O
DEPDC5	O
and	O
MICA	O
variants	O
are	O
associated	O
with	O
HCV	O
-	O
related	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
.	O

PHARC	S-Phenotype
(	O
polyneuropathy	S-Phenotype
,	O
hearing	B-Phenotype
loss	E-Phenotype
,	O
ataxia	S-Phenotype
,	O
retinitis	B-Phenotype
pigmentosa	E-Phenotype
,	O
and	O
cataracts	S-Phenotype
)	O
is	O
a	O
recently	O
described	O
autosomal	B-Phenotype
-	I-Phenotype
recessive	I-Phenotype
neurodegenerative	I-Phenotype
disease	E-Phenotype
caused	O
by	O
mutations	O
in	O
the	O
α	O
-	O
β	O
-	O
hydrolase	O
domain	O
-	O
containing	O
12	O
gene	O
(	O
ABHD12	O
)	O
.	O

Moreover	O
,	O
the	O
expression	O
levels	O
of	O
these	O
miRNAs	O
were	O
downregulated	O
in	O
cancer	S-Phenotype
cells	O
that	O
had	O
originated	O
from	O
these	O
tissues	O
,	O
resulting	O
in	O
PKM2	O
dominance	O
.	O

Furthermore	O
,	O
targeted	O
knockout	O
of	O
Slc7a14	O
in	O
mice	O
results	O
in	O
retinal	B-Phenotype
degeneration	E-Phenotype
with	O
abnormal	B-Phenotype
ERG	E-Phenotype
response	O
.	O

Our	O
data	O
indicate	O
that	O
5	O
-	O
hmC	O
might	O
serve	O
as	O
a	O
metastasis	O
marker	O
for	O
cancer	S-Phenotype
and	O
that	O
the	O
decreased	O
expression	O
of	O
LSH	O
is	O
likely	O
one	O
of	O
the	O
mechanisms	O
of	O
genome	O
instability	O
underlying	O
5	O
-	O
hmC	O
loss	O
in	O
cancer	S-Phenotype

Flii	O
was	O
highly	O
expressed	O
in	O
human	O
SCC	O
biopsies	O
particularly	O
by	O
the	O
invading	O
cells	O
at	O
the	O
tumor	S-Phenotype
edge	O
.	O

Type	O
III	O
(	O
simple	O
type	O
)	O
patients	O
with	O
SETBP1	O
alteration	O
show	O
their	O
major	O
symptom	O
is	O
development	O
delay	O
,	O
in	O
which	O
expressive	B-Phenotype
language	I-Phenotype
delay	E-Phenotype
is	O
the	O
most	O
striking	O
feature	O
.	O

In	O
an	O
unbiased	O
BioID	O
screen	O
for	O
Plk4	O
interactors	O
,	O
we	O
identified	O
members	O
of	O
the	O
Arp2	O
/	O
3	O
complex	O
and	O
confirmed	O
a	O
physical	O
and	O
functional	O
interaction	O
between	O
Plk4	O
and	O
Arp2	O
in	O
mediating	O
Plk4	O
-	O
driven	O
cancer	S-Phenotype
cell	O
movement	O
.	O

Multivariable	O
logistic	O
regression	O
analysis	O
with	O
adjustment	O
for	O
age	O
,	O
sex	O
and	O
the	O
prevalence	O
of	O
hypertension	S-Phenotype
revealed	O
that	O
rs138533962	O
of	O
STYK1	O
(	O
PAAAA1.0x10	O
-	O
23	O
;	O
odds	O
ratio	O
,	O
111.3	O
)	O
was	O
significantly	O
(	O
PAAAA2.60x10	O
-	O
4	O
)	O
associated	O
with	O
ICH	O
and	O
that	O
rs117564807	O
of	O
COL17A1	O
(	O
P=0.0009	O
;	O
odds	O
ratio	O
,	O
2.23x10	O
-	O
8	O
)	O
was	O
significantly	O
(	O
PAAAA0.0010	O
)	O
associated	O
with	O
SAH	O
.	O

T	B-Phenotype
cell	I-Phenotype
-	I-Phenotype
related	I-Phenotype
encephalopathy	E-Phenotype
(	O
CRES	S-Phenotype
)	O
syndrome	O
may	O
occur	O
concomitantly	O
.	O

The	O
ceRNA	O
network	O
indicated	O
that	O
lncRNA	O
MIR194	O
-	O
2HG	O
,	O
AATBC	O
and	O
circRNA	O
PGM5	O
could	O
harbor	O
bladder	B-Phenotype
cancer	E-Phenotype
-	O
related	O
microRNA	O
(	O
miRNA	O
)	O
recognition	O
elements	O
.	O

Hennekam	B-Phenotype
lymphangiectasia	I-Phenotype
-	I-Phenotype
lymphedema	E-Phenotype
syndrome	O
is	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
disorder	O
,	O
with	O
25	O
%	O
of	O
patients	O
having	O
mutations	O
in	O
CCBE1	O
.	O

Previously	O
,	O
a	O
homozygous	O
missense	O
mutation	O
in	O
THOC6	O
in	O
the	O
Hutterite	O
population	O
was	O
reported	O
in	O
association	O
with	O
syndromic	O
intellectual	B-Phenotype
disability	E-Phenotype
.	O

CCDC8	O
expression	O
was	O
closely	O
related	O
to	O
tumor	S-Phenotype
differentiation	O
(	O
P=.039	O
)	O
,	O
tumor	S-Phenotype
-	O
node	O
-	O
metastasis	O
stage	O
(	O
P=.009	O
)	O
,	O
lymph	O
node	O
metastasis	O
(	O
P=.038	O
)	O
,	O
and	O
prognosis	O
(	O
P=.043	O
)	O
of	O
lung	B-Phenotype
cancer	E-Phenotype
.	O

The	O
pattern	O
of	O
inheritance	O
is	O
autosomal	B-Phenotype
recessive	E-Phenotype
,	O
and	O
a	O
causative	O
mutation	O
is	O
evident	O
in	O
the	O
CTDP1	O
gene	O
.	O

Further	O
,	O
lLc	O
(	O
LyP	O
-	O
1	O
)	O
modified	O
PEG	O
-	O
PLA	O
micelles	O
displayed	O
much	O
higher	O
in	O
vivo	O
distribution	O
in	O
brain	B-Phenotype
metastatic	I-Phenotype
tumor	E-Phenotype
than	O
lDc	O
(	O
LyP	O
-	O
1	O
)	O
.	O

This	O
indicates	O
that	O
dopamine	O
-	O
mediated	O
synaptic	O
remodeling	O
and	O
plasticity	O
is	O
independent	O
of	O
dopamine	O
innervation	O
during	O
SPN	O
development	O
and	O
that	O
Pitx3	O
-	O
/	O
-	O
mice	O
are	O
a	O
good	O
model	O
because	O
they	O
develop	O
the	O
same	O
pathology	O
described	O
in	O
the	O
toxins	O
-	O
based	O
models	O
and	O
in	O
human	O
postmortem	O
studies	O
of	O
advanced	O
PD.SIGNIFICANCE	O
STATEMENT	O
As	O
the	O
only	O
genetic	O
model	O
of	O
Parkinson	O
*	O
s	O
disease	O
(	O
PD	O
)	O
that	O
develops	O
dyskinesia	S-Phenotype
,	O
Pitx3	O
-	O
/	O
-	O
mice	O
reproduce	O
the	O
behavioral	O
effects	O
seen	O
in	O
humans	O
and	O
are	O
a	O
good	O
system	O
for	O
studying	O
dopamine	O
-	O
induced	O
synaptic	O
remodeling	O
.	O

Here	O
,	O
we	O
show	O
in	O
colorectal	B-Phenotype
cancer	E-Phenotype
that	O
increased	O
expression	O
of	O
ZNF148	O
,	O
the	O
gene	O
coding	O
for	O
transcription	O
factor	O
ZBP	O
-	O
89	O
,	O
correlated	O
with	O
reduced	O
patient	O
survival	O
.	O

Our	O
results	O
indicate	O
that	O
gene	O
-	O
based	O
meta	O
-	O
analysis	O
of	O
GWAS	O
provides	O
a	O
useful	O
strategy	O
to	O
find	O
loci	O
of	O
interest	O
that	O
were	O
not	O
identified	O
in	O
standard	O
single	O
-	O
marker	O
analyses	O
due	O
to	O
high	O
allelic	O
heterogeneity	S-Phenotype
.	O

We	O
found	O
miR	O
-	O
4326	O
targets	O
tumor	S-Phenotype
suppressor	O
adenomatous	O
polyposis	O
coli	O
2	O
(	O
APC2	O
)	O
,	O
which	O
is	O
a	O
negative	O
regulator	O
of	O
Wnt	O
pathway	O
,	O
by	O
binding	O
to	O
the	O
3	O
*	O
UTR	O
of	O
APC2	O
.	O

We	O
found	O
that	O
the	O
human	O
colorectal	B-Phenotype
cancer	E-Phenotype
cell	O
line	O
,	O
HCT	O
-	O
116	O
,	O
displayed	O
reduced	O
expression	O
of	O
Raf1	O
-	O
tr	O
,	O
and	O
reintroduction	O
of	O
Raf1	O
-	O
tr	O
sensitized	O
the	O
cells	O
to	O
bleomycin	O
-	O
induced	O
apoptosis	O
.	O

Candidate	O
markers	O
were	O
further	O
characterized	O
for	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
responses	O
to	O
the	O
BET	O
inhibitor	O
ABBV	O
-	O
075	O
in	O
vitro	O
and	O
in	O
vivo	O
HEXIM1	O
was	O
found	O
to	O
be	O
the	O
only	O
gene	O
that	O
exhibited	O
robust	O
and	O
consistent	O
modulation	O
by	O
BET	O
inhibitors	O
across	O
multiple	O
cancer	S-Phenotype
indications	O
and	O
surrogate	O
tissues	O
.	O

Concurrently	O
,	O
CXCL1	O
displays	O
a	O
specific	O
microRNA	O
(	O
miR	O
)	O
upregulated	O
by	O
the	O
prototypical	O
colon	B-Phenotype
cancer	E-Phenotype
onco	O
-	O
miR	O
miR	O
-	O
105	O
.	O

Patients	O
did	O
not	O
present	O
with	O
visual	B-Phenotype
impairment	E-Phenotype
as	O
observed	O
in	O
a	O
previously	O
reported	O
SPG57	O
family	O
(	O
c.316CAAAAT	O
(	O
p.	O
(	O
Arg106Cys	O
)	O
)	O
in	O
coiled	O
-	O
coil	O
domain	O
)	O
,	O
suggesting	O
unique	O
contributions	O
of	O
the	O
PB1	O
and	O
coiled	O
-	O
coil	O
domains	O
in	O
TFG	O
complex	O
formation	O
/	O
function	O
and	O
a	O
possible	O
phenotype	O
correlation	O
to	O
variant	O
location	O
.	O

The	O
F	O
-	O
box	O
protein	O
FBXO31	O
is	O
a	O
tumor	S-Phenotype
suppressor	O
that	O
is	O
encoded	O
in	O
16q24.3	O
,	O
for	O
which	O
there	O
is	O
loss	O
of	O
heterozygosity	O
in	O
various	O
solid	O
tumors	S-Phenotype
.	O

As	O
a	O
result	O
,	O
14	O
SNPs	O
had	O
a	O
significant	O
odds	O
ratio	O
(	O
OR	O
)	O
for	O
lung	B-Phenotype
cancer	E-Phenotype
risk	O
with	O
P	O
FDR	O
AAAA	O
0.05	O
,	O
of	O
which	O
rs3115672	O
in	O
MSH5	O
(	O
OR	O
=	O
1.20	O
,	O
95	O
%	O
CI	O
=	O
1.14	O
-	O
1.27	O
)	O
and	O
rs114596632	O
in	O
GTF2H4	O
(	O
OR	O
=	O
1.19	O
,	O
95	O
%	O
CI	O
=	O
1.12	O
-	O
1.25	O
)	O
at	O
6q21.33	O
were	O
the	O
most	O
statistically	O
significant	O
(	O
P	O
combined	O
=	O
3.99×10	O
(	O
-	O
11	O
)	O
and	O
P	O
combined	O
=	O
5.40×10	O
(	O
-	O
10	O
)	O
,	O
respectively	O
)	O
.	O

We	O
used	O
CHi	O
-	O
C	O
to	O
investigate	O
long	O
-	O
range	O
interactions	O
at	O
three	O
breast	B-Phenotype
cancer	E-Phenotype
gene	O
deserts	O
mapping	O
to	O
2q35	O
,	O
8q24.21	O
,	O
and	O
9q31.2	O
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
prognostic	O
significance	O
of	O
NDRG1	O
and	O
/	O
or	O
c	O
-	O
Myc	O
expression	O
in	O
lung	B-Phenotype
adenocarcinoma	E-Phenotype
using	O
immunohistochemistry	O
with	O
a	O
tissue	O
microarray	O
.	O

These	O
observations	O
are	O
relevant	O
to	O
human	O
patients	O
,	O
since	O
DLBCLs	O
with	O
high	O
AICDA	O
expression	O
manifest	O
increased	O
methylation	O
heterogeneity	S-Phenotype
vs.	O
AICDA	O
-	O
low	O
DLBCLs	O
.	O

Evidence	O
is	O
accumulating	O
to	O
suggest	O
that	O
mutations	O
in	O
the	O
Ankyrin	O
and	O
SOCS	O
Box	O
-	O
containing	O
protein	O
-	O
10	O
(	O
ASB10	O
)	O
gene	O
are	O
associated	O
with	O
glaucoma	S-Phenotype
.	O

Our	O
results	O
revealed	O
that	O
in	O
both	O
tissue	O
samples	O
and	O
cell	O
lines	O
(	O
particularly	O
in	O
BxPC	O
-	O
3	O
and	O
PANC	O
-	O
1	O
cells	O
)	O
of	O
pancreatic	B-Phenotype
cancer	E-Phenotype
,	O
KLF9	O
exhibited	O
relatively	O
lower	O
expression	O
.	O

Synovial	B-Phenotype
sarcoma	E-Phenotype
(	O
SS	S-Phenotype
)	O
is	O
genetically	O
characterized	O
by	O
chromosomal	O
translocation	O
,	O
which	O
generates	O
SYT	O
-	O
SSX	O
fusion	O
transcripts	O
.	O

The	O
DACT1	O
c.1256GAAAAA	O
;	O
p.Trp419sup	O
*	O
/	O
sup	O
variant	O
segregated	O
appropriately	O
in	O
the	O
family	O
consistent	O
with	O
an	O
autosomal	O
dominant	O
mode	B-Phenotype
of	I-Phenotype
inheritance	E-Phenotype
.	O

Initial	O
antitumoral	O
responses	S-Phenotype
are	O
often	O
seen	O
,	O
but	O
drug	O
-	O
resistant	O
clones	O
with	O
reactivation	O
of	O
the	O
MEK	O
-	O
ERK	O
pathway	O
soon	O
appear	O
.	O

However	O
,	O
the	O
role	O
of	O
liRTEL1	O
/	O
i	O
mutations	O
in	O
other	O
bone	B-Phenotype
marrow	I-Phenotype
failure	E-Phenotype
(	O
BMF	S-Phenotype
)	O
syndromes	O
and	O
myeloid	B-Phenotype
neoplasms	E-Phenotype
,	O
and	O
the	O
contribution	O
of	O
monoallelic	O
liRTEL1	O
/	O
i	O
mutations	O
to	O
disease	O
development	O
are	O
not	O
well	O
defined	O
.	O

Amyotrophic	B-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
(	O
ALS	S-Phenotype
)	O
and	O
frontotemporal	B-Phenotype
dementia	E-Phenotype
(	O
FTD	S-Phenotype
)	O
are	O
neurodegenerative	B-Phenotype
diseases	E-Phenotype
that	O
overlap	O
in	O
their	O
clinical	O
presentation	O
,	O
pathology	O
and	O
genetics	O
,	O
and	O
likely	O
represent	O
a	O
spectrum	O
of	O
one	O
underlying	O
disease	O
.	O

In	O
the	O
third	O
family	O
,	O
POD	O
was	O
observed	O
in	O
father	O
and	O
child	O
with	O
early	O
onset	O
cone	O
-	O
rod	O
dystrophy	O
and	O
a	O
novel	O
autosomal	B-Phenotype
recessive	E-Phenotype
p.	O
(	O
W31	O
*	O
)	O
homozygous	O
mutation	O
in	O
ABCA4	O
.	O

Thus	O
,	O
research	O
directed	O
at	O
expanding	O
our	O
current	O
understanding	O
of	O
transcriptional	O
corepressors	O
could	O
impact	O
the	O
future	O
development	O
of	O
new	O
cancer	S-Phenotype
diagnostics	O
,	O
prognostics	O
,	O
and	O
therapies	O
.	O

These	O
studies	O
therefore	O
suggest	O
that	O
Flii	O
enhances	O
SCC	O
tumor	S-Phenotype
progression	O
by	O
decreasing	O
apoptosis	O
and	O
enhancing	O
tumor	S-Phenotype
cell	O
invasion	O
.	O

The	O
primary	O
endpoint	O
is	O
the	O
rate	O
of	O
pathological	O
complete	O
response	O
,	O
defined	O
as	O
the	O
absence	O
of	O
invasive	O
and	O
intraductal	O
tumor	S-Phenotype
cells	O
in	O
the	O
breast	O
at	O
surgery	O
,	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
with	O
HSD17B4	O
hypermethylation	O
.	O

Our	O
study	O
indicates	O
ER	O
stress	O
-	O
inducing	O
variants	O
in	O
CPB1	O
and	O
CPA1	O
are	O
associated	O
with	O
pancreatic	B-Phenotype
cancer	E-Phenotype
susceptibility	O
and	O
implicate	O
ER	O
stress	O
in	O
pancreatic	O
acinar	O
cells	O
in	O
pancreatic	B-Phenotype
cancer	E-Phenotype
development	O

CCBE1	O
and	O
LYVE1	O
expression	O
was	O
assessed	O
in	O
samples	O
from	O
normal	O
and	O
tumor	S-Phenotype
tissue	O
using	O
polymerase	O
chain	O
reaction	O
,	O
western	O
blot	O
analysis	O
and	O
immunohistochemistry	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
potential	O
for	O
genetic	O
susceptibility	O
to	O
schizophrenia	S-Phenotype
of	O
a	O
three	O
-	O
gene	O
cluster	O
region	O
,	O
AS3MT	O
-	O
CNNM2	O
-	O
NT5C2	O
.	O

In	O
mice	O
,	O
Sobp	O
(	O
also	O
known	O
as	O
Jxc1	O
)	O
is	O
critical	O
for	O
patterning	O
of	O
the	O
organ	O
of	O
Corti	O
;	O
one	O
of	O
our	O
patients	O
has	O
a	O
subclinical	B-Phenotype
cochlear	I-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
but	O
no	O
gross	O
cochlear	O
abnormalities	O
.	O

The	O
patients	O
were	O
classified	O
according	O
to	O
the	O
presence	O
of	O
significant	O
coronary	B-Phenotype
atherosclerosis	E-Phenotype
(	O
CAS	S-Phenotype
)	O
and	O
history	O
of	O
myocardial	B-Phenotype
infarction	E-Phenotype
(	O
MI	S-Phenotype
)	O
.	O

To	O
investigate	O
this	O
mechanism	O
,	O
we	O
developed	O
a	O
novel	O
uterine	B-Phenotype
sarcoma	E-Phenotype
tissue	O
-	O
derived	O
orthotopic	O
and	O
metastatic	O
model	O
in	O
KSN	O
nude	O
mice	O
using	O
a	O
green	O
fluorescent	O
protein	O
stably	O
expressed	O
uterine	B-Phenotype
sarcoma	E-Phenotype
cell	O
line	O
,	O
MES	O
-	O
SA	O
.	O

Inductions	O
of	O
FosB	O
and	O
phospho	O
-	O
acetylated	O
histone	O
3	O
(	O
molecular	O
correlates	O
of	O
dyskinesia	S-Phenotype
)	O
were	O
potentiated	O
in	O
the	O
lesioned	O
striatum	O
of	O
TG	O
mice	O
compared	O
with	O
their	O
WT	O
littermates	O
.	O

Here	O
,	O
genome	O
-	O
wide	O
quantitative	O
functional	O
profiling	O
,	O
DDR	O
measurements	O
and	O
genetic	O
interaction	O
assays	O
in	O
Schizosaccharomyces	O
pombe	O
reveal	O
a	O
chromate	O
toxicogenomic	O
profile	O
that	O
closely	O
resembles	O
the	O
cancer	S-Phenotype
chemotherapeutic	O
drug	O
camptothecin	O
(	O
CPT	O
)	O
,	O
which	O
traps	O
Topoisomerase	O
1	O
(	O
Top1	O
)	O
-	O
DNA	O
covalent	O
complex	O
(	O
Top1cc	O
)	O
at	O
the	O
3	O
*	O
end	O
of	O
single	O
-	O
stand	O
breaks	O
(	O
SSBs	O
)	O
,	O
resulting	O
in	O
replication	O
fork	O
collapse	O
.	O

As	O
a	O
potential	O
target	O
for	O
cancer	S-Phenotype
treatment	O
,	O
the	O
C	O
-	O
Myc	O
high	O
expresses	O
abnormally	O
in	O
a	O
variety	O
of	O
solid	O
tumors	S-Phenotype
and	O
hematological	O
malignancies	O
in	O
humans	O
.	O

In	O
previous	O
reports	O
,	O
a	O
total	O
of	O
6	O
cases	O
have	O
been	O
performed	O
esophagectomy	O
for	O
esophageal	B-Phenotype
cancer	E-Phenotype
with	O
ERF	O
in	O
Japan	O
.	O

Amyotrophic	B-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
(	O
ALS	S-Phenotype
)	O
is	O
a	O
devastating	O
adult	O
-	O
onset	O
progressive	O
neurodegenerative	B-Phenotype
disease	E-Phenotype
characterized	O
by	O
upper	O
and	O
lower	O
motoneuron	O
degeneration	O
.	O

Rather	O
,	O
we	O
observed	O
that	O
,	O
in	O
ADAM23	O
-	O
heterotypic	O
environments	O
,	O
ADAM23	O
-	O
negative	O
cells	O
promote	O
tumor	S-Phenotype
growth	O
and	O
metastasis	O
by	O
enhancing	O
the	O
proliferation	O
and	O
invasion	O
of	O
adjacent	O
A23	O
-	O
positive	O
cells	O
through	O
the	O
production	O
of	O
LGI4	O
(	O
Leucine	O
-	O
rich	O
Glioma	S-Phenotype
Inactivated	O
4	O
)	O
and	O
nitric	O
oxide	O
(	O
NO	O
)	O
.	O

In	O
addition	O
,	O
ectopic	O
CDK10	O
expression	O
inhibited	O
gastric	B-Phenotype
cancer	E-Phenotype
cell	O
proliferation	O
,	O
migration	O
and	O
invasion	O
,	O
while	O
knockdown	O
of	O
CDK10	O
promoted	O
these	O
phenotypes	O
.	O

Signiﬁcant	O
associations	O
between	O
Raf1	O
expression	O
and	O
invasion	O
and	O
metastasis	O
capability	O
in	O
lung	B-Phenotype
cancer	E-Phenotype
A549	O
and	O
H1299	O
cell	O
lines	O
were	O
identiﬁed	O
.	O

Immunohistochemically	O
,	O
tumor	S-Phenotype
cells	O
of	O
all	O
cases	O
were	O
positive	O
for	O
vimentin	O
(	O
100.0	O
%	O
,	O
60	O
/	O
60	O
)	O
,	O
STAT6	O
(	O
98.3	O
%	O
,	O
59	O
/	O
60	O
)	O
,	O
CD34	O
(	O
61.7	O
%	O
,	O
37	O
/	O
60	O
)	O
,	O
and	O
the	O
tumor	S-Phenotype
cells	O
were	O
typically	O
positive	O
for	O
CD99	O
,	O
bcl	O
-	O
2	O
,	O
EMA	O
and	O
SSTR2	O
as	O
well.Negative	O
for	O
S	O
-	O
100	O
protein	O
,	O
SOX10	O
,	O
E	O
-	O
cadherin	O
,	O
GFAP	O
.	O

Inactivating	O
mutations	O
in	O
Eda	O
or	O
Edar	O
cause	O
hypohidrotic	B-Phenotype
ectodermal	I-Phenotype
dysplasia	E-Phenotype
(	O
HED	S-Phenotype
)	O
,	O
a	O
condition	O
characterized	O
by	O
malformations	O
of	O
the	O
teeth	O
,	O
hair	O
and	O
glands	O
,	O
with	O
milder	O
deficiencies	O
affecting	O
only	O
the	O
teeth	O
.	O

All	O
results	O
suggested	O
that	O
lLc	O
(	O
LyP	O
-	O
1	O
)	O
had	O
a	O
better	O
performance	O
than	O
lDc	O
(	O
LyP	O
-	O
1	O
)	O
in	O
brain	O
metastatic	O
tumor	S-Phenotype
-	O
targeted	O
drug	O
delivery	O

Meanwhile	O
,	O
MLH3	O
rs175057	O
CAAAAT	O
locus	O
was	O
also	O
associated	O
with	O
longer	O
overall	O
survival	O
time	O
in	O
locally	O
advanced	O
rectal	B-Phenotype
cancer	E-Phenotype
(	O
HR=0.44	O
,	O
95	O
%	O
CI	O
:	O
0.20	O
-	O
0.96	O
,	O
P=0.038	O
)	O
,	O
whereas	O
MSH2	O
rs3771273	O
TAAAAA	O
,	O
rs10188090	O
AAAAAG	O
and	O
rs10191478	O
TAAAAG	O
loci	O
were	O
associated	O
with	O
shorter	O
overall	O
survival	O
time	O
(	O
HR=1.74	O
,	O
95	O
%	O
CI	O
:	O
1.06	O
-	O
2.84	O
,	O
P=0.028	O
;	O
HR=1.64	O
,	O
95	O
%	O
CI	O
:	O
1.01	O
-	O
2.66	O
,	O
P=0.046	O
;	O
HR=1.71	O
,	O
95	O
%	O
CI	O
:	O
1.01	O
-	O
2.91	O
,	O
P=0.047	O
,	O
respectively	O
)	O
.	O

The	O
c.808	O
+	O
1G	O
AAAA	O
A	O
variant	O
was	O
identified	O
in	O
a	O
boy	O
with	O
mild	O
ID	O
and	O
autism	S-Phenotype
traits	O
and	O
is	O
associated	O
with	O
a	O
significant	O
reduced	O
KDM5B	O
mRNA	O
expression	O
without	O
alteration	O
of	O
its	O
H3K4me3	O
pattern	O
.	O

We	O
present	O
detailed	O
phenotypic	O
information	O
on	O
seven	O
unrelated	O
individuals	O
with	O
a	O
recurrent	O
de	O
novo	O
nonsense	O
variant	O
(	O
c.2737CAAAAT	O
[	O
p.Arg913Ter	O
]	O
)	O
in	O
the	O
penultimate	O
exon	O
of	O
ZSWIM6	O
who	O
have	O
severe	O
-	O
profound	O
intellectual	B-Phenotype
disability	E-Phenotype
and	O
additional	O
central	O
and	O
peripheral	O
nervous	O
system	O
symptoms	O
but	O
an	O
absence	B-Phenotype
of	I-Phenotype
frontonasal	E-Phenotype
or	O
limb	B-Phenotype
malformations	E-Phenotype
.	O

None	O
of	O
the	O
patients	O
showed	O
CHCHD2	O
mutations	O
,	O
whereas	O
1	O
sporadic	S-Phenotype
MM	O
patient	O
carried	O
a	O
homozygous	O
Pro96Thr	O
substitution	O
in	O
CHCHD10	O
.	O

Additionally	O
,	O
CXCL1	O
increases	O
the	O
metastatic	O
ability	O
of	O
a	O
cancer	S-Phenotype
by	O
enhancing	O
cell	O
migration	O
,	O
matrix	O
metalloproteinase	O
-	O
7	O
expression	O
and	O
EMT	O
.	O

Although	O
the	O
expression	O
pattern	O
and	O
functions	O
of	O
the	O
CaSR	O
in	O
the	O
colonic	O
microenvironment	O
are	O
far	O
from	O
being	O
completely	O
understood	O
,	O
evidence	O
has	O
been	O
accumulating	O
that	O
the	O
CaSR	O
might	O
play	O
a	O
protective	O
role	O
against	O
both	O
colonic	B-Phenotype
inflammation	E-Phenotype
and	O
colorectal	B-Phenotype
cancer	E-Phenotype
.	O

Consequently	O
,	O
the	O
disruption	O
of	O
Ush2a	O
in	O
zebrafish	O
led	O
to	O
a	O
hearing	B-Phenotype
impairment	E-Phenotype
,	O
like	O
that	O
in	O
mammals	O
.	O

We	O
specifically	O
discuss	O
the	O
role	O
of	O
SALL2	O
in	O
the	O
regulation	O
of	O
cell	O
proliferation	O
and	O
survival	O
within	O
the	O
context	O
of	O
the	O
identified	O
target	O
genes	O
,	O
its	O
interaction	O
with	O
viral	O
oncogenes	O
,	O
and	O
its	O
association	O
with	O
the	O
TP53	O
tumor	S-Phenotype
suppressor	O
and	O
MYC	O
oncogene	O
.	O

Low	O
mitotic	O
tumor	S-Phenotype
grade	O
,	O
Weiss	O
score	O
,	O
global	O
loss	O
of	O
DAXX	O
expression	O
,	O
and	O
high	O
phospho	O
-	O
mTOR	O
expression	O
correlated	O
with	O
disease	O
-	O
free	O
survival	O
,	O
but	O
Weiss	O
score	O
and	O
biomarkers	O
failed	O
to	O
predict	O
adverse	O
outcome	O
in	O
low	O
-	O
grade	O
disease	O
.	O

Further	O
,	O
we	O
analyzed	O
the	O
expression	O
of	O
these	O
nine	O
genes	O
during	O
the	O
progression	O
of	O
cervical	B-Phenotype
cancer	E-Phenotype
,	O
and	O
found	O
that	O
SPARCL1	O
is	O
also	O
related	O
to	O
precancerous	O
lesions	O
and	O
migration	O
processes	O
during	O
cervical	B-Phenotype
cancer	E-Phenotype
pathogenesis	O
.	O

ERBB2	O
or	O
GPC3	O
)	O
can	O
be	O
evaluated	O
in	O
human	O
CD3	O
EDG	O
-	O
replaced	O
mice	O
engrafted	O
with	O
tumors	O
.	O

In	O
this	O
study	O
,	O
the	O
correlation	O
between	O
H19	O
and	O
vitamin	O
D	O
receptor	O
(	O
VDR	O
)	O
signaling	O
and	O
the	O
underlying	O
mechanisms	O
in	O
colon	B-Phenotype
cancer	E-Phenotype
were	O
investigated	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

These	O
results	O
demonstrate	O
a	O
previously	O
unrecognized	O
relationship	O
between	O
p53	O
and	O
REV3L	O
in	O
cancer	S-Phenotype
cell	O
metabolism	O
and	O
may	O
lead	O
to	O
improvements	O
in	O
chemotherapy	O
treatment	O
plans	O
that	O
reduce	O
cisplatin	O
resistance	O
in	O
lung	B-Phenotype
cancer	E-Phenotype

Importantly	O
,	O
loss	O
of	O
Arl13b	O
in	O
a	O
Ptch1	O
-	O
deleted	O
mouse	O
model	O
of	O
MB	O
inhibited	O
tumor	S-Phenotype
formation	O
.	O

Herein	O
,	O
we	O
report	O
that	O
CHRDL1	O
expression	O
was	O
significantly	O
down	O
-	O
regulated	O
in	O
gastric	B-Phenotype
cancer	E-Phenotype
tissues	O
and	O
associated	O
with	O
poor	O
survival	O
.	O

Genes	O
for	O
epileptic	B-Phenotype
encephalopathies	E-Phenotype
such	O
as	O
SLC2A1	O
were	O
rediscovered	O
in	O
GGE	O
,	O
highlighting	O
the	O
biological	O
continuum	O
between	O
different	O
epilepsies	S-Phenotype
.	O

Our	O
study	O
identifies	O
urine	O
D2HG	O
and	O
tissue	O
D2HGDH	O
expression	O
as	O
biomarkers	O
to	O
identify	O
patients	O
at	O
risk	O
for	O
progressing	O
from	O
colitis	S-Phenotype
to	O
cancer	S-Phenotype
.	O

We	O
also	O
tested	O
variants	O
within	O
exons	O
of	O
132	O
other	O
previously	O
-	O
identified	O
hearing	B-Phenotype
loss	E-Phenotype
genes	O
,	O
and	O
identified	O
two	O
common	O
additional	O
significant	O
SNPs	O
:	O
rs2877561	O
(	O
synonymous	O
change	O
in	O
ILDR1	O
,	O
p	O
=	O
6.2x10	O
-	O
5	O
)	O
,	O
which	O
replicated	O
in	O
the	O
UK	O
Biobank	O
(	O
p	O
=	O
0.00057	O
)	O
,	O
and	O
had	O
a	O
significant	O
GERA	O
SRT	O
(	O
p	O
=	O
0.00019	O
)	O
and	O
speech	O
discrimination	O
score	O
(	O
SDS	O
;	O
p	O
=	O
0.0019	O
)	O
;	O
and	O
rs9493627	O
(	O
missense	O
change	O
in	O
EYA4	O
,	O
p	O
=	O
0.00011	O
)	O
which	O
replicated	O
in	O
the	O
UK	O
Biobank	O
(	O
p	O
=	O
0.0095	O
)	O
,	O
other	O
GERA	O
groups	O
(	O
p	O
=	O
0.0080	O
)	O
,	O
and	O
had	O
a	O
consistent	O
significant	O
result	O
for	O
SRT	O
(	O
p	O
=	O
0.041	O
)	O
and	O
suggestive	O
result	O
for	O
SDS	O
(	O
p	O
=	O
0.081	O
)	O
.	O

The	O
contiguous	O
deletion	O
of	O
NDP	O
and	O
its	O
neighbouring	O
genes	O
,	O
MAOA	O
/	O
B	O
and	O
EFHC2	O
,	O
reportedly	O
leads	O
to	O
syndromic	O
clinical	O
features	O
such	O
as	O
microcephaly	S-Phenotype
,	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
and	O
epilepsy	S-Phenotype
.	O

Although	O
isolated	B-Phenotype
cases	E-Phenotype
of	O
adult	O
PKD	O
have	O
been	O
reported	O
in	O
Nigerians	O
;	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
case	O
is	O
the	O
first	O
to	O
be	O
reported	O
in	O
the	O
paediatric	O
age	O
group	O
in	O
Nigeria	O
.	O

The	O
clinical	O
presentation	O
of	O
PIGN	O
varies	O
from	O
a	O
benign	O
asymptomatic	O
condition	O
to	O
rapidly	O
progressive	O
glomerulonephritis	S-Phenotype
requiring	O
dialysis	O
.	O

This	O
variant	O
was	O
present	O
in	O
56	O
%	O
of	O
PRA	O
cases	O
and	O
87	O
%	O
of	O
obligate	O
carriers	O
,	O
and	O
displayed	O
a	O
recessive	O
mode	B-Phenotype
of	I-Phenotype
inheritance	E-Phenotype
with	O
full	O
penetrance	O
within	O
those	O
lineages	O
in	O
which	O
it	O
segregated	O
.	O

We	O
assessed	O
mGluR5	O
mRNA	O
and	O
protein	O
levels	O
in	O
the	O
dorsolateral	O
prefrontal	O
cortex	O
(	O
DLPFC	O
)	O
using	O
a	O
large	O
cohort	O
of	O
schizophrenia	S-Phenotype
and	O
control	O
subjects	O
(	O
n	O
=	O
37	O
/	O
group	O
)	O
,	O
and	O
additionally	O
measured	O
protein	O
levels	O
of	O
recently	O
discovered	O
mGluR5	O
endogenous	O
regulators	O
,	O
Norbin	O
(	O
neurochondrin	O
)	O
,	O
Tamalin	O
(	O
GRASP	O
-	O
1	O
)	O
,	O
and	O
Preso1	O
(	O
FRMPD4	O
)	O
,	O
which	O
regulate	O
mGluR5	O
localization	O
,	O
internalization	O
and	O
signaling	O
.	O

Objective	O
Hearing	B-Phenotype
loss	E-Phenotype
(	O
HL	S-Phenotype
)	O
is	O
the	O
most	O
common	O
sensory	O
-	O
neural	O
defect	O
and	O
the	O
most	O
heterogeneous	S-Phenotype
trait	O
in	O
humans	O
,	O
with	O
the	O
involvement	O
of	O
AAAA100	O
genes	O
,	O
which	O
make	O
a	O
molecular	O
diagnosis	O
problematic	O
.	O

Our	O
results	O
indicate	O
that	O
ALS5	O
/	O
SPG11	O
/	O
KIAA1840	O
is	O
the	O
causative	O
gene	O
of	O
a	O
wide	O
spectrum	O
of	O
clinical	O
features	O
,	O
including	O
autosomal	B-Phenotype
recessive	I-Phenotype
axonal	I-Phenotype
Charcot	I-Phenotype
-	I-Phenotype
Marie	I-Phenotype
-	I-Phenotype
Tooth	I-Phenotype
disease	E-Phenotype

Next	O
,	O
using	O
DLD	O
-	O
1	O
colon	B-Phenotype
cancer	E-Phenotype
cells	O
inducibly	O
expressing	O
SASS6	O
,	O
SASS6	O
overexpression	O
was	O
shown	O
to	O
induce	O
centrosome	O
amplification	O
,	O
mitotic	O
abnormalities	O
such	O
as	O
chromosomal	O
misalignment	O
and	O
lagging	O
chromosome	O
,	O
and	O
chromosomal	O
numerical	O
changes	O
.	O

In	O
two	O
different	O
patients	O
with	O
unilateral	B-Phenotype
cryptorchidism	E-Phenotype
,	O
we	O
found	O
the	O
variants	O
rs121912556	O
and	O
p.R105R	O
of	O
INSL3	O
gene	O
in	O
a	O
heterozygous	O
form	O
associated	O
with	O
cryptorchidism	S-Phenotype
,	O
so	O
we	O
could	O
considered	O
them	O
as	O
risk	O
factors	O
for	O
cryptorchidism	S-Phenotype
.	O

The	O
FOXO3	O
is	O
a	O
tumor	S-Phenotype
suppressor	O
gene	O
and	O
found	O
to	O
interact	O
with	O
p53	O
,	O
the	O
trigger	O
for	O
apoptosis	O
through	O
BCl2	O
family	O
genes	O
and	O
a	O
regulator	O
of	O
Notch	O
signaling	O
pathway	O
for	O
the	O
self	O
-	O
renewal	O
of	O
stem	O
cells	O
.	O

Here	O
,	O
we	O
show	O
that	O
TUFM	O
is	O
downregulated	O
in	O
human	O
cancer	S-Phenotype
tissues	O
.	O

Mutations	O
in	O
the	O
Pejvakin	O
(	O
Pjvk	O
)	O
gene	O
cause	O
autosomal	B-Phenotype
recessive	E-Phenotype
hearing	B-Phenotype
loss	E-Phenotype
DFNB59	O
with	O
audiological	O
features	O
of	O
auditory	B-Phenotype
neuropathy	I-Phenotype
spectrum	I-Phenotype
disorder	E-Phenotype
(	O
ANSD	S-Phenotype
)	O
or	O
cochlear	B-Phenotype
dysfunction	E-Phenotype
.	O

We	O
confirmed	O
it	O
in	O
MCF7	O
,	O
MDA	O
-	O
MB	O
-	O
436	O
and	O
two	O
human	O
primary	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
by	O
showing	O
reduced	O
thiamine	O
levels	O
upon	O
a	O
knock	O
-	O
down	O
of	O
miR	O
-	O
155	O
.	O

Pedigree	O
analysis	O
in	O
the	O
Haflinger	O
breed	O
supports	O
a	O
simple	O
recessive	O
mode	B-Phenotype
of	I-Phenotype
inheritance	E-Phenotype
and	O
a	O
genome	O
-	O
wide	O
association	O
study	O
(	O
N	O
=	O
23	O
)	O
identified	O
a	O
1.5	O
Mb	O
locus	O
on	O
ECA12	O
significantly	O
associated	O
with	O
limbal	O
SCC	O
(	O
Psubcorrected	O
/	O
sub	O
=	O
0.04	O
)	O
.	O

CMG2	O
protein	O
was	O
evaluated	O
in	O
52	O
tumor	S-Phenotype
samples	O
by	O
ELISA	O
.	O

The	O
finding	O
expands	O
the	O
molecular	O
basis	O
of	O
congenital	B-Phenotype
contractures	E-Phenotype
and	O
the	O
phenotypic	O
spectrum	O
of	O
ECEL1	O
mutations	O
.	O

Notably	O
,	O
genetic	O
deletion	O
or	O
pharmacological	O
inhibition	O
of	O
CENPE	O
significantly	O
decreases	O
tumor	S-Phenotype
growth	O
.	O

Alterations	O
in	O
liMEK1	O
/	O
2	O
/	O
i	O
occur	O
in	O
cancers	S-Phenotype
,	O
both	O
in	O
the	O
treatment	O
-	O
naïve	O
state	O
and	O
following	O
targeted	O
therapies	O
,	O
most	O
notably	O
BRAF	O
and	O
MEK	O
inhibitors	O
in	O
liBRAF	O
/	O
i	O
-	O
V600E	O
-	O
mutant	O
melanoma	S-Phenotype
and	O
colorectal	B-Phenotype
cancer	E-Phenotype
.	O

Such	O
dephosphorylation	O
of	O
Nedd4	O
-	O
2	O
is	O
surprisingly	O
caused	O
by	O
abnormally	O
stable	O
tumor	S-Phenotype
suppressor	O
p53	O
and	O
subsequently	O
destabilized	O
kinase	O
Akt	O
.	O

A	O
third	O
of	O
patients	O
with	O
paraganglial	O
tumors	S-Phenotype
,	O
pheochromocytoma	S-Phenotype
,	O
and	O
paraganglioma	S-Phenotype
,	O
carry	O
germline	O
mutations	O
in	O
one	O
of	O
the	O
susceptibility	O
genes	O
,	O
RET	O
,	O
VHL	O
,	O
NF1	O
,	O
SDHAF2	O
,	O
SDHA	O
,	O
SDHB	O
,	O
SDHC	O
,	O
SDHD	O
,	O
TMEM127	O
,	O
and	O
MAX	O
.	O

CONCLUSIONS	O
Gli	O
-	O
1	O
is	O
highly	O
expressed	O
in	O
human	O
esophageal	B-Phenotype
carcinoma	E-Phenotype
,	O
and	O
could	O
be	O
a	O
marker	O
for	O
use	O
in	O
assessing	O
tumor	S-Phenotype
stage	O
and	O
the	O
deciding	O
on	O
treatment	O
target	O

We	O
present	O
a	O
comprehensive	O
description	O
of	O
the	O
heterogeneous	S-Phenotype
clinical	O
features	O
of	O
the	O
CMS	O
caused	O
by	O
the	O
homozygous	O
1267delG	O
mutation	O
in	O
the	O
AChR	O
Ɛ	O
subunit	O
in	O
nine	O
members	O
of	O
two	O
large	O
Gipsy	O
kindreds	O
.	O

Alterations	O
of	O
von	O
Hippel	O
-	O
Lindau	O
(	O
VHL	O
)	O
,	O
succinate	O
dehydrogenase	O
(	O
SDHX	O
)	O
,	O
and	O
TMEM127	O
have	O
been	O
associated	O
with	O
the	O
development	O
of	O
pheochromocytomas	S-Phenotype
(	O
PCs	S-Phenotype
)	O
and	O
paragangliomas	S-Phenotype
(	O
PGLs	S-Phenotype
)	O
and	O
are	O
also	O
associated	O
with	O
the	O
development	O
of	O
renal	B-Phenotype
neoplasms	E-Phenotype
.	O

In	O
conclusion	O
,	O
we	O
have	O
identified	O
a	O
putative	O
functional	O
indel	O
variant	O
at	O
chr13q22.1	O
that	O
associates	O
with	O
decreased	O
DIS3	O
expression	O
in	O
carriers	O
of	O
pancreatic	B-Phenotype
cancer	E-Phenotype
risk	O
-	O
increasing	O
alleles	O
,	O
and	O
could	O
therefore	O
affect	O
nuclear	O
RNA	O
processing	O
and	O
/	O
or	O
decay	O

These	O
data	O
indicate	O
that	O
vIL	O
-	O
6	O
plays	O
a	O
role	O
in	O
KSHV	O
tumor	S-Phenotype
formation	O
in	O
B	O
cells	O
in	O
vivo	O
.	O

Of	O
the	O
included	O
24	O
CNS	O
patients	O
with	O
hemangioblastoma	S-Phenotype
(	O
14	O
intracranial	O
and	O
10	O
spinal	O
hemangioblastomas	O
)	O
,	O
5	O
patients	O
(	O
20.8	O
%	O
)	O
were	O
diagnosed	O
with	O
Von	O
Hippel	O
-	O
Lindau	O
disease	O
(	O
VHL	O
)	O
.	O

We	O
here	O
report	O
that	O
(	O
-	O
)	O
-	O
epigallocatechin	O
gallate	O
(	O
EGCG	O
)	O
inhibited	O
programmed	O
cell	O
death	O
ligand	O
1	O
(	O
PD	O
-	O
L1	O
)	O
expression	O
in	O
non⁻small	O
-	O
cell	O
lung	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
induced	O
by	O
both	O
interferon	O
(	O
IFN	O
)	O
-	O
γ	O
and	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
.	O

Using	O
whole	O
-	O
exome	O
sequencing	O
,	O
we	O
identified	O
a	O
homozygous	O
acceptor	O
splice	O
-	O
site	O
mutation	O
in	O
intron	O
6	O
of	O
the	O
KATNB1	O
gene	O
in	O
a	O
patient	O
from	O
a	O
consanguineous	O
Turkish	O
family	O
who	O
presented	O
with	O
congenital	B-Phenotype
microcephaly	E-Phenotype
,	O
lissencephaly	S-Phenotype
,	O
short	B-Phenotype
stature	E-Phenotype
,	O
polysyndactyly	S-Phenotype
,	O
and	O
dental	B-Phenotype
abnormalities	E-Phenotype
.	O

Analysis	O
using	O
Gene	O
Set	O
Enrichment	O
Analysis	O
(	O
GSEA	O
)	O
software	O
revealed	O
significant	O
enrichment	O
for	O
197	O
proteins	O
from	O
the	O
CM	O
of	O
lung	B-Phenotype
cancer	E-Phenotype
samples	O
in	O
maternal‑placental	O
interface	O
expression	O
profiles	O
for	O
a	O
mid‑term	O
placenta	O
with	O
strong	O
invasiveness	O
relative	O
to	O
RNA	O
expression	O
profiles	O
for	O
a	O
human	O
full‑term	O
placenta	O
after	O
delivery	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrated	O
that	O
OVOL2	O
,	O
a	O
zinc	O
finger	O
transcription	O
factor	O
,	O
inhibits	O
TGF	O
-	O
β	O
signaling	O
-	O
induced	O
EMT	O
in	O
mouse	O
and	O
human	O
mammary	O
tumor	S-Phenotype
cells	O
,	O
as	O
well	O
as	O
in	O
mouse	O
tumor	S-Phenotype
models	O
.	O

The	O
search	O
for	O
clinically	O
relevant	O
molecular	O
markers	O
in	O
classical	O
Hodgkin	B-Phenotype
lymphoma	E-Phenotype
(	O
cHL	S-Phenotype
)	O
is	O
hampered	O
by	O
the	O
histopathological	O
complexity	O
of	O
the	O
disease	O
,	O
resulting	O
from	O
the	O
admixture	O
of	O
a	O
small	O
number	O
of	O
neoplastic	O
Hodgkin	O
and	O
Reed	O
-	O
Sternberg	O
(	O
H	O
-	O
RS	O
)	O
cells	O
with	O
an	O
abundant	O
and	O
heterogeneous	S-Phenotype
microenvironment	O
.	O

Individuals	O
with	O
biallelic	O
TRIP13	O
or	O
BUB1B	O
mutations	O
have	O
a	O
high	O
risk	O
of	O
embryonal	B-Phenotype
tumors	E-Phenotype
,	O
and	O
here	O
we	O
show	O
that	O
their	O
cells	O
display	O
severe	O
SAC	O
impairment	O
.	O

Here	O
,	O
we	O
report	O
an	O
unusual	O
oropharyngeal	O
monomorphic	O
spindle	O
cell	O
sarcoma	S-Phenotype
in	O
a	O
53	O
-	O
year	O
-	O
old	O
man	O
that	O
revealed	O
a	O
novel	O
RREB1	O
-	O
MKL2	O
gene	O
fusion	O
by	O
RNA	O
sequencing	O
with	O
the	O
Illumina	O
TruSight	O
RNA	O
Fusion	O
Panel	O
.	O

This	O
result	O
suggests	O
that	O
COL4A3	O
and	O
COL4A4	O
digenic	O
mutations	O
in	O
cis	O
mimicking	O
an	O
autosomal	O
dominant	O
inheritance	S-Phenotype
should	O
be	O
considered	O
as	O
a	O
novel	O
inheritance	O
pattern	O
of	O
benign	B-Phenotype
familial	I-Phenotype
hematuria	E-Phenotype
,	O
although	O
the	O
disease	O
-	O
causing	O
mechanism	O
remains	O
unknown	O

In	O
conclusion	O
,	O
we	O
did	O
not	O
observe	O
a	O
clear	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
patients	O
with	O
DGKE	O
nephropathy	S-Phenotype
,	O
suggesting	O
additional	O
factors	O
mediating	O
phenotypic	O
heterogeneity	S-Phenotype
.	O

Their	O
seizures	S-Phenotype
started	O
within	O
the	O
first	O
day	O
and	O
could	O
not	O
be	O
controlled	O
by	O
pyridoxine	O
or	O
pyridoxal	O
-	O
5	O
'	O
-	O
phosphate	O
(	O
PLP	O
)	O
completely	O
.	O

The	O
pathogenic	O
allele	O
was	O
a	O
c.220C	O
AAAA	O
T	O
mutation	O
in	O
the	O
anoctamin	O
5	O
(	O
ANO5	O
)	O
gene.The	O
LGMD2L	O
family	O
was	O
characterized	O
by	O
mild	B-Phenotype
chronic	I-Phenotype
myopathy	E-Phenotype
and	O
bilateral	B-Phenotype
gastrocnemius	I-Phenotype
hypertrophy	E-Phenotype
with	O
obviously	O
increased	O
CK	O
levels	O
.	O

Here	O
we	O
demonstrate	O
new	O
functions	O
for	O
BRUCE	O
in	O
ATR	O
activation	O
in	O
vitro	O
and	O
liver	B-Phenotype
tumor	E-Phenotype
suppression	O
in	O
vivo	O
.	O

On	O
the	O
other	O
hand	O
,	O
patients	O
carrying	O
either	O
deletions	O
encompassing	O
solely	O
ANKRD11	O
or	O
its	O
loss	O
-	O
of	O
-	O
function	O
variants	O
were	O
reported	O
in	O
association	O
with	O
the	O
KBG	O
syndrome	O
,	O
characterized	O
by	O
a	O
very	O
similar	O
phenotype	O
,	O
including	O
mild	B-Phenotype
-	I-Phenotype
to	I-Phenotype
-	I-Phenotype
moderate	I-Phenotype
intellectual	I-Phenotype
disability	E-Phenotype
,	O
short	B-Phenotype
stature	E-Phenotype
and	O
macrodontia	B-Phenotype
of	I-Phenotype
upper	I-Phenotype
incisors	E-Phenotype
,	O
with	O
inter	O
and	O
intrafamilial	O
variability	O
.	O

Neph2	O
-	O
knockout	O
mice	O
may	O
provide	O
a	O
valuable	O
rodent	O
model	O
for	O
research	O
on	O
autism	S-Phenotype
spectrum	O
diseases	O
and	O
neurodevelopmental	O
disorders	O

To	O
explore	O
the	O
role	O
of	O
RASSF7	O
in	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
cells	O
proliferation	O
and	O
molecular	O
mechanism	O
.	O

For	O
validation	O
,	O
we	O
used	O
a	O
set	O
of	O
independent	O
tumors	S-Phenotype
previously	O
analyzed	O
with	O
the	O
Illumina	O
27K	O
methylation	O
arrays	O
,	O
which	O
confirmed	O
the	O
differentially	O
methylated	O
sites	O
.	O

Cervical	B-Phenotype
cancer	E-Phenotype
is	O
the	O
fourth	O
most	O
common	O
malignancy	O
among	O
women	O
worldwide	O
,	O
and	O
continued	O
research	O
to	O
discover	O
biomarkers	O
or	O
therapeutic	O
targets	O
will	O
aid	O
early	O
diagnosis	O
and	O
treatment	O
of	O
this	O
cancer	S-Phenotype
.	O

Recent	O
studies	O
indicate	O
that	O
such	O
scarring	S-Phenotype
has	O
a	O
high	O
female	O
propensity	O
;	O
females	O
are	O
also	O
almost	O
exclusively	O
affected	O
by	O
endometriosis	S-Phenotype
,	O
a	O
common	O
sex	O
steroid	O
-	O
dependent	O
fibrotic	O
disease	O
.	O

We	O
observed	O
that	O
the	O
alternatively	O
spliced	O
transcripts	O
of	O
a	O
subset	O
of	O
these	O
genes	O
,	O
involved	O
in	O
proliferation	O
and	O
tumor	S-Phenotype
cell	O
migration	O
like	O
REPIN1	O
/	O
AP4	O
,	O
ST3GAL6	O
,	O
TRNAU1AP	O
and	O
PFKM	O
are	O
degraded	O
upon	O
loss	O
of	O
PRMT5	O
.	O

HPS	O
-	O
5	O
therefore	O
appears	O
as	O
a	O
mild	O
form	O
of	O
HPS	O
,	O
which	O
is	O
often	O
clinically	O
undistinguishable	O
from	O
mild	O
oculocutaneous	O
or	O
ocular	O
forms	O
of	O
albinism	S-Phenotype
.	O

Mutations	O
in	O
SZT2	O
were	O
first	O
reported	O
in	O
2013	O
as	O
a	O
cause	O
of	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
epileptic	I-Phenotype
encephalopathy	E-Phenotype
.	O

The	O
antiglioma	O
effect	S-Phenotype
of	O
TMZ	O
in	O
nude	O
mice	O
xenografts	O
with	O
Dec1	O
expression	O
was	O
examined	O
in	O
vivo	O
.	O

By	O
immunohistochemistry	O
,	O
the	O
tumor	S-Phenotype
cells	O
were	O
diffusely	O
positive	O
for	O
CD34	O
while	O
negative	O
for	O
cytokeratin	O
(	O
CK	O
)	O
,	O
pan	O
CK	O
(	O
AE1	O
/	O
AE3	O
)	O
,	O
S100	O
protein	O
,	O
CD30	O
,	O
and	O
CD31	O
.	O

Expression	O
profile	O
analysis	O
,	O
immunohistochemical	O
staining	O
,	O
reverse	O
transcription	O
-	O
quantitative	O
polymerase	O
chain	O
reaction	O
analysis	O
and	O
western	O
blot	O
analysis	O
were	O
performed	O
to	O
evaluate	O
the	O
levels	O
of	O
MORC2	O
in	O
liver	B-Phenotype
cancer	E-Phenotype
patient	O
specimens	O
and	O
cell	O
lines	O
;	O
subsequently	O
the	O
expression	O
of	O
MORC2	O
was	O
suppressed	O
or	O
increased	O
in	O
liver	B-Phenotype
cancer	E-Phenotype
cells	O
and	O
the	O
effects	O
of	O
MORC2	O
on	O
the	O
cancerous	O
transformation	O
of	O
liver	B-Phenotype
cancer	E-Phenotype
cells	O
were	O
examined	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Recently	O
,	O
a	O
new	O
type	O
of	O
limb	B-Phenotype
-	I-Phenotype
girdle	I-Phenotype
muscular	I-Phenotype
dystrophy	E-Phenotype
(	O
LGMD	B-Phenotype
type	I-Phenotype
2Z	E-Phenotype
)	O
has	O
been	O
identified	O
due	O
to	O
a	O
missense	O
mutation	O
in	O
POGLUT1	O
(	O
protein	O
O	O
-	O
glucosyltransferase	O
-	O
Rumi	O
)	O
,	O
an	O
enzyme	O
capable	O
of	O
adding	O
glucose	O
to	O
a	O
distinct	O
serine	O
residue	O
of	O
epidermal	O
growth	O
factor	O
-	O
like	O
repeats	O
containing	O
a	O
C	O
-	O
X	O
-	O
S	O
-	O
X	O
-	O
(	O
P	O
/	O
A	O
)	O
-	O
C	O
consensus	O
sequence	O
such	O
as	O
Notch	O
receptors	O
.	O

In	O
Mfrprd6	O
eyes	O
,	O
a	O
significant	O
1.5	O
-	O
to	O
2.0	O
-	O
fold	O
decrease	O
was	O
observed	O
among	O
transcripts	O
of	O
genes	O
linked	O
to	O
retinal	B-Phenotype
degeneration	E-Phenotype
,	O
including	O
those	O
involved	O
in	O
visual	O
cycle	O
(	O
Rpe65	O
,	O
Lrat	O
,	O
Rgr	O
)	O
,	O
phototransduction	O
(	O
Pde6a	O
,	O
Guca1b	O
,	O
Rgs9	O
)	O
,	O
and	O
photoreceptor	O
disc	O
morphogenesis	O
(	O
Rpgrip1	O
and	O
Fscn2	O
)	O
.	O

In	O
conclusion	O
,	O
CPS1	O
4217CAAAAA	O
polymorphism	O
may	O
not	O
be	O
associated	O
with	O
the	O
development	O
of	O
hyperammonemia	S-Phenotype
in	O
Japanese	O
population	O

In	O
20	O
/	O
23	O
cases	O
,	O
MDRrel	O
BSI	O
occurred	O
during	O
neutropenia	S-Phenotype
.	O

The	O
bioinformatics	O
analysis	O
and	O
experimental	O
results	O
of	O
the	O
present	O
study	O
demonstrated	O
that	O
aberrant	O
promoter	O
methylation	O
led	O
to	O
increased	O
expression	O
of	O
USP18	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

These	O
results	O
suggest	O
that	O
this	O
N	O
-	O
glycan	O
of	O
POFUT1	O
is	O
not	O
required	O
for	O
its	O
proper	O
enzymatic	O
function	O
,	O
and	O
that	O
the	O
p.Ser162Leu	O
mutation	O
of	O
POFUT1	O
likely	O
causes	O
global	B-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
,	O
microcephaly	S-Phenotype
with	O
vascular	O
and	O
cardiac	O
defects	O

Their	O
phosphorylation	O
activity	O
has	O
also	O
linked	O
them	O
to	O
the	O
development	O
of	O
neurodegenerative	B-Phenotype
diseases	E-Phenotype
like	O
Alzheimer	O
's	O
disease	O
,	O
amyotrophic	B-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
or	O
spinocerebellar	B-Phenotype
ataxia	I-Phenotype
type	I-Phenotype
11	E-Phenotype
.	O

Our	O
findings	O
open	O
new	O
opportunities	O
for	O
targeted	O
therapy	O
,	O
as	O
tumors	S-Phenotype
with	O
GLI1	O
oncogenic	O
activation	O
,	O
and	O
subsequent	O
PTCH1	O
overexpression	O
,	O
might	O
be	O
sensitive	O
to	O
sonic	O
hedgehog	O
pathway	O
inhibitors	O

As	O
for	O
genes	O
relating	O
to	O
the	O
tumor	S-Phenotype
invasion	O
of	O
PLD2	O
,	O
we	O
found	O
that	O
angiogenin	O
(	O
ANG	O
)	O
was	O
positively	O
regulated	O
by	O
PLD2	O
.	O

ZNF687	O
overexpression	O
greatly	O
enhanced	O
HCC	O
cell	O
capability	O
for	O
tumorsphere	S-Phenotype
formation	O
,	O
invasion	O
and	O
chemoresistance	O
in	O
vitro	O
,	O
whereas	O
inhibiting	O
ZNF687	O
reduced	O
these	O
capabilities	O
and	O
inhibited	O
HCC	O
cell	O
tumorigenic	O
capability	O
in	O
vivo	O
.	O

Furthermore	O
,	O
in	O
utero	O
CRISPR	O
-	O
Cas9	O
-	O
mediated	O
genome	O
editing	O
of	O
Tsc1	O
or	O
Tsc2	O
induced	O
the	O
development	O
of	O
spontaneous	O
behavioral	O
seizures	S-Phenotype
,	O
as	O
well	O
as	O
cytomegalic	O
neurons	O
and	O
cortical	O
dyslamination	O
.	O

Moreover	O
,	O
comparison	O
of	O
the	O
porcine	O
results	O
to	O
those	O
reported	O
by	O
human	O
melanoma	S-Phenotype
GWAS	O
indicated	O
shared	O
association	O
signals	O
notably	O
at	O
CDKAL1	O
and	O
TERT	O
loci	O
but	O
also	O
nearby	O
CCND1	O
,	O
FTO	O
,	O
PLA2G6	O
and	O
TMEM38B	O
-	O
RAD23B	O
loci	O
.	O

Recent	O
studies	O
demonstrated	O
that	O
SGLT1	O
activation	O
improves	O
ischemia	O
-	O
reperfusion	O
-	O
induced	O
cardiac	O
injury	O
,	O
and	O
increased	O
SGLT1	O
gene	O
expression	O
is	O
observed	O
in	O
hypertrophic	O
,	O
ischemic	O
,	O
and	O
diabetic	O
cardiomyopathy	S-Phenotype
in	O
human	O
hearts	O
.	O

We	O
extended	O
our	O
findings	O
to	O
BRAF	O
WT	O
tumor	S-Phenotype
cell	O
lines	O
that	O
are	O
intrinsically	O
resistant	O
to	O
vemurafenib	O
and	O
dabrafenib	O
.	O

We	O
believe	O
that	O
this	O
study	O
will	O
shed	O
new	O
light	O
on	O
fundamental	O
aspects	O
for	O
understanding	O
the	O
molecular	O
pathogenesis	O
of	O
endometrial	B-Phenotype
cancer	E-Phenotype
and	O
may	O
aid	O
in	O
the	O
development	O
of	O
new	O
targeted	O
therapies	O
.	O

In	O
addition	O
,	O
TNFSF15	O
/	O
DR3	O
signaling	O
pathways	O
in	O
A549	O
cells	O
include	O
activation	O
of	O
NF	O
-	O
kB	O
during	O
tumor	S-Phenotype
lymphangiogenesis	O
.	O

In	O
humans	O
,	O
TPRN	O
mutations	O
cause	O
autosomal	B-Phenotype
recessive	I-Phenotype
nonsyndromic	I-Phenotype
deafness	E-Phenotype
(	O
DFNB79	S-Phenotype
)	O
by	O
an	O
unknown	O
mechanism	O
.	O

Chmp1A	O
functions	O
as	O
a	O
tumor	S-Phenotype
suppressor	O
gene	O
and	O
has	O
been	O
reported	O
in	O
pancreatic	B-Phenotype
tumor	E-Phenotype
cells	O
.	O

Deficiency	O
in	O
Krüppel	O
-	O
like	O
zinc	O
finger	O
transcription	O
factor	O
GLI	O
-	O
similar	O
3	O
(	O
GLIS3	O
)	O
in	O
humans	O
is	O
associated	O
with	O
the	O
development	O
of	O
congenital	B-Phenotype
hypothyroidism	E-Phenotype
.	O

Microfibrillar	O
-	O
associated	O
protein	O
5	O
(	O
MFAP5	O
)	O
is	O
a	O
component	O
of	O
extracellular	O
elastic	O
microfibril	O
which	O
has	O
been	O
confirmed	O
to	O
function	O
in	O
tissue	O
development	O
and	O
cancer	S-Phenotype
progression	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
association	O
between	O
Rab3IP	O
and	O
gastric	B-Phenotype
cancer	E-Phenotype
,	O
in	O
addition	O
to	O
its	O
functional	O
role	O
in	O
this	O
disease	O
.	O

Here	O
,	O
we	O
have	O
identified	O
two	O
novel	O
and	O
rare	O
heterozygous	O
variants	O
in	O
the	O
SEMA3D	O
and	O
DPT	O
genes	O
segregating	O
with	O
the	O
complete	O
phenotype	O
that	O
have	O
variable	B-Phenotype
expressivity	E-Phenotype
in	O
two	O
pedigrees	O
with	O
AD	O
-	O
FMD	O
.	O

The	O
tumor	S-Phenotype
cells	O
with	O
immunoreactivity	O
to	O
CK7	O
,	O
CK19	O
,	O
Cam5.2	O
,	O
COX2	O
,	O
EMA	O
,	O
BCL	O
-	O
2	O
,	O
MOC	O
-	O
31	O
and	O
AE1	O
/	O
AE3	O
,	O
supported	O
a	O
diagnosis	O
of	O
intrahepatic	O
cholangiocarcinoma	S-Phenotype
.	O

Previously	O
reported	O
patients	O
with	O
SLC35A3	O
-	O
CDG	O
have	O
been	O
described	O
with	O
syndromic	O
autism	S-Phenotype
,	O
epilepsy	S-Phenotype
,	O
and	O
arthrogryposis	S-Phenotype

We	O
identified	O
30	O
new	O
blood	O
pressure	O
-	O
or	O
hypertension	S-Phenotype
-	O
associated	O
genetic	O
regions	O
in	O
the	O
general	O
population	O
,	O
including	O
3	O
rare	O
missense	O
variants	O
in	O
RBM47	O
,	O
COL21A1	O
and	O
RRAS	O
with	O
larger	O
effects	O
(	O
AAAA1.5	O
mm	O
Hg	O
/	O
allele	O
)	O
than	O
common	O
variants	O
.	O

However	O
,	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
the	O
role	O
of	O
EMX2	O
in	O
human	O
colorectal	B-Phenotype
cancer	E-Phenotype
(	O
CRC	S-Phenotype
)	O
is	O
still	O
unclear	O
.	O

Subsequently	O
,	O
we	O
identified	O
another	O
homozygous	O
variant	O
in	O
2	O
of	O
the	O
10	O
probands	O
with	O
microphthalmia	S-Phenotype
we	O
specifically	O
screened	O
for	O
mutations	O
in	O
ALDH1A3	O
.	O

Unlike	O
previously	O
reported	O
patients	O
with	O
ACAN	O
mutations	O
,	O
our	O
four	O
patients	O
with	O
ACAN	O
variants	O
manifested	O
non	O
-	O
specific	O
short	B-Phenotype
stature	E-Phenotype
with	O
age	O
-	O
appropriate	O
or	O
mildly	O
delayed	B-Phenotype
bone	I-Phenotype
ages	E-Phenotype
,	O
and	O
had	O
parents	O
of	O
normal	O
stature	O
.	O

Variants	O
in	O
CPB1	O
,	O
CPA1	O
(	O
encoding	O
carboxypeptidase	O
B1	O
and	O
A1	O
)	O
,	O
and	O
CTRC	O
were	O
evaluated	O
in	O
a	O
second	O
set	O
of	O
cases	O
with	O
familial	B-Phenotype
pancreatic	I-Phenotype
cancer	E-Phenotype
and	O
controls	O
.	O

Therefore	O
,	O
the	O
current	O
study	O
specifically	O
investigated	O
bone	O
cell	O
activity	O
in	O
clinical	O
bone	O
metastases	O
in	O
relation	O
to	O
tumor	S-Phenotype
cell	O
AR	O
activity	O
,	O
in	O
order	O
to	O
gain	O
novel	O
insight	O
into	O
biological	O
heterogeneities	O
of	O
possible	O
importance	O
for	O
patient	O
stratification	O
into	O
bone	O
-	O
targeting	O
therapies	O
.	O

At	O
surgery	O
,	O
the	O
mass	O
was	O
located	O
within	O
the	O
epineurium	O
,	O
could	O
be	O
bluntly	O
dissected	O
from	O
the	O
nerve	O
fascicles	O
,	O
and	O
was	O
suspected	O
to	O
be	O
a	O
schwannoma	S-Phenotype
.	O

The	O
patient	O
together	O
with	O
her	O
younger	O
brother	O
was	O
diagnosed	O
at	O
the	O
age	O
of	O
5	O
years	O
with	O
familial	B-Phenotype
congenital	I-Phenotype
hypopituitarism	E-Phenotype
,	O
due	O
to	O
homozygous	O
mutation	O
c.150delA	O
in	O
PROP1	O
gene	O
.	O

iConclusion	O
:	O
/	O
i	O
TAZ	O
/	O
YAP	O
is	O
highly	O
expressed	O
in	O
malignant	B-Phenotype
melanoma	E-Phenotype
tumor	S-Phenotype
tissues	O
.	O

Here	O
,	O
we	O
report	O
that	O
in	O
prostate	B-Phenotype
cancer	E-Phenotype
cells	O
(	O
PCCs	O
)	O
microRNAs	O
(	O
miRNAs	O
)	O
greatly	O
contribute	O
to	O
deregulation	O
of	O
mitochondrial	O
fatty	O
acid	O
(	O
FA	O
)	O
oxidation	O
via	O
carnitine	O
system	O
modulation	O
.	O

We	O
also	O
analyzed	O
specific	O
mutations	O
within	O
the	O
12	O
genes	O
and	O
found	O
that	O
some	O
specific	O
mutations	O
within	O
the	O
MUC12	O
,	O
FOXD4L3	O
and	O
FOXD4L5	O
genes	O
showed	O
higher	O
frequencies	O
in	O
the	O
samples	O
of	O
FLC	O
and	O
/	O
or	O
lung	B-Phenotype
cancer	E-Phenotype
tissue	O
,	O
compared	O
with	O
the	O
healthy	O
population	O
.	O

These	O
include	O
other	O
keratin	O
genes	O
for	O
monilethrix	S-Phenotype
,	O
the	O
HR	O
gene	O
for	O
atrichia	S-Phenotype
congenita	O
,	O
the	O
genes	O
CDSN	O
,	O
APCDD1	O
and	O
SNRPE	O
for	O
the	O
autosomal	O
dominant	O
form	O
of	O
hypotrichosis	S-Phenotype
simplex	O
,	O
and	O
the	O
genes	O
DSG4	O
,	O
LIPH	O
and	O
LPAR6	O
for	O
the	O
autosomal	B-Phenotype
recessive	I-Phenotype
forms	I-Phenotype
of	I-Phenotype
hypotrichosis	E-Phenotype
as	O
well	O
as	O
U2HR	O
for	O
hypotrichosis	S-Phenotype
type	O
Marie	O
Unna	O
.	O

Although	O
the	O
4	O
PKPs	O
displayed	O
different	O
levels	O
and	O
patterns	O
of	O
subcellular	O
distribution	O
in	O
tumors	S-Phenotype
,	O
there	O
was	O
a	O
positive	O
correlation	O
between	O
immunoreactivity	O
for	O
PKP2	O
and	O
PKP3	O
,	O
as	O
well	O
as	O
for	O
PKP2	O
and	O
p0071	O
,	O
suggesting	O
possible	O
functional	O
similarities	O
associated	O
with	O
differentiation	O
,	O
tumor	S-Phenotype
growth	O
,	O
and	O
disease	O
prognosis	O
.	O

The	O
cleavage	O
of	O
fatty	O
acids	O
from	O
acylglycerols	O
(	O
lipolysis	O
)	O
has	O
been	O
implicated	O
in	O
cancer	S-Phenotype
.	O

In	O
humans	O
,	O
mutations	O
in	O
the	O
NMD	O
factor	O
gene	O
,	O
UPF3B	O
,	O
cause	O
intellectual	B-Phenotype
disability	E-Phenotype
(	O
ID	S-Phenotype
)	O
and	O
are	O
strongly	O
associated	O
with	O
autism	B-Phenotype
spectrum	I-Phenotype
disorder	E-Phenotype
(	O
ASD	S-Phenotype
)	O
,	O
attention	B-Phenotype
deficit	I-Phenotype
hyperactivity	I-Phenotype
disorder	E-Phenotype
(	O
ADHD	S-Phenotype
)	O
and	O
schizophrenia	S-Phenotype
(	O
SCZ	S-Phenotype
)	O
.	O

Moreover	O
,	O
Adenomatous	O
polyposis	O
coli	O
2	O
(	O
APC2	O
)	O
,	O
a	O
tumor	S-Phenotype
suppressor	O
and	O
a	O
negative	O
regulator	O
of	O
Wnt	O
signaling	O
,	O
was	O
found	O
to	O
be	O
the	O
direct	O
target	O
of	O
miR	O
-	O
3648	O
.	O

PINK1	O
,	O
a	O
mitochondrial	O
serine	O
/	O
threonine	O
kinase	O
,	O
is	O
the	O
product	O
of	O
a	O
gene	O
mutated	O
in	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
form	O
of	O
Parkinson	O
disease	O
.	O

To	O
personalize	O
nutrition	O
,	O
the	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
five	O
key	O
genes	O
in	O
the	O
folate	O
metabolism	O
pathway	O
,	O
and	O
dietary	O
parameters	O
and	O
related	O
interactive	O
parameters	O
as	O
predictors	O
of	O
colorectal	B-Phenotype
cancer	E-Phenotype
(	O
CRC	S-Phenotype
)	O
by	O
measuring	O
the	O
healthy	O
eating	O
index	O
(	O
HEI	O
)	O
in	O
multiethnic	O
families	O
.	O

Here	O
we	O
describe	O
four	O
additional	O
individuals	O
from	O
three	O
families	O
,	O
comprising	O
two	O
sporadic	S-Phenotype
subjects	O
(	O
one	O
of	O
whom	O
had	O
no	O
limb	O
malformation	O
)	O
and	O
a	O
mildly	O
affected	O
female	O
with	O
a	O
severely	O
affected	O
son	O
.	O

However	O
,	O
the	O
ectopic	O
expression	O
of	O
FSHR	O
was	O
recently	O
discovered	O
in	O
intra	O
-	O
tumoral	S-Phenotype
blood	O
vessels	O
endothelia	O
and	O
/	O
or	O
in	O
tumoral	O
cells	O
of	O
many	O
extra	O
-	O
gonadal	O
human	O
tumors	S-Phenotype
(	O
particularly	O
in	O
endocrine	O
tumours	S-Phenotype
)	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
FOXC1	O
regulation	O
of	O
RAB3GAP1	O
,	O
RAB3GAP2	O
and	O
SNAP25	O
affects	O
secretion	O
of	O
Myocilin	O
(	O
MYOC	O
)	O
,	O
a	O
protein	O
associated	O
with	O
juvenile	B-Phenotype
onset	I-Phenotype
glaucoma	E-Phenotype
and	O
steroid	B-Phenotype
-	I-Phenotype
induced	I-Phenotype
glaucoma	E-Phenotype
.	O

Here	O
,	O
we	O
aimed	O
to	O
investigate	O
the	O
clinical	O
impact	O
of	O
RAD50	O
germline	O
mutations	O
in	O
a	O
large	O
cohort	O
of	O
unselected	O
breast	B-Phenotype
cancer	E-Phenotype
patients	O
.	O

Hearing	O
impairment	O
(	O
HI	O
)	O
is	O
genetically	O
heterogeneous	S-Phenotype
which	O
hampers	O
genetic	O
counseling	O
and	O
molecular	O
diagnosis	O
.	O

The	O
expression	O
of	O
the	O
ID2	O
,	O
PRELP	O
and	O
SMOC2	O
genes	O
was	O
compared	O
between	O
the	O
endometrium	O
of	O
women	O
without	O
endometriosis	S-Phenotype
in	O
the	O
proliferative	O
phase	O
of	O
their	O
menstrual	O
cycle	O
and	O
the	O
eutopic	O
and	O
ectopic	O
endometrium	O
of	O
women	O
with	O
endometriosis	S-Phenotype
in	O
the	O
proliferative	O
phase	O
.	O

Genes	O
harboring	O
the	O
most	O
significant	O
mutations	O
include	O
PCDH9	O
,	O
KLHL12	O
,	O
DCAF4L1	O
,	O
and	O
VHL	O
in	O
sporadic	S-Phenotype
HBs	O
,	O
and	O
ZNF814	O
,	O
DLG2	O
,	O
RIMS1	O
,	O
PNN	O
,	O
and	O
MUC7	O
in	O
familial	O
HBs	O
.	O

The	O
aberrant	O
glucose	O
metabolism	O
is	O
one	O
of	O
the	O
hallmarks	O
of	O
cancer	S-Phenotype
cells	O
,	O
and	O
as	O
a	O
branch	O
of	O
glucose	O
metabolism	O
,	O
hexosamine	O
biosynthesis	O
pathway	O
(	O
HBP	O
)	O
has	O
been	O
reported	O
to	O
play	O
a	O
critical	O
role	O
in	O
the	O
insulin	B-Phenotype
resistance	E-Phenotype
and	O
progression	O
of	O
cancer	S-Phenotype
.	O

Cystinuria	S-Phenotype
is	O
a	O
heterogeneous	S-Phenotype
,	O
rare	O
but	O
important	O
cause	O
of	O
inherited	O
kidney	B-Phenotype
stone	E-Phenotype
disease	O
due	O
to	O
mutations	O
in	O
2	O
genes	O
:	O
SLC3A1	O
and	O
SLC7A9	O
.	O

FGFRL1	O
promoted	O
tumor	S-Phenotype
progression	O
by	O
crosstalk	O
with	O
Hedgehog	O
(	O
Hh	O
)	O
signaling	O
.	O

PRKCG	O
has	O
also	O
been	O
identified	O
as	O
an	O
important	O
node	O
in	O
ataxia	S-Phenotype
gene	O
networks	O
more	O
broadly	O
,	O
but	O
the	O
functional	O
role	O
of	O
PKC	O
in	O
other	O
forms	O
of	O
ataxia	S-Phenotype
remains	O
unexplored	O
,	O
and	O
the	O
mechanisms	O
by	O
which	O
PKC	O
isozymes	O
regulate	O
Purkinje	O
neuron	O
health	O
are	O
not	O
well	O
understood	O
.	O

At	O
present	O
,	O
four	O
loci	O
associated	O
with	O
non‑syndromic	B-Phenotype
auditory	I-Phenotype
neuropathy	E-Phenotype
have	O
been	O
mapped	O
:	O
Autosomal	B-Phenotype
recessive	I-Phenotype
deafness‑9	E-Phenotype
[	O
DFNB9	O
;	O
the	O
otoferlin	O
(	O
OTOF	O
)	O
gene	O
]	O
and	O
autosomal	B-Phenotype
recessive	I-Phenotype
deafness‑59	E-Phenotype
[	O
DFNB59	O
;	O
the	O
pejvakin	O
(	O
PJVK	O
)	O
gene	O
]	O
,	O
associated	O
with	O
autosomal	B-Phenotype
recessive	I-Phenotype
inheritance	E-Phenotype
;	O
the	O
autosomal	B-Phenotype
dominant	I-Phenotype
auditory	I-Phenotype
neuropathy	E-Phenotype
gene	O
[	O
AUNA1	O
;	O
the	O
diaphanous‑3	O
(	O
DIAPH3	O
)	O
gene	O
]	O
;	O
and	O
AUNX1	O
,	O
linked	O
to	O
chromosome	O
X	O
.	O

Activation	O
of	O
inflammatory	O
pathways	O
is	O
known	O
to	O
accompany	O
development	O
of	O
obesity	S-Phenotype
-	O
induced	O
non	B-Phenotype
-	I-Phenotype
alcoholic	I-Phenotype
fatty	I-Phenotype
liver	E-Phenotype
disease	O
(	O
NAFLD	S-Phenotype
)	O
,	O
insulin	B-Phenotype
resistance	E-Phenotype
and	O
type	B-Phenotype
2	I-Phenotype
diabetes	E-Phenotype
.	O

Clear	B-Phenotype
cell	I-Phenotype
renal	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
ccRCC	S-Phenotype
)	O
is	O
an	O
heterogeneous	B-Phenotype
tumour	E-Phenotype
at	O
architectural	O
,	O
cellular	O
and	O
molecular	O
level	O
,	O
a	O
reason	O
why	O
the	O
2014	O
International	O
Society	O
of	O
Urological	O
Pathology	O
consensus	O
recommended	O
wide	O
sampling	O
of	O
RCC	O
masses	O
to	O
include	O
at	O
least	O
1	O
block	O
/	O
cm	O
of	O
tumour	S-Phenotype
together	O
with	O
perpendicular	O
sections	O
of	O
the	O
tumour	S-Phenotype
/	O
perinephric	O
fat	O
interface	O
and	O
the	O
tumour	S-Phenotype
/	O
renal	O
sinus	O
interface	O
.	O

X	O
-	O
inactive	O
specific	O
transcript	O
(	O
XIST	O
)	O
,	O
premature	B-Phenotype
ovarian	I-Phenotype
failure	I-Phenotype
1B	E-Phenotype
(	O
POF1B	S-Phenotype
)	O
and	O
calmin	S-Phenotype
(	O
CLMN	S-Phenotype
)	O
were	O
identified	O
in	O
the	O
DEmRNA	O
-	O
DElncRNA	O
co	O
-	O
expression	O
network	O
.	O

Heparanase	O
(	O
liHPSE	O
/	O
i	O
)	O
expression	O
was	O
identified	O
in	O
50	O
%	O
of	O
GBM	O
tumours	S-Phenotype
by	O
immunostaining	O
,	O
and	O
was	O
characterised	O
by	O
a	O
high	B-Phenotype
intratumoural	I-Phenotype
heterogeneity	E-Phenotype
of	O
the	O
presence	O
of	O
the	O
HPSE	O
protein	O
.	O

Hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
is	O
known	O
as	O
a	O
highly	O
prevalent	O
cancer	S-Phenotype
with	O
a	O
poor	O
prognosis	O
and	O
short	O
survival	O
time	O
,	O
despite	O
intensive	O
research	O
and	O
clinical	O
efforts	O
.	O

Biallelic	O
mutations	O
in	O
IBA57	O
cause	O
a	O
mitochondrial	O
disorder	O
with	O
a	O
broad	O
phenotypic	O
spectrum	O
that	O
ranges	O
from	O
severe	O
intellectual	B-Phenotype
disability	E-Phenotype
to	O
adolescent	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
spastic	I-Phenotype
paraplegia	E-Phenotype
.	O

SNORD115	O
-	O
TAF1	O
and	O
SNORD	O
-	O
DPM2	O
dysfunction	O
introduce	O
possible	O
clues	O
to	O
the	O
parkinsonism	S-Phenotype
and	O
increased	B-Phenotype
creatinine	E-Phenotype
phosphokinase	O
in	O
NMS	O
,	O
while	O
abnormalities	O
of	O
SNORD115	O
-	O
RALGPS1	O
suggest	O
links	O
to	O
both	O
anti	O
-	O
NMDAR	O
encephalitis	S-Phenotype
and	O
the	O
proven	O
predisposing	O
catatonic	O
SHANK3	O
gene	O
.	O

We	O
found	O
a	O
significant	O
association	O
between	O
HACE1	O
rs9404576	O
polymorphism	O
and	O
decreased	O
Wilms	O
*	O
tumor	S-Phenotype
risk	O
.	O

These	O
subjects	O
share	O
a	O
set	O
of	O
common	O
facial	O
features	O
that	O
include	O
a	O
prominent	B-Phenotype
maxilla	E-Phenotype
and	O
upper	O
lip	O
that	O
readily	O
reveal	O
the	O
upper	O
gingiva	O
,	O
widely	B-Phenotype
spaced	I-Phenotype
teeth	E-Phenotype
,	O
and	O
a	O
broad	B-Phenotype
nasal	I-Phenotype
tip	E-Phenotype
.	O

Plant	O
homeo	O
domain	O
finger	O
protein	O
8	O
(	O
PHF8	O
)	O
,	O
as	O
an	O
oncogene	O
,	O
has	O
been	O
highlighted	O
in	O
cancer	S-Phenotype
development	O
and	O
progression	O
.	O

COG5	O
-	O
CDG	O
(	O
COG5	O
subunit	O
deficiency	O
)	O
is	O
a	O
multisystem	O
disease	O
with	O
dysmorphic	O
features	O
,	O
intellectual	B-Phenotype
disability	E-Phenotype
of	O
variable	O
degree	O
,	O
seizures	S-Phenotype
,	O
acquired	B-Phenotype
microcephaly	E-Phenotype
,	O
sensory	B-Phenotype
defects	E-Phenotype
and	O
autistic	B-Phenotype
behavior	E-Phenotype
.	O

We	O
found	O
that	O
(	O
i	O
)	O
KIF15	O
motility	O
differs	O
significantly	O
from	O
Eg5	O
;	O
(	O
ii	O
)	O
KIF15	O
-	O
IN	O
-	O
1	O
is	O
a	O
potent	O
inhibitor	O
of	O
KIF15	O
motility	O
;	O
(	O
iii	O
)	O
MT	O
gliding	O
powered	O
by	O
KIF15	O
and	O
Eg5	O
only	O
ceases	O
when	O
both	O
motors	O
are	O
inhibited	O
;	O
and	O
(	O
iv	O
)	O
pairing	O
KIF15	O
-	O
IN	O
-	O
1	O
with	O
Eg5	O
inhibitors	O
synergistically	O
reduces	O
cancer	S-Phenotype
cell	O
growth	O
.	O

Patients	O
also	O
present	O
a	O
variable	O
set	O
of	O
poorly	O
explained	O
additional	O
clinical	O
features	O
,	O
including	O
ichthyosis	S-Phenotype
,	O
impaired	B-Phenotype
intelligence	E-Phenotype
,	O
developmental	B-Phenotype
delay	E-Phenotype
and	O
anemia	S-Phenotype
.	O

We	O
provide	O
functional	O
evidence	O
to	O
support	O
the	O
pathogenicity	O
of	O
these	O
TMEM126B	O
variants	O
,	O
including	O
evidence	O
of	O
founder	O
effects	O
for	O
both	O
variants	O
,	O
and	O
establish	O
defects	O
within	O
this	O
gene	O
as	O
a	O
cause	O
of	O
complex	O
I	O
deficiency	O
in	O
association	O
with	O
either	O
pure	O
myopathy	S-Phenotype
in	O
adulthood	O
or	O
,	O
in	O
one	O
individual	O
,	O
a	O
severe	O
multisystem	O
presentation	O
(	O
chronic	B-Phenotype
renal	I-Phenotype
failure	E-Phenotype
and	O
cardiomyopathy	S-Phenotype
)	O
in	O
infancy	O
.	O

Chronic	B-Phenotype
hepatitis	E-Phenotype
B	O
virus	O
(	O
HBV	O
)	O
infection	O
is	O
partly	O
responsible	O
for	O
hepatitis	S-Phenotype
,	O
fatty	B-Phenotype
liver	E-Phenotype
disease	O
and	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
.	O

Furthermore	O
,	O
using	O
in	O
silico	O
pathogenicity	O
prediction	O
of	O
missense	O
variants	O
among	O
18	O
genes	O
associated	O
with	O
breast	B-Phenotype
/	I-Phenotype
ovarian	I-Phenotype
cancer	E-Phenotype
and	O
/	O
or	O
Lynch	B-Phenotype
syndrome	E-Phenotype
,	O
followed	O
by	O
KASP	O
genotyping	O
in	O
710	O
healthy	O
controls	O
,	O
we	O
identified	O
AAAAAAlikely	O
pathogenicAAAAAA	O
missense	O
variants	O
in	O
ATM	O
,	O
BRIP1	O
,	O
CHEK2	O
and	O
TP53	O
.	O

While	O
mGluR5	O
mRNA	O
expression	O
was	O
unchanged	O
,	O
mGluR5	O
protein	O
levels	O
were	O
significantly	O
higher	O
in	O
schizophrenia	S-Phenotype
subjects	O
compared	O
to	O
controls	O
(	O
total	O
:	O
+22	O
%	O
;	O
dimer	O
:	O
+54	O
%	O
;	O
p	O
AAAA	O
0.001	O
)	O
.	O

Therefore	O
,	O
PYCR1	O
might	O
serve	O
as	O
a	O
prognostic	O
biomaker	O
for	O
either	O
ER	O
-	O
positive	O
or	O
ER	O
-	O
negative	O
breast	B-Phenotype
cancer	E-Phenotype
subtypes	O
and	O
can	O
also	O
be	O
a	O
potential	O
target	O
for	O
breast	B-Phenotype
cancer	E-Phenotype
therapy	O

We	O
characterize	O
adult	O
-	O
onset	O
,	O
progressive	O
clinical	O
symptoms	O
of	O
two	O
afflicted	O
kindred	O
and	O
introduce	O
the	O
symptom	O
of	O
profound	B-Phenotype
spasticity	E-Phenotype
not	O
previously	O
associated	O
with	O
the	O
SCA13	O
phenotype	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
MNK	O
sustains	O
mTORC1	O
activity	O
following	O
rapamycin	O
treatment	O
and	O
contributes	O
to	O
mTORC1	O
signaling	O
following	O
T	O
cell	O
activation	O
and	O
growth	O
stimuli	O
in	O
cancer	S-Phenotype
cells	O
.	O

In	O
infants	O
and	O
children	O
,	O
it	O
can	O
lead	O
to	O
serious	O
and	O
permanent	O
damage	O
to	O
the	O
central	S-Phenotype
nervous	O
system	O
,	O
which	O
leads	O
to	O
the	O
manifesting	O
mental	B-Phenotype
retardation	E-Phenotype
.	O

VDR	O
gene	O
polymorphisms	O
BsmI	O
,	O
ApaI	O
,	O
and	O
TaqI	O
did	O
not	O
differ	O
between	O
the	O
papillary	O
thyroid	O
cancer	S-Phenotype
group	O
and	O
control	O
group	O
(	O
p	O
AAAA	O
0.05	O
,	O
each	O
)	O
.	O

Using	O
vectors	O
encoding	O
GATA3	O
with	O
mutations	O
frequently	O
occurring	O
in	O
mammary	O
tumors	S-Phenotype
,	O
we	O
found	O
that	O
several	O
mutations	O
on	O
GATA3	O
led	O
to	O
a	O
dysregulation	O
of	O
CtIP	O
,	O
and	O
therefore	O
HR	O
repair	O
.	O

The	O
genetic	O
model	O
analysis	O
found	O
that	O
GRM6	O
-	O
rs11746675	O
and	O
GRM6	O
-	O
rs2067011	O
were	O
suggestively	O
associated	O
with	O
high	B-Phenotype
myopia	E-Phenotype
in	O
the	O
recessive	O
model	O
(	O
OR=0.54	O
,	O
P=0.004	O
;	O
OR=0.52	O
,	O
P=0.003	O
;	O
respectively	O
)	O
.	O

The	O
estrogen	O
receptor	O
a	O
(	O
ER	O
)	O
and	O
the	O
progesterone	O
receptor	O
(	O
PgR	O
)	O
are	O
one	O
of	O
the	O
most	O
important	O
prognostic	O
and	O
predictive	O
immunohistochemical	O
markers	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

While	O
there	O
has	O
been	O
growing	O
interest	O
in	O
the	O
homodimeric	O
gene	O
products	O
of	O
CISD1	O
(	O
mitoNEET	O
)	O
and	O
CISD2	O
(	O
NAF	O
-	O
1	O
)	O
,	O
the	O
importance	O
of	O
the	O
inner	O
mitochondrial	O
CISD3	O
protein	O
has	O
only	O
recently	O
been	O
recognized	O
in	O
cancer	S-Phenotype
.	O

Although	O
no	O
overt	O
changes	O
in	O
corneal	B-Phenotype
opacity	E-Phenotype
were	O
detected	O
by	O
slit	O
-	O
lamp	O
examination	O
,	O
the	O
corneas	O
of	O
homozygous	O
mutant	O
mice	O
exhibited	O
histological	O
and	O
ultrastructural	O
epithelial	O
cell	O
fragility	O
phenotypes	O
.	O

Here	O
we	O
identify	O
a	O
novel	O
mechanism	O
of	O
NOTCH	O
regulation	O
and	O
TIC	S-Phenotype
induction	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
via	O
the	O
miR	O
-	O
106b	O
-	O
25	O
miRNA	O
cluster	O
.	O

For	O
diagnosis	O
of	O
central	B-Phenotype
nervous	I-Phenotype
system	I-Phenotype
degeneration	E-Phenotype
in	O
adolescents	O
with	O
bulbar	O
symptoms	O
,	O
great	O
attention	O
should	O
be	O
paid	O
to	O
JALS	O

Here	O
,	O
the	O
authors	O
investigate	O
driver	O
mutations	O
of	O
sporadic	B-Phenotype
chordoma	E-Phenotype
in	O
104	O
cases	O
,	O
revealing	O
duplications	O
in	O
notochordal	O
transcription	O
factor	O
brachyury	O
(	O
T	O
)	O
,	O
PI3K	O
signalling	O
mutations	O
,	O
and	O
mutations	O
in	O
LYST	O
,	O
a	O
potential	O
novel	O
cancer	S-Phenotype
gene	O
in	O
chordoma	S-Phenotype

the	O
association	O
between	O
SNPs	O
in	O
the	O
PALB2	O
gene	O
and	O
the	O
susceptibility	O
to	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

PDSS2	O
is	O
a	O
putative	O
tumor	S-Phenotype
suppressor	O
,	O
and	O
promoter	O
hypermethylation	O
is	O
a	O
key	O
regulatory	O
mechanism	O
in	O
HCC	O
.	O

Moreover	O
,	O
adoptively	O
transferred	O
human	O
naive	O
CD4+	O
T	O
cells	O
infiltrate	O
human	O
breast	B-Phenotype
cancer	E-Phenotype
orthotopic	O
xenografts	O
in	O
a	O
CCL18	O
-	O
dependent	O
manner	O
.	O

Notably	O
,	O
we	O
demonstrated	O
that	O
aberrant	O
SF3B4	O
overexpression	O
altered	O
the	O
progress	O
of	O
splicing	O
progress	O
of	O
the	O
tumor	S-Phenotype
suppressor	O
gene	O
,	O
kruppel	O
like	O
factor	O
4	O
(	O
KLF4	O
)	O
,	O
and	O
resulted	O
in	O
non	O
-	O
functional	O
skipped	O
exon	O
transcripts	O
.	O

ACTB	O
-	O
GLI1	O
fusions	O
have	O
been	O
reported	O
as	O
the	O
pathognomonic	O
genetic	O
abnormality	O
defining	O
an	O
unusual	O
subset	O
of	O
actin	O
-	O
positive	O
,	O
perivascular	O
myoid	O
tumors	S-Phenotype
,	O
known	O
as	O
AAAAAApericytoma	O
with	O
the	O
t	O
(	O
7	O
;	O
12	O
)	O
translocation.AAAAA	O
;	O
In	O
addition	O
,	O
GLI1	O
oncogenic	O
activation	O
through	O
a	O
related	O
MALAT1	O
-	O
GLI1	O
gene	O
fusion	O
has	O
been	O
recently	O
reported	O
in	O
2	O
unrelated	O
gastric	B-Phenotype
tumors	E-Phenotype
,	O
namely	O
plexiform	O
fibromyxoma	O
and	O
gastroblastoma	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
isolate	O
cancer	S-Phenotype
stem	O
-	O
like	O
cells	O
marked	O
by	O
high	O
expression	O
of	O
CD44	O
,	O
a	O
putative	O
cancer	S-Phenotype
stem	O
cell	O
marker	O
,	O
from	O
primary	O
oral	O
squamous	B-Phenotype
cell	I-Phenotype
carcinomas	E-Phenotype
and	O
identify	O
distinctive	O
gene	O
expression	O
patterns	O
in	O
these	O
cells	O
.	O

Our	O
study	O
revealed	O
that	O
LIFR	O
attenuates	O
tumor	S-Phenotype
metastasis	O
by	O
suppressing	O
YAP	O
expression	O
,	O
suggesting	O
that	O
LIFR	O
may	O
serve	O
as	O
a	O
potential	O
target	O
for	O
ccRCC	O
treatment	O

Finally	O
,	O
twenty	O
-	O
four	O
important	O
hub	O
genes	O
(	O
RASGRP2	O
,	O
IKZF1	O
,	O
CXCR5	O
,	O
LTB	O
,	O
BLK	O
,	O
LINGO3	O
,	O
CCR6	O
,	O
P2RY10	O
,	O
RHOH	O
,	O
JUP	O
,	O
KRT14	O
,	O
PLA2G3	O
,	O
SPRR1A	O
,	O
KRT78	O
,	O
SFN	O
,	O
CLDN4	O
,	O
IL1RN	O
,	O
PKP3	O
,	O
CBLC	O
,	O
KRT16	O
,	O
TMEM79	O
,	O
KLK8	O
,	O
LYPD3	O
and	O
LYPD5	O
)	O
were	O
treated	O
as	O
valuable	O
factors	O
involved	O
in	O
the	O
immune	O
response	O
and	O
tumor	S-Phenotype
cell	O
development	O
in	O
tumorigenesis	O
.	O

Here	O
,	O
a	O
novel	O
animal	O
model	O
was	O
used	O
to	O
study	O
how	O
vIL	O
-	O
6	O
affects	O
tumor	S-Phenotype
development	O
.	O

Our	O
results	O
demonstrated	O
pairwise	O
epistatic	O
interactions	O
between	O
ERCC6	O
and	O
ERCC8	O
SNPs	O
that	O
ERCC6	O
rs1917799	O
-	O
ERCC8	O
rs158572	O
combination	O
was	O
associated	O
with	O
decreased	O
risk	O
of	O
chronic	B-Phenotype
atrophic	I-Phenotype
gastritis	E-Phenotype
and	O
increased	O
risk	O
of	O
gastric	B-Phenotype
cancer	E-Phenotype
.	O

Three	O
predicted	O
driver	O
genes	O
(	O
CDKN2A	O
,	O
AKT1	O
,	O
RNF139	O
)	O
were	O
found	O
common	O
in	O
these	O
three	O
cancers	S-Phenotype
by	O
comparative	O
analysis	O
.	O

Additionally	O
,	O
despite	O
GDAP1	O
affecting	O
mitochondrial	O
functionality	O
,	O
and	O
hence	O
being	O
of	O
great	O
importance	O
to	O
cellular	O
function	O
,	O
the	O
GDAP1	O
-	O
associated	O
Charcot	O
-	O
Marie	O
-	O
Tooth	O
disease	O
is	O
mainly	O
characterized	O
by	O
axonal	B-Phenotype
degeneration	E-Phenotype
.	O

The	O
resulting	O
loss	O
of	O
cellular	O
respiration	O
ultimately	O
induces	O
mitochondrial	S-Phenotype
genetic	O
diseases	O
,	O
including	O
mtDNA	O
depletion	O
syndromes	O
(	O
MDS	O
)	O
such	O
as	O
Alpers	O
or	O
early	O
infantile	O
hepatocerebral	O
syndromes	O
,	O
and	O
mtDNA	O
deletion	O
disorders	O
such	O
as	O
progressive	B-Phenotype
external	I-Phenotype
ophthalmoplegia	E-Phenotype
,	O
ataxia	S-Phenotype
-	O
neuropathy	S-Phenotype
,	O
or	O
mitochondrial	B-Phenotype
neurogastrointestinal	I-Phenotype
encephalomyopathy	E-Phenotype
.	O

ZC4H2	O
is	O
a	O
small	O
nuclear	O
protein	O
associated	O
with	O
intellectual	B-Phenotype
disability	E-Phenotype
and	O
neural	O
development	O
in	O
humans	O
.	O

We	O
reinforce	O
the	O
potential	O
of	O
CASP3	O
as	O
an	O
interesting	O
target	O
to	O
be	O
explored	O
in	O
adult	O
and	O
pediatric	O
cHL	O
,	O
and	O
alert	O
for	O
its	O
dual	O
biological	O
role	O
in	O
H	O
-	O
RS	O
cells	O
and	O
tumor	S-Phenotype
microenvironment	O

Statins	O
are	O
the	O
first	O
line	O
of	O
lipid	O
-	O
lowering	O
drugs	O
for	O
treating	O
FH	O
and	O
other	O
types	O
of	O
hypercholesterolemia	S-Phenotype
,	O
but	O
new	O
approaches	O
are	O
emerging	O
,	O
in	O
particular	O
PCSK9	O
antibodies	O
,	O
which	O
are	O
now	O
being	O
tested	O
in	O
clinical	O
trials	O
.	O

Pain	S-Phenotype
was	O
significantly	O
higher	O
in	O
LZTR1	O
-	O
mutant	O
than	O
in	O
SMARCB1	O
-	O
mutant	O
patients	O
,	O
though	O
spinal	B-Phenotype
tumor	E-Phenotype
location	O
did	O
not	O
significantly	O
correlate	O
with	O
pain	S-Phenotype
.	O

Other	O
EXOSC3	O
mutations	O
and	O
EXOSC8	O
cases	O
are	O
intermediate	O
-	O
SMA	O
type	O
1	O
-	O
like	O
presentation	O
,	O
spasticity	S-Phenotype
(	O
mostly	O
in	O
EXOSC8	O
)	O
and	O
death	O
between	O
3	O
months	O
and	O
5	O
years	O
.	O

ASXL1	O
(	O
additional	O
sex	O
combs	O
like	O
1	O
)	O
is	O
a	O
gene	O
that	O
is	O
mutated	O
in	O
a	O
number	O
of	O
hematological	B-Phenotype
neoplasms	E-Phenotype
.	O

Our	O
findings	O
suggest	O
that	O
SBF1	O
mutations	O
may	O
cause	O
a	O
syndromic	O
form	O
of	O
autosomal	B-Phenotype
recessive	I-Phenotype
axonal	I-Phenotype
neuropathy	E-Phenotype
(	O
AR	B-Phenotype
-	I-Phenotype
CMT2	E-Phenotype
)	O
in	O
addition	O
to	O
CMT4B3	O

Progressive	B-Phenotype
retinal	I-Phenotype
atrophy	E-Phenotype
(	O
PRA	S-Phenotype
)	O
in	O
dogs	O
,	O
the	O
canine	O
equivalent	O
of	O
retinitis	B-Phenotype
pigmentosa	E-Phenotype
(	O
RP	S-Phenotype
)	O
in	O
humans	O
,	O
is	O
characterised	O
by	O
vision	B-Phenotype
loss	E-Phenotype
due	O
to	O
degeneration	O
of	O
the	O
photoreceptor	O
cells	O
in	O
the	O
retina	O
,	O
eventually	O
leading	O
to	O
complete	O
blindness	S-Phenotype
.	O

Family	B-Phenotype
hyperaldosteronism	I-Phenotype
type	I-Phenotype
I	E-Phenotype
(	O
glucocorticoids	B-Phenotype
-	I-Phenotype
remediable	I-Phenotype
hyperaldosteronism	E-Phenotype
)	O
is	O
a	O
rare	O
form	O
of	O
symptomatic	O
arterial	B-Phenotype
hypertension	E-Phenotype
(	O
AH	S-Phenotype
)	O
,	O
which	O
often	O
leads	O
to	O
the	O
development	O
of	O
cerebrovascular	O
complications	O
.	O

The	O
PI	O
for	O
both	O
markers	O
was	O
significantly	O
higher	O
in	O
neuroblastomas	S-Phenotype
from	O
patients	O
with	O
unfavorable	O
clinical	O
(	O
high	O
-	O
risk	O
group	O
,	O
advanced	O
stage	O
,	O
age	O
≥18	O
months	O
at	O
presentation	O
,	O
primary	O
abdominal	O
compared	O
to	O
extra	O
-	O
abdominal	O
sites	O
)	O
,	O
biological	O
(	O
MYCN	O
amplification	O
,	O
1p	O
deletion	O
,	O
17q	O
gain	O
)	O
,	O
and	O
pathological	O
(	O
undifferentiated	O
or	O
poorly	O
differentiated	O
status	O
,	O
high	O
mitosis	O
-	O
karyorrhexis	O
index	O
,	O
[	O
MKI	O
]	O
,	O
unfavorable	O
histology	O
)	O
factors	O
.	O

Reverse	O
phenotyping	O
of	O
12	O
affected	O
individuals	O
from	O
eight	O
families	O
revealed	O
a	O
homogeneous	O
EOEE	O
phenotype	O
characterized	O
by	O
severe	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
poor	B-Phenotype
visual	I-Phenotype
contact	E-Phenotype
with	O
optic	B-Phenotype
atrophy	E-Phenotype
,	O
and	O
postnatal	B-Phenotype
microcephaly	E-Phenotype
.	O

We	O
report	O
here	O
that	O
t	O
-	O
butyl	O
alcohol	O
,	O
which	O
is	O
neither	O
a	O
substrate	O
nor	O
an	O
inhibitor	O
of	O
alcohol	O
dehydrogenases	O
or	O
Cyp2E1	O
,	O
is	O
a	O
potent	O
inducer	O
of	O
holoprosencephaly	S-Phenotype
in	O
Cdon	O
mutant	O
mice	O
.	O

These	O
findings	O
suggest	O
that	O
ADAM10	O
could	O
potentially	O
contribute	O
to	O
metastases	O
of	O
oral	O
cancer	S-Phenotype
.	O

Phaeochromocytoma	S-Phenotype
and	O
paraganglioma	S-Phenotype
(	O
PHEO	S-Phenotype
/	O
PGL	S-Phenotype
)	O
are	O
rare	O
tumours	S-Phenotype
with	O
an	O
estimated	O
annual	O
incidence	O
of	O
3	O
per	O
million	O
.	O

Like	O
other	O
macular	B-Phenotype
degenerations	E-Phenotype
,	O
pathogenesis	O
within	O
the	O
retinal	O
pigment	O
epithelium	O
(	O
RPE	O
)	O
appears	O
to	O
contribute	O
to	O
the	O
loss	O
of	O
photoreceptors	O
from	O
the	O
central	O
retina	O
.	O

One	O
upregulated	O
candidate	O
named	O
transmembrane	O
protein	O
98	O
(	O
TMEM98	O
)	O
was	O
found	O
to	O
be	O
overexpressed	O
in	O
80	O
of	O
118	O
(	O
67.80	O
%	O
)	O
of	O
patients	O
with	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
.	O

We	O
suggest	O
that	O
the	O
combination	O
of	O
reduced	O
NM23	O
-	O
H1	O
,	O
induced	O
MACC1	O
,	O
and	O
the	O
presence	O
of	O
tumor	S-Phenotype
budding	O
are	O
promising	O
biomarkers	O
for	O
the	O
prediction	O
of	O
recurrence	O
and	O
may	O
aid	O
the	O
stratification	O
of	O
patients	O
with	O
stage	O
II	O
colon	B-Phenotype
cancer	E-Phenotype
for	O
adjuvant	O
chemotherapy	O

TREM2	O
protein	O
levels	O
were	O
also	O
negatively	O
correlated	O
with	O
the	O
severity	O
of	O
symptoms	O
in	O
humans	O
affected	O
by	O
autism	S-Phenotype
.	O

Dihydropyrimidinase	O
(	O
DHP	O
)	O
deficiency	O
is	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
disease	O
caused	O
by	O
mutations	O
in	O
the	O
DPYS	O
gene	O
.	O

Mutations	O
in	O
IFT172	O
lead	O
to	O
diseases	O
ranging	O
from	O
isolated	O
retinal	B-Phenotype
degeneration	E-Phenotype
to	O
severe	O
syndromic	O
ciliopathies	S-Phenotype
.	O

Amyotrophic	B-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
(	O
ALS	S-Phenotype
)	O
is	O
a	O
complex	O
neurodegenerative	B-Phenotype
disease	E-Phenotype
,	O
characterized	O
genetically	O
by	O
a	O
disproportionately	O
large	O
contribution	O
of	O
rare	O
genetic	O
variation	O
.	O

CD133	O
has	O
been	O
shown	O
to	O
be	O
an	O
important	O
stem	O
cell	O
factor	O
that	O
promotes	O
glioma	S-Phenotype
progression	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
functional	O
role	O
of	O
BKCa	O
in	O
endometrial	B-Phenotype
cancer	E-Phenotype
HEC	O
-	O
1	O
-	O
B	O
cells	O
.	O

STXBP1	O
mutations	O
cause	O
early	B-Phenotype
infantile	I-Phenotype
epileptic	I-Phenotype
encephalopathy	E-Phenotype
(	O
EIEE	S-Phenotype
)	O
,	O
various	O
intractable	O
epilepsies	S-Phenotype
,	O
and	O
neurodevelopmental	O
disorders	O
.	O

Beyond	O
neoplasms	S-Phenotype
,	O
several	O
congenital	O
developmental	O
functional	O
disorders	O
such	O
as	O
Coffin	O
-	O
Siris	O
syndrome	O
and	O
intellectual	B-Phenotype
disability	E-Phenotype
are	O
now	O
known	O
to	O
be	O
SWI	O
/	O
SNF	O
-	O
related	O
.	O

However	O
,	O
siRNA	O
-	O
based	O
therapeutics	O
face	O
important	O
challenges	O
,	O
including	O
rapid	O
serum	O
degradation	O
,	O
poor	O
tumor	S-Phenotype
cell	O
uptake	O
and	O
cellular	O
uptake	O
,	O
leading	O
to	O
off	O
-	O
target	O
effects	O
.	O

In	O
the	O
single	O
-	O
locus	O
analysis	O
,	O
two	O
variants	O
,	O
the	O
NBS1	O
rs1805794	O
(	O
OR	O
1.42	O
,	O
95	O
%	O
CI	O
1.15	O
-	O
1.76	O
,	O
P	O
=	O
0.001	O
)	O
,	O
and	O
RAD54L	O
rs1048771	O
(	O
OR	O
1.61	O
,	O
95	O
%	O
CI	O
1.17	O
-	O
2.22	O
,	O
P	O
=	O
0.002	O
)	O
were	O
significantly	O
associated	O
with	O
glioma	S-Phenotype
risk	O
.	O

Autosomal	O
recessive	O
ataxias	S-Phenotype
are	O
a	O
clinically	O
diverse	O
group	O
of	O
syndromes	O
that	O
in	O
some	O
cases	O
are	O
caused	O
by	O
mutations	O
in	O
genes	O
with	O
roles	O
in	O
the	O
DNA	O
damage	O
response	O
,	O
transcriptional	O
regulation	O
or	O
mitochondrial	O
function	O
.	O

In	O
fact	O
,	O
HDAC6	O
inhibitors	O
effectively	O
limit	O
the	O
progression	O
of	O
kidney	B-Phenotype
diseases	E-Phenotype
,	O
suggesting	O
that	O
targeting	O
HDAC6	O
may	O
provide	O
a	O
novel	O
treatment	O
approach	O
.	O

The	O
postsynaptic	O
density	O
(	O
PSD	O
)	O
contains	O
a	O
complex	O
set	O
of	O
proteins	O
of	O
known	O
relevance	O
to	O
neuropsychiatric	O
disorders	O
,	O
and	O
schizophrenia	S-Phenotype
specifically	O
.	O

Several	O
studies	O
suggested	O
that	O
alcohol	O
promotes	O
tumor	S-Phenotype
growth	O
by	O
altering	O
immune	O
cell	O
phenotypesin	O
the	O
liver.Arginine	O
methylation	O
is	O
a	O
common	O
posttranslational	O
modification	O
generated	O
mostly	O
by	O
a	O
single	O
protein	O
,	O
PRMT1	O
.	O

Since	O
prion	O
diseases	O
have	O
quite	O
heterogeneous	S-Phenotype
phenotypes	O
,	O
a	O
complex	O
analysis	O
,	O
a	O
combination	O
of	O
genetic	O
screening	O
,	O
cerebrospinal	O
fluid	O
biomarker	O
analysis	O
and	O
imaging	O
technologies	O
could	O
improve	O
the	O
early	O
disease	O
diagnosis	O

Naive	O
CD4sup+	O
/	O
sup	O
T	O
cells	O
adhere	O
to	O
tumor	S-Phenotype
slices	O
in	O
proportion	O
to	O
the	O
abundance	O
of	O
CCL18	O
-	O
producing	O
macrophages	O
.	O

We	O
show	O
that	O
HOXB1	O
expression	O
is	O
significantly	O
downregulated	O
in	O
glioma	S-Phenotype
tissues	O
and	O
cell	O
lines	O
,	O
and	O
that	O
its	O
expression	O
may	O
be	O
closely	O
associated	O
with	O
the	O
degree	O
of	O
malignancy	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
sequenced	O
the	O
CLDN14	O
risk	O
haplotype	O
in	O
a	O
cohort	O
of	O
children	O
with	O
idiopathic	B-Phenotype
hypercalciuria	E-Phenotype
and	O
kidney	B-Phenotype
stones	E-Phenotype
.	O

To	O
further	O
understand	O
why	O
AHCY	O
inhibitors	O
decreased	O
prostate	B-Phenotype
cancer	E-Phenotype
cell	O
growth	O
,	O
we	O
performed	O
microRNA	O
expression	O
profiling	O
with	O
LNCaP	O
-	O
hr	O
cells	O
.	O

Methods	O
:	O
Ten	O
potentially	O
functional	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
seven	O
prostate	O
CSC	O
marker	O
genes	O
,	O
TACSTD2	O
,	O
PROM1	O
,	O
ITGA2	O
,	O
POU5F1	O
,	O
EZH2	O
,	O
PSCA	O
,	O
and	O
CD44	O
,	O
were	O
selected	O
for	O
analysis	O
of	O
their	O
association	O
with	O
disease	O
recurrence	O
by	O
Kaplan	O
-	O
Meier	O
analysis	O
and	O
Cox	O
regression	O
in	O
a	O
cohort	O
of	O
320	O
patients	O
with	O
localized	O
prostate	B-Phenotype
cancer	E-Phenotype
receiving	O
radical	O
prostatectomy	O
.	O

Although	O
many	O
new	O
anti	O
-	O
cancer	S-Phenotype
drugs	O
were	O
developed	O
in	O
the	O
last	O
years	O
,	O
it	O
is	O
unclear	O
which	O
of	O
these	O
drugs	O
can	O
be	O
safely	O
combined	O
to	O
improve	O
standard	O
therapy	O
without	O
antagonizing	O
anti	O
-	O
CD20	O
efficacy	O
.	O

Of	O
the	O
genes	O
detected	O
out	O
,	O
GJB2	O
gene	O
mutation	O
was	O
with	O
significant	O
difference	O
(	O
χsup2	O
/	O
sup	O
=	O
75.132	O
,	O
p	O
=	O
0.000	O
)	O
between	O
audio	O
-	O
no	O
-	O
pass	O
group	O
(	O
417	O
/	O
1315	O
,	O
31.711	O
%	O
)	O
and	O
random	O
-	O
selected	O
cohort	O
(	O
159	O
/	O
1000	O
,	O
15.900	O
%	O
)	O
;	O
c.109G	O
AAAA	O
A	O
was	O
the	O
most	O
common	O
allele	O
,	O
as	O
well	O
as	O
the	O
only	O
one	O
with	O
significantly	O
different	O
allele	O
frequency	O
(	O
χsup2	O
/	O
sup	O
=	O
79.327	O
,	O
p	O
=	O
0.000	O
)	O
between	O
audio	O
-	O
no	O
-	O
pass	O
group	O
(	O
392	O
/	O
1315	O
,	O
16.84	O
%	O
)	O
and	O
random	O
-	O
selected	O
cohort	O
(	O
140	O
/	O
1000	O
,	O
7.55	O
%	O
)	O
,	O
which	O
suggested	O
c.109G	O
AAAA	O
A	O
mutation	O
was	O
critical	O
for	O
newborns	O
'	O
hearing	B-Phenotype
loss	E-Phenotype
.	O

Patients	O
exhibit	O
a	O
variety	O
of	O
symptoms	O
predominantly	O
linked	O
to	O
the	O
function	O
of	O
FMRP	O
protein	O
in	O
the	O
nervous	O
system	O
like	O
autistic	B-Phenotype
behavior	E-Phenotype
and	O
mild	O
-	O
to	O
-	O
severe	O
intellectual	B-Phenotype
disability	E-Phenotype
.	O

A	O
major	O
implication	O
of	O
our	O
study	O
is	O
that	O
inhibition	O
of	O
miR	O
-	O
587	O
or	O
restoration	O
of	O
PPP2R1B	O
expression	O
may	O
have	O
significant	O
therapeutic	O
potential	O
to	O
overcome	O
drug	B-Phenotype
resistance	E-Phenotype
in	O
colorectal	B-Phenotype
cancer	E-Phenotype
patients	O
and	O
that	O
the	O
combined	O
use	O
of	O
an	O
AKT	O
inhibitor	O
with	O
5	O
-	O
FU	O
may	O
increase	O
efficacy	O
in	O
colorectal	B-Phenotype
cancer	E-Phenotype
treatment	O

Serine	O
biosynthesis	O
defects	O
result	O
from	O
deficiencies	O
in	O
PGDH	O
,	O
PSAT	O
,	O
or	O
PSP	O
and	O
have	O
a	O
broad	O
phenotypic	O
spectrum	O
ranging	O
from	O
Neu	O
-	O
Laxova	O
syndrome	O
,	O
a	O
lethal	O
multiple	O
congenital	O
anomaly	O
disease	O
at	O
the	O
severe	O
end	O
to	O
a	O
childhood	O
disease	O
with	O
intellectual	B-Phenotype
disability	E-Phenotype
at	O
the	O
mild	O
end	O
,	O
with	O
infantile	B-Phenotype
growth	I-Phenotype
deficiency	E-Phenotype
,	O
and	O
severe	O
neurological	O
manifestations	O
as	O
an	O
intermediate	O
phenotype	O
.	O

Our	O
findings	O
provide	O
a	O
unique	O
insight	O
into	O
the	O
roles	O
and	O
effects	O
of	O
NSUN2	O
overexpression	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
and	O
highlight	O
the	O
necessity	O
of	O
the	O
investigation	O
of	O
novel	O
therapeutic	O
targets	O
,	O
such	O
as	O
NSUN2	O
,	O
for	O
the	O
improvement	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
treatments	O

Chylomicron	O
retention	O
disease	O
(	O
CRD	O
)	O
is	O
a	O
rare	O
autosomal	B-Phenotype
recessive	I-Phenotype
hereditary	I-Phenotype
hypocholesterolemic	I-Phenotype
disorder	E-Phenotype
.	O

Activating	O
mutations	O
in	O
the	O
KIT	O
or	O
PDGFRA	O
receptor	O
tyrosine	O
kinases	O
are	O
hallmarks	O
of	O
gastrointestinal	B-Phenotype
stromal	I-Phenotype
tumor	E-Phenotype
(	O
GIST	S-Phenotype
)	O
.	O

We	O
performed	O
whole	O
-	O
exome	O
sequencing	O
on	O
a	O
12	O
-	O
year	O
-	O
old	O
Japanese	O
male	O
with	O
severe	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
congenital	B-Phenotype
bilateral	I-Phenotype
cataracts	E-Phenotype
,	O
spasticity	S-Phenotype
,	O
hypotonia	S-Phenotype
with	O
motor	B-Phenotype
regression	E-Phenotype
and	O
progressive	B-Phenotype
cerebellar	I-Phenotype
atrophy	E-Phenotype
with	O
hyperintensity	O
of	O
the	O
cerebellar	O
cortex	O
on	O
T2	O
-	O
weighted	O
images	O
.	O

C1QBP	O
deficiency	O
represents	O
an	O
important	O
mitochondrial	O
disorder	O
associated	O
with	O
a	O
clinical	O
spectrum	O
ranging	O
from	O
infantile	B-Phenotype
lactic	I-Phenotype
acidosis	E-Phenotype
to	O
childhood	O
(	O
cardio	O
)	O
myopathy	S-Phenotype
and	O
late	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
progressive	I-Phenotype
external	I-Phenotype
ophthalmoplegia	E-Phenotype

We	O
also	O
found	O
that	O
increased	O
miR	O
-	O
663	O
expression	O
in	O
breast	B-Phenotype
tumors	E-Phenotype
consistently	O
correlates	O
with	O
increased	O
patient	O
survival	O
.	O

A	O
branch	O
-	O
site	O
mutation	O
in	O
the	O
human	O
gene	O
encoding	O
assembly	O
factor	O
NUBPL	O
has	O
recently	O
been	O
associated	O
with	O
mitochondrial	B-Phenotype
encephalopathy	E-Phenotype
and	O
complex	O
I	O
deficiency	O
in	O
seven	O
independent	O
cases	O
.	O

A	O
retrospective	O
series	O
of	O
52	O
sporadic	O
primary	O
surgically	O
resected	O
SI	O
-	O
NETs	O
,	O
which	O
were	O
metastatic	O
at	O
diagnosis	O
,	O
was	O
analyzed	O
by	O
high	O
-	O
coverage	O
target	O
sequencing	O
(	O
HCTS	O
)	O
for	O
the	O
mutational	O
status	O
of	O
57	O
genes	O
and	O
copy	O
number	O
status	O
of	O
40	O
genes	O
selected	O
from	O
recently	O
published	O
genome	O
sequencing	O
data	O
.	O

Our	O
results	O
demonstrate	O
that	O
adenomyoepitheliomas	O
are	O
genetically	O
heterogeneous	S-Phenotype
,	O
and	O
qualify	O
mutations	O
in	O
HRAS	O
,	O
a	O
gene	O
whose	O
mutations	O
are	O
vanishingly	O
rare	O
in	O
common	O
-	O
type	O
breast	B-Phenotype
cancers	E-Phenotype
,	O
as	O
likely	O
drivers	O
of	O
ER	O
-	O
negative	O
adenomyoepitheliomas	O

Genome	O
-	O
wide	O
association	O
studies	O
have	O
identified	O
SNPs	O
near	O
ZNF365	O
at	O
10q21.2	O
that	O
are	O
associated	O
with	O
both	O
breast	B-Phenotype
cancer	E-Phenotype
risk	O
and	O
mammographic	O
density	O
.	O

In	O
an	O
effort	O
to	O
circumvent	O
resistance	O
to	O
rapamycin	O
-	O
-	O
an	O
mTOR	O
inhibitor	O
-	O
-	O
we	O
searched	O
for	O
novel	O
rapamycin	O
-	O
downstream	O
-	O
targets	O
that	O
may	O
be	O
key	O
players	O
in	O
the	O
response	O
of	O
cancer	S-Phenotype
cells	O
to	O
therapy	O
.	O

Objective	O
:	O
To	O
study	O
the	O
effect	O
and	O
mechanism	O
of	O
S1PR2	O
inhibition	O
on	O
epithelial	B-Phenotype
ovarian	I-Phenotype
cancer	E-Phenotype
SKOV3	O
cell	O
proliferation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Patients	O
with	O
KCNK9	O
imprinting	O
syndrome	O
demonstrate	O
congenital	B-Phenotype
hypotonia	E-Phenotype
,	O
variable	O
cleft	B-Phenotype
palate	E-Phenotype
,	O
normal	O
MRIs	O
and	O
EEGs	O
,	O
delayed	B-Phenotype
development	E-Phenotype
,	O
and	O
feeding	O
problems	O
.	O

SAA1	O
was	O
identified	O
from	O
MS	O
analysis	O
,	O
and	O
its	O
level	O
was	O
revealed	O
to	O
be	O
correlated	O
with	O
the	O
disease	O
grade	O
,	O
clinical	O
severity	O
,	O
and	O
survival	O
rate	O
of	O
patients	O
with	O
gliomas	S-Phenotype
.	O

We	O
identified	O
DNAJC12	O
homozygous	O
null	O
variants	O
(	O
c.187AAAAAT	O
;	O
p.K63	O
*	O
and	O
c.79	O
-	O
2AAAAAG	O
;	O
p.V27Wfs	O
*	O
14	O
)	O
in	O
two	O
kindreds	O
with	O
early	O
-	O
onset	O
parkinsonism	S-Phenotype
.	O

Using	O
in	O
situ	O
hybridization	O
,	O
we	O
show	O
that	O
CRG	O
-	O
L2	O
mRNA	O
levels	O
are	O
increased	O
early	O
during	O
the	O
development	O
of	O
liver	B-Phenotype
tumors	E-Phenotype
in	O
C3H	O
/	O
HeJ	O
mice	O
,	O
and	O
that	O
in	O
normal	O
tissues	O
CRG	O
-	O
L2	O
mRNA	O
is	O
restricted	O
to	O
the	O
murine	O
testis	O
and	O
human	O
placenta	O
.	O

A	O
founder	O
mutation	O
in	O
RIC1	O
(	O
KIAA1432	O
)	O
was	O
identified	O
in	O
patients	O
with	O
cataract	S-Phenotype
,	O
brain	B-Phenotype
atrophy	E-Phenotype
,	O
microcephaly	S-Phenotype
with	O
or	O
without	O
cleft	B-Phenotype
lip	I-Phenotype
and	I-Phenotype
palate	E-Phenotype
.	O

Three	O
SCAR	S-Phenotype
markers	O
(	O
BC10	O
-	O
1	O
,	O
BC13	O
-	O
4	O
and	O
BC31	O
-	O
2	O
)	O
had	O
high	O
levels	O
of	O
genomic	O
DNA	O
amplification	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

Additionally	O
,	O
our	O
results	O
displayed	O
that	O
Licl	O
had	O
antitumor	O
activity	S-Phenotype
against	O
PC	O
-	O
3	O
through	O
the	O
inhibition	O
of	O
Wnt	O
/	O
β	O
-	O
catenin	O
pathway	O
.	O

Genetic	O
studies	O
on	O
consanguineous	O
families	O
with	O
primary	B-Phenotype
microcephaly	E-Phenotype
have	O
identified	O
15	O
(	O
MCPH	O
)	O
causative	O
genes	O
that	O
include	O
MCPH1	O
,	O
WDR62	O
,	O
CDK5RAP2	O
,	O
CASC5	O
,	O
ASPM	O
,	O
CENPJ	O
,	O
STIL	O
,	O
CEP135	O
,	O
CEP152	O
,	O
ZNF335	O
,	O
PHC1	O
,	O
CDK6	O
,	O
CENPE	O
,	O
SASS6	O
MFSD2A	O
ANKLE2	O
and	O
CIT	O
(	O
Khan	O
et	O
al	O
.	O

Inhibiting	O
naive	O
CD4+	O
T	O
cell	O
recruitment	O
into	O
tumors	S-Phenotype
by	O
interfering	O
with	O
PITPNM3	O
recognition	O
of	O
CCL18	O
may	O
be	O
an	O
attractive	O
strategy	O
for	O
anticancer	O
immunotherapy	S-Phenotype

These	O
results	O
indicated	O
that	O
the	O
HFD	O
aggravates	O
BDE47	O
-	O
inhibited	O
testosterone	O
production	O
through	O
hyperinsulinemia	S-Phenotype
,	O
and	O
the	O
accumulation	O
of	O
testicular	O
BDE47	O
that	O
induces	O
the	O
up	O
-	O
regulation	O
of	O
DAX	O
-	O
1	O
and	O
the	O
subsequent	O
down	O
-	O
regulation	O
of	O
steroidogenic	O
proteins	O
,	O
i.e.	O
,	O
StAR	O
and	O
3β	O
-	O
HSD	O
,	O
in	O
Leydig	O
cells	O

Eleven	O
of	O
the	O
43	O
kindreds	O
affected	O
by	O
sporadic	O
disease	O
(	O
26	O
%	O
)	O
carry	O
RPSA	O
mutations	O
,	O
whereas	O
12	O
of	O
the	O
13	O
multiplex	O
kindreds	O
(	O
92	O
%	O
)	O
carry	O
RPSA	O
mutations	O
.	O

The	O
latter	O
SNP	O
lies	O
just	O
outside	O
exon	O
8	O
and	O
is	O
highly	O
correlated	O
(	O
r2	O
=	O
0.96	O
)	O
with	O
the	O
missense	O
SNP	O
rs5756795	O
in	O
exon	O
7	O
of	O
TRIOBP	O
,	O
a	O
gene	O
previously	O
associated	O
with	O
prelingual	B-Phenotype
nonsyndromic	I-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
.	O

Moreover	O
,	O
the	O
disrupted	O
balance	O
between	O
HFs	O
and	O
SGs	O
,	O
especially	O
in	O
the	O
Hoxc13	O
-	O
/	O
-	O
rabbits	O
,	O
can	O
be	O
used	O
as	O
an	O
ideal	O
animal	O
model	O
for	O
dermatology	O
ailments	O
,	O
such	O
as	O
acne	S-Phenotype
and	O
hypotrichosis	S-Phenotype
,	O
in	O
preclinical	O
studies	O
.	O

It	O
has	O
been	O
proposed	O
that	O
transcobalamin	O
2	O
(	O
TCN2	O
)	O
and	O
the	O
transcobalamin	O
2	O
receptor	O
(	O
TCN2R	O
)	O
are	O
associated	O
with	O
idiopathic	B-Phenotype
recurrent	I-Phenotype
spontaneous	I-Phenotype
abortion	E-Phenotype
(	O
RSA	S-Phenotype
)	O
.	O

Anaplastic	O
lymphoma	S-Phenotype
kinase	O
(	O
ALK	O
)	O
rearrangements	O
were	O
first	O
implicated	O
as	O
driving	O
mutations	O
in	O
non	B-Phenotype
-	I-Phenotype
small	I-Phenotype
cell	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
in	O
2007	O
.	O

Cushing	O
's	O
disease	O
results	O
from	O
corticotroph	O
adenomas	O
of	O
the	O
pituitary	O
that	O
hypersecrete	O
adrenocorticotropin	O
(	O
ACTH	O
)	O
,	O
leading	O
to	O
excess	O
glucocorticoid	O
and	O
hypercortisolism	S-Phenotype
.	O

In	O
T2D	O
patients	O
,	O
PAX4	O
Arg192His	O
was	O
associated	O
with	O
earlier	O
age	O
at	O
diagnosis	O
,	O
and	O
GLP1R	O
Arg131Gln	O
was	O
associated	O
with	O
decreased	O
risk	O
of	O
cardiovascular	B-Phenotype
disease	E-Phenotype
.	O

We	O
provide	O
functional	O
evidence	O
to	O
support	O
the	O
pathogenicity	O
of	O
these	O
TMEM126B	O
variants	O
,	O
including	O
evidence	O
of	O
founder	O
effects	O
for	O
both	O
variants	O
,	O
and	O
establish	O
defects	O
within	O
this	O
gene	O
as	O
a	O
cause	O
of	O
complex	O
I	O
deficiency	O
in	O
association	O
with	O
either	O
pure	O
myopathy	S-Phenotype
in	O
adulthood	O
or	O
,	O
in	O
one	O
individual	O
,	O
a	O
severe	O
multisystem	O
presentation	O
(	O
chronic	B-Phenotype
renal	I-Phenotype
failure	E-Phenotype
and	O
cardiomyopathy	S-Phenotype
)	O
in	O
infancy	O
.	O

p53R2	O
may	O
be	O
a	O
useful	O
prognostic	O
biomarker	O
and	O
therapeutic	O
target	O
for	O
cervical	O
cancer	O

In	O
a	O
family	O
with	O
sensory	B-Phenotype
neuropathy	E-Phenotype
with	O
loss	O
of	O
pain	S-Phenotype
perception	O
and	O
destruction	O
of	O
the	O
pedal	O
skeleton	O
we	O
report	O
a	O
missense	O
mutation	O
in	O
a	O
highly	O
conserved	O
amino	O
acid	O
residue	O
of	O
atlastin	O
GTPase	O
3	O
(	O
ATL3	O
)	O
,	O
an	O
endoplasmic	O
reticulum	O
-	O
shaping	O
GTPase	O
.	O

We	O
reported	O
a	O
milder	O
form	O
of	O
COG5	O
defect	O
showing	O
Friedreich	O
*	O
s	O
-	O
ataxia	S-Phenotype
-	O
like	O
phenotypes	O
without	O
hypotonia	S-Phenotype
,	O
microcephaly	S-Phenotype
,	O
and	O
short	B-Phenotype
stature	E-Phenotype
that	O
were	O
observed	O
in	O
most	O
patients	O
with	O
COG5	O
defect	O

Here	O
we	O
report	O
a	O
novel	O
missense	O
mutation	O
in	O
ARSB	O
gene	O
that	O
is	O
inherited	O
as	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
mode	O
and	O
probably	O
explain	O
the	O
clinical	O
status	O
of	O
the	O
proband	O
.	O

However	O
,	O
this	O
reduction	O
in	O
PC	O
-	O
VLC	O
-	O
PUFA	O
content	O
in	O
the	O
all	O
-	O
cone	O
retina	O
had	O
no	O
impact	O
on	O
morphology	O
or	O
function	O
and	O
did	O
not	O
accelerate	O
retinal	B-Phenotype
degeneration	E-Phenotype
in	O
the	O
R91W	O
;	O
Nrl	O
-	O
/	O
-	O
;	O
Elovl4	O
mice	O
.	O

The	O
second	O
was	O
a	O
neonate	O
with	O
growth	B-Phenotype
deficiency	E-Phenotype
,	O
microcephaly	S-Phenotype
,	O
ichthyotic	B-Phenotype
skin	E-Phenotype
lesions	O
,	O
seizures	S-Phenotype
,	O
contractures	S-Phenotype
,	O
hypertonia	S-Phenotype
,	O
distinctive	O
facial	O
features	O
,	O
and	O
a	O
homozygous	O
mutation	O
in	O
PSAT1	O
.	O

EEF1A2	O
-	O
deficient	O
zebrafish	O
had	O
skeletal	B-Phenotype
muscle	I-Phenotype
weakness	E-Phenotype
,	O
cardiac	B-Phenotype
failure	E-Phenotype
and	O
small	B-Phenotype
heads	E-Phenotype
.	O

The	O
tumor	S-Phenotype
-	O
cell	O
activated	O
phenotype	O
of	O
EPC	O
was	O
associated	O
with	O
increased	O
migration	O
and	O
elevated	O
expression	O
of	O
ephrin	O
-	O
B2	O
,	O
and	O
Delta	O
-	O
like	O
4	O
ligand	O
(	O
DLL4	O
)	O
.	O

TCS	O
has	O
a	O
variable	O
phenotype	O
with	O
typical	O
clinical	O
characteristics	O
including	O
downward	B-Phenotype
-	I-Phenotype
slant	I-Phenotype
of	I-Phenotype
palpebral	I-Phenotype
fissure	E-Phenotype
,	O
malar	B-Phenotype
hypoplasia	E-Phenotype
,	O
mandibular	B-Phenotype
hypoplasia	E-Phenotype
and	O
microtia	S-Phenotype
.	O

Although	O
three	O
patients	O
with	O
MAMLD1	O
mutations	O
were	O
reported	O
to	O
have	O
hypergonadotropic	B-Phenotype
hypogonadism	E-Phenotype
in	O
their	O
teens	O
,	O
the	O
functional	O
significance	O
of	O
MAMLD1	O
in	O
the	O
postnatal	O
testis	O
remains	O
unclear	O
.	O

Conclusion	O
:	O
Cases	O
with	O
NBAS	O
gene	O
defects	O
often	O
manifests	O
as	O
short	B-Phenotype
stature	E-Phenotype
,	O
optic	B-Phenotype
nerve	I-Phenotype
atrophy	E-Phenotype
,	O
Pelger	B-Phenotype
-	I-Phenotype
Huet	I-Phenotype
anomaly	E-Phenotype
,	O
skeletal	B-Phenotype
dysplasia	E-Phenotype
,	O
recurrent	B-Phenotype
infections	E-Phenotype
,	O
abnormality	B-Phenotype
of	I-Phenotype
liver	I-Phenotype
enzymes	E-Phenotype
,	O
progeroid	B-Phenotype
appearance	E-Phenotype
,	O
proptosis	S-Phenotype
,	O
hypotonia	S-Phenotype
and	O
immunodeficiency	S-Phenotype
.	O

MIB1	O
/	O
Ki	O
-	O
67	O
was	O
low	O
and	O
highlighted	O
4	O
%	O
-	O
5	O
%	O
tumor	S-Phenotype
nuclei	O
.	O

In	O
a	O
large	O
Scottish	O
pedigree	O
,	O
a	O
balanced	O
translocation	O
t	O
(	O
1	O
;	O
11	O
)	O
(	O
q42.1	O
;	O
q14.3	O
)	O
disrupting	O
the	O
DISC1	O
and	O
DISC2	O
genes	O
segregates	O
with	O
major	O
mental	O
illness	O
,	O
including	O
schizophrenia	S-Phenotype
and	O
depression	S-Phenotype
.	O

In	O
the	O
present	O
case	O
,	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
obtained	O
during	O
infancy	O
revealed	O
symmetric	O
lesions	O
in	O
the	O
substantia	O
nigra	O
of	O
a	O
patient	O
with	O
Leigh	O
syndrome	O
with	O
an	O
NDUFA1	O
mutation	O
;	O
lesions	O
of	O
the	O
bilateral	S-Phenotype
putamen	O
and	O
brainstem	O
were	O
subsequently	O
observed	O
.	O

Improvements	O
in	O
our	O
understanding	O
of	O
the	O
molecular	O
subtypes	O
of	O
gliomas	S-Phenotype
and	O
the	O
underlying	O
alterations	O
in	O
specific	O
signaling	O
pathways	O
may	O
impact	O
both	O
the	O
diagnosis	O
and	O
the	O
treatment	O
strategies	O
for	O
patients	O
with	O
gliomas	S-Phenotype
.	O

The	O
identification	O
of	O
genetic	O
alterations	O
responsible	O
for	O
auditory	O
neuropathy	S-Phenotype
is	O
one	O
of	O
the	O
challenges	O
contributing	O
to	O
understand	O
the	O
molecular	O
bases	O
of	O
the	O
different	O
phenotypes	O
of	O
hearing	B-Phenotype
loss	E-Phenotype
.	O

Therefore	O
,	O
DLL4	O
expression	O
was	O
detected	O
in	O
clinical	O
specimens	O
using	O
quantum	O
dots	O
(	O
QDs	O
)	O
‑immunohistochemistry	O
(	O
IHC	O
)	O
and	O
lung	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
by	O
quantitative	O
real‑time	O
polymerase	O
chain	O
reaction	O
.	O

HCRP1	O
downregulation	O
was	O
found	O
in	O
57	O
of	O
137	O
human	O
gastric	B-Phenotype
cancer	E-Phenotype
samples	O
and	O
correlated	O
with	O
advanced	O
TNM	O
stage	O
,	O
positive	O
nodal	O
status	O
,	O
and	O
relapse	O
.	O

Our	O
data	O
provide	O
evidence	O
for	O
structural	O
and	O
functional	O
heterogeneity	S-Phenotype
in	O
radial	O
spokes	O
,	O
suggest	O
a	O
mechanism	O
for	O
the	O
milder	O
RSPH1	O
PCD	O
phenotype	O
and	O
demonstrate	O
that	O
cryo	O
-	O
electron	O
tomography	O
can	O
be	O
applied	O
to	O
human	O
disease	O
by	O
directly	O
imaging	O
patient	O
samples	O
.	O

PEPCK	O
-	O
M	O
(	O
PCK2	O
)	O
,	O
the	O
mitochondrial	O
isoform	O
of	O
phosphoenolpyruvate	O
carboxykinase	O
(	O
PEPCK	O
)	O
,	O
has	O
been	O
shown	O
by	O
us	O
and	O
others	O
to	O
be	O
functionally	O
expressed	O
and	O
to	O
mediate	O
gluconeogenesis	O
,	O
the	O
reverse	O
pathway	O
of	O
glycolysis	O
,	O
in	O
different	O
cancer	S-Phenotype
cells	O
.	O

The	O
genes	O
HLA	O
complex	O
P5	O
(	O
HCP5	O
)	O
,	O
spermatogenesis	O
associated	O
2	O
(	O
SPATA2	O
)	O
,	O
tumour	S-Phenotype
necrosis	O
factor	O
alpha	O
-	O
induced	O
protein	O
3	O
(	O
TNFAIP3	O
)	O
,	O
TNFAIP3	O
-	O
interacting	O
protein	O
1	O
(	O
TNIP1	O
)	O
and	O
the	O
component	O
of	O
oligomeric	O
Golgi	O
complex	O
6	O
(	O
COG6	O
)	O
were	O
reported	O
to	O
be	O
associated	O
with	O
psoriasis	S-Phenotype
in	O
western	O
populations	O
by	O
genome	O
-	O
wide	O
association	O
studies	O
.	O

The	O
current	O
study	O
aims	O
to	O
investigate	O
the	O
biological	O
roles	O
and	O
clinical	O
significance	O
of	O
HCRP1	O
in	O
human	O
gastric	B-Phenotype
cancer	E-Phenotype
.	O

The	O
present	O
study	O
was	O
aimed	O
to	O
investigate	O
the	O
relationship	O
between	O
the	O
expression	O
of	O
collagen	O
type	O
V	O
alpha	O
2	O
chain	O
(	O
COL5A2	O
)	O
and	O
clinical	O
outcomes	O
of	O
patients	O
with	O
bladder	O
cancer.Chi	S-Phenotype
-	O
square	O
test	O
and	O
log	O
-	O
rank	O
-	O
based	O
survival	O
analysis	O
were	O
performed	O
to	O
assess	O
the	O
correlation	O
of	O
COL5A2	O
expression	O
with	O
clinical	O
characteristics	O
and	O
survivals	O
of	O
patients	O
with	O
bladder	B-Phenotype
cancer	E-Phenotype
using	O
GSE13507	O
.	O

CGD	O
is	O
a	O
genetically	O
heterogeneous	S-Phenotype
disease	O
with	O
an	O
X	O
-	O
linked	O
recessive	O
(	O
XR	O
-	O
CGD	O
)	O
form	O
caused	O
by	O
mutations	O
in	O
the	O
CYBB	O
(	O
OMIM	O
#	O
300481	O
)	O
gene	O
encoding	O
the	O
gp91	O
(	O
phox	O
)	O
protein	O
,	O
and	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
(	O
AR	O
-	O
CGD	O
)	O
form	O
caused	O
by	O
mutations	O
in	O
the	O
CYBA	O
(	O
OMIM	O
#	O
608508	O
)	O
,	O
NCF1	O
(	O
OMIM	O
#	O
608512	O
)	O
,	O
NCF2	O
(	O
OMIM	O
#	O
608515	O
)	O
and	O
NCF4	O
(	O
OMIM	O
#	O
601488	O
)	O
genes	O
encoding	O
p22	O
(	O
phox	O
)	O
,	O
p47	O
(	O
phox	O
)	O
,	O
p67	O
(	O
phox	O
)	O
and	O
p40	O
(	O
phox	O
)	O
,	O
respectively	O
.	O

Essential	O
hypersomnia	S-Phenotype
(	O
EHS	O
)	O
is	O
another	O
type	O
of	O
sleep	O
disorder	O
that	O
is	O
characterized	O
by	O
excessive	B-Phenotype
daytime	I-Phenotype
sleepiness	E-Phenotype
without	O
cataplexy	S-Phenotype
.	O

Diamond	B-Phenotype
-	I-Phenotype
Blackfan	I-Phenotype
anemia	E-Phenotype
(	O
DBA	S-Phenotype
)	O
,	O
an	O
inherited	O
bone	B-Phenotype
marrow	I-Phenotype
failure	E-Phenotype
syndrome	O
characterized	O
by	O
anemia	S-Phenotype
that	O
usually	O
presents	O
before	O
the	O
first	O
birthday	O
or	O
in	O
early	O
childhood	O
,	O
is	O
associated	O
with	O
birth	O
defects	O
and	O
an	O
increased	O
risk	O
of	O
cancer	S-Phenotype
.	O

We	O
report	O
83	O
patients	O
affected	O
by	O
cystinuria	S-Phenotype
:	O
44	O
presented	O
prenatally	O
with	O
a	O
HEC	O
(	O
HEC	O
group	O
)	O
and	O
39	O
with	O
a	O
classical	O
postnatal	O
form	O
(	O
CC	O
group	O
)	O
.	O

Similarly	O
,	O
recent	O
genome	O
-	O
wide	O
association	O
studies	O
in	O
case	O
-	O
controlled	O
cohorts	O
have	O
identified	O
common	O
variations	O
in	O
and	O
around	O
HGF	O
,	O
RAB3GAP1	O
and	O
LOX	O
as	O
candidate	O
risk	O
factors	O
for	O
keratoconus	S-Phenotype
.	O

Further	O
in	O
silico	O
functional	O
analyses	O
revealed	O
that	O
rs2394882	O
affects	O
POU5F1	O
expression	O
,	O
which	O
in	O
turn	O
is	O
significantly	O
correlated	O
with	O
prostate	B-Phenotype
cancer	E-Phenotype
aggressiveness	S-Phenotype
and	O
patient	O
prognosis	O
.	O

These	O
294	O
differentially	O
expressed	O
genes	O
and	O
non	O
-	O
coding	O
RNA	O
transcripts	O
provide	O
here	O
a	O
set	O
to	O
specifically	O
define	O
skull	O
base	O
chordomas	S-Phenotype
and	O
to	O
identify	O
novel	O
and	O
potentially	O
important	O
targets	O
for	O
diagnosis	O
,	O
prognosis	O
,	O
and	O
therapy	O
of	O
this	O
cancer	S-Phenotype
.	O

However	O
,	O
correlation	O
between	O
CR	O
-	O
1	O
and	O
prostate	B-Phenotype
cancer	E-Phenotype
(	O
PCa	S-Phenotype
)	O
remains	O
still	O
unclear	O
.	O

These	O
findings	O
establish	O
these	O
mutant	O
mice	O
as	O
a	O
suitable	O
model	O
system	O
to	O
elucidate	O
how	O
SERPINB6	O
deficiency	O
causes	O
deafness	S-Phenotype
in	O
humans	O

Moreover	O
,	O
primary	O
corticotroph	O
tumor	S-Phenotype
cells	O
harboring	O
BRAF	O
V600E	O
are	O
sensitive	O
to	O
the	O
BRAF	O
inhibitor	O
vemurafenib	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
33	O
month	O
-	O
old	O
male	O
referred	O
for	O
developmental	B-Phenotype
delay	E-Phenotype
that	O
was	O
found	O
to	O
have	O
an	O
Xp21.2	O
duplication	O
containing	O
IL1RAPL1	O
and	O
multiple	O
midline	O
brain	O
malformations	O

Cell	O
surface	O
carbohydrates	O
are	O
important	O
for	O
cell	O
migration	O
and	O
invasion	O
of	O
prostate	B-Phenotype
cancer	E-Phenotype
(	O
PCa	S-Phenotype
)	O
.	O

However	O
,	O
the	O
relationship	O
between	O
MEGF10	O
and	O
autism	S-Phenotype
remains	O
poorly	O
understood	O
.	O

The	O
TECPR2	O
gene	O
has	O
been	O
reported	O
as	O
a	O
positive	O
regulator	O
of	O
autophagy	O
which	O
is	O
an	O
essential	O
mechanism	O
for	O
maintaining	O
neuron	O
homeostasis	O
and	O
survival	O
and	O
plays	O
a	O
key	O
role	O
in	O
major	O
adult	O
and	O
pediatric	O
neurodegenerative	B-Phenotype
diseases	E-Phenotype
.	O

Additionally	O
,	O
novel	O
or	O
rare	O
heterozygous	O
FIG4	O
missense	O
variants	O
predicted	O
to	O
be	O
deleterious	O
were	O
detected	O
in	O
five	O
sporadic	S-Phenotype
ALS	O
patients	O
revealing	O
an	O
overall	O
FIG4	O
variant	O
frequency	O
of	O
3	O
%	O
in	O
our	O
cohort	O
.	O

Using	O
data	O
from	O
the	O
Women	O
's	O
Circle	O
of	O
Health	O
Study	O
(	O
WCHS	O
)	O
of	O
1,307	O
European	O
-	O
American	O
(	O
EA	O
)	O
and	O
1,365	O
African	O
-	O
American	O
(	O
AA	O
)	O
breast	B-Phenotype
cancer	E-Phenotype
cases	O
and	O
controls	O
,	O
we	O
aimed	O
to	O
replicate	O
53	O
earlier	O
GWAS	O
variants	O
for	O
AM	O
and	O
ANM	O
in	O
AA	O
and	O
EA	O
groups	O
and	O
to	O
perform	O
analyses	O
on	O
total	O
and	O
net	O
reproductive	O
lifespan	O
(	O
TRLS	O
;	O
NRLS	O
)	O
.	O

The	O
schizophrenia	S-Phenotype
-	O
associated	O
gene	O
GRIN2A	O
(	O
glutamate	O
ionotropic	O
receptor	O
NMDA	O
type	O
subunit	O
2a	O
)	O
codes	O
for	O
a	O
protein	O
subunit	O
of	O
the	O
NMDA	O
(	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
)	O
receptor	O
that	O
underlies	O
central	O
aspects	O
of	O
human	O
cognition	O
.	O

We	O
investigated	O
the	O
impact	O
of	O
the	O
biomarkers	O
of	O
S	O
-	O
G2	O
-	O
M	O
phases	O
of	O
cell	O
cycle	O
,	O
Aurora	O
kinase	O
B	O
(	O
AURKB	O
)	O
and	O
geminin	O
(	O
GMNN	O
)	O
,	O
on	O
disease	O
progression	O
in	O
neuroblastomas	S-Phenotype
.	O

However	O
,	O
analogous	O
advanced	O
treatments	O
are	O
not	O
available	O
for	O
patients	O
with	O
lung	B-Phenotype
squamous	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
lung	B-Phenotype
SCC	E-Phenotype
)	O
.	O

Functional	O
studies	O
support	O
intraocular	O
pressure	O
-	O
related	O
influences	O
of	O
FMNL2	O
and	O
LMX1B	O
,	O
with	O
certain	O
Lmx1b	O
mutations	O
causing	O
high	O
IOP	O
and	O
glaucoma	S-Phenotype
resembling	O
POAG	O
in	O
mice	O
.	O

We	O
previously	O
reported	O
that	O
tyrosine	O
phosphorylation	O
activates	O
and	O
inhibits	O
mitochondrial	O
pyruvate	O
dehydrogenase	O
kinase	O
(	O
PDK	O
)	O
and	O
phosphatase	O
(	O
PDP	O
)	O
,	O
respectively	O
,	O
leading	O
to	O
enhanced	O
inhibitory	O
serine	O
phosphorylation	O
of	O
pyruvate	O
dehydrogenase	O
(	O
PDH	O
)	O
and	O
consequently	O
inhibition	O
of	O
pyruvate	O
dehydrogenase	O
complex	O
(	O
PDC	O
)	O
in	O
cancer	S-Phenotype
cells	O
.	O

WWS	O
is	O
a	O
multigenic	O
disorder	O
characterised	O
by	O
muscular	B-Phenotype
dystrophy	E-Phenotype
as	O
well	O
as	O
brain	O
and	O
eye	O
anomalies	O
.	O

The	O
present	O
study	O
,	O
therefore	O
,	O
aimed	O
to	O
evaluate	O
the	O
expression	O
levels	O
of	O
the	O
following	O
growth	O
factors	O
and	O
receptors	O
in	O
squamous	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
SCC	S-Phenotype
)	O
of	O
the	O
tongue	O
:	O
the	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
‑C	O
and	O
VEGF‑D	O
,	O
which	O
bind	O
to	O
the	O
cell	O
surface	O
tyrosine	O
kinase	O
receptor	O
VEGF	O
receptor‑3	O
(	O
VEGFR‑3	O
)	O
;	O
C‑C	O
motif	O
chemokine	O
receptor	O
7	O
(	O
CCR7	O
)	O
;	O
neuropilin	O
(	O
NRP	O
)	O
1	O
and	O
NRP2	O
;	O
and	O
semaphorin	O
3E	O
(	O
SEMA3E	O
)	O
.	O

Through	O
epigenomic	O
study	O
of	O
a	O
colon	B-Phenotype
cancer	E-Phenotype
cell	O
line	O
pair	O
(	O
HCT116	O
and	O
DKO	O
)	O
,	O
we	O
identified	O
liJPH3	O
/	O
i	O
as	O
a	O
methylated	O
novel	O
tumor	S-Phenotype
suppressor	O
gene	O
(	O
TSG	O
)	O
candidate	O
at	O
16q24	O
.	O

Taken	O
together	O
,	O
our	O
data	O
provide	O
robust	O
evidence	O
implicating	O
PSD	O
-	O
associated	O
proteins	O
and	O
genes	O
in	O
schizophrenia	S-Phenotype
,	O
and	O
suggest	O
that	O
within	O
the	O
PSD	O
,	O
NMDA	O
-	O
interacting	O
and	O
endocytosis	O
-	O
related	O
proteins	O
contribute	O
to	O
disease	O
pathophysiology	O

Magnetic	O
resonance	O
imaging	O
and	O
tumor	S-Phenotype
region	O
-	O
specific	O
microarray	O
analysis	O
identified	O
a	O
correlation	O
between	O
SAA1	O
and	O
GBM	O
cell	O
infiltration	O
in	O
patients	O
.	O

The	O
toxic	O
subcellular	O
accumulation	O
of	O
lipids	O
predisposes	O
several	O
human	O
metabolic	O
syndromes	O
,	O
including	O
obesity	S-Phenotype
,	O
type	B-Phenotype
2	I-Phenotype
diabetes	E-Phenotype
,	O
and	O
some	O
forms	O
of	O
neurodegeneration	S-Phenotype
.	O

Our	O
data	O
indicate	O
that	O
TNFSF15	O
,	O
a	O
cytokine	O
mainly	O
produced	O
by	O
blood	O
endothelial	O
cells	O
,	O
facilitates	O
tumor	S-Phenotype
lymphangiogenesis	O
by	O
upregulating	O
VEGFC	O
expression	O
in	O
A549	O
cells	O
,	O
contributing	O
to	O
lymphatic	O
metastasis	O
in	O
tumor	S-Phenotype
-	O
bearing	O
mice	O
.	O

The	O
expression	O
of	O
DLL4	O
in	O
non‑small	B-Phenotype
cell	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
(	O
NSCLC	S-Phenotype
)	O
remains	O
unclear	O
.	O

High	O
-	O
throughput	O
sequencing	O
analysis	O
has	O
accelerated	O
searches	O
for	O
genes	O
associated	O
with	O
risk	O
for	O
colorectal	B-Phenotype
cancer	E-Phenotype
(	O
CRC	S-Phenotype
)	O
;	O
germline	O
mutations	O
in	O
NTHL1	O
,	O
RPS20	O
,	O
FANCM	O
,	O
FAN1	O
,	O
TP53	O
,	O
BUB1	O
,	O
BUB3	O
,	O
LRP6	O
,	O
and	O
PTPN12	O
have	O
been	O
recently	O
proposed	O
to	O
increase	O
CRC	O
risk	O
.	O

In	O
xenograft	O
and	O
genetically	O
engineered	O
mouse	O
models	O
,	O
the	O
WDR4	O
/	O
PML	O
axis	O
elevates	O
intratumoral	O
Tregs	S-Phenotype
and	O
M2	O
-	O
like	O
macrophages	O
and	O
reduces	O
CD8+	O
T	O
cells	O
to	O
promote	O
lung	B-Phenotype
tumor	E-Phenotype
growth	O
.	O

Inactivating	O
NF1	O
mutations	O
were	O
present	O
in	O
46	O
%	O
of	O
melanomas	S-Phenotype
expressing	O
wild	O
-	O
type	O
BRAF	O
and	O
RAS	O
,	O
occurred	O
in	O
older	O
patients	O
and	O
showed	O
a	O
distinct	O
pattern	O
of	O
co	O
-	O
mutation	O
with	O
other	O
RASopathy	O
genes	O
,	O
particularly	O
RASA2	O
.	O

This	O
work	O
associates	O
missense	O
mutations	O
in	O
NSMCE3	O
with	O
an	O
autosomal	B-Phenotype
recessive	I-Phenotype
chromosome	I-Phenotype
breakage	E-Phenotype
syndrome	O
that	O
leads	O
to	O
defective	O
T	O
and	O
B	O
cell	O
function	O
and	O
acute	B-Phenotype
respiratory	I-Phenotype
distress	I-Phenotype
syndrome	E-Phenotype
in	O
early	O
childhood	O

Also	O
,	O
the	O
generated	O
liCIB2	O
/	O
isup	O
-	O
/	O
-	O
/	O
sup	O
mice	O
display	O
an	O
early	B-Phenotype
onset	I-Phenotype
profound	I-Phenotype
deafness	E-Phenotype
and	O
have	O
normal	O
balance	O
and	O
retinal	O
functions	O
.	O

The	O
signaling	O
of	O
DNA	O
damage	O
and	O
replication	O
stress	O
involves	O
a	O
multitude	O
of	O
proteins	O
,	O
including	O
the	O
kinases	O
ataxia	B-Phenotype
-	I-Phenotype
telangiectasia	I-Phenotype
mutated	E-Phenotype
(	O
ATM	S-Phenotype
)	O
and	O
ATM	O
and	O
Rad3	O
-	O
related	O
(	O
ATR	O
)	O
,	O
and	O
proteins	O
with	O
BRCA1	O
COOH	O
-	O
terminal	O
(	O
BRCT	O
)	O
domains	O
.	O

Very	O
recently	O
,	O
SLX4	O
has	O
been	O
established	O
as	O
a	O
new	O
FA	O
gene	O
raising	O
the	O
question	O
of	O
its	O
implication	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
risk	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
expression	O
and	O
clinical	O
significance	O
of	O
p53R2	O
in	O
early	B-Phenotype
-	I-Phenotype
stage	I-Phenotype
cervical	I-Phenotype
cancer	E-Phenotype
.	O

Biallelic	O
GLDN	O
mutations	O
have	O
recently	O
been	O
identified	O
among	O
infants	O
with	O
lethal	B-Phenotype
congenital	I-Phenotype
contracture	I-Phenotype
syndrome	I-Phenotype
11	E-Phenotype
(	O
LCCS11	S-Phenotype
)	O
.	O

RNF170	O
is	O
an	O
endoplasmic	O
reticulum	O
membrane	O
ubiquitin	O
ligase	O
that	O
contributes	O
to	O
the	O
ubiquitination	O
of	O
activated	O
inositol	O
1,4,5	O
-	O
trisphosphate	O
(	O
IP3	O
)	O
receptors	O
,	O
and	O
also	O
,	O
when	O
point	O
mutated	O
(	O
arginine	O
to	O
cysteine	O
at	O
position	O
199	O
)	O
,	O
causes	O
autosomal	B-Phenotype
dominant	I-Phenotype
sensory	I-Phenotype
ataxia	E-Phenotype
(	O
ADSA	S-Phenotype
)	O
,	O
a	O
disease	O
characterized	O
by	O
neurodegeneration	S-Phenotype
in	O
the	O
posterior	O
columns	O
of	O
the	O
spinal	O
cord	O
.	O

BCOR	O
immunohistochemical	O
staining	O
is	O
a	O
highly	B-Phenotype
sensitive	E-Phenotype
marker	O
for	O
YWHAE	O
-	O
NUTM2	O
high	O
-	O
grade	O
endometrial	O
stromal	O
sarcoma	S-Phenotype
with	O
both	O
classic	O
and	O
unusual	O
morphology	O
and	O
identifies	O
a	O
subset	O
of	O
high	O
-	O
grade	O
endometrial	O
stromal	O
sarcoma	S-Phenotype
with	O
BCOR	O
alterations	O
,	O
including	O
BCOR	O
rearrangement	O
and	O
internal	O
tandem	O
duplication	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
conduct	O
a	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
of	O
studies	O
investigating	O
the	O
relationship	O
between	O
dietary	O
fiber	O
intake	O
and	O
subsite	O
-	O
specific	O
colon	O
cancer.The	S-Phenotype
PubMed	O
database	O
was	O
searched	O
to	O
identify	O
relevant	O
cohort	O
studies	O
published	O
from	O
inception	O
to	O
August	O
2016	O
in	O
order	O
to	O
examine	O
individually	O
the	O
association	O
between	O
dietary	O
fiber	O
intake	O
and	O
the	O
risk	O
of	O
proximal	B-Phenotype
colon	I-Phenotype
cancer	E-Phenotype
(	O
PCC	S-Phenotype
)	O
,	O
and	O
that	O
between	O
dietary	O
fiber	O
intake	O
and	O
the	O
risk	O
of	O
distal	B-Phenotype
colon	I-Phenotype
cancer	E-Phenotype
(	O
DCC	S-Phenotype
)	O
.	O

Conversely	O
,	O
Tsc1	O
loss	O
led	O
to	O
the	O
early	O
-	O
onset	O
death	O
of	O
cochlear	O
hair	O
cells	O
and	O
consequently	O
accelerated	O
hearing	B-Phenotype
loss	E-Phenotype
.	O

In	O
this	O
review	O
article	O
,	O
we	O
summarize	O
the	O
discovery	O
of	O
TYMP	O
and	O
the	O
potential	O
molecular	O
mechanisms	O
of	O
TYMP	O
involved	O
in	O
the	O
development	O
of	O
various	O
diseases	O
,	O
especially	O
cardiovascular	B-Phenotype
diseases	E-Phenotype
.	O

We	O
found	O
that	O
a	O
downregulation	O
of	O
rRNA	O
synthesis	O
,	O
induced	O
by	O
silencing	O
the	O
POLR1A	O
gene	O
coding	O
for	O
the	O
RNA	O
polymerase	O
I	O
catalytic	O
subunit	O
,	O
stabilised	O
p53	O
without	O
altering	O
the	O
nucleolar	O
integrity	O
in	O
human	O
cancer	S-Phenotype
cells	O
.	O

This	O
is	O
the	O
first	O
report	O
showing	O
that	O
the	O
PCYT1A	O
gene	O
can	O
be	O
responsible	O
for	O
isolated	O
forms	O
of	O
retinal	B-Phenotype
dystrophy	E-Phenotype
,	O
particularly	O
without	O
any	O
skeletal	O
involvement	O
,	O
thus	O
further	O
expanding	O
the	O
phenotypic	O
spectrum	O
induced	O
by	O
mutations	O
in	O
this	O
gene	O

This	O
case	O
-	O
control	O
study	O
was	O
aimed	O
to	O
evaluate	O
the	O
influence	O
of	O
cytochrome	O
P450	O
family	O
17	O
subfamily	O
A	O
member	O
1	O
(	O
CYP17A1	O
)	O
gene	O
rs743572	O
polymorphism	O
for	O
the	O
susceptibility	O
to	O
endometriosis.Polymerase	S-Phenotype
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
PCR	O
-	O
RFLP	O
)	O
was	O
used	O
to	O
genotype	O
rs743572	O
polymorphism	O
in	O
143	O
endometriosis	S-Phenotype
patients	O
and	O
148	O
healthy	O
controls	O
.	O

In	O
severe	O
bilateral	O
cases	O
(	O
anophthalmia	S-Phenotype
or	O
severe	O
microphthalmia	S-Phenotype
)	O
the	O
genetic	O
cause	O
is	O
now	O
identifiable	O
in	O
approximately	O
80	O
percent	O
of	O
cases	O
,	O
with	O
de	O
novo	O
heterozygous	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
SOX2	O
or	O
OTX2	O
being	O
the	O
most	O
common	O
.	O

Danon	O
disease	O
,	O
an	O
X	O
-	O
linked	O
dominant	O
cardioskeletal	O
myopathy	S-Phenotype
,	O
is	O
caused	O
by	O
primary	O
deficiency	O
of	O
lysosome	O
-	O
associated	O
membrane	O
protein	O
-	O
2	O
(	O
LAMP	O
-	O
2	O
)	O
.	O

The	O
most	O
likely	O
causal	O
variant	O
identified	O
was	O
a	O
novel	O
missense	O
variant	O
in	O
the	O
X	O
-	O
linked	O
GRIA3	O
gene	O
,	O
which	O
has	O
been	O
implicated	O
in	O
intellectual	B-Phenotype
disability	E-Phenotype
.	O

The	O
current	O
results	O
thus	O
support	O
our	O
previous	O
observations	O
in	O
bladder	B-Phenotype
cancer	E-Phenotype
and	O
further	O
suggest	O
that	O
phospho	O
-	O
ELK1	O
overexpression	O
serves	O
as	O
a	O
predictor	O
of	O
poor	O
prognosis	O
in	O
patients	O
with	O
UUTUC	O

A	O
decreased	O
gene	O
expression	O
(	O
RQ	O
AAAA	O
0.7	O
)	O
was	O
observed	O
for	O
DLEC1	O
in	O
60.9	O
%	O
of	O
tumour	S-Phenotype
samples	O
,	O
for	O
MLH1	O
in	O
50.7	O
%	O
and	O
for	O
TUSC4	O
in	O
26	O
%	O
of	O
NSCLC	O
samples	O
.	O

Here	O
in	O
,	O
we	O
review	O
the	O
recent	O
evidence	O
of	O
association	O
of	O
the	O
genetic	O
variants	O
with	O
hypercholesterolemia	S-Phenotype
and	O
the	O
three	O
lipid	O
traits	O
;	O
total	O
cholesterol	O
(	O
TC	O
)	O
,	O
HDL	O
-	O
cholesterol	O
(	O
HDL	O
-	O
C	O
)	O
and	O
LDL	O
-	O
cholesterol	O
(	O
LDL	O
-	O
C	O
)	O
,	O
their	O
biological	O
pathways	O
and	O
the	O
associated	O
pathogenetic	O
mechanisms	O
.	O

After	O
HDM	O
challenge	O
,	O
these	O
mice	O
also	O
had	O
fewer	O
airway	O
inflammatory	O
cells	O
,	O
reduced	O
interleukin	O
(	O
IL	O
)	O
-	O
5	O
,	O
IL	O
-	O
13	O
,	O
IL	O
-	O
33	O
,	O
tumour	S-Phenotype
necrosis	O
factor	O
(	O
TNF	O
)	O
and	O
CXCL1	O
levels	O
in	O
the	O
lungs	O
,	O
and	O
reduced	O
IL	O
-	O
5	O
,	O
IL	O
-	O
33	O
and	O
TNF	O
levels	O
in	O
lung	O
-	O
draining	O
lymph	O
nodes	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrated	O
that	O
CDKN1C	O
was	O
dramatically	O
downregulated	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
compared	O
with	O
normal	O
tissues	O
by	O
using	O
real	O
-	O
time	O
quantitative	O
polymerase	O
chain	O
reaction	O
,	O
western	O
blot	O
and	O
two	O
public	O
data	O
portals	O
:	O
The	O
Cancer	S-Phenotype
Genome	O
Atlas	O
(	O
TCGA	O
)	O
and	O
Oncomine	O
datasets	O
.	O

In	O
lung	B-Phenotype
adenocarcinoma	E-Phenotype
(	O
LADC	S-Phenotype
)	O
,	O
specific	O
thyroxin	O
kinase	O
inhibitors	O
against	O
EGFR	O
mutations	O
and	O
ALK	O
fusions	O
are	O
used	O
as	O
a	O
standard	O
treatment	O
regimen	O
and	O
show	O
significant	O
positive	O
efficacy	O
.	O

By	O
comparing	O
the	O
clinical	O
and	O
genetic	O
features	O
of	O
our	O
patients	O
with	O
those	O
previously	O
reported	O
,	O
we	O
show	O
that	O
the	O
severity	O
of	O
the	O
neurological	O
phenotype	O
and	O
the	O
frequency	O
of	O
congenital	B-Phenotype
heart	I-Phenotype
defects	E-Phenotype
characterize	O
the	O
deletions	O
that	O
,	O
besides	O
ANKRD11	O
,	O
contain	O
ZFPM1	O
,	O
CDH15	O
and	O
ZNF778	O
as	O
well	O
.	O

Our	O
study	O
attempted	O
to	O
delineate	O
whether	O
genetic	O
variants	O
of	O
liCHRM3	O
/	O
i	O
contribute	O
to	O
bladder	B-Phenotype
cancer	E-Phenotype
in	O
Chinese	O
Han	O
population	O
in	O
south	O
Taiwan	O
.	O

Heterozygous	O
KRT74	O
mutations	O
have	O
previously	O
been	O
associated	O
with	O
autosomal	B-Phenotype
dominant	I-Phenotype
woolly	I-Phenotype
hair	E-Phenotype
/	O
hypotrichosis	B-Phenotype
simplex	E-Phenotype
(	O
ADWH	S-Phenotype
)	O
.	O

Traditionally	O
,	O
idiopathic	B-Phenotype
hypogonadotropic	I-Phenotype
hypogonadism	E-Phenotype
(	O
IHH	S-Phenotype
)	O
is	O
divided	O
into	O
two	O
major	O
categories	O
:	O
Kallmann	B-Phenotype
syndrome	E-Phenotype
(	O
KS	B-Phenotype
)	O
and	O
normosmic	B-Phenotype
IHH	E-Phenotype
(	O
nIHH	S-Phenotype
)	O
.	O

A	O
bioinformatic	O
analysis	O
of	O
miRNA	O
array	O
and	O
metabolite	O
-	O
profiling	O
data	O
from	O
NCI	O
-	O
60	O
cancer	S-Phenotype
cell	O
panel	O
revealed	O
thiamine	O
as	O
a	O
metabolite	O
positively	O
correlated	O
with	O
the	O
miR	O
-	O
155	O
expression	O
level	O
.	O

By	O
using	O
quantitative	O
(	O
real	O
-	O
time	O
)	O
PCR	O
,	O
western	O
blot	O
analysis	O
,	O
and	O
immunocytochemical	O
staining	O
,	O
three	O
non	B-Phenotype
-	I-Phenotype
small	I-Phenotype
cell	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
(	O
NSCLC	S-Phenotype
)	O
cell	O
lines	O
(	O
A427	O
,	O
A549	O
and	O
NCI	O
-	O
H358	O
)	O
were	O
analyzed	O
for	O
the	O
expression	O
of	O
EpoR	O
and	O
its	O
specific	O
downstream	O
signaling	O
pathways	O
[	O
Janus	O
kinase	O
2	O
(	O
Jak2	O
)	O
-	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
5	O
(	O
STAT5	O
)	O
,	O
phosphatidylinositol	O
-	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
-	O
Akt	O
,	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinase	O
]	O
.	O

Without	O
SIRT1	O
,	O
cervical	B-Phenotype
cancer	E-Phenotype
cells	O
could	O
no	O
longer	O
survive	O
because	O
of	O
the	O
derepression	O
of	O
the	O
AIM2	O
inflammasome	O
.	O

This	O
study	O
aimed	O
to	O
elucidate	O
the	O
potential	O
functional	O
mechanism	O
of	O
miR	O
-	O
135b	O
-	O
5p	O
in	O
migration	O
,	O
invasion	O
and	O
epithelial	O
-	O
to	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
of	O
pancreatic	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

The	O
underlying	O
molecular	O
mechanisms	O
of	O
age	B-Phenotype
-	I-Phenotype
related	I-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
(	O
ARHL	S-Phenotype
)	O
in	O
humans	O
and	O
many	O
strains	O
of	O
mice	O
have	O
not	O
been	O
fully	O
characterized	O
.	O

We	O
found	O
evidence	O
for	O
at	O
least	O
five	O
independent	O
causal	O
variants	O
,	O
each	O
associated	O
with	O
different	O
phenotype	O
sets	O
,	O
including	O
estrogen	O
receptor	O
(	O
ER	O
(	O
+	O
)	O
or	O
ER	O
(	O
-	O
)	O
)	O
and	O
human	O
ERBB2	O
(	O
HER2	O
(	O
+	O
)	O
or	O
HER2	O
(	O
-	O
)	O
)	O
tumor	S-Phenotype
subtypes	O
,	O
mammographic	O
density	O
and	O
tumor	S-Phenotype
grade	O
.	O

Our	O
analyses	O
revealed	O
that	O
the	O
primary	O
tumor	S-Phenotype
and	O
NCC	O
-	O
SS1	O
-	O
C1	O
cell	O
line	O
harbored	O
the	O
SS18	O
-	O
SSX1	O
fusion	O
gene	O
typical	O
of	O
synovial	B-Phenotype
sarcoma	E-Phenotype
and	O
similar	O
proteomics	O
profiles	O
.	O

The	O
association	O
between	O
low	O
Eps8	O
expression	O
and	O
p16sup+	O
/	O
sup	O
HNSCCs	O
suggests	O
that	O
alternative	O
signaling	O
pathways	O
may	O
be	O
used	O
for	O
their	O
tumorigenesis	S-Phenotype

A	O
significantly	O
lower	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
and	O
protein	O
level	O
of	O
LASS2	O
was	O
seen	O
in	O
3AO	O
cell	O
compared	O
with	O
those	O
in	O
other	O
types	O
of	O
ovarian	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

The	O
aberrant	O
expression	O
or	O
alteration	O
of	O
microRNAs	O
(	O
miRNAs	O
/	O
miRs	O
)	O
contributes	O
to	O
the	O
development	O
and	O
progression	O
of	O
cancer	S-Phenotype
.	O

Metastasis	O
is	O
the	O
most	O
important	O
feature	O
of	O
gastric	B-Phenotype
cancer	E-Phenotype
(	O
GC	S-Phenotype
)	O
and	O
the	O
most	O
widely	O
recognized	O
reason	O
for	O
GC	O
-	O
related	O
deaths	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
expression	O
of	O
the	O
cancer	S-Phenotype
/	O
testis	O
antigens	O
ADAM2	O
,	O
CALR3	O
and	O
SAGE1	O
in	O
lung	B-Phenotype
and	I-Phenotype
breast	I-Phenotype
cancer	E-Phenotype
,	O
the	O
two	O
most	O
frequent	O
human	O
cancers	S-Phenotype
,	O
with	O
the	O
purpose	O
of	O
providing	O
novel	O
therapeutic	O
targets	O
for	O
these	O
diseases	O
.	O

WES	O
also	O
unraveled	O
pathogenic	O
mutations	O
in	O
genes	O
not	O
commonly	O
linked	O
to	O
FTD	O
,	O
including	O
mutations	O
in	O
Alzheimer	O
(	O
PSEN1	O
,	O
PSEN2	O
)	O
,	O
lysosomal	O
(	O
CTSF	O
,	O
7	O
-	O
exon	O
macro	O
-	O
deletion	O
)	O
and	O
cholesterol	O
homeostasis	O
pathways	O
(	O
CYP27A1	O
)	O
.ConclusionOur	O
unbiased	O
approach	O
reveals	O
a	O
wide	O
genetic	O
spectrum	O
underlying	O
clinical	O
FTD	O
,	O
including	O
11	O
%	O
of	O
seemingly	O
sporadic	O
FTD	O
.	O

Over	O
the	O
last	O
decade	O
,	O
altered	O
RNA	O
regulation	O
and	O
aberrant	O
RNA	O
-	O
binding	O
protein	O
function	O
have	O
emerged	O
as	O
a	O
central	O
theme	O
in	O
motor	O
neuron	O
disease	O
pathogenesis	O
,	O
with	O
evidence	O
suggesting	O
that	O
sporadic	O
ALS	O
disease	O
pathology	O
may	O
overlap	O
with	O
the	O
molecular	O
pathology	O
uncovered	O
in	O
familial	O
ALS	O
.	O

For	O
instance	O
,	O
mutations	O
in	O
both	O
BFSP1	O
and	O
BFSP2	O
cause	O
cataract	S-Phenotype
in	O
humans	O
.	O

These	O
results	O
demonstrate	O
that	O
Piccolo	O
contributes	O
to	O
tumor	S-Phenotype
aggressiveness	S-Phenotype
in	O
ESCC	O
,	O
likely	O
by	O
stabilizing	O
EGFR	O
and	O
promoting	O
EGFR	O
-	O
dependent	O
signaling	O
.	O

We	O
show	O
here	O
that	O
HDAC11	O
depletion	O
in	O
MYCN	O
-	O
driven	O
neuroblastoma	S-Phenotype
cell	O
lines	O
strongly	O
induces	O
cell	O
death	O
,	O
mostly	O
mediated	O
by	O
apoptotic	O
programs	O
.	O

Kluver	O
-	O
Bucy	O
syndrome	O
(	O
KBS	O
)	O
comprises	O
a	O
set	O
of	O
neurobehavioral	O
symptoms	O
with	O
psychic	O
blindness	S-Phenotype
,	O
hypersexuality	S-Phenotype
,	O
disinhibition	S-Phenotype
,	O
hyperorality	S-Phenotype
,	O
and	O
hypermetamorphosis	S-Phenotype
that	O
were	O
originally	O
observed	O
after	O
bilateral	O
lobectomy	O
in	O
Rhesus	O
monkeys	O
.	O

JAK2V617F	O
(	O
+	O
)	O
myeloproliferative	B-Phenotype
neoplasms	E-Phenotype
(	O
MPNs	S-Phenotype
)	O
frequently	O
progress	O
into	O
leukemias	S-Phenotype
,	O
but	O
the	O
factors	O
driving	O
this	O
process	O
are	O
not	O
understood	O
.	O

Genome	O
-	O
wide	O
association	O
studies	O
have	O
identified	O
genomic	O
loci	O
,	O
whose	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
predispose	O
to	O
prostate	B-Phenotype
cancer	E-Phenotype
(	O
PCa	S-Phenotype
)	O
.	O

In	O
this	O
work	O
,	O
we	O
report	O
a	O
new	O
progressive	O
myoclonus	S-Phenotype
epilepsy	S-Phenotype
associated	O
with	O
Lafora	B-Phenotype
bodies	E-Phenotype
,	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
Lafora	I-Phenotype
body	E-Phenotype
disease	O
,	O
map	O
its	O
locus	O
to	O
chromosome	O
4q21.21	O
,	O
identify	O
its	O
gene	O
and	O
mutation	O
and	O
characterize	O
the	O
relationship	O
of	O
its	O
gene	O
product	O
with	O
laforin	O
and	O
malin	O
.	O

Overall	O
,	O
our	O
study	O
proposes	O
that	O
TRPS1	O
acts	O
as	O
a	O
central	O
hub	O
in	O
the	O
control	O
of	O
cell	O
cycle	O
and	O
proliferation	O
during	O
cancer	S-Phenotype
development	O
.	O

They	O
present	O
with	O
global	O
BMF	O
,	O
and	O
one	O
individual	O
developed	O
a	O
hematological	O
cancer	S-Phenotype
(	O
acute	B-Phenotype
myeloid	I-Phenotype
leukemia	E-Phenotype
)	O
in	O
childhood	O
.	O

The	O
core	O
phenotype	O
of	O
X	O
-	O
linked	O
NAA10	O
-	O
related	O
N	O
-	O
terminal	O
-	O
acetyltransferase	O
deficiency	O
in	O
both	O
males	O
and	O
females	O
includes	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
severe	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
postnatal	B-Phenotype
growth	I-Phenotype
failure	E-Phenotype
with	O
severe	O
microcephaly	S-Phenotype
,	O
and	O
skeletal	B-Phenotype
or	I-Phenotype
cardiac	I-Phenotype
anomalies	E-Phenotype
.	O

These	O
loci	O
have	O
previously	O
demonstrated	O
association	O
with	O
axial	O
length	O
(	O
ZC3H11B	O
)	O
,	O
myopia	S-Phenotype
(	O
NPLOC4	O
)	O
,	O
spherical	O
equivalent	O
refractive	O
error	O
(	O
LINC00340	O
)	O
and	O
eye	O
colour	O
(	O
HERC2	O
)	O
.	O

We	O
identified	O
a	O
homozygous	O
ATOH7	O
mutation	O
(	O
N46H	O
)	O
in	O
a	O
large	O
family	O
with	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
PHPV	O
disease	O
trait	O
linked	O
to	O
10q21	O
,	O
and	O
a	O
heterozygous	O
variant	O
(	O
R65G	O
,	O
p.Arg65Gly	O
)	O
in	O
one	O
of	O
five	O
sporadic	O
ONA	O
patients	O
.	O

Herein	O
,	O
we	O
report	O
a	O
third	O
patient	O
(	O
not	O
related	O
to	O
the	O
previously	O
reported	O
family	O
)	O
with	O
bilateral	B-Phenotype
colobomatous	I-Phenotype
microphthalmia	E-Phenotype
and	O
developmental	B-Phenotype
delay	E-Phenotype
in	O
whom	O
genetic	O
studies	O
identified	O
a	O
homozygous	O
TENM3	O
splicing	O
mutation	O
c.2968	O
-	O
2AAAAAT	O
(	O
p.Val990Cysfs	O
*	O
13	O
)	O
.	O

The	O
result	O
showed	O
that	O
both	O
liERCC1	O
rs11615	O
and	O
liXPC	O
rs2228000	O
were	O
significantly	O
associated	O
with	O
reduced	O
risk	O
of	O
ovarian	B-Phenotype
cancer	E-Phenotype
under	O
dominant	O
genetic	O
model	O
(	O
adjusted	O
OR	O
=	O
0.35	O
,	O
95	O
%	O
CI	O
=	O
0.20	O
-	O
0.61	O
,	O
liP=0.0002	O
and	O
adjusted	O
OR	O
=	O
0.49	O
,	O
95	O
%	O
CI	O
=	O
0.30	O
-	O
0.81	O
,	O
liP=0.005	O
respectively	O
)	O
.	O

Several	O
publications	O
had	O
illustrated	O
the	O
relationship	O
of	O
between	O
CAV1	O
polymorphism	O
and	O
urinary	B-Phenotype
cancer	E-Phenotype
,	O
but	O
the	O
results	O
were	O
not	O
consistent	O
.	O

However	O
,	O
HoFH	O
is	O
clinically	O
heterogeneous	S-Phenotype
,	O
reflecting	O
residual	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
(	O
LDLR	O
)	O
activity	O
.	O

Defects	O
in	O
ISC	O
biogenesis	O
lead	O
to	O
multiple	O
mitochondrial	B-Phenotype
dysfunction	E-Phenotype
syndromes	O
including	O
:	O
ISCA2	O
with	O
infantile	B-Phenotype
onset	I-Phenotype
leukodystrophy	E-Phenotype
.	O

Moreover	O
,	O
myostatin	O
inhibitors	O
are	O
known	O
to	O
promote	O
muscle	O
regeneration	O
and	O
ameliorate	O
fibrosis	O
in	O
animal	O
models	O
of	O
Duchenne	B-Phenotype
muscular	I-Phenotype
dystrophy	E-Phenotype
(	O
DMD	S-Phenotype
)	O
,	O
a	O
human	O
disease	O
characterized	O
by	O
chronic	B-Phenotype
muscle	I-Phenotype
degeneration	E-Phenotype
.	O

We	O
report	O
that	O
MIR22HG	O
was	O
downregulated	O
in	O
120	O
HCC	O
samples	O
compared	O
with	O
adjacent	O
nontumor	O
liver	S-Phenotype
tissues	O
.	O

Moreover	O
,	O
immunohistochemistry	O
demonstrates	O
that	O
EpCAM	O
is	O
highly	O
expressed	O
in	O
80	O
%	O
of	O
H	O
-	O
ChC	O
,	O
implying	O
the	O
stemness	O
of	O
such	O
liver	B-Phenotype
cancer	E-Phenotype
.	O

Single	O
marker	O
-	O
based	O
association	O
tests	O
for	O
corneal	B-Phenotype
astigmatism	E-Phenotype
identified	O
four	O
genome	O
-	O
wide	O
significant	O
loci	O
(	O
P	O
AAAA	O
5	O
×	O
10sup	O
-	O
8	O
/	O
sup	O
)	O
near	O
the	O
genes	O
ZC3H11B	O
(	O
1q41	O
)	O
,	O
LINC00340	O
(	O
6p22.3	O
)	O
,	O
HERC2	O
/	O
OCA2	O
(	O
15q13.1	O
)	O
and	O
NPLOC4	O
/	O
TSPAN10	O
(	O
17q25.3	O
)	O
.	O

Germline	O
mutations	O
in	O
BAP1	O
are	O
responsible	O
for	O
a	O
rare	O
cancer	S-Phenotype
predisposition	O
syndrome	O
that	O
includes	O
predisposition	O
to	O
mesothelioma	O
.	O

By	O
targeting	O
DDR2	O
,	O
WRG	O
-	O
28	O
inhibits	O
tumor	S-Phenotype
invasion	O
and	O
migration	O
,	O
as	O
well	O
as	O
tumor	S-Phenotype
-	O
supporting	O
roles	O
of	O
the	O
stroma	O
,	O
and	O
inhibits	O
metastatic	O
breast	B-Phenotype
tumor	E-Phenotype
cell	O
colonization	O
in	O
the	O
lungs	O
.	O

Some	O
of	O
them	O
were	O
cancer	S-Phenotype
-	O
related	O
according	O
to	O
COSMIC	O
and	O
HGMD	O
databases	O
(	O
no	O
founder	O
mutations	O
in	O
BRCA1	O
and	O
BRCA2	O
have	O
been	O
found	O
)	O
.	O

Promoters	O
of	O
several	O
genes	O
from	O
the	O
KEGG	O
HER2+	O
breast	B-Phenotype
cancer	E-Phenotype
pathway	O
and	O
11	O
signaling	O
pathways	O
linked	O
to	O
6	O
hallmarks	O
of	O
cancer	S-Phenotype
contain	O
the	O
NRF1	O
motif	O
.	O

WTX	O
is	O
also	O
known	O
as	O
a	O
tumor	S-Phenotype
suppressor	O
gene	O
,	O
and	O
somatic	O
mutations	O
in	O
that	O
gene	O
have	O
been	O
identified	O
in	O
Wilms	B-Phenotype
tumors	E-Phenotype
.	O

Real	O
-	O
time	O
fluorescence	O
quantitative	O
PCR	O
and	O
Western	O
blot	O
were	O
used	O
to	O
detect	O
the	O
expression	O
level	O
of	O
Twist2	O
mRNA	O
and	O
protein	O
in	O
61	O
cases	O
of	O
fresh	O
glioma	S-Phenotype
tissue	O
(	O
WHO	O
grade	O
Ⅱ	O
16	O
cases	O
,	O
Ⅲ	O
21	O
cases	O
,	O
Ⅳ	O
24	O
cases	O
)	O
and	O
12	O
cases	O
of	O
adjacent	O
tissues	O
,	O
and	O
the	O
expression	O
levels	O
of	O
E	O
-	O
cadherin	O
,	O
N	O
-	O
cadherin	O
and	O
vimentin	O
were	O
also	O
investigated	O
in	O
fresh	O
glioma	S-Phenotype
tissue	O
.	O

In	O
summary	O
,	O
these	O
results	O
suggest	O
that	O
miR	O
-	O
214	O
serves	O
as	O
tumor	S-Phenotype
promoter	O
to	O
promote	O
proliferation	O
,	O
migration	O
,	O
invasion	O
and	O
inhibit	O
apoptosis	O
of	O
ESCC	O
cells	O
by	O
targeting	O
LZTS1	O
via	O
PI3K	O
/	O
AKT	O
/	O
mTOR	O
signaling	O
pathway	O
.	O

Muscarinic	O
acetylcholine	O
receptor	O
M3	O
(	O
CHRM3	O
)	O
was	O
reported	O
as	O
a	O
key	O
receptor	O
in	O
different	O
cancer	S-Phenotype
types	O
.	O

Relationship	O
between	O
TAZ	O
/	O
YAP	O
and	O
clinical	O
data	O
of	O
malignant	B-Phenotype
melanoma	E-Phenotype
were	O
analyzed	O
.	O

MTORC1	O
/	O
2	O
inhibition	O
shows	O
antitumor	O
activity	S-Phenotype
in	O
cell	O
culture	O
models	O
of	O
DIPG	O
due	O
to	O
the	O
effect	O
of	O
MTORC2	O
inhibition	O
on	O
AKT	O
.	O

Impaired	O
lysine	O
degradation	O
with	O
accumulation	O
of	O
PDE	O
biomarkers	O
,	O
B6	O
deficiency	O
,	O
and	O
low	O
γ	O
-	O
aminobutyric	O
acid	O
levels	O
were	O
observed	O
in	O
the	O
lialdh7a1	O
/	O
isup	O
-	O
/	O
-	O
/	O
sup	O
larvae	O
,	O
which	O
may	O
play	O
a	O
significant	O
role	O
in	O
the	O
seizure	S-Phenotype
phenotype	O
and	O
PDE	O
pathogenesis	O
.	O

Abnormalities	O
in	O
nucleic	O
acid	O
processing	O
are	O
associated	O
with	O
the	O
development	O
of	O
amyotrophic	B-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
(	O
ALS	S-Phenotype
)	O
and	O
frontotemporal	B-Phenotype
dementia	E-Phenotype
(	O
FTD	S-Phenotype
)	O
.	O

ADAMTS18	O
promoter	O
methylation	O
was	O
detected	O
in	O
70.8	O
%	O
of	O
tumor	S-Phenotype
tissues	O
by	O
methylation	O
-	O
specific	O
PCR	O
,	O
but	O
none	O
of	O
the	O
normal	O
tissues	O
.	O

Polymorphisms	O
rs2910164	O
in	O
miR	O
-	O
146a	O
and	O
rs486907	O
in	O
the	O
RNASEL	O
gene	O
have	O
both	O
independently	O
been	O
associated	O
with	O
the	O
risk	O
of	O
different	O
cancers	S-Phenotype
,	O
and	O
an	O
interaction	O
between	O
them	O
has	O
been	O
observed	O
in	O
nonmelanoma	O
skin	B-Phenotype
cancer	E-Phenotype
.	O

Nuclear	O
receptor	O
small	O
heterodimer	O
partner	O
(	O
SHP	O
/	O
Nr0b2	O
)	O
is	O
a	O
hepatic	B-Phenotype
tumor	E-Phenotype
suppressor	O
and	O
a	O
critical	O
regulator	O
of	O
liver	O
function	O
.	O

Keppen	O
-	O
Lubinsky	O
syndrome	O
(	O
KPLBS	O
)	O
is	O
a	O
rare	O
disease	O
mainly	O
characterized	O
by	O
severe	O
developmental	B-Phenotype
delay	E-Phenotype
and	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
microcephaly	S-Phenotype
,	O
large	O
prominent	B-Phenotype
eyes	E-Phenotype
,	O
a	O
narrow	B-Phenotype
nasal	I-Phenotype
bridge	E-Phenotype
,	O
a	O
tented	B-Phenotype
upper	I-Phenotype
lip	E-Phenotype
,	O
a	O
high	B-Phenotype
palate	E-Phenotype
,	O
an	O
open	B-Phenotype
mouth	E-Phenotype
,	O
tightly	O
adherent	O
skin	O
,	O
an	O
aged	O
appearance	O
,	O
and	O
severe	O
generalized	B-Phenotype
lipodystrophy	E-Phenotype
.	O

MSP	O
was	O
further	O
performed	O
for	O
101	O
ccRCC	O
primary	O
tumors	S-Phenotype
and	O
20	O
adjacent	O
normal	O
tissues	O
.	O

The	O
18	O
new	O
diagnoses	O
made	O
with	O
WGS	O
included	O
structural	O
and	O
non	O
-	O
exonic	O
sequence	O
variants	O
not	O
detectable	O
with	O
whole	O
-	O
exome	O
sequencing	O
,	O
and	O
confirmed	O
recent	O
disease	O
associations	O
with	O
the	O
genes	O
PIGG	O
,	O
RNU4ATAC	O
,	O
TRIO	O
,	O
and	O
UNC13A.ConclusionWGS	O
as	O
a	O
primary	O
clinical	O
test	O
provided	O
a	O
higher	O
diagnostic	O
yield	O
than	O
conventional	O
genetic	O
testing	O
in	O
a	O
clinically	O
heterogeneous	S-Phenotype
cohort	O

The	O
present	O
study	O
identified	O
a	O
functional	O
long	O
non	O
-	O
coding	O
RNA	O
,	O
SLC6A9	O
-	O
5:2	O
,	O
which	O
was	O
involved	O
in	O
the	O
radioactive	O
therapy	O
resistance	O
of	O
thyroid	B-Phenotype
cancer	E-Phenotype
.	O

In	O
this	O
mini	O
-	O
review	O
,	O
we	O
update	O
the	O
current	O
knowledge	O
for	O
the	O
functional	O
roles	O
of	O
WWOX	O
under	O
physiological	O
and	O
pathological	O
settings	O
,	O
and	O
provide	O
new	O
insights	O
regarding	O
pS14	O
-	O
WWOX	O
in	O
T	O
leukemia	S-Phenotype
cell	O
maturation	O
,	O
and	O
switching	O
the	O
anticancer	O
pY33	S-Phenotype
-	O
WWOX	O
to	O
pS14	O
-	O
WWOX	O
for	O
cancer	S-Phenotype
promotion	O
and	O
disease	O
progression	O
.	O

Norepinephrine	O
transporter	O
(	O
NET	O
)	O
transfection	O
leads	O
to	O
significant	O
uptake	O
of	O
iodine	O
-	O
131	O
-	O
labeled	O
metaiodobenzylguanidine	O
(	O
lsup131	O
/	O
supI	O
-	O
MIBG	O
)	O
in	O
non	O
-	O
neuroendocrine	O
tumors	S-Phenotype
.	O

We	O
found	O
that	O
hypermethylation	O
of	O
TRIM36	O
and	O
reduced	O
gene	O
expression	O
was	O
prevalent	O
in	O
several	O
types	O
of	O
human	O
cancers	S-Phenotype
.	O

DLX3	O
mutations	O
have	O
been	O
found	O
to	O
be	O
responsible	O
for	O
Tricho	O
-	O
Dento	O
-	O
Osseous	O
(	O
TDO	O
)	O
syndrome	O
,	O
characterized	O
by	O
kinky	B-Phenotype
hair	E-Phenotype
,	O
thin	B-Phenotype
-	I-Phenotype
pitted	I-Phenotype
enamel	E-Phenotype
and	O
increased	B-Phenotype
bone	I-Phenotype
density	E-Phenotype
.	O

An	O
abnormality	O
in	O
the	O
Lin28	O
/	O
let	O
-	O
7a	O
axis	O
is	O
relevant	O
to	O
the	O
progression	O
of	O
hepatitis	S-Phenotype
B	O
virus	O
(	O
HBV	O
)	O
-	O
positive	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
,	O
which	O
could	O
be	O
a	O
novel	O
therapeutic	O
target	O
for	O
this	O
malignant	O
tumor	S-Phenotype
.	O

However	O
,	O
the	O
underlying	O
mechanisms	O
involved	O
in	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
progression	O
remain	O
poorly	O
understood	O
.	O

An	O
accurate	O
spatial	O
and	O
temporal	O
control	O
of	O
NL	O
-	O
NRX	O
signaling	O
is	O
crucial	O
to	O
balance	O
excitatory	O
and	O
inhibitory	O
neurotransmission	O
,	O
and	O
perturbations	O
are	O
linked	O
with	O
neurodevelopmental	O
and	O
psychiatric	B-Phenotype
disorders	E-Phenotype
.	O

Through	O
Sanger	O
sequencing	O
of	O
a	O
proband	O
with	O
bilateral	B-Phenotype
congenital	I-Phenotype
pedal	I-Phenotype
edema	I-Phenotype
resembling	I-Phenotype
Milroy	I-Phenotype
disease	E-Phenotype
,	O
we	O
identified	O
a	O
novel	O
mutation	O
(	O
NM_005429.2	O
;	O
c.361+5GAAAAA	O
)	O
in	O
liVEGFC	O
/	O
i	O
.	O

Cytochrome	O
P450	O
3A5	O
(	O
CYP3A5	O
)	O
metabolizes	O
these	O
compounds	O
in	O
tumors	S-Phenotype
of	O
the	O
exocrine	O
-	O
like	O
subtype	O
,	O
and	O
pharmacological	O
or	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
-	O
mediated	O
CYP3A5	O
inhibition	O
sensitizes	O
tumor	S-Phenotype
cells	O
to	O
these	O
drugs	O
.	O

MSX2	O
might	O
be	O
a	O
new	O
drug	B-Phenotype
resistance	E-Phenotype
related	O
gene	O
in	O
pancreatic	B-Phenotype
cancer	E-Phenotype
cells	O
by	O
up	O
-	O
regulation	O
of	O
MRP2	O
expression	O

We	O
evaluated	O
the	O
genetic	O
impact	O
of	O
the	O
amyotrophic	B-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
(	O
ALS	S-Phenotype
)	O
risk	O
gene	O
never	O
in	O
mitosis	O
gene	O
a	O
-	O
related	O
kinase	O
1	O
(	O
NEK1	O
)	O
in	O
a	O
Belgian	O
cohort	O
of	O
278	O
patients	O
with	O
ALS	O
(	O
n	O
=	O
245	O
)	O
or	O
ALS	O
with	O
frontotemporal	B-Phenotype
dementia	E-Phenotype
(	O
ALS	O
-	O
FTD	O
,	O
n	O
=	O
33	O
)	O
and	O
609	O
control	O
individuals	O
.	O

GEMIN4	O
was	O
independently	O
mutated	O
in	O
families	O
with	O
a	O
syndrome	O
of	O
cataract	S-Phenotype
,	O
global	B-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
with	O
or	O
without	O
renal	O
involvement	O
.	O

EYA4	O
,	O
one	O
of	O
the	O
four	O
members	O
of	O
the	O
EYA	O
gene	O
family	O
,	O
is	O
associated	O
with	O
several	O
human	O
cancers	S-Phenotype
.	O

To	O
investigate	O
alterations	O
in	O
the	O
expression	O
and	O
functional	O
role	O
of	O
NSUN2	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
,	O
NSUN2	O
expression	O
was	O
assessed	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
and	O
tissues	O
obtained	O
from	O
cancers	S-Phenotype
at	O
different	O
American	O
Joint	O
Committee	O
on	O
Cancer	S-Phenotype
(	O
AJCC	O
)	O
stages	O
,	O
and	O
its	O
functions	O
were	O
investigated	O
using	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

We	O
report	O
a	O
surgical	O
case	O
of	O
51	O
-	O
year	O
-	O
old	O
woman	O
with	O
myoepithelioma	O
occurring	O
in	O
the	O
posterior	O
mediastinum	O
that	O
harbored	O
the	O
Ewing	B-Phenotype
sarcoma	E-Phenotype
breakpoint	O
region1	O
(	O
EWSR1	O
)	O
gene	O
rearrangement	O
.	O

Mutations	O
of	O
the	O
human	O
SIPA1L3	O
gene	O
result	O
in	O
congenital	B-Phenotype
cataracts	E-Phenotype
.	O

This	O
in	O
silico	O
study	O
suggests	O
that	O
in	O
glioblastoma	S-Phenotype
multiforme	O
,	O
karyotypic	O
changes	O
have	O
the	O
potential	O
to	O
cause	O
multiple	O
abnormalities	O
in	O
sets	O
of	O
genes	O
involved	O
in	O
phosphoinositide	O
metabolism	O
and	O
this	O
may	O
be	O
important	O
for	O
understanding	O
drug	B-Phenotype
resistance	E-Phenotype
and	O
phosphoinositide	O
pathway	O
redundancy	O
in	O
the	O
advanced	O
disease	O
state	O
.	O

Patients	O
with	O
the	O
combination	O
of	O
dystonia	S-Phenotype
and	O
ataxia	S-Phenotype
and	O
a	O
family	O
history	O
of	O
a	O
neurodegenerative	O
disorder	O
should	O
be	O
tested	O
for	O
SCA31	O
.	O

This	O
study	O
allowed	O
the	O
identification	O
of	O
the	O
genetic	O
cause	O
of	O
the	O
retinal	B-Phenotype
dystrophy	E-Phenotype
and	O
the	O
establishment	O
of	O
a	O
correct	O
diagnosis	O
in	O
four	O
families	O
,	O
including	O
a	O
large	O
heterozygous	O
deletion	O
in	O
PRPF31	O
,	O
typically	O
considered	O
one	O
of	O
the	O
pitfalls	O
of	O
this	O
method	O
.	O

Recent	O
studies	O
indicated	O
that	O
the	O
estrogen	O
receptor	O
beta	O
(	O
ERβ	O
)	O
could	O
affect	O
the	O
progression	O
of	O
prostate	B-Phenotype
and	I-Phenotype
bladder	I-Phenotype
tumors	E-Phenotype
,	O
however	O
,	O
its	O
roles	O
in	O
the	O
renal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
RCC	S-Phenotype
)	O
,	O
remain	O
to	O
be	O
elucidated	O
.	O

Clinically	O
,	O
TRIP13	O
expression	O
is	O
positively	O
associated	O
with	O
tumor	S-Phenotype
size	O
,	O
T	O
-	O
stage	O
,	O
and	O
N	O
-	O
stage	O
,	O
and	O
Kaplan	O
-	O
Meier	O
analysis	O
revealed	O
that	O
heightened	O
TRIP13	O
expression	O
is	O
associated	O
with	O
lower	O
overall	O
survival	O
.	O

Through	O
biological	O
and	O
in	O
silico	O
analyses	O
,	O
our	O
study	O
suggests	O
an	O
association	O
between	O
SIX1	O
/	O
EYA1	O
mutations	O
and	O
cardiovascular	B-Phenotype
malformations	E-Phenotype
,	O
SIX1	O
/	O
EYA1	O
mutations	O
might	O
be	O
partially	O
responsible	O
for	O
CTDs	O

Objective	O
Hearing	B-Phenotype
loss	E-Phenotype
(	O
HL	S-Phenotype
)	O
is	O
the	O
most	O
common	O
sensory	O
-	O
neural	O
defect	O
and	O
the	O
most	O
heterogeneous	S-Phenotype
trait	O
in	O
humans	O
,	O
with	O
the	O
involvement	O
of	O
AAAA100	O
genes	O
,	O
which	O
make	O
a	O
molecular	O
diagnosis	O
problematic	O
.	O

After	O
diagnosis	O
of	O
granular	O
cell	O
tumour	S-Phenotype
by	O
core	O
needle	O
biopsy	O
,	O
the	O
masses	O
were	O
excised	O
with	O
histopathological	O
and	O
immunohistochemical	O
analysis	O
of	O
both	O
specimens	O
confirming	O
the	O
presence	O
of	O
non	O
-	O
malignant	O
granular	O
cell	O
tumours	S-Phenotype
.	O

Recently	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
,	O
mutations	O
of	O
LRTOMT	O
are	O
associated	O
with	O
profound	B-Phenotype
nonsyndromic	I-Phenotype
hearing	I-Phenotype
impairment	E-Phenotype
at	O
the	O
DFNB63	O
locus	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
detailed	O
clinical	O
information	O
of	O
16	O
novel	O
individuals	O
with	O
biallelic	O
NALCN	O
variants	O
,	O
1	O
individual	O
with	O
a	O
heterozygous	O
de	O
novo	O
NALCN	O
missense	O
variant	O
and	O
an	O
interesting	O
clinical	O
phenotype	O
without	O
contractures	S-Phenotype
,	O
and	O
12	O
individuals	O
with	O
biallelic	O
UNC80	O
variants	O
.	O

Chemotherapy	O
and	O
radiation	O
not	O
only	O
trigger	O
cancer	S-Phenotype
cell	O
apoptosis	O
but	O
also	O
damage	O
stromal	O
cells	O
in	O
the	O
tumour	S-Phenotype
microenvironment	O
(	O
TME	O
)	O
,	O
inducing	O
a	O
senescence	O
-	O
associated	O
secretory	O
phenotype	O
(	O
SASP	O
)	O
characterized	O
by	O
chronic	O
secretion	O
of	O
diverse	O
soluble	O
factors	O
.	O

In	O
recent	O
years	O
,	O
high	O
-	O
throughput	O
sequencing	O
has	O
been	O
used	O
to	O
analyze	O
exomes	O
of	O
virtually	O
all	O
human	O
tumors	S-Phenotype
,	O
which	O
allowed	O
to	O
construct	O
phylogenetic	O
trees	O
of	O
clonal	O
cancer	S-Phenotype
evolution	O
with	O
special	O
emphasis	O
on	O
driver	O
mutations	O
in	O
FGFR1	O
-	O
4	O
genes	O
.	O

Expression	O
of	O
PSMB8	O
as	O
well	O
as	O
Ki	O
-	O
67	O
was	O
higher	O
in	O
glioma	S-Phenotype
tissues	O
demonstrated	O
by	O
western	O
blot	O
and	O
immunohistochemistry	O
.	O

bConclusions	O
:	O
/	O
b	O
The	O
expression	O
of	O
Twist2	O
in	O
human	O
glioma	S-Phenotype
is	O
positively	O
correlated	O
with	O
the	O
malignant	O
grade	O
of	O
glioma	S-Phenotype
,	O
which	O
may	O
be	O
involved	O
in	O
the	O
malignant	O
progression	O
of	O
glioma	S-Phenotype
by	O
EMT	O

Exposure	O
to	O
BMAA	O
has	O
been	O
implicated	O
in	O
the	O
development	O
of	O
neurodegenerative	B-Phenotype
diseases	E-Phenotype
including	O
amyotrophic	B-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
(	O
ALS	S-Phenotype
)	O
,	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
and	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
.	O

We	O
compared	O
the	O
early	O
transcriptome	O
profile	O
between	O
DKD	O
-	O
resistant	O
C57BL	O
/	O
6J	O
and	O
DKD	O
-	O
susceptible	O
DBA	O
/	O
2J	O
(	O
D2	O
)	O
glomeruli	O
and	O
demonstrated	O
a	O
significant	O
downregulation	O
of	O
essential	O
mitochondrial	O
genes	O
in	O
glomeruli	O
from	O
diabetic	O
D2	O
mice	O
,	O
but	O
not	O
in	O
C57BL	O
/	O
6J	O
,	O
with	O
comparable	O
hyperglycemia	S-Phenotype
.	O

Various	O
genes	O
(	O
eg	O
,	O
SPG7	O
,	O
SYNE1	O
,	O
PNPLA6	O
)	O
traditionally	O
rooted	O
in	O
either	O
the	O
ataxia	S-Phenotype
or	O
hereditary	B-Phenotype
spastic	I-Phenotype
paraplegia	E-Phenotype
classification	O
system	O
have	O
now	O
been	O
shown	O
to	O
cause	O
ataxia	S-Phenotype
on	O
the	O
one	O
end	O
of	O
the	O
disease	O
continuum	O
and	O
hereditary	B-Phenotype
spastic	I-Phenotype
paraplegia	E-Phenotype
on	O
the	O
other	O
.	O

Recently	O
,	O
a	O
new	O
type	O
of	O
limb	B-Phenotype
-	I-Phenotype
girdle	I-Phenotype
muscular	I-Phenotype
dystrophy	E-Phenotype
(	O
LGMD	B-Phenotype
type	I-Phenotype
2Z	E-Phenotype
)	O
has	O
been	O
identified	O
due	O
to	O
a	O
missense	O
mutation	O
in	O
POGLUT1	O
(	O
protein	O
O	O
-	O
glucosyltransferase	O
-	O
Rumi	O
)	O
,	O
an	O
enzyme	O
capable	O
of	O
adding	O
glucose	O
to	O
a	O
distinct	O
serine	O
residue	O
of	O
epidermal	O
growth	O
factor	O
-	O
like	O
repeats	O
containing	O
a	O
C	O
-	O
X	O
-	O
S	O
-	O
X	O
-	O
(	O
P	O
/	O
A	O
)	O
-	O
C	O
consensus	O
sequence	O
such	O
as	O
Notch	O
receptors	O
.	O

The	O
up	O
-	O
regulation	O
of	O
STX3	O
is	O
correlated	O
with	O
high	O
disease	O
stage	O
and	O
predicts	O
overall	O
and	O
disease	O
-	O
free	O
survival	O
in	O
patients	O
with	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

Pediatric	O
refractory	O
epilepsy	S-Phenotype
is	O
a	O
broad	O
phenotypic	O
spectrum	O
with	O
great	O
genetic	O
heterogeneity	S-Phenotype
.	O

Neonatal	O
-	O
onset	O
multiple	O
acyl	O
-	O
CoA	O
dehydrogenase	O
deficiency	O
(	O
MADD	O
type	O
I	O
)	O
is	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
disorder	O
of	O
the	O
electron	O
transfer	O
flavoprotein	O
function	O
characterized	O
by	O
a	O
severe	O
clinical	O
and	O
biochemical	O
phenotype	O
,	O
including	O
congenital	O
abnormalities	O
with	O
unresponsiveness	O
to	O
riboflavin	O
treatment	O
as	O
distinguishing	O
features	O
.	O

An	O
abnormality	O
in	O
the	O
Lin28	O
/	O
let	O
-	O
7a	O
axis	O
is	O
relevant	O
to	O
the	O
progression	O
of	O
hepatitis	S-Phenotype
B	O
virus	O
(	O
HBV	O
)	O
-	O
positive	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
,	O
which	O
could	O
be	O
a	O
novel	O
therapeutic	O
target	O
for	O
this	O
malignant	O
tumor	S-Phenotype
.	O

Deficits	O
in	O
miRNA	O
biogenesis	O
have	O
been	O
linked	O
to	O
neurological	O
deficits	O
in	O
humans	O
,	O
and	O
widespread	O
changes	O
in	O
miRNA	O
levels	O
occur	O
in	O
epilepsy	S-Phenotype
,	O
traumatic	O
brain	O
injury	O
,	O
and	O
in	O
response	O
to	O
less	O
dramatic	O
brain	O
insults	O
in	O
rodent	O
models	O
.	O

However	O
,	O
as	O
a	O
classical	O
cell	O
surface	O
adhesion	O
molecule	O
,	O
we	O
found	O
ITGA3	O
correlated	O
negatively	O
with	O
the	O
migration	O
and	O
invasion	O
of	O
ICC	O
cell	O
lines	O
,	O
which	O
differs	O
from	O
other	O
malignant	O
tumors	S-Phenotype
.	O

Low	O
GABRA5	O
expression	O
typified	O
hyperproliferative	O
tumors	S-Phenotype
,	O
and	O
loss	O
of	O
taurine	O
signaling	O
correlated	O
with	O
reduced	O
patient	O
survival	O
,	O
suggesting	O
this	O
tumor	S-Phenotype
suppressive	O
mechanism	O
operates	O
in	O
vivo	O

Array	O
methylation	O
-	O
based	O
analysis	O
uncovered	O
a	O
somatic	O
epigenetic	O
mutation	O
in	O
SDHC	O
in	O
a	O
patient	O
with	O
multiple	O
pheochromocytomas	S-Phenotype
and	O
a	O
gastrointestinal	B-Phenotype
stromal	I-Phenotype
tumor	E-Phenotype
.	O

Mutations	O
in	O
both	O
proteins	O
cause	O
lens	O
cataract	S-Phenotype
and	O
careful	O
consideration	O
of	O
the	O
detail	O
of	O
these	O
cataract	S-Phenotype
phenotypes	O
alerts	O
us	O
to	O
several	O
interesting	O
features	O
concerning	O
the	O
function	O
of	O
filensin	O
(	O
BFSP1	O
)	O
and	O
CP49	O
(	O
BFSP2	O
)	O
in	O
the	O
lens	O
.	O

Methods	O
:	O
Fourteen	O
haplotype	O
-	O
tagging	O
single	O
nucleotide	O
polymorphisms	O
(	O
htSNPs	O
)	O
of	O
MLH1	O
,	O
MLH3	O
and	O
MSH2	O
genes	O
were	O
genotyped	O
by	O
Sequenom	O
MassARRAY	O
method	O
in	O
146	O
patients	O
with	O
locally	O
advanced	O
rectal	O
cancer	S-Phenotype
who	O
received	O
preoperative	O
chemoradiotherapy	O
.	O

Here	O
we	O
show	O
that	O
the	O
microphthalmia	S-Phenotype
-	O
associated	O
transcription	O
factor	O
,	O
MITF	O
,	O
which	O
plays	O
a	O
central	O
role	O
in	O
the	O
development	O
and	O
function	O
of	O
RPE	O
cells	O
,	O
regulates	O
the	O
expression	O
of	O
two	O
visual	O
cycle	O
genes	O
,	O
Rlbp1	O
which	O
encodes	O
retinaldehyde	O
binding	O
protein	O
-	O
1	O
(	O
RLBP1	O
)	O
,	O
and	O
Rdh5	O
,	O
which	O
encodes	O
retinol	O
dehydrogenase	O
-	O
5	O
(	O
RDH5	O
)	O
.	O

Our	O
data	O
suggest	O
that	O
ZNF674	O
-	O
AS1	O
may	O
play	O
some	O
role	O
during	O
cancer	S-Phenotype
occurrence	O
and	O
progression	O
and	O
may	O
be	O
a	O
new	O
biomarker	O
for	O
HCC	O

Older	O
members	O
of	O
a	O
previously	O
reported	O
Arab	O
-	O
Israeli	O
family	O
have	O
intellectual	B-Phenotype
disability	E-Phenotype
of	O
variable	O
severity	O
,	O
persistent	O
feeding	B-Phenotype
difficulties	E-Phenotype
in	O
infancy	O
with	O
dysphagia	S-Phenotype
of	O
liquids	O
and	O
dysphonia	S-Phenotype
with	O
a	O
muffled	O
voice	O
in	O
early	O
adulthood	O
,	O
generalized	B-Phenotype
hypotonia	E-Phenotype
,	O
weakness	S-Phenotype
of	O
proximal	S-Phenotype
muscles	O
,	O
elongated	O
face	O
with	O
narrow	B-Phenotype
bitemporal	I-Phenotype
diameter	E-Phenotype
,	O
and	O
reduced	O
facial	O
movements	O
.	O

In	O
order	O
to	O
expand	O
the	O
mutation	O
spectrum	O
of	O
the	O
causative	O
genes	O
in	O
Chinese	O
adult	O
population	O
,	O
we	O
investigated	O
three	O
genes	O
,	O
SLC39A5	O
,	O
LEPREL1	O
and	O
LRPAP1	O
,	O
in	O
a	O
cohort	O
of	O
187	O
independent	O
Chinese	O
patients	O
with	O
high	B-Phenotype
myopia	E-Phenotype
.	O

We	O
investigated	O
molecular	O
mechanisms	O
of	O
degeneration	O
and	O
show	O
that	O
IFT172	O
protein	O
reduction	O
leads	O
to	O
mislocalization	O
of	O
specific	O
photoreceptor	O
outersegment	O
(	O
OS	O
)	O
proteins	O
(	O
RHO	O
,	O
RP1	O
,	O
IFT139	O
)	O
,	O
aberrant	O
light	O
-	O
driven	O
translocation	O
of	O
alpha	O
transducin	O
and	O
altered	O
localization	O
of	O
glioma	S-Phenotype
-	O
associated	O
oncogene	O
family	O
member	O
1	O
(	O
GLI1	O
)	O
.	O

5	O
'	O
-	O
Aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
(	O
5	O
-	O
Aza	O
-	O
dC	O
)	O
is	O
a	O
demethylating	O
drug	O
that	O
causes	O
genome	O
-	O
wide	O
hypomethylation	O
resulting	O
in	O
the	O
expression	O
of	O
several	O
tumor	S-Phenotype
suppressor	O
genes	O
causing	O
growth	O
arrest	O
of	O
cancer	S-Phenotype
cells	O
.	O

Functional	O
assays	O
indicate	O
that	O
SPINT2	O
reactivation	O
ameliorates	O
the	O
malignant	O
phenotype	O
,	O
specifically	O
reducing	O
cell	O
viability	O
,	O
migration	O
and	O
invasion	O
in	O
diverse	O
cancer	S-Phenotype
cell	O
lines	O
.	O

The	O
expression	O
of	O
CD133	O
,	O
ALDH1	O
and	O
Lgr5	O
was	O
found	O
to	O
be	O
positive	O
in	O
55.6	O
,	O
47.2	O
and	O
78.9	O
%	O
of	O
the	O
primary	O
tumour	S-Phenotype
samples	O
,	O
respectively	O
.	O

In	O
both	O
settings	O
,	O
PLAG1	O
transactivates	O
insulin	O
-	O
like	O
growth	O
factor	O
2	O
(	O
IGF2	O
)	O
,	O
a	O
key	O
Wilms	B-Phenotype
tumor	E-Phenotype
oncogene	O
,	O
and	O
drives	O
mammalian	O
target	O
of	O
rapamycin	O
complex	O
1	O
(	O
mTORC1	O
)	O
signaling	O
.	O

However	O
,	O
the	O
role	O
INPP5E	O
plays	O
in	O
cancer	S-Phenotype
is	O
unknown	O
and	O
the	O
contribution	O
of	O
PI3	O
-	O
kinase	O
signaling	O
to	O
cilia	O
function	O
is	O
little	O
characterized	O
.	O

We	O
identified	O
DNAJC12	O
homozygous	O
null	O
variants	O
(	O
c.187AAAAAT	O
;	O
p.K63	O
*	O
and	O
c.79	O
-	O
2AAAAAG	O
;	O
p.V27Wfs	O
*	O
14	O
)	O
in	O
two	O
kindreds	O
with	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
parkinsonism	E-Phenotype
.	O

Zebrafish	O
with	O
ryroxD1	O
knock	O
-	O
down	O
recapitulate	O
features	O
of	O
PYROXD1	O
myopathy	S-Phenotype
with	O
sarcomeric	B-Phenotype
disorganization	E-Phenotype
,	O
myofibrillar	B-Phenotype
aggregates	E-Phenotype
,	O
and	O
marked	B-Phenotype
swimming	I-Phenotype
defect	E-Phenotype
.	O

Interaction	O
study	O
showed	O
the	O
association	O
between	O
CORIN	O
polymorphisms	O
and	O
hypertension	S-Phenotype
could	O
be	O
changed	O
by	O
overweight	S-Phenotype
(	O
BMI	O
G	O
25	O
kg	O
/	O
m2	O
)	O
.	O

ALDOA	O
has	O
been	O
revealed	O
to	O
be	O
related	O
with	O
many	O
carcinomas	S-Phenotype
,	O
but	O
its	O
expression	O
and	O
function	O
in	O
renal	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
RCC	S-Phenotype
)	O
remain	O
unknown	O
.	O

Our	O
study	O
confirms	O
linkage	O
of	O
a	O
variant	O
clinical	O
form	O
of	O
hair	B-Phenotype
-	I-Phenotype
nail	I-Phenotype
ectodermal	I-Phenotype
dysplasia	E-Phenotype
to	O
chromosome	O
12	O
without	O
any	O
mutation	O
in	O
the	O
coding	O
sequences	O
of	O
the	O
KRTHB5	O
gene	O
.	O

Herein	O
,	O
we	O
investigated	O
the	O
role	O
of	O
LTBP3	O
in	O
the	O
distinct	O
processes	O
involved	O
in	O
cancer	S-Phenotype
metastasis	O
.	O

In	O
neonatal	B-Phenotype
seizures	E-Phenotype
,	O
defects	O
in	O
ALDH7A1	O
and	O
PNPO	O
explain	O
a	O
major	O
fraction	O
of	O
cases	O
.	O

In	O
addition	O
to	O
the	O
in	O
vitro	O
experiments	O
,	O
WDR34	O
negativity	O
was	O
correlated	O
with	O
tumoral	S-Phenotype
growth	O
of	O
OSCCs	O
.	O

Finally	O
,	O
we	O
show	O
that	O
PCP	O
genes	O
liVANGL2	O
/	O
i	O
and	O
liSCRIB	O
/	O
i	O
are	O
significantly	O
downregulated	O
in	O
lung	O
tissue	O
from	O
patients	O
with	O
emphysema	S-Phenotype
.	O

The	O
modulation	O
of	O
these	O
molecular	O
processes	O
may	O
represent	O
a	O
strategy	O
for	O
inhibiting	O
breast	B-Phenotype
cancer	E-Phenotype
invasion	O
by	O
restoring	O
OVOL2	O
expression	O

Importantly	O
,	O
extreme	O
limiting	O
dilution	O
analysis	O
revealed	O
that	O
even	O
1	O
x	O
102	O
ZNF687	O
-	O
transduced	O
cells	O
could	O
form	O
tumors	S-Phenotype
in	O
vivo	O
,	O
indicating	O
that	O
ZNF687	O
contributes	O
to	O
HCC	O
recurrence	O
.	O

We	O
identified	O
eight	O
hub	O
genes	O
which	O
likely	O
play	O
important	O
roles	O
in	O
obesity	S-Phenotype
metabolism	O
and	O
identified	O
microRNAs	O
that	O
significantly	O
negatively	O
correlated	O
with	O
hub	O
genes	O
.	O

In	O
this	O
study	O
,	O
we	O
sequenced	O
112	O
patients	O
with	O
phenotypes	O
within	O
the	O
epilepsy	B-Phenotype
-	I-Phenotype
aphasia	E-Phenotype
spectrum	O
(	O
EAS	O
)	O
to	O
determine	O
the	O
frequency	O
of	O
CNKSR2	O
mutation	O
within	O
this	O
complex	O
set	O
of	O
disorders	O
.	O

Glioblastoma	S-Phenotype
(	O
GBM	S-Phenotype
)	O
is	O
the	O
most	O
prevalent	O
and	O
lethal	O
type	O
of	O
primary	B-Phenotype
malignant	I-Phenotype
brain	I-Phenotype
tumour	E-Phenotype
.	O

Individuals	O
had	O
microcephaly	S-Phenotype
,	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
epilepsy	S-Phenotype
,	O
and	O
recessive	O
mutations	O
in	O
TRIT1	O
.	O

This	O
autosomal	B-Phenotype
recessive	E-Phenotype
disease	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
encoding	O
barttin	O
,	O
BSND	O
,	O
an	O
essential	O
subunit	O
of	O
the	O
ClC	O
-	O
K	O
chloride	O
channels	O
expressed	O
in	O
renal	O
and	O
inner	O
ear	O
epithelia	O
.	O

Different	O
from	O
other	O
types	O
of	O
PAH	O
,	O
PVOD	O
patients	O
have	O
a	O
dismal	O
prognosis	O
because	O
of	O
the	O
progressive	O
nature	O
of	O
pulmonary	O
vascular	O
involvement	O
and	O
fatal	B-Phenotype
pulmonary	I-Phenotype
edema	E-Phenotype
induced	O
by	O
PAH	O
-	O
targeted	O
drugs	O
.	O

We	O
characterize	O
variants	O
in	O
the	O
oxidoreductase	O
PYROXD1	O
as	O
a	O
cause	O
of	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
myopathy	E-Phenotype
with	O
distinctive	O
histopathology	O
and	O
introduce	O
altered	O
redox	O
regulation	O
as	O
a	O
primary	O
cause	O
of	O
congenital	O
muscle	O
disease	O

The	O
variants	O
GJB2	O
c.235delC	O
,	O
SLC26A4	O
c.919	O
-	O
2AAAAAG	O
,	O
and	O
mitochondrial	S-Phenotype
variants	O
m.1555AAAAAG	O
and	O
m.1494CAAAAT	O
were	O
assayed	O
using	O
real	O
time	O
PCR	O
.	O

Since	O
women	O
with	O
breast	B-Phenotype
cancer	E-Phenotype
and	O
men	O
and	O
women	O
with	O
other	O
disorders	O
are	O
often	O
treated	O
with	O
aromatase	O
inhibitors	O
(	O
AI	O
)	O
,	O
these	O
populations	O
might	O
be	O
especially	O
vulnerable	O
to	O
cognitive	B-Phenotype
deficits	E-Phenotype
due	O
to	O
low	O
neuroE2	O
synthesis	O
,	O
i.e.	O
,	O
synthesis	O
of	O
E2	O
directly	O
within	O
the	O
brain	O
.	O

A	O
recent	O
syndromic	O
condition	O
with	O
craniofacial	O
dysmorphisms	O
,	O
comprising	O
congenital	O
ocular	O
defect	O
and	O
neurodevelopmental	B-Phenotype
delay	E-Phenotype
named	O
Helsmoortel	O
-	O
Van	O
der	O
Aa	O
Syndrome	O
(	O
HVDAS	O
)	O
(	O
OMIM	O
#	O
615873	O
)	O
,	O
has	O
been	O
described	O
and	O
molecularly	O
defined	O
,	O
identifying	O
pathogenic	O
mutations	O
in	O
the	O
ADNP	O
gene	O
(	O
OMIM	O
#	O
611386	O
)	O
as	O
biological	O
cause	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
detailed	O
clinicopathological	O
investigation	O
of	O
SMARCB1	B-Phenotype
/	I-Phenotype
INI1	I-Phenotype
-	I-Phenotype
deficient	I-Phenotype
sinonasal	I-Phenotype
carcinomas	E-Phenotype
,	O
including	O
molecular	O
genetic	O
analysis	O
of	O
mutational	O
status	O
and	O
DNA	O
methylation	O
of	O
selected	O
protooncogenes	O
and	O
tumor	S-Phenotype
suppressor	O
genes	O
by	O
means	O
of	O
next	O
generation	O
sequencing	O
(	O
NGS	O
)	O
and	O
methylation	O
-	O
specific	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
(	O
MS	O
-	O
MLPA	O
)	O
.	O

AF1q	O
knockdown	O
by	O
shRNA	O
inhibited	O
tumor	S-Phenotype
cell	O
proliferation	O
,	O
migration	O
,	O
invasion	O
,	O
and	O
epithelial	O
-	O
mesenchymal	O
transition	O
in	O
vitro	O
,	O
as	O
well	O
as	O
tumorigenesis	O
and	O
liver	O
metastasis	O
in	O
vivo	O
,	O
whereas	O
these	O
effects	O
were	O
reversed	O
following	O
AF1q	O
overexpression	O
.	O

Testicular	O
germ	O
cell	O
cancer	S-Phenotype
(	O
TGCC	O
)	O
is	O
derived	O
from	O
germ	B-Phenotype
cell	I-Phenotype
neoplasia	E-Phenotype
in	O
situ	O
(	O
GCNIS	O
)	O
,	O
which	O
arises	O
due	O
to	O
niche	O
disturbances	O
affecting	O
the	O
Sertoli	O
cells	O
.	O

Treatment	O
of	O
tumor	S-Phenotype
cells	O
with	O
the	O
inhibitor	O
GSK2830371	O
increases	O
phosphorylation	O
of	O
Wip1	O
substrates	O
and	O
causes	O
growth	O
inhibition	O
in	O
both	O
hematopoietic	O
tumor	S-Phenotype
cell	O
lines	O
and	O
Wip1	O
-	O
amplified	O
breast	B-Phenotype
tumor	E-Phenotype
cells	O
harboring	O
wild	O
-	O
type	O
TP53	O
.	O

The	O
biomarker	O
panel	O
and	O
the	O
predictive	O
model	O
,	O
when	O
validated	O
by	O
more	O
samples	O
in	O
a	O
multi	O
-	O
center	O
setting	O
,	O
may	O
be	O
used	O
as	O
an	O
auxiliary	O
diagnostic	O
tool	O
along	O
with	O
imaging	O
technology	O
for	O
lung	B-Phenotype
cancer	E-Phenotype
detection	O

An	O
increased	O
ISG	O
expression	O
was	O
also	O
induced	O
by	O
ADAR	O
and	O
RNASEH2B	O
variants	O
in	O
tumor	S-Phenotype
cells	O
and	O
was	O
blocked	O
by	O
the	O
JAK	O
inhibitor	O
Ruxolitinib	O
.	O

The	O
prognostic	O
significance	O
and	O
performance	O
of	O
PYCR1	O
mRNA	O
were	O
validated	O
on	O
13	O
worldwide	O
independent	O
microarray	O
data	O
sets	O
,	O
composed	O
of	O
2500	O
assessable	O
breast	B-Phenotype
cancer	E-Phenotype
cases	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
autosomal	B-Phenotype
recessive	I-Phenotype
inheritance	E-Phenotype
of	O
cochlea	B-Phenotype
-	I-Phenotype
vestibular	I-Phenotype
dysfunction	E-Phenotype
caused	O
by	O
a	O
pathogenic	O
variant	O
in	O
the	O
COCH	O
gene	O
.	O

Independently	O
,	O
another	O
group	O
has	O
recently	O
observed	O
SRD5A3	O
mutations	O
in	O
several	O
families	O
with	O
a	O
type	O
1	O
congenital	O
disorder	O
of	O
glycosylation	O
(	O
CDG	O
type	O
Ix	O
,	O
OMIM	O
212067	O
)	O
,	O
mental	B-Phenotype
retardation	E-Phenotype
,	O
cerebellar	B-Phenotype
ataxia	E-Phenotype
and	O
eye	O
disorders	O
.	O

Finally	O
,	O
exome	O
sequencing	O
enabled	O
us	O
to	O
characterize	O
a	O
heterozygous	O
de	O
novo	O
missense	O
(	O
p.Val408Ala	O
)	O
in	O
KCNA2	O
encoding	O
the	O
potassium	O
channel	O
Kv	O
1.2	O
in	O
a	O
girl	O
with	O
infantile	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
seizures	E-Phenotype
variant	O
of	O
RTT	O
.	O

Interestingly	O
,	O
RAB23	O
null	O
allele	O
homozygosity	O
in	O
humans	O
is	O
not	O
lethal	O
,	O
but	O
instead	O
causes	O
the	O
developmental	O
disorder	O
Carpenter	O
*	O
s	O
syndrome	O
(	O
CS	O
)	O
,	O
which	O
is	O
characterized	O
by	O
craniofacial	B-Phenotype
malformations	E-Phenotype
,	O
polysyndactyly	S-Phenotype
,	O
obesity	S-Phenotype
and	O
intellectual	B-Phenotype
disability	E-Phenotype
.	O

Missense	O
mutations	O
of	O
the	O
human	O
mitochondrial	O
citrate	O
carrier	O
,	O
encoded	O
by	O
the	O
SLC25A1	O
gene	O
,	O
lead	O
to	O
an	O
autosomal	O
recessive	O
neurometabolic	O
disorder	O
characterised	O
by	O
neonatal	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
encephalopathy	E-Phenotype
with	O
severe	O
muscular	B-Phenotype
weakness	E-Phenotype
,	O
intractable	O
seizures	S-Phenotype
,	O
respiratory	B-Phenotype
distress	E-Phenotype
,	O
and	O
lack	B-Phenotype
of	I-Phenotype
psychomotor	I-Phenotype
development	E-Phenotype
,	O
often	O
resulting	O
in	O
early	O
death	O
.	O

Lucitanib	O
is	O
a	O
small	O
molecule	O
inhibitor	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
receptors	O
1	O
to	O
3	O
(	O
VEGFR1	O
to	O
3	O
)	O
,	O
platelet	O
derived	O
growth	O
factor	O
α	O
/	O
β	O
(	O
PDGFRα	O
/	O
β	O
)	O
and	O
FGFR1	O
-	O
3	O
tyrosine	O
kinases	O
and	O
has	O
demonstrated	O
activity	O
in	O
a	O
phase	O
I	O
/	O
II	O
clinical	O
study	O
,	O
with	O
objective	O
RECIST	O
responses	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
patients	O
with	O
FGFR1	O
or	O
FGF3	O
/	O
4	O
/	O
19	O
gene	O
amplification	O
,	O
as	O
well	O
as	O
in	O
patients	O
anticipated	O
to	O
benefit	O
from	O
anti	O
-	O
angiogenic	O
agents	O
.	O

This	O
review	O
highlights	O
recent	O
advances	O
in	O
understanding	O
how	O
the	O
OVOL1	O
-	O
OVOL2	O
axis	O
modulates	O
cell	O
differentiation	O
and	O
proliferation	O
in	O
human	O
keratinocytes	O
,	O
hair	O
follicles	O
,	O
and	O
benign	O
or	O
malignant	O
skin	B-Phenotype
tumors	E-Phenotype
including	O
squamous	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
and	O
malignant	B-Phenotype
melanoma	E-Phenotype
.	O

Mutations	O
of	O
the	O
five	O
genes	O
(	O
ARHGEF5	O
,	O
ANKRD20A2	O
,	O
ZNF595	O
,	O
ZNF812	O
,	O
MYO18B	O
)	O
may	O
be	O
potential	O
germline	O
mutations	O
of	O
lung	B-Phenotype
cancer	E-Phenotype
.	O

Finally	O
,	O
we	O
reveal	O
that	O
papillary	B-Phenotype
craniopharyngioma	E-Phenotype
(	O
PCP	S-Phenotype
)	O
,	O
a	O
benign	O
human	O
pituitary	O
tumour	S-Phenotype
harbouring	O
liBRAF	O
p.V600E	O
/	O
i	O
also	O
contains	O
Sox2sup+	O
/	O
sup	O
cells	O
with	O
sustained	O
proliferative	O
capacity	O
and	O
disrupted	O
pituitary	O
differentiation	O
.	O

Mutations	O
in	O
the	O
elongation	O
of	O
very	O
long	O
chain	O
fatty	O
acid	O
4	O
(	O
ELOVL4	O
)	O
gene	O
cause	O
Stargardt	B-Phenotype
macular	I-Phenotype
dystrophy	I-Phenotype
3	E-Phenotype
(	O
STGD3	S-Phenotype
)	O
,	O
a	O
rare	O
,	O
juvenile	O
-	O
onset	O
,	O
autosomal	O
dominant	O
form	O
of	O
macular	B-Phenotype
degeneration	E-Phenotype
.	O

Bio	O
-	O
functional	O
investigation	O
revealed	O
that	O
LTBP1	O
inhibited	O
cell	O
proliferation	O
in	O
HCC	O
cell	O
lines	O
,	O
suggesting	O
its	O
potential	O
role	O
as	O
a	O
tumor	S-Phenotype
suppressor	O
in	O
HCC	O
.	O

High	O
expression	O
level	O
of	O
SNIP1	O
in	O
tumor	S-Phenotype
patients	O
was	O
significantly	O
correlated	O
with	O
poor	O
prognosis	O
in	O
NSCLC	O
(	O
log	O
-	O
rank	O
P	O
for	O
OS	O
=	O
0.01	O
,	O
log	O
-	O
rank	O
P	O
for	O
DFS	O
=	O
0.001	O
)	O
.	O

GCNT2	O
-	O
positive	O
cells	O
were	O
significantly	O
lesser	O
in	O
organ	O
-	O
confined	O
disease	O
than	O
in	O
that	O
with	O
extra	O
-	O
capsular	O
extensions	O
,	O
and	O
GCNT2	O
-	O
negative	O
tumors	S-Phenotype
were	O
associated	O
with	O
significantly	O
better	O
prostate	O
-	O
specific	O
antigen	O
-	O
free	O
survival	O
compared	O
with	O
GCNT2	O
-	O
positive	O
tumors	S-Phenotype
.	O

Here	O
we	O
find	O
,	O
launching	O
from	O
Drosophila	O
models	O
of	O
amyotrophic	B-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
and	O
frontotemporal	B-Phenotype
dementia	E-Phenotype
,	O
that	O
TDP	O
-	O
43	O
impairs	O
the	O
induction	O
of	O
multiple	O
key	O
stress	O
genes	O
required	O
to	O
protect	O
from	O
disease	O
by	O
reducing	O
the	O
recruitment	O
of	O
the	O
chromatin	O
remodeler	O
Chd1	O
to	O
chromatin	O
.	O

The	O
formation	O
of	O
neurofibrillary	B-Phenotype
tangles	E-Phenotype
(	O
NFT	S-Phenotype
)	O
and	O
its	O
precursor	O
tau	O
oligomers	O
have	O
been	O
suggested	O
as	O
main	O
cause	O
of	O
neuronal	O
degeneration	O
because	O
of	O
a	O
direct	O
correlation	O
of	O
their	O
density	O
to	O
the	O
degree	O
of	O
dementia	S-Phenotype
.	O

The	O
mechanism	O
of	O
GRM6	O
in	O
the	O
development	O
of	O
high	B-Phenotype
myopia	E-Phenotype
need	O
to	O
be	O
further	O
investigated	O
.	O

During	O
drug	O
discovery	O
efforts	O
targeting	O
inhibition	O
of	O
cytochrome	O
P450	O
11B2	O
(	O
CYP11B2	O
)	O
-	O
mediated	O
production	O
of	O
aldosterone	O
as	O
a	O
therapeutic	O
approach	O
for	O
the	O
treatment	O
of	O
chronic	B-Phenotype
kidney	I-Phenotype
disease	E-Phenotype
and	O
hypertension	S-Phenotype
,	O
(	O
S	O
)	O
-	O
6	O
-	O
(	O
5	O
-	O
fluoro	O
-	O
4	O
-	O
(	O
1	O
-	O
hydroxyethyl	O
)	O
pyridin	O
-	O
3	O
-	O
yl	O
)	O
-	O
3,4	O
-	O
dihydro	O
-	O
1,8	O
-	O
naphthyridine	O
-	O
1	O
(	O
2H	O
)	O
-	O
carboxamide	O
(	O
1	O
)	O
was	O
identified	O
as	O
a	O
potent	O
and	O
selective	O
inhibitor	O
of	O
CYP11B2	O
.	O

Doxorubicin	O
and	O
the	O
ERBB2	O
targeted	O
therapy	O
,	O
trastuzumab	O
,	O
are	O
routinely	O
used	O
in	O
the	O
treatment	O
of	O
HER2+	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

ALG2	O
mutation	O
results	O
in	O
a	O
heterogeneous	S-Phenotype
phenotype	O
and	O
care	O
should	O
be	O
taken	O
in	O
categorization	O
and	O
treatment	O
of	O
these	O
patients	O
.	O

Transmissible	O
spongiform	O
encephalopathies	S-Phenotype
,	O
characterized	O
by	O
long	O
incubation	O
periods	O
and	O
spongiform	O
changes	O
associated	O
with	O
neuronal	B-Phenotype
loss	E-Phenotype
in	O
the	O
brain	O
,	O
have	O
been	O
described	O
in	O
several	O
mammalian	O
species	O
appearing	O
either	O
naturally	O
(	O
scrapie	O
in	O
sheep	O
and	O
goats	O
,	O
bovine	O
spongiform	O
encephalopathy	S-Phenotype
in	O
cattle	O
,	O
chronic	O
wasting	O
disease	O
in	O
cervids	O
,	O
Creutzfeldt	O
-	O
Jakob	O
disease	O
in	O
humans	O
)	O
or	O
by	O
experimental	O
transmission	O
studies	O
(	O
scrapie	O
in	O
mice	O
and	O
hamsters	O
)	O
.	O

Moreover	O
,	O
elevated	O
Trak1	O
protein	O
expression	O
is	O
associated	O
with	O
several	O
types	O
of	O
cancers	S-Phenotype
and	O
variants	O
in	O
Trak1	O
are	O
linked	O
to	O
childhood	O
absence	O
epilepsy	S-Phenotype
in	O
humans	O
.	O

Taken	O
together	O
,	O
these	O
data	O
open	O
venues	O
for	O
exploring	O
the	O
possibility	O
that	O
sporadic	O
breast	B-Phenotype
cancer	E-Phenotype
patients	O
with	O
EMSY	O
amplification	O
might	O
benefit	O
from	O
epigenetic	O
combination	O
therapy	O
targeting	O
both	O
the	O
KDM5A	O
demethylase	O
and	O
histone	O
deacetylases	O
.	O

No	O
other	O
novel	O
mutation	O
or	O
this	O
deletion	O
was	O
detected	O
in	O
POFUT1	O
in	O
a	O
second	O
DDD	O
family	O
and	O
a	O
sporadic	O
DDD	O
case	O
by	O
Sanger	O
Sequencing	O
.	O

Lynch	O
syndrome	O
,	O
a	O
hereditary	O
cancer	S-Phenotype
syndrome	O
,	O
occurs	O
because	O
of	O
germline	O
mutations	O
in	O
at	O
least	O
one	O
of	O
four	O
DNA	O
mismatch	O
repair	O
genes	O
(	O
MutL	O
Homolog	O
1	O
(	O
MLH1	O
)	O
,	O
MutS	O
Homolog	O
2	O
(	O
MSH2	O
)	O
,	O
MutS	O
Homolog	O
6	O
(	O
MSH6	O
)	O
,	O
and	O
PMS1	O
Homolog	O
2	O
(	O
PMS2	O
)	O
)	O
.	O

Here	O
we	O
show	O
that	O
a	O
series	O
of	O
transcription	O
factors	O
,	O
including	O
C	O
/	O
EBPβ	O
,	O
GCM1	O
,	O
and	O
GATA1	O
,	O
could	O
act	O
as	O
potential	O
modulators	O
of	O
histone	O
methylation	O
in	O
tumor	S-Phenotype
cells	O
.	O

Therefore	O
,	O
these	O
results	O
indicated	O
that	O
miR	O
-	O
129	O
-	O
5p	O
functioned	O
as	O
a	O
tumor	S-Phenotype
suppressor	O
in	O
GC	O
and	O
may	O
be	O
a	O
potential	O
target	O
of	O
GC	O
treatment	O

Depletion	O
of	O
PRODH	O
and	O
GSALDH	O
in	O
humans	O
leads	O
to	O
hyperprolinemia	S-Phenotype
,	O
which	O
is	O
associated	O
with	O
mental	O
disorders	O
such	O
as	O
schizophrenia	S-Phenotype
.	O

Previously	O
(	O
Pappas	O
et	O
al.	O
,	O
2015	O
;	O
4	O
:	O
e08352	O
)	O
,	O
we	O
reported	O
that	O
Dlx5	O
/	O
6	O
-	O
Cre	O
mediated	O
forebrain	O
deletion	O
of	O
the	O
DYT1	O
dystonia	S-Phenotype
protein	O
torsinA	O
(	O
Dlx	O
-	O
CKO	O
)	O
causes	O
abnormal	O
twisting	O
and	O
selective	O
degeneration	O
of	O
dorsal	O
striatal	O
cholinergic	O
interneurons	O
(	O
ChI	O
)	O
(	O
Pappas	O
et	O
al.	O
,	O
2015	O
)	O
.	O

Nagashima	B-Phenotype
-	I-Phenotype
type	I-Phenotype
palmoplantar	I-Phenotype
keratosis	E-Phenotype
(	O
NPPK	S-Phenotype
)	O
is	O
an	O
autosomal	O
recessive	O
skin	O
disorder	O
with	O
a	O
high	O
,	O
unmet	O
medical	O
need	O
that	O
is	O
caused	O
by	O
mutations	O
in	O
SERPINB7	O
.	O

We	O
conducted	O
a	O
case	O
-	O
control	O
study	O
within	O
the	O
Hispanic	O
Community	O
Health	O
Study	O
/	O
Study	O
of	O
Latinos	O
to	O
investigate	O
whether	O
sleep	O
disordered	O
breathing	O
,	O
as	O
a	O
model	O
of	O
hypoxemia	S-Phenotype
,	O
is	O
independently	O
associated	O
with	O
elevated	O
cFGF23	O
levels	O
in	O
the	O
general	O
population	O
and	O
with	O
elevated	O
cFGF23	O
and	O
iFGF23	O
levels	O
in	O
patients	O
with	O
chronic	B-Phenotype
kidney	I-Phenotype
disease	E-Phenotype
(	O
CKD	S-Phenotype
)	O
,	O
in	O
whom	O
FGF23	O
cleavage	O
may	O
be	O
impaired	O
.	O

Recent	O
studies	O
have	O
reported	O
that	O
SRPX2	O
overexpression	O
is	O
observed	O
in	O
gastrointestinal	B-Phenotype
cancer	E-Phenotype
,	O
and	O
promotes	O
migration	O
and	O
invasion	O
of	O
cancer	S-Phenotype
cells	O
.	O

Mutations	O
have	O
previously	O
been	O
reported	O
in	O
several	O
members	O
of	O
the	O
TRAPP	O
complex	O
of	O
proteins	O
,	O
including	O
TRAPPC2	O
,	O
TRAPPC9	O
and	O
TRAPPC11	O
,	O
resulting	O
in	O
disorders	O
involving	O
skeletal	B-Phenotype
abnormalities	E-Phenotype
,	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
speech	B-Phenotype
impairment	E-Phenotype
and	O
developmental	B-Phenotype
delay	E-Phenotype
.	O

Peroxisome	O
biogenesis	O
factor	O
10	O
(	O
PEX10	O
)	O
is	O
involved	O
in	O
the	O
import	O
of	O
peroxisomal	O
matrix	O
proteins	O
,	O
and	O
the	O
mutation	O
of	O
this	O
gene	O
causes	O
3	O
subtypes	O
of	O
peroxisome	O
biogenesis	O
disorders	O
,	O
namely	O
Zellweger	O
syndrome	O
(	O
severe	O
)	O
,	O
neonatal	O
adrenoleukodystrophy	O
(	O
moderate	O
)	O
and	O
an	O
ataxic	O
form	O
(	O
mild	O
)	O
.	O

Up	O
to	O
this	O
time	O
,	O
only	O
heterozygous	O
mutations	O
of	O
COL9A3	O
gene	O
have	O
been	O
reported	O
in	O
human	O
and	O
related	O
to	O
:	O
(	O
1	O
)	O
multiple	B-Phenotype
epiphyseal	I-Phenotype
dysplasia	E-Phenotype
type	O
3	O
,	O
(	O
2	O
)	O
susceptibility	O
to	O
an	O
intervertebral	O
disc	O
disease	O
,	O
and	O
(	O
3	O
)	O
hearing	B-Phenotype
loss	E-Phenotype
.	O

This	O
was	O
consistent	O
with	O
our	O
observation	O
of	O
higher	O
NRF1	O
protein	O
expression	O
in	O
the	O
experimental	O
model	O
of	O
HER2+	O
breast	B-Phenotype
cancer	E-Phenotype
brain	O
metastasis	O
.	O

In	O
summary	O
,	O
we	O
identified	O
novel	O
immunogenic	O
proteins	O
,	O
which	O
frequently	O
induce	O
tumor	S-Phenotype
-	O
specific	O
T	O
cell	O
responses	O
in	O
GBM	O
patients	O
and	O
were	O
also	O
detected	O
in	O
vitro	O
in	O
therapy	O
-	O
resistant	O
quiescent	O
,	O
slow	O
-	O
cycling	O
GSCs	O
.	O

Screening	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
showed	O
that	O
the	O
mRNA	O
expression	O
levels	O
for	O
the	O
PHKG2	O
and	O
DPEP1	O
were	O
lower	O
in	O
non	O
-	O
tumorigenic	O
mammary	O
epithelial	O
cell	O
MCF10A	O
,	O
but	O
elevated	O
in	O
other	O
cell	O
lines	O
.	O

To	O
evaluate	O
the	O
role	O
of	O
constitutive	O
epigenetic	O
changes	O
in	O
normal	O
body	O
cells	O
of	O
BRCA1	O
/	O
BRCA2	O
-	O
mutation	O
negative	O
patients	O
,	O
we	O
have	O
developed	O
a	O
deep	O
bisulfite	O
sequencing	O
assay	O
targeting	O
the	O
promoter	O
regions	O
of	O
8	O
tumor	S-Phenotype
suppressor	O
(	O
TS	O
)	O
genes	O
(	O
BRCA1	O
,	O
BRCA2	O
,	O
RAD51C	O
,	O
ATM	O
,	O
PTEN	O
,	O
TP53	O
,	O
MLH1	O
,	O
RB1	O
)	O
and	O
the	O
estrogene	O
receptor	O
gene	O
(	O
ESR1	O
)	O
,	O
which	O
plays	O
a	O
role	O
in	O
tumor	S-Phenotype
progression	O
.	O

The	O
trio	O
was	O
studied	O
by	O
whole	O
-	O
exome	O
sequencing	O
to	O
identify	O
candidate	O
genes	O
responsible	O
for	O
causing	O
the	O
complex	O
EA	B-Phenotype
/	I-Phenotype
seizure	E-Phenotype
phenotype	O
.	O

Mammographic	O
density	O
and	O
PAM50	O
molecular	O
subtypes	O
were	O
considered.Results	O
:	O
In	O
the	O
univariate	O
analyses	O
,	O
TP53	O
,	O
PPP1R3A	O
,	O
and	O
KMT2B	O
were	O
significantly	O
more	O
frequently	O
mutated	O
in	O
interval	O
cancers	S-Phenotype
than	O
in	O
screen	O
-	O
detected	O
cancers	S-Phenotype
.	O

In	O
distal	O
renal	O
tubules	O
,	O
FGF23	O
signaling	O
activates	O
with	O
-	O
no	O
-	O
lysine	O
kinase	O
4	O
,	O
leading	O
to	O
increased	O
renal	O
tubular	O
reabsorption	O
of	O
calcium	O
and	O
sodium	O
.	O

The	O
qRT	O
-	O
PCR	O
and	O
immunoblot	O
analyses	O
showed	O
that	O
tenovin	O
-	O
1	O
inhibition	O
of	O
SIRT1	O
resulted	O
in	O
a	O
downregulation	O
of	O
BUB3	O
,	O
BUB1	O
and	O
BUBR1	O
in	O
multiple	O
melanoma	S-Phenotype
cell	O
lines	O
.	O

Thus	O
,	O
here	O
we	O
report	O
a	O
new	O
candidate	O
gene	O
(	O
NOL4	O
)	O
and	O
a	O
haplotype	O
of	O
IRF6	O
forVWS	O
,	O
and	O
highlight	O
the	O
genetic	O
heterogeneity	S-Phenotype
of	O
this	O
disorder	O
in	O
the	O
Indian	O
population	O

Cisplatin	O
(	O
CDDP	O
)	O
is	O
used	O
in	O
the	O
treatment	O
of	O
non	B-Phenotype
-	I-Phenotype
small	I-Phenotype
cell	I-Phenotype
lung	I-Phenotype
cancer	E-Phenotype
(	O
NSCLC	S-Phenotype
)	O
,	O
but	O
due	O
to	O
the	O
development	O
of	O
resistance	O
,	O
the	O
benefit	O
has	O
been	O
limited	O
.	O

These	O
results	O
revealed	O
that	O
upregulation	O
of	O
the	O
Kankl	O
gene	O
inhibited	O
the	O
progression	O
of	O
lung	B-Phenotype
cancer	E-Phenotype
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
and	O
its	O
mechanism	O
was	O
closely	O
related	O
to	O
cell	O
apoptosis	O
as	O
well	O
as	O
tumor	S-Phenotype
invasion	O
and	O
metastasis	O

These	O
experiments	O
suggest	O
that	O
excessive	O
phosphorylation	O
of	O
eIF2a	O
decreases	O
survival	O
of	O
cancer	S-Phenotype
cells	O
;	O
making	O
eIF2a	O
a	O
worthy	O
target	O
for	O
drug	O
development	O
,	O
with	O
the	O
potential	O
to	O
enhance	O
the	O
cytotoxic	O
effects	O
of	O
established	O
anti	O
-	O
neoplastic	O
therapies	O
and	O
circumvent	O
resistance	O
to	O
rapalogues	O
and	O
possibly	O
to	O
other	O
drugs	O
that	O
inhibit	O
upstream	O
components	O
of	O
the	O
mTOR	O
pathway	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrated	O
that	O
PAK4	O
was	O
overexpressed	O
in	O
neuroblastoma	S-Phenotype
tissues	O
and	O
was	O
correlated	O
with	O
tumor	S-Phenotype
malignance	O
and	O
prognosis	O
.	O

Retinitis	S-Phenotype
pigmentosa	O
(	O
RP	O
)	O
describes	O
a	O
group	O
of	O
inherited	O
retinopathies	S-Phenotype
that	O
are	O
characterized	O
by	O
the	O
progressive	O
degeneration	O
of	O
photoreceptor	O
neurons	O
,	O
which	O
causes	O
night	B-Phenotype
blindness	E-Phenotype
,	O
a	O
reduction	B-Phenotype
in	I-Phenotype
the	I-Phenotype
peripheral	I-Phenotype
visual	I-Phenotype
field	E-Phenotype
and	O
decreased	B-Phenotype
visual	I-Phenotype
acuity	E-Phenotype
.	O

To	O
better	O
understand	O
the	O
molecular	O
changes	O
in	O
the	O
AH	O
content	O
under	O
such	O
conditions	O
,	O
we	O
analyzed	O
the	O
miRNA	O
profiles	O
of	O
AH	O
samples	O
from	O
patients	O
with	O
POAG	O
and	O
XFG	O
compared	O
to	O
non	O
-	O
glaucoma	S-Phenotype
controls	O
.	O

To	O
address	O
this	O
,	O
we	O
performed	O
exome	O
sequencing	O
and	O
copy	O
number	O
variant	O
analysis	O
on	O
1511	O
frozen	O
human	O
brains	O
with	O
a	O
diagnosis	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
,	O
n	O
=	O
289	O
)	O
,	O
frontotemporal	B-Phenotype
dementia	E-Phenotype
/	O
amyotrophic	B-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
(	O
FTD	O
/	O
ALS	O
,	O
n	O
=	O
252	O
)	O
,	O
Creutzfeldt	O
-	O
Jakob	O
disease	O
(	O
CJD	O
,	O
n	O
=	O
239	O
)	O
,	O
Parkinson	O
's	O
disease	O
(	O
PD	O
,	O
n	O
=	O
39	O
)	O
,	O
dementia	S-Phenotype
with	O
Lewy	B-Phenotype
bodies	E-Phenotype
(	O
DLB	O
,	O
n	O
=	O
58	O
)	O
,	O
other	O
neurodegenerative	O
,	O
vascular	O
,	O
or	O
neurogenetic	O
disorders	O
(	O
n	O
=	O
266	O
)	O
,	O
and	O
controls	O
with	O
no	O
significant	O
neuropathology	O
(	O
n	O
=	O
368	O
)	O
.	O

However	O
,	O
there	O
is	O
limited	O
knowledge	O
on	O
the	O
selenoprotein	O
expression	O
in	O
colorectal	B-Phenotype
adenoma	E-Phenotype
(	O
CRA	S-Phenotype
)	O
and	O
colorectal	B-Phenotype
cancer	E-Phenotype
(	O
CRC	S-Phenotype
)	O
patients	O
,	O
or	O
the	O
interaction	O
with	O
Se	O
status	O
levels	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
45	O
year	O
old	O
woman	O
diagnosed	O
with	O
CTX	B-Phenotype
-	I-Phenotype
related	I-Phenotype
cerebellar	I-Phenotype
ataxia	E-Phenotype
.	O

This	O
study	O
aimed	O
at	O
answering	O
this	O
question	O
sequencing	O
the	O
entire	O
coding	O
region	O
of	O
SLX4	O
in	O
526	O
familial	O
breast	B-Phenotype
cancer	E-Phenotype
cases	O
from	O
Italy	O
.	O

To	O
confirm	O
that	O
V286L	O
-	O
TG	O
rats	O
exhibit	O
seizures	S-Phenotype
similar	O
to	O
those	O
observed	O
in	O
humans	O
,	O
gene	O
expression	O
patterns	O
and	O
behavioral	O
phenotypes	O
were	O
analyzed	O
.	O

The	O
results	O
indicated	O
that	O
compared	O
with	O
the	O
adjacent	O
non	O
-	O
tumor	S-Phenotype
tissues	O
and	O
a	O
normal	O
gastric	O
epithelial	O
cell	O
line	O
,	O
gastric	B-Phenotype
cancer	E-Phenotype
tissues	O
and	O
cell	O
lines	O
exhibited	O
significantly	O
higher	O
expression	O
of	O
CUL4B	O
.	O

We	O
here	O
report	O
on	O
the	O
existence	O
of	O
Leber	B-Phenotype
*	I-Phenotype
s	I-Phenotype
hereditary	I-Phenotype
optic	I-Phenotype
neuropathy	E-Phenotype
(	O
LHON	S-Phenotype
)	O
associated	O
with	O
peculiar	O
combinations	O
of	O
individually	O
non	O
-	O
pathogenic	O
missense	O
mitochondrial	O
DNA	O
(	O
mtDNA	O
)	O
variants	O
,	O
affecting	O
the	O
MT	O
-	O
ND4	O
,	O
MT	O
-	O
ND4L	O
and	O
MT	O
-	O
ND6	O
subunit	O
genes	O
of	O
Complex	O
I	O
.	O

We	O
generated	O
calpain	O
-	O
1	O
knockout	O
Townes	O
sickle	O
(	O
SSCKO	O
)	O
mice	O
to	O
investigate	O
the	O
role	O
of	O
calpain	O
-	O
1	O
in	O
steady	O
state	O
and	O
hypoxia	S-Phenotype
/	O
reoxygenation	O
(	O
H	O
/	O
R	O
)	O
-	O
induced	O
sickle	O
platelet	O
activation	O
and	O
aggregation	S-Phenotype
,	O
clot	B-Phenotype
retraction	E-Phenotype
,	O
and	O
pulmonary	B-Phenotype
arterial	I-Phenotype
hypertension	E-Phenotype
.	O

In	O
addition	O
,	O
forced	O
expression	O
of	O
RANK	O
-	O
c	O
in	O
ER	O
-	O
negative	O
breast	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
inhibited	O
stimuli	O
-	O
induced	O
NF	O
-	O
κB	O
activation	O
and	O
attenuated	O
migration	O
,	O
invasion	O
,	O
colony	O
formation	O
,	O
and	O
adhesion	O
of	O
cancer	S-Phenotype
cells	O
.	O

An	O
assay	O
for	O
transposase	O
-	O
accessible	O
chromatin	O
with	O
high	O
throughput	O
sequencing	O
(	O
ATAC	O
-	O
seq	O
)	O
identified	O
1677	O
tumor	S-Phenotype
-	O
specific	O
chromatin	O
-	O
accessible	O
regions	O
in	O
NASH	O
-	O
derived	O
HCC	O
tissue	O
samples	O
.	O

Mutations	O
in	O
MYH2	O
are	O
associated	O
with	O
skeletal	B-Phenotype
myopathies	E-Phenotype
,	O
characterized	O
by	O
ophthalmoplegia	S-Phenotype
.	O

Global	O
Ptchd1	O
deletion	O
recapitulates	O
learning	O
impairment	O
,	O
hyper	O
-	O
aggression	S-Phenotype
,	O
and	O
motor	O
defects	O
,	O
all	O
of	O
which	O
are	O
insensitive	O
to	O
SK	O
pharmacological	O
targeting	O
and	O
not	O
found	O
in	O
the	O
TRN	O
-	O
restricted	O
deletion	O
mouse	O
.	O

Some	O
genes	O
,	O
such	O
as	O
GSTM1	O
,	O
DNMT3L	O
,	O
and	O
CYP1A1	O
,	O
have	O
been	O
shown	O
to	O
be	O
potentially	O
associated	O
with	O
oligospermia	S-Phenotype
;	O
some	O
,	O
such	O
as	O
CATSPER1	O
,	O
CRISP2	O
,	O
SEPT4	O
,	O
TCTE3	O
,	O
TEKT4	O
,	O
and	O
DNAH1	O
,	O
with	O
asthenospermia	S-Phenotype
;	O
and	O
still	O
others	O
,	O
such	O
as	O
DPY19L2	O
and	O
AURKC	O
,	O
with	O
teratospermia	S-Phenotype
.	O

In	O
particular	O
,	O
the	O
TMEM132D	O
,	O
SPTA1	O
and	O
VPS13B	O
genes	O
were	O
commonly	O
mutated	O
in	O
both	O
early	O
and	O
late	O
stage	O
tumors	S-Phenotype
,	O
primary	O
tumors	S-Phenotype
and	O
metastases	O
,	O
and	O
tumors	S-Phenotype
before	O
and	O
after	O
chemotherapy	O
,	O
as	O
in	O
the	O
case	O
of	O
the	O
TP53	O
and	O
RB1	O
genes	O
.	O

Constitutive	O
activation	O
of	O
interferon	O
signaling	O
pathways	O
has	O
been	O
reported	O
in	O
colorectal	B-Phenotype
cancer	E-Phenotype
(	O
CRC	S-Phenotype
)	O
,	O
leading	O
to	O
a	O
strong	O
CD8+	O
T	O
cell	O
response	O
through	O
stimulation	O
of	O
NLRC5	O
expression	O
.	O

However	O
,	O
the	O
functional	O
role	O
of	O
HOXB1	O
and	O
the	O
mechanism	O
regulating	O
HOXB1	O
expression	O
in	O
glioma	S-Phenotype
are	O
not	O
fully	O
understood	O
.	O

IL17RD	O
expression	O
was	O
increased	O
in	O
ulcerative	B-Phenotype
colitis	E-Phenotype
cancers	S-Phenotype
,	O
and	O
miR	O
-	O
193a	O
-	O
3p	O
treatment	O
decreased	O
growth	O
and	O
EGFR	O
signaling	O
of	O
HCT116	O
cells	O
in	O
xenografts	O
expressing	O
both	O
IL17RD	O
with	O
WT	O
3'UTR	O
compared	O
with	O
cells	O
expressing	O
IL17RD	O
with	O
mutant	O
3'UTR.Conclusions	O
:	O
miR	O
-	O
193a	O
-	O
3p	O
is	O
downregulated	O
in	O
ulcerative	B-Phenotype
colitis	I-Phenotype
neoplasia	E-Phenotype
,	O
and	O
its	O
loss	O
promotes	O
carcinogenesis	O
through	O
upregulation	O
of	O
IL17RD	O
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
the	O
results	O
of	O
a	O
phase	O
I	O
/	O
II	O
study	O
of	O
a	O
DC	O
-	O
based	O
vaccination	O
for	O
advanced	O
breast	B-Phenotype
,	I-Phenotype
ovarian	I-Phenotype
,	I-Phenotype
and	I-Phenotype
gastric	I-Phenotype
cancers	E-Phenotype
,	O
and	O
we	O
offer	O
evidence	O
that	O
patients	O
can	O
be	O
effectively	O
vaccinated	O
with	O
autologous	O
DCs	O
pulsed	O
with	O
WT1	O
peptide	O
.	O

In	O
our	O
study	O
,	O
we	O
identified	O
a	O
set	O
of	O
susceptibility	O
genes	O
that	O
had	O
been	O
missed	O
in	O
single	O
-	O
marker	O
GWAS	O
,	O
and	O
our	O
findings	O
could	O
promote	O
the	O
study	O
of	O
the	O
genetic	O
mechanisms	O
in	O
schizophrenia	S-Phenotype
.	O

Our	O
data	O
revealed	O
that	O
ALDOA	O
functions	O
as	O
a	O
tumor	S-Phenotype
promoter	O
,	O
plays	O
a	O
prominent	O
role	O
in	O
proliferation	O
,	O
migration	O
,	O
and	O
invasion	O
of	O
RCC	O
cells	O
with	O
high	O
expression	O
,	O
and	O
may	O
promote	O
EMT	O
and	O
activate	O
the	O
Wnt	O
/	O
b	O
-	O
catenin	O
signaling	O
pathway	O

However	O
,	O
clinical	O
significance	O
of	O
PPM1B	O
as	O
a	O
pharmacological	O
target	O
in	O
cancer	S-Phenotype
therapy	O
has	O
not	O
been	O
explored	O
.	O

We	O
first	O
develop	O
a	O
doxycycline	O
-	O
inducible	O
cell	O
line	O
expressing	O
GFP	O
-	O
tagged	O
cytoplasmic	O
TDP	O
-	O
43	O
protein	O
(	O
iGFP	O
-	O
NLSm	O
)	O
as	O
a	O
cell	O
-	O
based	O
system	O
to	O
screen	O
and	O
identify	O
seeding	O
activity	O
of	O
human	O
brain	O
-	O
derived	O
pathological	O
TDP	O
-	O
43	O
isolated	O
from	O
sporadic	O
FTLD	O
-	O
TDP	O
and	O
familial	O
cases	O
with	O
Granulin	O
(	O
FTLD	O
-	O
TDP	O
-	O
GRN	O
)	O
or	O
C9orf72	O
repeat	O
expansion	O
mutations	O
(	O
FTLD	O
-	O
TDP	O
-	O
C9+	O
)	O
.	O

VPS13C	O
mutations	O
are	O
associated	O
with	O
a	O
distinct	O
form	O
of	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
parkinsonism	E-Phenotype
characterized	O
by	O
rapid	O
and	O
severe	O
disease	O
progression	O
and	O
early	B-Phenotype
cognitive	I-Phenotype
decline	E-Phenotype
;	O
the	O
pathological	O
features	O
were	O
striking	O
and	O
reminiscent	O
of	O
diffuse	O
Lewy	B-Phenotype
body	E-Phenotype
disease	O
.	O

To	O
test	O
whether	O
this	O
gene	O
can	O
confer	O
a	O
wide	O
variety	O
of	O
psychiatric	B-Phenotype
disorders	E-Phenotype
,	O
we	O
carried	O
out	O
a	O
case	O
-	O
control	O
association	O
analysis	O
of	O
three	O
tagging	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
rs2074896	O
,	O
rs2074897	O
,	O
and	O
rs2074898	O
)	O
in	O
the	O
NDUFS7	O
gene	O
by	O
sequencing	O
330	O
Han	O
Chinese	O
patients	O
with	O
schizophrenia	S-Phenotype
and	O
330	O
well	O
-	O
matched	O
healthy	O
controls	O
.	O

Recently	O
,	O
TMEM38B	O
,	O
a	O
gene	O
that	O
encodes	O
TRIC	O
-	O
B	O
,	O
a	O
monovalent	O
cation	O
-	O
specific	O
channel	O
involved	O
in	O
calcium	O
flux	O
from	O
intracellular	O
stores	O
and	O
in	O
cell	O
differentiation	O
,	O
has	O
been	O
associated	O
with	O
autosomal	B-Phenotype
recessive	E-Phenotype
OI	O
.	O

Our	O
purpose	O
of	O
this	O
study	O
is	O
to	O
discover	O
the	O
physiological	O
effects	O
and	O
mechanism	O
of	O
FUZ	O
in	O
non	O
-	O
small	O
-	O
cell	O
lung	B-Phenotype
cancer	E-Phenotype
(	O
NSCLC	O
)	O
in	O
vitro	O
.	O

We	O
found	O
that	O
PRMT1	O
knockout	O
mice	O
showed	O
significantly	O
lower	O
expression	O
of	O
IL10	O
and	O
IL6	O
cytokines	O
in	O
the	O
liverand	O
downstream	O
STAT3	O
activation	O
,	O
which	O
correlated	O
with	O
reduced	O
number	O
of	O
surface	O
tumors	S-Phenotype
,	O
reduced	O
proliferation	O
and	O
reduced	O
number	O
of	O
M2	O
macrophages	O
in	O
the	O
liver	O
as	O
well	O
as	O
within	O
proliferating	O
nodules	O
.	O

By	O
targeted	O
sequencing	O
,	O
we	O
identified	O
novel	O
ADAR	O
and	O
RNASEH2B	O
variants	O
,	O
and	O
a	O
3	O
-	O
to	O
17	O
-	O
fold	O
frequency	O
increase	O
of	O
the	O
AGS	O
mutations	O
ADAR	O
,	O
c.577CAAAAG	O
;	O
p.	O
(	O
P193A	O
)	O
and	O
RNASEH2B	O
,	O
c.529GAAAAA	O
;	O
p.	O
(	O
A177T	O
)	O
in	O
the	O
germline	O
of	O
familial	O
glioma	S-Phenotype
patients	O
as	O
well	O
as	O
in	O
test	O
and	O
validation	O
cohorts	O
of	O
glioblastomas	S-Phenotype
and	O
prostate	O
carcinomas	S-Phenotype
versus	O
ethnicity	O
-	O
matched	O
controls	O
,	O
whereby	O
rare	O
RNASEH2B	O
variants	O
were	O
significantly	O
more	O
frequent	O
in	O
familial	O
glioma	S-Phenotype
patients	O
.	O

The	O
created	O
databases	O
include	O
ACAD8	O
(	O
isobutyryl	O
-	O
CoA	O
dehydrogenase	O
deficiency	O
(	O
IBD	O
)	O
)	O
,	O
ACADSB	O
(	O
short	O
-	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
(	O
SCAD	O
)	O
deficiency	O
)	O
,	O
AUH	O
(	O
3	B-Phenotype
-	I-Phenotype
methylglutaconic	I-Phenotype
aciduria	E-Phenotype
(	O
3	O
-	O
MGCA	O
)	O
)	O
,	O
DHCR7	O
(	O
Smith	O
-	O
Lemli	O
-	O
Opitz	O
syndrome	O
)	O
,	O
HMGCS2	O
(	O
3	O
-	O
hydroxy	O
-	O
3	O
-	O
methylglutaryl	O
-	O
CoA	O
synthase	O
2	O
deficiency	O
)	O
,	O
HSD17B10	O
(	O
17	O
-	O
beta	O
-	O
hydroxysteroid	O
dehydrogenase	O
X	O
deficiency	O
)	O
,	O
FKBP14	O
(	O
Ehlers	O
-	O
Danlos	O
syndrome	O
with	O
progressive	O
kyphoscoliosis	S-Phenotype
,	O
myopathy	S-Phenotype
,	O
and	O
hearing	B-Phenotype
loss	E-Phenotype
;	O
EDSKMH	O
)	O
and	O
ROGDI	O
(	O
Kohlschütter	O
-	O
Tönz	O
syndrome	O
)	O
.	O

We	O
originally	O
discovered	O
TERE1	O
as	O
a	O
potential	O
tumor	S-Phenotype
suppressor	O
protein	O
based	O
upon	O
reduced	O
expression	O
in	O
bladder	O
and	O
prostate	B-Phenotype
cancer	E-Phenotype
specimens	O
and	O
growth	O
inhibition	O
of	O
tumor	S-Phenotype
cell	O
lines	O
/	O
xenografts	O
upon	O
ectopic	O
expression	O
.	O

MATERIAL	O
AND	O
METHODS	O
Gli	O
-	O
1	O
in	O
tumor	S-Phenotype
tissue	O
was	O
measured	O
by	O
immunohistochemistry	O
(	O
IHC	O
)	O
.	O

Giantin	O
-	O
knockout	O
zebrafish	O
exhibit	O
hyperostosis	S-Phenotype
and	O
ectopic	O
calcium	O
deposits	O
,	O
recapitulating	O
phenotypes	O
of	O
hyperphosphatemic	B-Phenotype
familial	I-Phenotype
tumoral	I-Phenotype
calcinosis	E-Phenotype
,	O
a	O
disease	O
caused	O
by	O
mutations	O
in	O
GALNT3	O
.	O

Here	O
,	O
we	O
applied	O
this	O
method	O
to	O
identify	O
differentially	O
expressed	O
proteins	O
(	O
such	O
as	O
coatomer	O
subunit	O
beta	O
2	O
[	O
COPB2	O
]	O
)	O
and	O
evaluated	O
the	O
functions	O
and	O
molecular	O
mechanisms	O
of	O
these	O
proteins	O
in	O
prostate	B-Phenotype
cancer	E-Phenotype
(	O
PCA	O
)	O
cell	O
proliferation	O
.	O

In	O
Mfrprd6	O
eyes	O
,	O
a	O
significant	O
1.5	O
-	O
to	O
2.0	O
-	O
fold	O
decrease	O
was	O
observed	O
among	O
transcripts	O
of	O
genes	O
linked	O
to	O
retinal	B-Phenotype
degeneration	E-Phenotype
,	O
including	O
those	O
involved	O
in	O
visual	O
cycle	O
(	O
Rpe65	O
,	O
Lrat	O
,	O
Rgr	O
)	O
,	O
phototransduction	O
(	O
Pde6a	O
,	O
Guca1b	O
,	O
Rgs9	O
)	O
,	O
and	O
photoreceptor	O
disc	O
morphogenesis	O
(	O
Rpgrip1	O
and	O
Fscn2	O
)	O
.	O

Taken	O
together	O
these	O
data	O
suggest	O
that	O
the	O
PRMT1	O
-	O
IL6	O
-	O
STAT3	O
axis	O
is	O
an	O
important	O
mechanism	O
of	O
alcohol	O
-	O
associated	O
tumor	S-Phenotype
progression	O

Finally	O
,	O
we	O
report	O
that	O
9	O
retained	O
cytotoxicity	O
against	O
several	O
pediatric	O
cancer	S-Phenotype
cell	O
lines	O
with	O
ECsub50	O
/	O
sub	O
values	O
comparable	O
to	O
BET	O
inhibitor	O
(	O
BETi	O
)	O
clinical	O
candidates	O

We	O
find	O
that	O
STX3	O
promotes	O
the	O
proliferation	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
by	O
increasing	O
the	O
activation	O
of	O
the	O
Akt	O
-	O
mTOR	O
signaling	O
,	O
and	O
Akt	O
inhibitor	O
Ipatasertib	O
or	O
MK	O
-	O
2206	O
represses	O
STX3	O
effects	O
on	O
the	O
growth	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

The	O
mitochondrial	O
protein	O
SLC25A46	O
has	O
been	O
recently	O
identified	O
as	O
a	O
novel	O
pathogenic	O
cause	O
in	O
a	O
wide	O
spectrum	O
of	O
neurological	O
diseases	O
,	O
including	O
inherited	B-Phenotype
optic	I-Phenotype
atrophy	E-Phenotype
,	O
Charcot	B-Phenotype
-	I-Phenotype
Marie	I-Phenotype
-	I-Phenotype
Tooth	I-Phenotype
type	I-Phenotype
2	E-Phenotype
,	O
Leigh	B-Phenotype
syndrome	E-Phenotype
,	O
progressive	B-Phenotype
myoclonic	I-Phenotype
ataxia	E-Phenotype
and	O
lethal	B-Phenotype
congenital	I-Phenotype
pontocerebellar	I-Phenotype
hypoplasia	E-Phenotype
.	O

Taken	O
together	O
,	O
PSMD1	O
was	O
identified	O
as	O
a	O
potential	O
gene	O
that	O
plays	O
a	O
role	O
in	O
the	O
development	O
of	O
tamoxifen	O
resistance	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Our	O
objective	O
was	O
to	O
identify	O
the	O
CpG	O
loci	O
that	O
are	O
persistently	O
hyper	O
-	O
methylated	O
during	O
serrated	O
carcinogenesis	O
,	O
from	O
the	O
early	O
SSA	O
/	O
P	O
lesion	O
through	O
the	O
later	O
cancer	S-Phenotype
phases	O
of	O
neoplasia	S-Phenotype
development	O
.	O

Six	O
novel	O
CRYGC	O
mutations	O
(	O
p.Asp65ThrfsX38	O
,	O
p.Arg142GlyfsX5	O
,	O
p.Arg142AlafsX22	O
,	O
p.Tyr144X	O
,	O
p.Arg169X	O
,	O
and	O
p.Tyr46Asp	O
)	O
were	O
identified	O
in	O
other	O
six	O
families	O
with	O
congenital	B-Phenotype
nuclear	I-Phenotype
cataracts	E-Phenotype
,	O
respectively	O
.	O

The	O
CSIRO	O
National	O
NBN	O
Telehealth	O
Trial	O
investigated	O
the	O
effects	O
of	O
introducing	O
at	O
home	O
telemonitoring	O
of	O
vital	O
signs	O
for	O
the	O
management	O
of	O
a	O
heterogeneous	S-Phenotype
group	O
of	O
chronically	O
ill	O
patients	O
.	O

Mutation	O
in	O
the	O
INVS	O
gene	O
causes	O
nephronophthisis	B-Phenotype
type	I-Phenotype
II	E-Phenotype
(	O
NPHP2	S-Phenotype
)	O
,	O
an	O
autosomal	B-Phenotype
recessive	I-Phenotype
chronic	I-Phenotype
tubulointerstitial	I-Phenotype
nephropathy	E-Phenotype
.	O

Thus	O
,	O
we	O
propose	O
that	O
OGFOD1	O
is	O
required	O
for	O
breast	B-Phenotype
cancer	E-Phenotype
cell	O
proliferation	O
and	O
is	O
associated	O
with	O
poor	O
prognosis	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

Like	O
USP22	O
,	O
USP51	O
and	O
USP27X	O
are	O
required	O
for	O
normal	O
cell	O
proliferation	O
,	O
and	O
their	O
depletion	O
suppresses	O
tumor	S-Phenotype
growth	O
.	O

This	O
is	O
consistent	O
with	O
previous	O
studies	O
reporting	O
arthrogryposis	S-Phenotype
in	O
Lgi4	O
-	O
deficient	O
mice	O
due	O
to	O
peripheral	B-Phenotype
hypomyelination	E-Phenotype
.	O

Integration	O
of	O
cell	O
culture	O
genomes	O
,	O
transcriptomes	O
and	O
tumour	S-Phenotype
phenotypes	O
with	O
functional	O
studies	O
and	O
human	O
data	O
reveals	O
additional	O
widespread	O
effects	O
of	O
oncogenic	O
dosage	O
variation	O
on	O
cell	O
morphology	O
and	O
plasticity	O
,	O
histopathology	O
and	O
clinical	O
outcome	O
,	O
with	O
the	O
highest	O
KrassupMUT	O
/	O
sup	O
levels	O
underlying	O
aggressive	O
undifferentiated	O
phenotypes	O
.	O

Lynch	O
syndrome	O
(	O
LS	O
)	O
patients	O
with	O
isolated	O
PMS2	O
loss	O
in	O
the	O
colon	B-Phenotype
cancer	E-Phenotype
,	O
while	O
intact	O
MMR	O
in	O
the	O
prostate	B-Phenotype
cancer	E-Phenotype
,	O
are	O
exceedingly	O
rare	O
.	O

Mutation	O
of	O
aspartic	O
acid	O
378	O
of	O
hnRNPDL	O
to	O
either	O
asparagine	O
or	O
histidine	O
has	O
been	O
associated	O
with	O
limb	B-Phenotype
girdle	I-Phenotype
muscular	I-Phenotype
dystrophy	E-Phenotype
.	O

Currently	O
the	O
only	O
established	O
high	O
penetrance	O
familial	O
melanoma	S-Phenotype
genes	O
are	O
CDKN2A	O
and	O
CDK4	O
.	O

ME	O
attenuated	O
the	O
influence	O
of	O
APOB	O
rs512535	O
and	O
TNFA	O
rs361525	O
on	O
obesity	S-Phenotype
risk	O
in	O
FMP	O
.	O

In	O
contrast	O
,	O
the	O
SYT8	O
/	O
TNNI2	O
fusion	O
transcript	O
resulting	O
from	O
transcription	O
-	O
induced	O
chimerism	O
by	O
read	O
-	O
through	O
mechanisms	O
was	O
a	O
rather	O
common	O
and	O
tumor	S-Phenotype
-	O
specific	O
event	O
occurring	O
in	O
37.5	O
%	O
(	O
18	O
/	O
48	O
)	O
of	O
the	O
UC	O
specimens	O
.	O

Taken	O
together	O
,	O
these	O
data	O
provide	O
novel	O
information	O
for	O
comprehending	O
the	O
tumor	S-Phenotype
-	O
suppressive	O
role	O
of	O
miR	O
-	O
200a	O
in	O
HCC	O
pathogenesis	O
through	O
inhibition	O
of	O
GAB1	O
translation	O

Together	O
these	O
new	O
findings	O
expand	O
our	O
knowledge	O
of	O
how	O
natural	O
variation	O
modulates	O
seizures	S-Phenotype
,	O
and	O
highlights	O
the	O
feasibility	O
of	O
characterizing	O
and	O
validating	O
modifiers	O
in	O
mouse	O
strains	O
and	O
substrains	O
in	O
the	O
post	O
-	O
genome	O
sequence	O
era	O
.	O

Mitochondrial	B-Phenotype
neurogastrointestinal	I-Phenotype
encephalopathy	E-Phenotype
(	O
MNGIE	S-Phenotype
)	O
,	O
usually	O
an	O
autosomal	O
-	O
recessive	O
inherited	O
condition	O
,	O
causes	O
gastrointestinal	B-Phenotype
dysmotility	E-Phenotype
,	O
ophthalmoplegia	S-Phenotype
,	O
ptosis	S-Phenotype
,	O
leukoencephalopathy	S-Phenotype
and	O
neuropathy	S-Phenotype
.	O

We	O
further	O
review	O
the	O
variety	O
of	O
melanocytic	O
tumors	S-Phenotype
associated	O
with	O
such	O
BRAF	O
fusions	O

In	O
a	O
cohort	O
of	O
Australians	O
of	O
European	O
descent	O
,	O
consisting	O
of	O
385	O
keratoconus	S-Phenotype
cases	O
and	O
396	O
controls	O
,	O
we	O
screened	O
21	O
keratoconus	S-Phenotype
candidate	O
genes	O
:	O
BANP	O
,	O
CAST	O
,	O
COL4A3	O
,	O
COL4A4	O
,	O
COL5A1	O
,	O
FOXO1	O
,	O
FNDC3B	O
,	O
HGF	O
,	O
IL1A	O
,	O
IL1B	O
,	O
ILRN	O
,	O
IMMP2L	O
,	O
MPDZ	O
,	O
NFIB	O
,	O
RAB3GAP1	O
,	O
RAD51	O
,	O
RXRA	O
,	O
SLC4A11	O
,	O
SOD1	O
,	O
TF	O
and	O
VSX1	O
.	O

A	O
10	O
-	O
year	O
-	O
old	O
girl	O
had	O
progressive	B-Phenotype
neurologic	I-Phenotype
deterioration	E-Phenotype
,	O
macular	B-Phenotype
cherry	I-Phenotype
-	I-Phenotype
red	I-Phenotype
spot	E-Phenotype
,	O
and	O
cornea	B-Phenotype
verticillata	E-Phenotype
.	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
increased	O
a	O
-	O
actinin	O
-	O
1	O
expression	O
destabilizes	O
E	O
-	O
cadherin	O
-	O
based	O
adhesions	O
,	O
which	O
is	O
likely	O
to	O
promote	O
the	O
migratory	O
potential	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

In	O
humans	O
,	O
CERKL	O
mutations	O
cause	O
widespread	O
retinal	B-Phenotype
degeneration	E-Phenotype
:	O
early	O
dysfunction	O
and	O
loss	O
of	O
rod	O
and	O
cone	O
photoreceptors	O
in	O
the	O
outer	O
retina	O
and	O
,	O
progressively	O
,	O
death	O
of	O
cells	O
in	O
the	O
inner	O
retina	O
.	O

The	O
results	O
suggest	O
a	O
conditional	O
regulation	O
of	O
KRT16	O
gene	O
by	O
ATF4	O
that	O
may	O
be	O
inhibited	O
in	O
normal	O
cells	O
,	O
but	O
engaged	O
during	O
cancer	S-Phenotype
progression	O
.	O

Of	O
the	O
136	O
PDAC	O
tumor	S-Phenotype
tissues	O
,	O
93	O
(	O
68.38	O
%	O
)	O
were	O
strong	O
and	O
43	O
(	O
31.62	O
%	O
)	O
were	O
weak	O
B7	O
-	O
H5	O
expression	O
.	O

HNF1A	O
variants	O
can	O
cause	O
diabetes	O
and	O
might	O
be	O
involved	O
in	O
the	O
development	O
of	O
primary	O
liver	O
neoplasm	S-Phenotype
.	O

This	O
work	O
associates	O
missense	O
mutations	O
in	O
NSMCE3	O
with	O
an	O
autosomal	B-Phenotype
recessive	I-Phenotype
chromosome	I-Phenotype
breakage	E-Phenotype
syndrome	O
that	O
leads	O
to	O
defective	O
T	O
and	O
B	O
cell	O
function	O
and	O
acute	B-Phenotype
respiratory	I-Phenotype
distress	I-Phenotype
syndrome	E-Phenotype
in	O
early	O
childhood	O

Spinocerebellar	O
ataxia	S-Phenotype
type	O
11	O
(	O
SCA11	O
)	O
is	O
a	O
rare	O
,	O
dominantly	O
inherited	O
human	O
ataxia	S-Phenotype
characterized	O
by	O
atrophy	O
of	O
Purkinje	O
neurons	O
in	O
the	O
cerebellum	O
.	O

Fasting	O
serum	O
tumor	S-Phenotype
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
like	O
antigen	O
1A	O
(	O
TL1A	O
)	O
and	O
its	O
receptor	O
death	O
receptor	O
3	O
(	O
DR3	O
)	O
,	O
NOGO	O
-	O
B	O
(	O
reticulon	O
4B	O
)	O
and	O
its	O
receptor	O
NUS1	O
,	O
high	O
-	O
sensitivity	O
C	O
-	O
reactive	O
protein	O
(	O
hsCRP	O
)	O
,	O
A	O
disintegrin	O
and	O
metalloproteinase	O
with	O
thrombospondin	O
motifs	O
(	O
ADAMTS	O
)	O
1	O
,	O
4	O
,	O
5	O
and	O
interleukin	O
(	O
IL	O
)	O
6	O
levels	O
were	O
determined	O
.	O

2014	O
;	O
Alakbarzade	O
et	O
al	O
.	O

Currently	O
,	O
21	O
genes	O
(	O
BBS1	O
-	O
21	O
)	O
present	O
on	O
different	O
chromosomes	O
have	O
been	O
mapped	O
:	O
these	O
genes	O
are	O
responsible	O
for	O
BBS	O
phenotypes	O
and	O
they	O
show	O
a	O
great	O
heterogeneity	S-Phenotype
of	O
mutations	O
.	O

The	O
most	O
common	O
genes	O
are	O
BBS1	O
(	O
locus	O
11q13	O
)	O
and	O
BBS10.We	O
show	O
here	O
the	O
case	O
of	O
a	O
50	O
year	O
old	O
patient	O
with	O
BBS	O
.	O

(	O
2014	O
)	O
De	O
Novo	O
truncating	O
mutations	O
in	O
AHDC1	O
in	O
individuals	O
with	O
syndromic	O
expressive	O
language	B-Phenotype
delay	E-Phenotype
,	O
hypotonia	S-Phenotype
,	O
and	O
sleep	B-Phenotype
apnea	E-Phenotype
.	O

The	O
tumor	S-Phenotype
was	O
diagnosed	O
ACC	O
with	O
immunohistochemistry	O
;	O
positive	O
to	O
ACC	O
phenotype	O
(	O
a1	O
-	O
antitrypsin	O
,	O
a1	O
-	O
antichymotrypsin	O
,	O
BCL10	O
)	O
.	O

Our	O
data	O
,	O
for	O
the	O
first	O
time	O
,	O
functionally	O
link	O
Jalili	O
syndrome	O
gene	O
CNNM4	O
to	O
LCA	O
gene	O
IQCB1	O
,	O
providing	O
important	O
insights	O
into	O
the	O
molecular	O
pathogenic	O
mechanism	O
of	O
retinal	B-Phenotype
dystrophy	E-Phenotype
in	O
Jalili	O
syndrome	O

Notably	O
,	O
WWOX	O
with	O
Ser14	O
phosphorylation	O
is	O
upregulated	O
in	O
the	O
lesions	O
of	O
cancer	S-Phenotype
,	O
as	O
well	O
as	O
in	O
the	O
brain	O
hippocampus	O
and	O
cortex	O
with	O
Alzheimer	O
*	O
s	O
disease	O
.	O

These	O
include	O
an	O
enhancer	O
in	O
an	O
ataxia	S-Phenotype
telangiectasia	S-Phenotype
mutated	O
(	O
ATM	O
)	O
intron	O
that	O
has	O
SNPs	O
in	O
linkage	O
disequilibrium	O
with	O
a	O
metformin	O
treatment	O
response	O
GWAS	O
lead	O
SNP	O
(	O
rs11212617	O
)	O
that	O
showed	O
increased	O
enhancer	O
activity	O
for	O
the	O
associated	O
haplotype	O
.	O

ARHGAP17	O
expression	O
in	O
cervical	O
cancer	S-Phenotype
tissues	O
and	O
normal	O
tissues	O
was	O
assessed	O
by	O
immunohistochemistry	O
.	O

This	O
result	O
has	O
clinical	O
and	O
genetic	O
counseling	O
implications	O
for	O
genetically	O
unsolved	O
male	O
case	O
subjects	O
with	O
a	O
classic	O
PCD	O
phenotype	O
that	O
lack	O
additional	O
phenotypes	O
such	O
as	O
intellectual	B-Phenotype
disability	E-Phenotype
or	O
retinitis	S-Phenotype
pigmentosa	O

qRT	O
-	O
PCR	O
results	O
showed	O
that	O
high	O
expression	O
of	O
HMGB3	O
had	O
positive	O
correlation	O
with	O
serosal	O
invasion	O
,	O
lymph	O
metastasis	O
,	O
and	O
tumor	S-Phenotype
-	O
node	O
-	O
metastasis	O
(	O
TNM	O
)	O
stage	O
in	O
CRC	O
patient	O
.	O

To	O
identify	O
network	O
-	O
based	O
pathways	O
involved	O
in	O
the	O
susceptibility	O
to	O
the	O
ER	O
/	O
PR	O
-	O
ve	O
HER2	O
+ve	O
breast	B-Phenotype
cancer	E-Phenotype
subtype	O
,	O
the	O
NRF1	O
transcriptional	O
regulatory	O
genome	O
-	O
wide	O
landscape	O
was	O
analyzed	O
using	O
the	O
approach	O
consisting	O
of	O
a	O
systematic	O
integration	O
of	O
ChIP	O
DNA	O
-	O
seq	O
,	O
RNA	O
-	O
Microarray	O
,	O
NRF1	O
protein	O
-	O
DNA	O
motif	O
binding	O
,	O
signal	O
pathway	O
analysis	O
,	O
and	O
Bayesian	O
machine	O
learning	O
.	O

This	O
included	O
identification	O
of	O
:	O
complex	O
ocular	O
phenotypes	O
due	O
to	O
two	O
novel	O
PAX6	O
mutations	O
;	O
progressive	O
cortical	B-Phenotype
cataract	E-Phenotype
and	O
lamellar	B-Phenotype
cataract	E-Phenotype
with	O
lens	B-Phenotype
subluxation	E-Phenotype
due	O
to	O
two	O
novel	O
CRYGS	O
mutations	O
.	O

Mutations	O
in	O
Vps33	O
isoforms	O
cause	O
pigment	O
dilution	O
in	O
mice	O
(	O
Vps33a	O
,	O
buff	O
)	O
and	O
Drosophila	O
(	O
car	O
)	O
and	O
the	O
neurogenic	B-Phenotype
arthrogryposis	E-Phenotype
,	O
renal	B-Phenotype
dysfunction	E-Phenotype
and	O
cholestasis	S-Phenotype
syndrome	O
in	O
humans	O
(	O
ARC1	O
,	O
VPS33B	O
)	O
.	O

Finally	O
,	O
since	O
trigonocephaly	S-Phenotype
has	O
not	O
been	O
previously	O
reported	O
in	O
FOXP1	O
syndrome	O
,	O
it	O
remains	O
to	O
be	O
proved	O
whether	O
it	O
may	O
be	O
associated	O
with	O
the	O
FOXP1	O
mutation	O

The	O
mutations	O
in	O
both	O
LIPH	O
and	O
LPAR6	O
/	O
P2RY5	O
are	O
responsible	O
for	O
autosomal	B-Phenotype
recessive	I-Phenotype
woolly	I-Phenotype
hair	E-Phenotype
with	O
or	O
without	O
hypotrichosis	S-Phenotype
(	O
ARWH	O
/	O
HT	O
)	O
.	O

The	O
known	O
pathogenic	O
molecules	O
involved	O
in	O
ichthyosis	S-Phenotype
syndromes	O
with	O
prominent	O
hair	B-Phenotype
abnormalities	E-Phenotype
include	O
SPINK5	O
,	O
ERCC2	O
,	O
ERCC3	O
,	O
GTF2H5	O
,	O
MPLKIP	O
,	O
ST14	O
,	O
CLDN1	O
and	O
MBTPS2	O
.	O

We	O
observed	O
a	O
negative	O
correlation	O
between	O
XIAP	O
and	O
p62	O
expression	O
in	O
normal	O
and	O
cancer	S-Phenotype
tissues	O
of	O
breast	O
and	O
colon	O
,	O
and	O
that	O
the	O
ratio	O
of	O
XIAP	O
and	O
p62	O
expression	O
determines	O
the	O
cancer	S-Phenotype
phenotype	O
.	O

After	O
exclusive	O
analysis	O
of	O
10	O
common	O
variations	O
of	O
three	O
hearing	B-Phenotype
loss	E-Phenotype
-	O
related	O
genes	O
,	O
GJB2	O
,	O
mtDNA12srRNA	O
and	O
SLC26A4	O
,	O
a	O
novel	O
truncated	O
variant	O
of	O
SMPX	O
,	O
c.87dupA	O
(	O
p.Gly30Argfs	O
*	O
12	O
)	O
(	O
NCBI	O
ClinVar	O
Submission	O
ID	O
:	O
SUB3136126	O
)	O
,	O
was	O
identified	O
by	O
whole	O
-	O
exome	O
sequencing	O
.	O

An	O
in	O
-	O
frame	O
insertion	O
polymorphism	O
in	O
the	O
murine	O
Ltbp4	O
gene	O
associates	O
with	O
partial	O
protection	O
against	O
muscular	B-Phenotype
dystrophy	E-Phenotype
.	O

The	O
expression	O
of	O
uncarboxylated	O
MGP	O
(	O
ucMGP	O
)	O
,	O
carboxylated	O
MGP	O
(	O
cMGP	O
)	O
,	O
matrix	O
metalloproteinase	O
(	O
MMP	O
)	O
‑13	O
,	O
collagen	O
type	O
X	O
,	O
collagen	O
type	O
II	O
,	O
tumor	S-Phenotype
necrosis	O
factor	O
(	O
TNF	O
)	O
‑α	O
and	O
interleukin	O
(	O
IL	O
)	O
‑1β	O
were	O
detected	O
by	O
ELISA	O
,	O
immunohistochemistry	O
,	O
reverse	O
transcription‑quantitative	O
polymerase	O
chain	O
reaction	O
and	O
western	O
blotting	O
.	O

Smith	O
-	O
Magenis	O
syndrome	O
(	O
SMS	O
)	O
,	O
a	O
neurodevelopmental	O
disorder	O
characterized	O
by	O
dysmorphic	O
features	O
,	O
intellectual	B-Phenotype
disability	E-Phenotype
(	O
ID	S-Phenotype
)	O
,	O
and	O
sleep	B-Phenotype
disturbances	E-Phenotype
,	O
results	O
from	O
a	O
17p11.2	O
microdeletion	O
or	O
a	O
mutation	O
in	O
the	O
RAI1	O
gene	O
.	O

Interventions	O
on	O
FLNB	O
-	O
related	O
diseases	O
require	O
prenatal	O
surveillance	O
by	O
sonography	O
,	O
gene	O
testing	O
in	O
high	O
-	O
risk	O
carriers	O
,	O
and	O
proper	O
orthosis	O
or	O
orthopedic	O
surgeries	O
to	O
correct	O
malformations	O
including	O
scoliosis	S-Phenotype
,	O
cervical	B-Phenotype
spine	I-Phenotype
instability	E-Phenotype
,	O
large	B-Phenotype
joint	I-Phenotype
dislocation	E-Phenotype
,	O
and	O
clubfoot	S-Phenotype
.	O

Pre	O
-	O
NACT	O
core	O
needle	O
biopsies	O
and	O
postoperative	O
tumor	S-Phenotype
samples	O
were	O
immunohistochemically	O
stained	O
for	O
nuclear	O
factor	O
erythroid	O
2	O
-	O
related	O
factor	O
2	O
(	O
Nrf2	O
)	O
,	O
Kelch	O
-	O
like	O
ECH	O
-	O
associated	O
protein	O
1	O
(	O
Keap1	O
)	O
,	O
thioredoxin	O
(	O
Trx	O
)	O
,	O
and	O
peroxiredoxin	O
I	O
(	O
Prx	O
I	O
)	O
.	O

Lack	O
-	O
of	O
-	O
function	O
mutations	O
in	O
EDC4	O
were	O
detected	O
in	O
BRCA1	O
/	O
2	O
-	O
mutation	O
-	O
negative	O
breast	B-Phenotype
cancer	E-Phenotype
cases	O
,	O
suggesting	O
a	O
role	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
susceptibility	O
.	O

Sjögren	O
-	O
Larsson	O
syndrome	O
(	O
SLS	O
)	O
is	O
a	O
rare	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
ichthyosis	S-Phenotype
,	O
spasticity	S-Phenotype
and	O
intellectual	B-Phenotype
disability	E-Phenotype
.	O

Esophageal	B-Phenotype
atresia	E-Phenotype
and	O
tracheoesophageal	B-Phenotype
fistula	E-Phenotype
(	O
EA	O
/	O
TEF	O
)	O
are	O
relatively	O
common	O
malformations	O
in	O
newborns	O
,	O
but	O
the	O
etiology	O
of	O
EA	O
/	O
TEF	O
remains	O
unknown	O
.	O

Ectopic	O
expression	O
of	O
miR	O
-	O
451a	O
significantly	O
inhibited	O
cancer	S-Phenotype
cell	O
migration	O
and	O
invasion	O
by	O
RCC	O
cell	O
lines	O
,	O
suggesting	O
that	O
miR	O
-	O
451a	O
had	O
antitumor	O
roles	O
.	O

In	O
patients	O
with	O
recurrent	O
glioblastoma	S-Phenotype
,	O
there	O
was	O
a	O
negative	O
correlation	O
between	O
Dec1	O
expression	O
and	O
the	O
apoptotic	O
index	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
a	O
male	O
child	O
demonstrating	O
recurrent	O
febrile	O
episodes	O
,	O
spasticity	S-Phenotype
,	O
and	O
basal	B-Phenotype
ganglia	I-Phenotype
calcification	E-Phenotype
suggestive	O
of	O
Aicardi	O
-	O
Goutières	O
syndrome	O
,	O
who	O
carries	O
the	O
same	O
Arg822Gln	O
mutation	O
in	O
IFIH1	O
previously	O
associated	O
with	O
SMS	O
.	O

Monogenic	O
hypertriglyceridemia	S-Phenotype
is	O
the	O
result	O
of	O
mutations	O
in	O
genes	O
that	O
regulate	O
the	O
metabolism	O
of	O
triglyceride	O
rich	O
lipoproteins	O
(	O
eg	O
LPL	O
,	O
APOC2	O
,	O
APOA5	O
,	O
LMF1	O
,	O
GPIHBP1	O
)	O
.	O

Therefore	O
,	O
we	O
concluded	O
that	O
AHI1	O
c.3257AAAAAG	O
and	O
NEB	O
c.914	O
AAAAAG	O
were	O
potential	O
causal	O
variants	O
in	O
this	O
strabismus	S-Phenotype
pedigree	O
.	O

Further	O
,	O
immunohistochemistry	O
was	O
done	O
to	O
identify	O
FRG1	O
expression	O
levels	O
in	O
various	O
cancers	S-Phenotype
and	O
its	O
association	O
with	O
tumor	S-Phenotype
angiogenesis	O
.	O

On	O
the	O
other	O
hand	O
,	O
tumor	S-Phenotype
suppressor	O
roles	O
of	O
YY1	O
appear	O
to	O
involve	O
YY1	O
stimulation	O
of	O
tumor	S-Phenotype
suppressor	O
BRCA1	O
,	O
increased	O
Bax	O
transcription	O
and	O
apoptosis	O
involving	O
cytochrome	O
c	O
release	O
and	O
caspase	O
-	O
3	O
/	O
-	O
7	O
cleavage	O
,	O
induction	O
of	O
heme	O
oxygenase	O
-	O
1	O
,	O
inhibition	O
of	O
pRb	O
phosphorylation	O
and	O
p21	O
binding	O
to	O
cyclin	O
D1	O
and	O
cdk4	O
,	O
reduced	O
expression	O
of	O
long	O
noncoding	O
RNA	O
of	O
SOX2	O
overlapping	O
transcript	O
,	O
and	O
MUC4	O
/	O
ErbB2	O
/	O
p38	O
/	O
MEF2C	O
-	O
dependent	O
downregulation	O
of	O
MMP	O
-	O
10	O
.	O

Whole	O
exome	O
sequencing	O
identified	O
a	O
truncating	O
pathogenic	O
variant	O
in	O
IQSEC2	O
at	O
NM_001111125.2	O
:	O
c.2679_2680insA	O
,	O
p.	O
(	O
D894fs	O
*	O
10	O
)	O
,	O
a	O
recently	O
identified	O
cause	O
of	O
epileptic	B-Phenotype
encephalopathy	E-Phenotype
in	O
females	O
(	O
MIM	O
300522	O
)	O
.	O

Amyotrophic	B-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
(	O
ALS	S-Phenotype
)	O
is	O
the	O
major	O
adult	O
-	O
onset	O
motor	O
neuron	O
disease	O
,	O
and	O
is	O
clinically	O
,	O
pathologically	O
,	O
and	O
genetically	O
associated	O
with	O
frontotemporal	B-Phenotype
dementia	E-Phenotype
,	O
the	O
second	O
cause	O
of	O
dementia	S-Phenotype
in	O
the	O
elderly	O
.	O

MSI	O
-	O
H	O
phenotype	O
and	O
PMS2	O
mutation	O
in	O
the	O
colon	B-Phenotype
cancer	E-Phenotype
were	O
confirmed	O
by	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
PCR	O
and	O
next	O
-	O
generation	O
sequencing	O
(	O
NGS	O
)	O
,	O
respectively	O
.	O

Hyperphosphatasia	B-Phenotype
with	I-Phenotype
mental	I-Phenotype
retardation	E-Phenotype
syndrome	O
(	O
HPMRS	S-Phenotype
)	O
is	O
caused	O
by	O
mutations	O
in	O
PIGV	O
and	O
includes	O
hyperphosphatasia	S-Phenotype
as	O
a	O
diagnostic	O
hallmark	O
.	O

Prior	O
studies	O
that	O
explored	O
the	O
hypothesis	O
that	O
EMT	O
gene	O
variants	O
contribute	O
to	O
epithelial	B-Phenotype
ovarian	I-Phenotype
carcinoma	E-Phenotype
(	O
EOC	S-Phenotype
)	O
risk	O
have	O
been	O
based	O
on	O
small	O
sample	O
sizes	O
and	O
none	O
have	O
sought	O
replication	O
in	O
an	O
independent	O
population	O
.	O

Shh	O
signaling	O
mutations	O
,	O
like	O
those	O
that	O
remove	O
Patched1	O
(	O
Ptch1	O
)	O
or	O
activate	O
Smoothened	O
(	O
Smo	O
)	O
,	O
cause	O
tumors	S-Phenotype
dependent	O
on	O
the	O
presence	O
of	O
cilia	O
.	O

A	O
mapping	O
of	O
the	O
expression	O
data	O
to	O
a	O
comprehensive	O
genome	O
-	O
scale	O
reconstruction	O
of	O
human	O
metabolism	O
allowed	O
for	O
the	O
in	O
-	O
depth	O
functional	O
characterization	O
of	O
24	O
h	O
-	O
oscillating	O
transcripts	O
and	O
pointed	O
to	O
a	O
clock	O
-	O
driven	O
metabolic	O
reprogramming	O
in	O
tumorigenesis	S-Phenotype
.	O

Our	O
results	O
validate	O
Plk4	O
as	O
a	O
therapeutic	O
target	O
in	O
cancer	S-Phenotype
patients	O
and	O
reveal	O
a	O
new	O
role	O
for	O
Plk4	O
in	O
regulating	O
Arp2	O
/	O
3	O
-	O
mediated	O
actin	O
cytoskeletal	O
rearrangement	O
.	O

The	O
original	O
tumor	S-Phenotype
harbors	O
mutations	O
in	O
PBRM1	O
,	O
while	O
the	O
second	O
harbors	O
mutations	O
in	O
KDM5C	O
.	O

Mitochondrial	O
disorders	O
are	O
an	O
extremely	O
heterogeneous	S-Phenotype
group	O
of	O
diseases	O
sharing	O
,	O
in	O
common	O
,	O
the	O
fact	O
that	O
they	O
all	O
ultimately	O
impair	O
the	O
function	O
of	O
the	O
mitochondrial	O
respiratory	O
chain	O
.	O

We	O
have	O
generated	O
four	O
thyroid	O
cancer	S-Phenotype
cell	O
lines	O
with	O
a	O
greater	O
than	O
30	O
-	O
fold	O
increase	O
in	O
acquired	O
resistance	O
to	O
the	O
Src	O
inhibitor	O
dasatinib	O
.	O

Single	O
nucleotide	O
polymorphisms	O
in	O
GLIS3	O
genes	O
have	O
been	O
associated	O
with	O
increased	O
risk	O
of	O
several	O
diseases	O
,	O
including	O
type	B-Phenotype
1	I-Phenotype
and	I-Phenotype
type	I-Phenotype
2	I-Phenotype
diabetes	E-Phenotype
,	O
glaucoma	S-Phenotype
,	O
and	O
neurological	O
disorders	O
.	O

We	O
addressed	O
this	O
issue	O
using	O
mouse	O
pancreatic	O
acinar	O
tumor	S-Phenotype
cell	O
line	O
266	O
-	O
6	O
and	O
primary	O
PAC	S-Phenotype
of	O
wild	O
-	O
type	O
and	O
transgenic	O
mice	O
carrying	O
the	O
SLC25A19	O
promoter	O
that	O
were	O
fed	O
alcohol	O
chronically	O
.	O

We	O
found	O
that	O
RFX5	O
is	O
significantly	O
upregulated	O
in	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
tumors	S-Phenotype
and	O
cell	O
lines	O
compared	O
with	O
non	O
-	O
tumor	S-Phenotype
tissues	O
in	O
mRNA	O
expression	O
levels	O
,	O
but	O
it	O
fails	O
to	O
induce	O
the	O
expression	O
of	O
MHCII	O
.	O

Cullin7	O
(	O
CUL7	O
)	O
is	O
a	O
member	O
of	O
Cullin	O
protein	O
family	O
and	O
exhibits	O
a	O
tumor	S-Phenotype
-	O
promoting	O
role	O
in	O
several	O
types	O
of	O
tumors	S-Phenotype
,	O
including	O
breast	O
,	O
liver	O
and	O
ovarian	O
.	O

Together	O
,	O
these	O
cellular	O
studies	O
suggest	O
that	O
impaired	O
protein	O
stability	O
and	O
STXBP1	O
haploinsufficiency	O
explain	O
STXBP1	O
-	O
encephalopathy	S-Phenotype
and	O
that	O
,	O
therefore	O
,	O
Stxbp1+	O
/	O
-	O
mice	O
provide	O
a	O
valid	O
mouse	O
model	O
.	O

This	O
enrichment	O
of	O
rare	O
potentially	O
pathogenic	O
alleles	O
in	O
ZNF469	O
in	O
12.5	O
%	O
of	O
keratoconus	S-Phenotype
patients	O
represents	O
a	O
significant	O
mutational	O
load	O
and	O
highlights	O
ZNF469	O
as	O
the	O
most	O
significant	O
genetic	O
factor	O
responsible	O
for	O
keratoconus	S-Phenotype
identified	O
to	O
date	O
.	O

In	O
T2D	O
patients	O
,	O
PAX4	O
Arg192His	O
was	O
associated	O
with	O
earlier	O
age	O
at	O
diagnosis	O
,	O
and	O
GLP1R	O
Arg131Gln	O
was	O
associated	O
with	O
decreased	O
risk	O
of	O
cardiovascular	B-Phenotype
disease	E-Phenotype
.	O

We	O
therefore	O
studied	O
the	O
molecular	O
characteristics	O
of	O
drug	O
-	O
resistant	O
CXCR4	O
-	O
positive	O
cells	O
on	O
epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
for	O
the	O
future	O
identification	O
of	O
the	O
tumor	S-Phenotype
cells	O
with	O
the	O
properties	O
of	O
both	O
EMT	O
and	O
stemness	O
.	O

Moreover	O
,	O
overexpression	O
of	O
TPI1	O
led	O
to	O
slowed	O
tumor	S-Phenotype
growth	O
and	O
decreased	O
tumor	S-Phenotype
weight	O
in	O
vivo	O
.	O

In	O
conclusion	O
,	O
glycerol	O
phosphate	O
formation	O
for	O
de	O
novo	O
GPL	O
synthesis	O
via	O
glyceroneogenesis	O
is	O
a	O
newly	O
characterized	O
anabolic	O
pathway	O
in	O
cancer	S-Phenotype
cells	O
mediated	O
by	O
PEPCK	O
-	O
M	O
under	O
conditions	O
of	O
severe	O
nutrient	O
deprivation	O

nuclear	O
and	O
nuclear	B-Phenotype
pulverulent	I-Phenotype
cataracts	E-Phenotype
.	O

Friedreich	B-Phenotype
's	I-Phenotype
ataxia	E-Phenotype
(	O
FRDA	S-Phenotype
)	O
is	O
an	O
autosomal	O
recessive	O
neurodegenerative	O
disorder	O
resulting	O
from	O
reduced	O
expression	O
of	O
the	O
protein	O
frataxin	O
(	O
FXN	O
)	O
.	O

Single	O
-	O
nucleotide	O
polymorphisms	O
in	O
the	O
TMEM106B	O
gene	O
have	O
been	O
identified	O
as	O
a	O
risk	O
factor	O
in	O
frontotemporal	B-Phenotype
dementia	E-Phenotype
(	O
FTD	S-Phenotype
)	O
.	O

Finally	O
,	O
the	O
proteasome	O
inhibitor	O
bortezomib	O
is	O
a	O
potent	O
enhancer	O
of	O
global	B-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
in	O
our	O
fly	O
model	O
,	O
evidence	O
of	O
a	O
defective	O
proteasome	O
AAAAAAbounce	O
-	O
backAAAAAA	O
response	O
that	O
is	O
also	O
observed	O
in	O
nematode	O
and	O
cellular	O
models	O
of	O
NGLY1	O
Deficiency	O
.	O

Further	O
Cox	O
proportional	O
hazard	O
models	O
analysis	O
revealed	O
that	O
the	O
reduced	O
expression	O
of	O
PLIN1	O
is	O
an	O
independent	O
predictor	O
of	O
overall	O
survival	O
in	O
estrogen	O
receptor	O
positive	O
(	O
p	O
AAAA	O
0.0001	O
,	O
HR	O
=	O
0.87	O
,	O
95	O
%	O
CI	O
=	O
0.81	O
-	O
0.92	O
,	O
N	O
=	O
3,600	O
)	O
and	O
luminal	O
A	O
-	O
subtype	O
(	O
p	O
=	O
0.02	O
,	O
HR	O
=	O
0.88	O
,	O
95	O
%	O
CI	O
=	O
0.78	O
-	O
0.98	O
,	O
N	O
=	O
1,469	O
)	O
breast	B-Phenotype
cancer	E-Phenotype
patients	O
.	O

We	O
examined	O
47628	O
SNPs	O
in	O
61	O
mTOR	O
pathway	O
genes	O
in	O
the	O
genome	O
wide	O
association	O
study	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
in	O
the	O
African	O
Diaspora	O
study	O
(	O
The	O
Root	O
consortium	O
)	O
,	O
which	O
included	O
3686	O
participants	O
(	O
1657	O
cases	O
)	O
.	O

For	O
in	O
vitro	O
studies	O
,	O
inhibition	O
of	O
PYCR1	O
by	O
small	O
-	O
hairpin	O
RNA	O
significantly	O
reduced	O
the	O
growth	O
and	O
invasion	O
capabilities	O
of	O
the	O
cells	O
,	O
while	O
enhancing	O
the	O
cytotoxicity	O
of	O
doxorubicin	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
MCF	O
-	O
7	O
(	O
ER	O
positive	O
)	O
and	O
MDA	O
-	O
MB	O
-	O
231	O
(	O
ER	O
negative	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
describe	O
the	O
phenotypic	O
spectrum	O
of	O
distal	B-Phenotype
hereditary	I-Phenotype
motor	I-Phenotype
neuropathy	E-Phenotype
caused	O
by	O
mutations	O
in	O
the	O
small	O
heat	O
shock	S-Phenotype
proteins	O
HSPB1	O
and	O
HSPB8	O
and	O
investigate	O
the	O
functional	O
consequences	O
of	O
newly	O
discovered	O
variants	O
.	O

Ablation	O
of	O
SRC	O
-	O
3	O
or	O
PFKFB4	O
suppresses	O
breast	B-Phenotype
tumour	E-Phenotype
growth	O
in	O
mice	O
and	O
prevents	O
metastasis	O
to	O
the	O
lung	O
from	O
an	O
orthotopic	O
setting	O
,	O
as	O
does	O
Ser857Ala	O
-	O
mutant	O
SRC	O
-	O
3	O
.	O

Our	O
previous	O
studies	O
reported	O
gastric	B-Phenotype
cancer	E-Phenotype
cells	O
are	O
insensitive	O
to	O
TRAIL	O
.	O

In	O
this	O
study	O
,	O
we	O
expand	O
the	O
genotype	O
-	O
phenotype	O
repertoire	O
of	O
SCA13	O
by	O
describing	O
the	O
novel	O
KCNC3	O
deletion	O
p.Pro583_Pro585del	O
highlighting	O
the	O
allelic	O
heterogeneity	S-Phenotype
observed	O
in	O
SCA13	O
patients	O
.	O

Taken	O
together	O
,	O
these	O
data	O
open	O
venues	O
for	O
exploring	O
the	O
possibility	O
that	O
sporadic	O
breast	B-Phenotype
cancer	E-Phenotype
patients	O
with	O
EMSY	O
amplification	O
might	O
benefit	O
from	O
epigenetic	O
combination	O
therapy	O
targeting	O
both	O
the	O
KDM5A	O
demethylase	O
and	O
histone	O
deacetylases	O
.	O

It	O
mainly	O
differentiates	O
from	O
other	O
retinal	B-Phenotype
dystrophies	E-Phenotype
,	O
and	O
in	O
particular	O
from	O
the	O
more	O
frequent	O
disease	O
retinitis	S-Phenotype
pigmentosa	O
,	O
because	O
cone	O
photoreceptors	O
degenerate	O
at	O
a	O
higher	O
rate	O
than	O
rod	O
photoreceptors	O
,	O
causing	O
severe	O
deficiency	O
of	O
central	O
vision	O
.	O

This	O
study	O
doubles	O
the	O
number	O
of	O
known	O
mutations	O
for	O
this	O
disorder	O
,	O
confirms	O
that	O
truncating	O
mutations	O
in	O
C2orf37	O
are	O
the	O
only	O
known	O
cause	O
of	O
WSS	O
,	O
and	O
suggests	O
that	O
mutations	O
in	O
this	O
gene	O
do	O
not	O
contribute	O
significantly	O
to	O
cases	O
presenting	O
with	O
isolated	O
elements	O
of	O
WSS	O
such	O
as	O
deafness	S-Phenotype
and	O
dystonia	S-Phenotype
.	O

Finally	O
,	O
ATRA	O
replacement	O
suppressed	O
15	O
-	O
PGDH	O
inhibition	O
-	O
induced	O
tumor	S-Phenotype
progression	O
in	O
KC	O
mice	O
,	O
and	O
ATRA	O
treatment	O
attenuated	O
Aldh1	O
activity	O
in	O
tumor	S-Phenotype
cells	O
isolated	O
from	O
the	O
pancreas	O
of	O
15	O
-	O
Pgdhsup	O
-	O
/	O
-	O
/	O
sup	O
KC	O
mice	O
.	O

p16	O
is	O
an	O
important	O
tumor	S-Phenotype
suppressor	O
gene	O
encoded	O
by	O
the	O
INK4A	O
/	O
ARF	O
/	O
INK4B	O
gene	O
locus	O
that	O
is	O
conserved	O
in	O
humans	O
,	O
rodents	O
,	O
and	O
canids	O
.	O

GATA3	O
,	O
a	O
critical	O
transcription	O
factor	O
involved	O
in	O
the	O
development	O
of	O
the	O
mammary	O
gland	O
,	O
also	O
plays	O
important	O
roles	O
in	O
mammary	O
tumorigenesis	S-Phenotype
by	O
regulating	O
transcription	O
in	O
coordination	O
with	O
two	O
essential	O
DNA	O
repair	O
factors	O
,	O
PARP1	O
and	O
BRCA1	O
.	O

The	O
role	O
of	O
leukemia	S-Phenotype
inhibitory	O
factor	O
receptor	O
(	O
LIFR	O
)	O
,	O
which	O
is	O
important	O
in	O
the	O
signal	O
transduction	O
of	O
the	O
interleukin	O
-	O
6	O
cytokine	O
family	O
,	O
is	O
still	O
undefined	O
in	O
clear	B-Phenotype
cell	I-Phenotype
renal	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
ccRCC	S-Phenotype
)	O
.	O

CONCLUSIONS	O
This	O
was	O
the	O
first	O
study	O
that	O
demonstrated	O
variants	O
in	O
FOXL2	O
and	O
HYDIN	O
associated	O
with	O
sporadic	O
ASD	O
,	O
and	O
supported	O
the	O
use	O
of	O
WES	O
and	O
bioinformatics	O
analysis	O
to	O
identify	O
disease	O
-	O
associated	O
mutations	O

The	O
Random	O
Forest	O
algorithm	O
selected	O
FGFR2	O
,	O
MAP3K1	O
and	O
age	O
as	O
important	O
breast	B-Phenotype
cancer	E-Phenotype
predictors	O
.	O

An	O
analysis	O
of	O
human	O
SCLC	O
specimens	O
revealed	O
that	O
POU2F3	O
is	O
expressed	O
exclusively	O
in	O
variant	O
SCLC	O
tumors	S-Phenotype
that	O
lack	O
expression	O
of	O
neuroendocrine	O
markers	O
and	O
instead	O
express	O
markers	O
of	O
a	O
chemosensory	O
lineage	O
known	O
as	O
tuft	O
cells	O
.	O

Dp	O
did	O
not	O
affect	O
body	B-Phenotype
weight	E-Phenotype
,	O
energy	B-Phenotype
intake	E-Phenotype
,	O
hyperglycemia	S-Phenotype
,	O
insulin	B-Phenotype
resistance	E-Phenotype
,	O
or	O
histological	B-Phenotype
abnormalities	I-Phenotype
elicited	I-Phenotype
by	I-Phenotype
the	I-Phenotype
HFHC	I-Phenotype
diet	E-Phenotype
.	O

The	O
plasma	O
concentrations	O
of	O
LRG1	O
,	O
CRP	O
,	O
and	O
C9	O
showed	O
significant	O
positive	O
correlations	O
with	O
tumor	S-Phenotype
size	O
(	O
R2	O
=	O
0.534	O
,	O
0.495	O
,	O
and	O
0.452	O
,	O
respectively	O
)	O

Our	O
data	O
suggest	O
that	O
increased	O
expressions	O
in	O
certain	O
mt	O
genes	O
and	O
elevated	O
levels	O
of	O
ROS	O
may	O
potentially	O
play	O
a	O
critical	O
role	O
in	O
the	O
colorectal	B-Phenotype
tumors	E-Phenotype
evolving	O
from	O
adenopolyps	O
to	O
malignant	O
lesions	O

Several	O
studies	O
have	O
demonstrated	O
that	O
N	O
-	O
butyldeoxynojirimycin	O
(	O
NB	O
-	O
DNJ	O
,	O
also	O
known	O
as	O
miglustat	O
)	O
,	O
an	O
inhibitor	O
of	O
the	O
enzyme	O
glucosylceramide	O
synthase	O
(	O
GCS	O
)	O
,	O
successfully	O
delays	O
the	O
onset	O
of	O
motor	O
deficits	O
,	O
improves	O
longevity	O
,	O
and	O
rescues	O
some	O
of	O
the	O
cerebellar	B-Phenotype
abnormalities	E-Phenotype
(	O
e.g.	O
,	O
Purkinje	O
cell	O
death	O
)	O
seen	O
in	O
another	O
lysosomal	O
disease	O
known	O
as	O
Niemann	O
-	O
Pick	O
type	O
C	O
(	O
NPC	O
)	O
.	O

The	O
student	O
's	O
t	O
-	O
test	O
was	O
used	O
to	O
compare	O
FOXP1	O
expression	O
in	O
the	O
tumour	S-Phenotype
and	O
the	O
adjacent	O
normal	O
tissues	O
.	O

This	O
result	O
represents	O
another	O
indication	O
for	O
the	O
genetic	O
heterogeneity	S-Phenotype
of	O
BBS	O
and	O
extends	O
the	O
mutational	O
spectrum	O
of	O
the	O
disease	O
by	O
introducing	O
nine	O
novel	O
mutations	O
in	O
five	O
BBS	O
genes	O
.	O

Here	O
we	O
show	O
in	O
a	O
child	O
with	O
microthrombocytopenia	S-Phenotype
,	O
eosinophilia	S-Phenotype
and	O
inflammatory	O
disease	O
,	O
a	O
homozygous	O
frameshift	O
mutation	O
in	O
ARPC1B	O
(	O
p.Val91Trpfs	O
*	O
30	O
)	O
.	O

Here	O
we	O
used	O
Sanger	O
sequencing	O
to	O
detect	O
mutations	O
in	O
exons	O
of	O
TMEM240	O
in	O
340	O
unrelated	O
probands	O
with	O
spinocerebellar	B-Phenotype
ataxia	E-Phenotype
for	O
whom	O
commonly	O
known	O
causative	O
mutations	O
have	O
been	O
excluded	O
(	O
96	O
probands	O
of	O
autosomal	O
dominant	O
spinocerebellar	B-Phenotype
ataxia	E-Phenotype
families	O
and	O
244	O
patients	O
with	O
sporadic	B-Phenotype
spinocerebellar	I-Phenotype
ataxia	E-Phenotype
)	O
.	O

Our	O
results	O
indicate	O
that	O
GRXCR2	O
should	O
be	O
considered	O
in	O
differential	O
genetic	O
diagnosis	O
for	O
individuals	O
with	O
early	O
onset	O
,	O
moderate	O
-	O
to	O
-	O
severe	O
and	O
progressive	B-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
.	O

These	O
findings	O
implicate	O
for	O
the	O
first	O
time	O
perturbed	O
TGF	O
-	O
β	O
signaling	O
in	O
the	O
genesis	O
of	O
retinal	B-Phenotype
dystrophies	E-Phenotype
,	O
support	O
the	O
study	O
of	O
related	O
morphogenetic	O
genes	O
for	O
comparable	O
roles	O
in	O
retinal	B-Phenotype
disease	E-Phenotype
and	O
may	O
offer	O
additional	O
therapeutic	O
opportunities	O
for	O
genetically	B-Phenotype
heterogeneous	E-Phenotype
disorders	O
presently	O
only	O
treatable	O
with	O
gene	O
therapy	O

We	O
show	O
that	O
the	O
extent	O
of	O
spatial	O
heterogeneity	S-Phenotype
is	O
positively	O
associated	O
with	O
the	O
size	O
of	O
biopsied	O
focal	O
lesions	O
consistent	O
with	O
regional	O
outgrowth	O
of	O
advanced	O
clones	O
.	O

Therefore	O
,	O
we	O
decided	O
to	O
look	O
into	O
its	O
role	O
in	O
tumor	S-Phenotype
progression	O
,	O
tumor	S-Phenotype
angiogenesis	O
,	O
and	O
its	O
impact	O
on	O
cellular	O
properties	O
.	O

Methylation	O
profiling	O
,	O
metabolite	O
assessment	O
and	O
additional	O
analyses	O
were	O
also	O
performed	O
in	O
selected	O
cases.Results	O
:	O
One	O
of	O
the	O
11	O
tumors	S-Phenotype
was	O
found	O
to	O
carry	O
a	O
known	O
cancer	S-Phenotype
-	O
predisposing	O
somatic	B-Phenotype
mutation	E-Phenotype
in	O
IDH1	O
A	O
variant	O
in	O
GOT2	O
,	O
c.357AAAAAT	O
,	O
found	O
in	O
a	O
patient	O
with	O
multiple	O
tumors	S-Phenotype
,	O
was	O
associated	O
with	O
higher	O
tumor	S-Phenotype
mRNA	O
and	O
protein	O
expression	O
levels	O
,	O
increased	O
GOT2	O
enzymatic	O
activity	O
in	O
lymphoblastic	O
cells	O
,	O
and	O
altered	O
metabolite	O
ratios	O
both	O
in	O
tumors	S-Phenotype
and	O
in	O
GOT2	O
knockdown	O
HeLa	O
cells	O
transfected	O
with	O
the	O
variant	O
.	O

Furthermore	O
,	O
the	O
methylation	O
status	O
of	O
ADAMTS18	O
was	O
not	O
significantly	O
associated	O
with	O
gender	O
,	O
age	O
,	O
location	O
,	O
tumor	S-Phenotype
diameter	O
,	O
pathological	O
stage	O
,	O
nuclear	O
grade	O
or	O
short	O
-	O
term	O
DFS	O
in	O
patients	O
with	O
ccRCC	O
(	O
p	O
AAAA	O
0.05	O
)	O
.	O

The	O
importance	O
of	O
this	O
process	O
is	O
highlighted	O
in	O
a	O
patient	O
with	O
mitochondrial	O
disease	O
caused	O
by	O
biallelic	O
pathogenic	O
variants	O
in	O
TOP3A	O
,	O
characterized	O
by	O
muscle	O
-	O
restricted	O
mtDNA	O
deletions	O
and	O
chronic	B-Phenotype
progressive	I-Phenotype
external	I-Phenotype
ophthalmoplegia	E-Phenotype
(	O
CPEO	S-Phenotype
)	O
plus	O
syndrome	O
.	O

In	O
sum	O
,	O
the	O
SPINT2	O
gene	O
is	O
epigenetically	O
silenced	O
or	O
downregulated	O
in	O
human	O
cancers	S-Phenotype
,	O
altering	O
the	O
balance	O
of	O
HGF	O
activation	O
/	O
inhibition	O
ratio	O
,	O
which	O
contributes	O
to	O
cancer	S-Phenotype
development	O
and	O
progression	O

We	O
established	O
for	O
the	O
first	O
time	O
9	O
probes	O
that	O
could	O
distinguish	O
HBV	O
-	O
negative	O
cirrhotic	O
patients	O
who	O
subsequently	O
developed	O
HCC	O
from	O
those	O
who	O
stayed	O
cancer	S-Phenotype
-	O
free	O
.	O

The	O
brains	O
of	O
liUbe3b	O
-	O
/	O
-	O
mice	O
had	O
hypoplasia	B-Phenotype
of	I-Phenotype
the	I-Phenotype
corpus	I-Phenotype
callosum	E-Phenotype
,	O
enlarged	B-Phenotype
ventricles	E-Phenotype
,	O
and	O
decreased	B-Phenotype
thickness	I-Phenotype
of	I-Phenotype
the	I-Phenotype
somatosensory	I-Phenotype
cortex	E-Phenotype
.	O

The	O
protein	O
levels	O
of	O
DLL4	O
were	O
decreased	O
in	O
the	O
tumor	S-Phenotype
tissues	O
of	O
NSCLC	O
patients	O
and	O
lung	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
.	O

To	O
elucidate	O
the	O
influence	O
of	O
cerebellum	B-Phenotype
atrophy	E-Phenotype
and	O
ataxia	S-Phenotype
on	O
the	O
obtained	O
results	O
,	O
the	O
behavioral	O
and	O
neurophysiological	O
findings	O
in	O
reeler	O
mice	O
were	O
reproduced	O
using	O
the	O
Disabled	O
-	O
1	O
(	O
Dab1	O
)	O
cKO	O
mice	O
,	O
in	O
which	O
the	O
Reelin	O
-	O
Dab1	O
signal	O
deficiency	O
is	O
confined	O
to	O
the	O
cerebral	O
cortex	O
.	O

Furthermore	O
,	O
a	O
close	O
correlation	O
was	O
found	O
to	O
exist	O
between	O
the	O
expression	O
of	O
NIBP	O
and	O
NF	O
-	O
kB	O
p65	O
(	O
p	O
-	O
p65	O
)	O
in	O
gastric	B-Phenotype
cancer	E-Phenotype
tissues	O
.	O

Jeune	O
asphyxiating	O
thoracic	O
dystrophy	O
(	O
JATD	O
)	O
is	O
a	O
skeletal	B-Phenotype
dysplasia	E-Phenotype
characterized	O
by	O
a	B-Phenotype
small	I-Phenotype
thoracic	I-Phenotype
cage	E-Phenotype
and	O
a	B-Phenotype
range	I-Phenotype
of	I-Phenotype
skeletal	I-Phenotype
and	I-Phenotype
extra	I-Phenotype
-	I-Phenotype
skeletal	I-Phenotype
anomalies	E-Phenotype
.	O

To	O
retrospectively	O
analyze	O
and	O
quantitatively	O
correlate	O
UGT1A1	O
(	O
bilirubin	O
UDP	O
-	O
glucuronosyltransferase	O
gene	O
)	O
genotypes	O
and	O
unconjugated	B-Phenotype
hyperbilirubinemia	E-Phenotype
(	O
UCH	S-Phenotype
)	O
phenotypes	O
among	O
Chinese	O
children.We	O
retrospectively	O
reviewed	O
UCH	O
patients	O
,	O
quantitatively	O
analyzed	O
genotype	O
-	O
phenotype	O
correlation	O
by	O
comparing	O
with	O
healthy	O
controls	O
.	O

In	O
order	O
to	O
provide	O
an	O
additional	O
insight	O
into	O
its	O
functional	O
role	O
we	O
compared	O
target	O
gene	O
expression	O
levels	O
between	O
human	O
neuroblastoma	S-Phenotype
cells	O
(	O
SH	O
-	O
SY5Y	O
)	O
stably	O
overexpressing	O
liFOXP2	O
/	O
i	O
cDNA	O
of	O
either	O
humans	O
or	O
the	O
common	O
chimpanzee	O
,	O
Rhesus	O
monkey	O
,	O
and	O
marmoset	O
,	O
respectively	O
.	O

We	O
identified	O
568	O
proteins	O
in	O
the	O
CSF	O
of	O
infants	O
with	O
spina	B-Phenotype
bifida	E-Phenotype
,	O
which	O
is	O
the	O
most	O
common	O
type	O
of	O
NTD	O
.	O

CAM	O
also	O
improved	O
survival	O
in	O
post	O
-	O
influenza	O
,	O
CAM	O
-	O
resistant	O
pneumococcal	O
pneumonia	S-Phenotype
,	O
with	O
improved	O
lung	O
pathology	O
as	O
well	O
as	O
decreased	O
interferon	O
(	O
IFN	O
)	O
-	O
y	O
and	O
increased	O
IL	O
-	O
10	O
levels	O
.	O

AMH	O
is	O
regarded	O
as	O
a	O
promising	O
predictor	O
for	O
ovarian	O
reserve	O
in	O
humans	O
and	O
non	O
-	O
human	O
primate	O
,	O
and	O
widely	O
used	O
in	O
human	O
medicine	O
to	O
predict	O
ovarian	O
response	O
to	O
gonadotropin	O
,	O
menopause	O
and	O
premature	B-Phenotype
ovarian	I-Phenotype
failure	E-Phenotype
.	O

The	O
gene	O
expression	O
levels	O
of	O
Ki	O
-	O
67	O
,	O
BCL11A	O
,	O
FOXC1	O
,	O
HOXD13	O
,	O
PCDHGB7	O
and	O
her	O
-	O
2	O
were	O
used	O
as	O
an	O
auxiliary	O
diagnostic	O
index	O
for	O
patients	O
with	O
breast	B-Phenotype
cancer	E-Phenotype
in	O
the	O
early	O
stage	O
.	O

Moreover	O
,	O
we	O
show	O
that	O
most	O
SCLC	O
tumors	S-Phenotype
can	O
be	O
classified	O
into	O
one	O
of	O
three	O
lineages	O
based	O
on	O
the	O
expression	O
of	O
POU2F3	O
,	O
ASCL1	O
,	O
or	O
NEUROD1	O
.	O

Peripheral	O
schwannomas	S-Phenotype
were	O
detected	O
in	O
3	O
LZTR1	O
-	O
mutant	O
(	O
60	O
%	O
)	O
and	O
10	O
SMARCB1	O
-	O
mutant	O
subjects	O
(	O
66.7	O
%	O
)	O
.	O

Across	O
the	O
years	O
the	O
CCNs	O
have	O
been	O
increasingly	O
implicated	O
in	O
the	O
development	O
of	O
obesity	S-Phenotype
,	O
diabetes	S-Phenotype
and	O
its	O
complications	O
.	O

The	O
possible	O
involvement	O
of	O
haploinsufficiency	O
for	O
GINS1	O
,	O
a	O
DNA	O
replication	O
complex	O
protein	O
,	O
in	O
the	O
short	B-Phenotype
stature	E-Phenotype
of	O
the	O
patient	O
and	O
her	O
mother	O
requires	O
further	O
studies	O
.	O

In	O
four	O
families	O
with	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
recessive	I-Phenotype
optic	I-Phenotype
neuropathy	E-Phenotype
,	O
we	O
identified	O
mutations	O
in	O
RTN4IP1	O
,	O
which	O
encodes	O
a	O
mitochondrial	O
ubiquinol	O
oxydo	O
-	O
reductase	O
.	O

We	O
replicated	O
previously	O
reported	O
breast	B-Phenotype
cancer	E-Phenotype
susceptibility	O
alleles	O
in	O
these	O
BRCA2	O
mutation	O
carriers	O
and	O
for	O
several	O
regions	O
(	O
including	O
FGFR2	O
,	O
MAP3K1	O
,	O
CDKN2A	O
/	O
B	O
,	O
and	O
PTHLH	O
)	O
identified	O
SNPs	O
that	O
have	O
stronger	O
evidence	O
of	O
association	O
than	O
those	O
previously	O
published	O
.	O

Recently	O
,	O
mutations	O
in	O
the	O
gene	O
encoding	O
the	O
enzyme	O
asparagine	O
synthetase	O
(	O
ASNS	O
)	O
were	O
associated	O
to	O
microcephaly	S-Phenotype
and	O
so	O
far	O
24	O
different	O
mutations	O
in	O
ASNS	O
causing	O
microcephaly	S-Phenotype
have	O
been	O
described	O
.	O

Here	O
,	O
we	O
report	O
the	O
first	O
case	O
in	O
humans	O
of	O
SLC35A3	O
-	O
related	O
vertebral	B-Phenotype
anomalies	E-Phenotype
.	O

The	O
expression	O
assays	O
did	O
not	O
detect	O
ZDHHC15	O
gene	O
expression	O
in	O
the	O
patient	O
,	O
thus	O
questioning	O
its	O
involvement	O
in	O
intellectual	B-Phenotype
disability	E-Phenotype
.	O

We	O
report	O
a	O
sibling	O
pair	O
with	O
FTHS	O
caused	O
by	O
a	O
homozygous	O
,	O
novel	O
mutation	O
pLys133Glnfs	O
*	O
13	O
in	O
the	O
SH3PXD2B	O
gene	O
:	O
one	O
sibling	O
had	O
bilateral	B-Phenotype
ocular	I-Phenotype
hypertension	E-Phenotype
and	O
unilateral	B-Phenotype
colobomas	E-Phenotype
of	O
iris	O
,	O
choroid	O
and	O
retina	O
;	O
the	O
other	O
,	O
unilateral	O
myelinated	O
nerve	O
fiber	O
layer	O
of	O
the	O
optic	O
disk	O
and	O
papilledema	S-Phenotype
due	O
to	O
idiopathic	B-Phenotype
intracranial	I-Phenotype
hypertension	E-Phenotype
.	O

In	O
humans	O
,	O
CERKL	O
mutations	O
cause	O
widespread	O
retinal	B-Phenotype
degeneration	E-Phenotype
:	O
early	O
dysfunction	O
and	O
loss	O
of	O
rod	O
and	O
cone	O
photoreceptors	O
in	O
the	O
outer	O
retina	O
and	O
,	O
progressively	O
,	O
death	O
of	O
cells	O
in	O
the	O
inner	O
retina	O
.	O

In	O
mouse	O
models	O
of	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
,	O
SIRT6	O
downregulation	O
and	O
consequent	O
induction	O
of	O
ANXA2	O
were	O
critical	O
for	O
UBE3A	O
-	O
mediated	O
tumorigenesis	S-Phenotype
.	O

Here	O
,	O
we	O
report	O
on	O
a	O
female	O
Danish	O
patient	O
with	O
a	O
novel	O
homozygous	O
IARS2	O
mutation	O
,	O
p.Gly874Arg	O
,	O
who	O
presented	O
at	O
birth	O
with	O
bilateral	B-Phenotype
hip	I-Phenotype
dislocation	E-Phenotype
and	O
short	B-Phenotype
stature	E-Phenotype
.	O

To	O
explore	O
novel	O
molecular	O
mechanisms	O
underlying	O
obesity	S-Phenotype
,	O
we	O
applied	O
a	O
systems	O
genetics	O
framework	O
to	O
integrate	O
risk	O
genetic	O
loci	O
from	O
the	O
largest	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
genome	O
-	O
wide	O
association	O
studies	O
(	O
GWAS	O
)	O
meta	O
-	O
analysis	O
with	O
mRNA	O
and	O
microRNA	O
profiling	O
in	O
adipose	O
tissue	O
from	O
200	O
subjects	O
.	O

Using	O
whole	O
-	O
exome	O
sequencing	O
,	O
we	O
identified	O
a	O
novel	O
de	O
novo	O
missense	O
(	O
c.1132GAAAAC	O
,	O
p.V378L	O
)	O
KCNB1	O
mutation	O
in	O
a	O
patient	O
with	O
global	B-Phenotype
developmental	I-Phenotype
delay	E-Phenotype
,	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
severe	O
speech	B-Phenotype
impairment	E-Phenotype
,	O
but	O
no	O
episode	O
of	O
epilepsy	S-Phenotype
until	O
the	O
lastly	O
examined	O
age	O
of	O
6	O
years	O
old	O
.	O

Therefore	O
,	O
this	O
study	O
suggests	O
that	O
the	O
stop	O
loss	O
and	O
translational	O
elongations	O
by	O
the	O
3	O
'	O
UTR	O
of	O
the	O
NEFH	O
mutations	O
may	O
be	O
a	O
relatively	O
frequent	O
genetic	O
cause	O
of	O
axonal	B-Phenotype
peripheral	I-Phenotype
neuropathy	E-Phenotype
with	O
the	O
specific	O
characteristics	O
of	O
proximal	B-Phenotype
dominant	I-Phenotype
weakness	E-Phenotype

Our	O
results	O
indicate	O
that	O
AMHR2	O
-	O
ED	O
vaccination	O
may	O
be	O
particularly	O
useful	O
in	O
providing	O
safe	O
and	O
effective	O
preemptive	O
immunity	O
against	O
EOC	O
in	O
women	O
at	O
high	O
genetic	O
or	O
familial	O
risk	O
who	O
have	O
the	O
greatest	O
need	O
for	O
a	O
preventive	O
vaccine	O
and	O
ultimately	O
in	O
cancer	S-Phenotype
-	O
free	O
postmenopausal	O
women	O
who	O
account	O
for	O
75	O
%	O
of	O
all	O
EOC	O
cases	O
.	O

In	O
a	O
mouse	O
model	O
of	O
colitis	S-Phenotype
-	O
associated	O
colon	B-Phenotype
cancer	E-Phenotype
(	O
CAC	O
)	O
,	O
urine	O
level	O
of	O
D2HG	O
during	O
colitis	S-Phenotype
correlates	O
positively	O
with	O
subsequent	O
polyp	O
counts	O
and	O
severity	O
of	O
dysplasia	O
.	O

In	O
summary	O
,	O
we	O
described	O
four	O
cases	O
of	O
SMARCB1	B-Phenotype
/	I-Phenotype
INI1	I-Phenotype
-	I-Phenotype
deficient	I-Phenotype
sinonasal	I-Phenotype
carcinoma	E-Phenotype
with	O
detailed	O
clinicopathological	O
data	O
indicating	O
that	O
these	O
tumors	S-Phenotype
can	O
be	O
regarded	O
as	O
a	O
distinct	O
entity	O
with	O
aggressive	B-Phenotype
behaviour	E-Phenotype
.	O

Thus	O
,	O
our	O
results	O
suggest	O
that	O
aberrantly	O
expressed	O
Aurora	O
-	O
C	O
in	O
somatic	O
cancer	S-Phenotype
cells	O
may	O
impair	O
SAC	O
by	O
displacing	O
the	O
centromeric	O
localization	O
of	O
CPCs	O
.	O

Similar	O
differences	O
were	O
found	O
among	O
a	O
single	O
gene	O
group	O
,	O
comparing	O
23	O
patients	O
with	O
CACNA1A	O
expansions	O
(	O
spinocerebellar	B-Phenotype
ataxia	E-Phenotype
6	O
)	O
to	O
22	O
patients	O
with	O
CACNA1A	O
point	O
mutations	O
,	O
which	O
had	O
lower	O
average	O
age	O
at	O
onset	O
(	O
25.2	O
versus	O
47.3	O
years	O
)	O
with	O
longer	O
disease	O
duration	O
(	O
18.7	O
versus	O
10.9	O
)	O
,	O
but	O
lower	O
severity	O
indexes	O
(	O
0.39	O
versus	O
0.44	O
)	O
,	O
indicating	O
slower	O
progression	O
of	O
the	O
disease	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
anti	O
-	O
tumor	S-Phenotype
response	O
of	O
combining	O
IL	O
PV	O
-	O
10	O
with	O
blockade	O
of	O
the	O
PD	O
-	O
1	O
/	O
PD	O
-	O
L1	O
pathway	O
and	O
the	O
role	O
of	O
immune	O
cell	O
populations	O
in	O
eliciting	O
this	O
response	O
.	O

CONCLUSIONS	O
ANXA11	O
plays	O
a	O
critical	O
role	O
in	O
regulating	O
GC	O
proliferation	O
,	O
migration	O
,	O
and	O
invasion	O
via	O
the	O
AKT	O
/	O
GSK	O
-	O
3b	O
pathway	O
,	O
and	O
can	O
potentially	O
be	O
used	O
as	O
a	O
prognostic	O
factor	O
and	O
therapeutic	O
target	O
for	O
gastric	B-Phenotype
cancer	E-Phenotype
patients	O

We	O
further	O
show	O
that	O
upregulation	O
of	O
NOTCH1	O
is	O
necessary	O
for	O
TIC	S-Phenotype
induction	O
downstream	O
of	O
miR	O
-	O
106b	O
-	O
25	O
in	O
both	O
ER	O
+	O
and	O
TNBC	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
and	O
that	O
re	O
-	O
expression	O
of	O
NEDD4L	O
is	O
sufficient	O
to	O
reverse	O
miR106b	O
-	O
25	O
-	O
mediated	O
NOTCH1	O
upregulation	O
and	O
TIC	S-Phenotype
induction	O
.	O

Insufficient	O
signaling	O
through	O
one	O
or	O
more	O
of	O
these	O
metabolite	O
-	O
sensing	O
GPCRs	O
likely	O
contributes	O
to	O
human	O
diseases	O
such	O
as	O
asthma	S-Phenotype
,	O
food	B-Phenotype
allergies	E-Phenotype
,	O
type	B-Phenotype
1	I-Phenotype
and	I-Phenotype
type	I-Phenotype
2	I-Phenotype
diabetes	E-Phenotype
,	O
hepatic	B-Phenotype
steatosis	E-Phenotype
,	O
cardiovascular	B-Phenotype
disease	E-Phenotype
,	O
and	O
inflammatory	B-Phenotype
bowel	I-Phenotype
diseases	E-Phenotype

However	O
,	O
no	O
study	O
has	O
investigated	O
the	O
relationship	O
between	O
aromatase	O
in	O
living	O
brains	O
and	O
personality	O
traits	O
including	O
aggression	S-Phenotype
.	O

Here	O
,	O
we	O
report	O
that	O
variants	O
in	O
TRAPPC12	O
result	O
in	O
progressive	O
childhood	O
encephalopathy	S-Phenotype
.	O

We	O
here	O
review	O
the	O
current	O
knowledge	O
and	O
recent	O
findings	O
in	O
the	O
known	O
genes	O
for	O
isolated	O
dystonia	S-Phenotype
TOR1A	O
,	O
THAP1	O
,	O
and	O
GNAL	O
as	O
well	O
as	O
for	O
the	O
combined	O
dystonias	O
due	O
to	O
mutations	O
in	O
GCH1	O
,	O
ATP1A3	O
,	O
and	O
SGCE	O
.	O

In	O
addition	O
to	O
replicating	O
previously	O
reported	O
loci	O
,	O
we	O
identify	O
five	O
novel	O
loci	O
significantly	O
associated	O
with	O
endometriosis	S-Phenotype
risk	O
(	O
PAAAA5	O
×	O
10sup	O
-	O
8	O
/	O
sup	O
)	O
,	O
implicating	O
genes	O
involved	O
in	O
sex	O
steroid	O
hormone	O
pathways	O
(	O
FN1	O
,	O
CCDC170	O
,	O
ESR1	O
,	O
SYNE1	O
and	O
FSHB	O
)	O
.	O

Despite	O
significant	O
progress	O
,	O
the	O
high	O
genetic	O
heterogeneity	S-Phenotype
of	O
these	O
disorders	O
often	O
requires	O
large	O
sample	O
sizes	O
to	O
identify	O
a	O
critical	O
mass	O
of	O
individuals	O
with	O
disease	O
-	O
causing	O
mutations	O
in	O
a	O
single	O
gene	O
.	O

More	O
importantly	O
,	O
XPNPEP3	O
expression	O
was	O
upregulated	O
compared	O
to	O
normal	O
samples	O
in	O
published	O
expression	O
data	O
sets	O
from	O
several	O
cancers	S-Phenotype
including	O
CRC	O
.	O

Up	O
to	O
15	O
%	O
of	O
the	O
population	O
have	O
mild	B-Phenotype
to	I-Phenotype
moderate	I-Phenotype
chronic	I-Phenotype
hypomagnesemia	E-Phenotype
,	O
which	O
is	O
associated	O
with	O
type	B-Phenotype
2	I-Phenotype
diabetes	I-Phenotype
mellitus	E-Phenotype
,	O
hypertension	S-Phenotype
,	O
metabolic	O
syndrome	O
,	O
and	O
chronic	B-Phenotype
kidney	I-Phenotype
disease	E-Phenotype
.	O

ADAMTS18	O
,	O
located	O
at	O
16q23.1	O
,	O
has	O
been	O
reported	O
to	O
be	O
a	O
critical	O
TSG	O
in	O
multiple	O
primary	O
tumors	S-Phenotype
;	O
however	O
,	O
this	O
has	O
not	O
yet	O
been	O
verified	O
in	O
clear	B-Phenotype
cell	I-Phenotype
renal	I-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
(	O
ccRCC	S-Phenotype
)	O
.	O

Grossly	O
,	O
the	O
neoplasm	S-Phenotype
was	O
lobulated	O
,	O
with	O
a	O
fleshy	O
cut	O
surface	O
and	O
a	O
diameter	O
ranging	O
between	O
0.8	O
and	O
8	O
cm	O
(	O
mean	O
3.4	O
cm	O
)	O
.	O

Here	O
we	O
describe	O
novel	O
sequence	O
variants	O
in	O
SBF1	O
(	O
c.1168CAAAAG	O
and	O
c.2209_2210del	O
)	O
as	O
the	O
potential	O
causative	O
mutations	O
in	O
two	O
siblings	O
with	O
severe	O
axonal	B-Phenotype
neuropathy	E-Phenotype
,	O
hearing	B-Phenotype
loss	E-Phenotype
,	O
facial	B-Phenotype
weakness	E-Phenotype
and	O
bulbar	O
features	O
.	O

As	O
for	O
the	O
prognostic	O
analysis	O
,	O
it	O
revealed	O
that	O
tumor	S-Phenotype
size	O
,	O
mitotic	O
count	O
,	O
surgical	O
margins	O
,	O
multivisceral	O
resection	O
,	O
and	O
TNC	O
expression	O
were	O
independent	O
predictors	O
of	O
PFS	O
for	O
gastric	O
GISTs	O
(	O
P	O
AAAA	O
.05	O
)	O
.	O

Furthermore	O
,	O
CSTA	O
expression	O
was	O
observed	O
in	O
all	O
22	O
lymph	O
node	O
metastases	O
analyzed.Relatively	O
high	O
levels	O
of	O
CSTA	O
expression	O
in	O
tumors	S-Phenotype
were	O
correlated	O
with	O
tumor	S-Phenotype
progression	O
and	O
advanced	O
cancer	S-Phenotype
stage	O
,	O
including	O
lymph	O
node	O
metastasis	O

In	O
the	O
framework	O
of	O
this	O
heterogeneity	S-Phenotype
,	O
we	O
report	O
the	O
clinical	O
description	O
of	O
a	O
neonate	O
,	O
first	O
child	O
of	O
consanguineous	O
parents	O
,	O
who	O
had	O
osteoclast	O
-	O
rich	O
osteopetrosis	S-Phenotype
and	O
bone	B-Phenotype
marrow	I-Phenotype
failure	E-Phenotype
in	O
early	O
life	O
,	O
but	O
no	O
other	O
usual	O
classical	O
features	O
of	O
infantile	O
malignant	O
OPT	O
,	O
such	O
as	O
visual	B-Phenotype
or	I-Phenotype
hearing	I-Phenotype
impairments	E-Phenotype
.	O

These	O
findings	O
,	O
along	O
with	O
the	O
role	O
of	O
NOX2	O
in	O
maintaining	O
self	O
-	O
tolerance	O
,	O
imply	O
that	O
NOX2	O
is	O
a	O
targetable	O
immune	O
checkpoint	O
in	O
cancer	S-Phenotype
.	O

Pfam	O
database	O
,	O
SWISS	O
-	O
model	O
,	O
and	O
Pymol	O
were	O
used	O
for	O
UGT1A1	O
protein	O
domain	O
analysis	O
and	O
protein	O
modeling	O
for	O
assessing	O
the	O
effect	O
of	O
novel	O
missense	O
variants	O
on	O
protein	O
structure.Seventy	O
four	O
cases	O
,	O
including	O
21	O
prolonged	B-Phenotype
unconjugated	I-Phenotype
hyperbilirubinemia	E-Phenotype
(	O
PUCH	S-Phenotype
)	O
,	O
30	O
Gilbert	B-Phenotype
syndrome	E-Phenotype
(	O
GS	S-Phenotype
)	O
,	O
22	O
Crigler	B-Phenotype
-	I-Phenotype
Najjar	I-Phenotype
syndrome	I-Phenotype
type	I-Phenotype
II	E-Phenotype
(	O
CNS	B-Phenotype
-	I-Phenotype
II	E-Phenotype
)	O
,	O
and	O
1	O
Crigler	B-Phenotype
-	I-Phenotype
Najjar	I-Phenotype
syndrome	I-Phenotype
type	I-Phenotype
I	E-Phenotype
(	O
CNS	B-Phenotype
-	I-Phenotype
I	E-Phenotype
)	O
phenotypes	O
were	O
analyzed	O
.	O

Taken	O
all	O
together	O
,	O
these	O
findings	O
provide	O
convincing	O
evidence	O
implicating	O
FIBP	O
aberrations	O
in	O
the	O
newly	O
recognized	O
overgrowth	S-Phenotype
syndrome	O
and	O
expand	O
the	O
associated	O
phenotypes	O
to	O
include	O
possible	O
Wilms	B-Phenotype
tumor	E-Phenotype
predisposition	O
.	O

Our	O
results	O
indicated	O
that	O
HACE1	O
rs9404576	O
polymorphism	O
may	O
be	O
associated	O
with	O
Wilms	O
*	O
tumor	S-Phenotype
susceptibility	O
in	O
the	O
Chinese	O
population	O

DLC1	O
is	O
a	O
critical	O
AKT	O
target	O
in	O
DLC1	O
-	O
positive	O
cancer	S-Phenotype
because	O
AKT	O
inhibition	O
has	O
potent	O
antitumor	O
activity	S-Phenotype
in	O
the	O
DLC1	O
-	O
positive	O
transgenic	O
cancer	S-Phenotype
model	O
and	O
in	O
a	O
DLC1	O
-	O
positive	O
cancer	S-Phenotype
cell	O
line	O
but	O
not	O
in	O
an	O
isogenic	O
DLC1	O
-	O
negative	O
cell	O
line	O

However	O
,	O
the	O
associations	O
between	O
RAD50	O
germline	O
mutations	O
and	O
the	O
survival	O
and	O
risk	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
have	O
not	O
been	O
fully	O
elucidated	O
.	O

Similar	O
to	O
the	O
human	O
phenotype	O
,	O
Lima1	O
-	O
deficient	O
mice	O
displayed	O
reduced	O
cholesterol	O
absorption	O
and	O
were	O
resistant	O
to	O
diet	O
-	O
induced	O
hypercholesterolemia	S-Phenotype
.	O

Using	O
human	O
neuroblastoma	S-Phenotype
SH	O
-	O
SY5Y	O
cells	O
in	O
culture	O
,	O
we	O
also	O
observed	O
that	O
human	O
DDI1	O
is	O
ubiquitinated	O
by	O
UBE3A	O
,	O
without	O
being	O
targeted	O
for	O
degradation	O
.	O

Therefore	O
,	O
we	O
concluded	O
that	O
AHI1	O
c.3257AAAAAG	O
and	O
NEB	O
c.914	O
AAAAAG	O
were	O
potential	O
causal	O
variants	O
in	O
this	O
strabismus	S-Phenotype
pedigree	O
.	O

Pathogenic	O
variants	O
in	O
EBF3	O
were	O
recently	O
described	O
in	O
three	O
back	O
-	O
to	O
-	O
back	O
publications	O
in	O
association	O
with	O
a	O
novel	O
neurodevelopmental	O
disorder	O
characterized	O
by	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
speech	B-Phenotype
delay	E-Phenotype
,	O
ataxia	S-Phenotype
,	O
and	O
facial	O
dysmorphisms	O
.	O

Previous	O
investigations	O
have	O
demonstrated	O
that	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
of	O
NER	O
pathway	O
genes	O
were	O
associated	O
with	O
various	O
types	O
of	O
cancer	S-Phenotype
.	O

Two	O
of	O
these	O
genes	O
were	O
independently	O
mutated	O
in	O
more	O
than	O
one	O
family	O
with	O
similar	O
phenotypes	O
,	O
which	O
substantiates	O
their	O
link	O
to	O
human	O
disease	O
(	O
AKAP6	O
in	O
intellectual	B-Phenotype
disability	E-Phenotype
and	O
UBR4	O
in	O
early	O
dementia	S-Phenotype
)	O
.	O

Many	O
cancer	S-Phenotype
-	O
causing	O
chromosomal	O
translocations	O
result	O
in	O
transactivating	O
protein	O
products	O
encoding	O
FET	O
family	O
(	O
FUS	O
,	O
EWSR1	O
,	O
TAF15	O
)	O
low	O
-	O
complexity	O
(	O
LC	O
)	O
domains	O
fused	O
to	O
a	O
DNA	O
binding	O
domain	O
from	O
one	O
of	O
several	O
transcription	O
factors	O
.	O

By	O
whole	O
-	O
exome	O
sequencing	O
,	O
recessive	O
protein	O
-	O
truncating	O
mutations	O
in	O
CWC27	O
were	O
found	O
in	O
seven	O
unrelated	O
families	O
that	O
show	O
a	O
range	O
of	O
clinical	O
phenotypes	O
,	O
including	O
retinal	B-Phenotype
degeneration	E-Phenotype
,	O
brachydactyly	S-Phenotype
,	O
craniofacial	B-Phenotype
abnormalities	E-Phenotype
,	O
short	B-Phenotype
stature	E-Phenotype
,	O
and	O
neurological	O
defects	O
.	O

Familial	O
clustering	O
of	O
schizophrenia	S-Phenotype
(	O
SCZ	S-Phenotype
)	O
,	O
bipolar	B-Phenotype
disorder	E-Phenotype
(	O
BPD	S-Phenotype
)	O
,	O
and	O
major	O
depressive	B-Phenotype
disorder	E-Phenotype
(	O
MDD	O
)	O
was	O
systematically	O
reported	O
(	O
Aukes	O
et	O
al	O
,	O
Genet	O
Med	O
2012	O
,	O
14	O
,	O
338	O
-	O
341	O
)	O
and	O
convergent	O
evidence	O
from	O
genetics	O
,	O
symptomatology	O
,	O
and	O
psychopharmacology	O
imply	O
that	O
there	O
are	O
intrinsic	O
connections	O
between	O
these	O
three	O
major	O
psychiatric	B-Phenotype
disorders	E-Phenotype
,	O
for	O
example	O
,	O
any	O
two	O
or	O
even	O
three	O
of	O
these	O
disorders	O
could	O
co	O
-	O
exist	O
in	O
some	O
families	O
.	O

Our	O
data	O
extend	O
the	O
spectrum	O
of	O
allelic	O
variation	O
underlying	O
blood	O
pressure	O
traits	O
and	O
hypertension	S-Phenotype
,	O
provide	O
new	O
insights	O
into	O
the	O
pathophysiology	O
of	O
hypertension	S-Phenotype
and	O
indicate	O
new	O
targets	O
for	O
clinical	O
intervention	O

Our	O
findings	O
highlight	O
the	O
significance	O
of	O
recalibrating	O
tumor	S-Phenotype
cell	O
metabolism	O
by	O
fine	O
-	O
tuning	O
nucleotide	O
and	O
NAD	O
synthesis	O
in	O
tumor	S-Phenotype
growth	O
.	O

Significance	O
:	O
Our	O
findings	O
elucidate	O
an	O
instrumental	O
function	O
of	O
AMPK	O
in	O
direct	O
regulation	O
of	O
nucleic	O
acid	O
and	O
NAD	O
synthesis	O
in	O
tumor	S-Phenotype
cells	O
in	O
response	O
to	O
energy	O
stress	O
.	O

MIR22HG	O
is	O
an	O
lncRNA	O
that	O
contributes	O
to	O
the	O
initiation	O
and	O
progression	O
of	O
many	O
human	O
cancers	S-Phenotype
,	O
including	O
hepatocellular	B-Phenotype
carcinoma	E-Phenotype
(	O
HCC	S-Phenotype
)	O
.	O

Our	O
findings	O
establish	O
that	O
defective	O
TBCD	O
function	O
underlies	O
a	O
recognizable	O
encephalopathy	S-Phenotype
and	O
drives	O
accelerated	O
microtubule	O
polymerization	O
and	O
enhanced	O
microtubule	O
stability	O
,	O
underscoring	O
an	O
additional	O
cause	O
of	O
altered	O
microtubule	O
dynamics	O
with	O
impact	O
on	O
neuronal	O
function	O
and	O
survival	O
in	O
the	O
developing	O
brain	O

Biological	O
activities	O
of	O
compounds	O
3	O
-	O
7	O
towards	O
human	O
cancer	S-Phenotype
cells	O
,	O
COX	O
-	O
2	O
,	O
ROCK1	O
,	O
and	O
JAK3	O
were	O
evaluated	O

Only	O
overexpression	O
of	O
LAT	O
induced	O
a	O
reduction	O
of	O
brain	O
proliferating	O
cells	O
and	O
concomitant	O
microcephaly	S-Phenotype
.	O

Therefore	O
,	O
STX3	O
promotes	O
the	O
growth	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
by	O
regulating	O
the	O
PTEN	O
-	O
PI3K	O
-	O
Akt	O
-	O
mTOR	O
signaling	O

Here	O
,	O
we	O
found	O
that	O
ADAMTS18	O
was	O
silenced	O
or	O
downregulated	O
in	O
breast	B-Phenotype
cancer	E-Phenotype
cell	O
lines	O
.	O

It	O
is	O
autosomal	B-Phenotype
recessively	E-Phenotype
inherited	O
,	O
and	O
caused	O
by	O
SPINT2	O
mutations	O
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
the	O
construct	O
,	O
face	O
and	O
predictive	O
validity	O
of	O
Stxbp1+	O
/	O
-	O
mice	O
and	O
point	O
to	O
protein	O
instability	O
,	O
haploinsufficiency	O
and	O
imbalanced	O
excitation	O
in	O
neocortex	O
,	O
as	O
the	O
underlying	O
mechanism	O
of	O
STXBP1	O
-	O
encephalopathy	S-Phenotype
.	O

This	O
study	O
describes	O
the	O
first	O
use	O
of	O
PGD	O
for	O
GJB2	O
associated	O
non	O
-	O
syndromic	O
deafness	S-Phenotype
in	O
Iran	O
.	O

We	O
find	O
that	O
SWELL1	O
-	O
mediated	O
VRAC	O
is	O
augmented	O
in	O
hypertrophic	O
murine	O
and	O
human	O
adipocytes	O
in	O
the	O
setting	O
of	O
obesity	S-Phenotype
.	O

Hereditary	B-Phenotype
angioedema	E-Phenotype
(	O
HAE	S-Phenotype
)	O
,	O
due	O
to	O
C1	O
-	O
inhibitor	O
deficiency	O
,	O
is	O
a	O
rare	O
autosomal	O
dominant	O
and	O
potentially	O
life	O
-	O
threatening	O
disease	O
characterised	O
by	O
recurrent	O
oedema	S-Phenotype
attacks	O
of	O
skin	O
,	O
mucosa	O
and	O
viscera	O
.	O

Consistent	O
with	O
a	O
role	O
in	O
transition	O
zone	O
function	O
,	O
mutation	O
of	O
mouse	O
Tmem231	O
disrupts	O
the	O
localization	O
of	O
proteins	O
including	O
Arl13b	O
and	O
Inpp5e	O
to	O
cilia	O
,	O
resulting	O
in	O
phenotypes	O
characteristic	O
of	O
MKS	O
such	O
as	O
polydactyly	S-Phenotype
and	O
kidney	B-Phenotype
cysts	E-Phenotype
.	O

Two	O
novel	O
heterozygous	O
missense	O
mutations	O
in	O
CCNF	O
,	O
p.S222P	O
(	O
c.664TAAAAC	O
)	O
and	O
p.S532R	O
(	O
c.1596CAAAAT	O
)	O
,	O
were	O
identified	O
;	O
1	O
in	O
each	O
patient	O
with	O
apparently	O
sporadic	O
ALS	O
.	O

Sickle	O
cell	O
disease	O
(	O
SCD	O
)	O
is	O
one	O
of	O
the	O
most	O
common	O
autosomal	B-Phenotype
recessive	E-Phenotype
diseases	O
in	O
humans	O
,	O
occurring	O
at	O
a	O
frequency	O
of	O
1	O
in	O
365	O
African	O
-	O
American	O
and	O
1	O
in	O
50	O
sub	O
-	O
Saharan	O
African	O
births	O
.	O

Intriguingly	O
,	O
five	O
CPGs	O
showed	O
concordance	O
between	O
CNL	O
and	O
down	O
-	O
regulation	O
in	O
50	O
or	O
more	O
tumor	S-Phenotype
samples	O
:	O
MTAP	O
(	O
216	O
samples	O
)	O
,	O
PTEN	O
(	O
143	O
)	O
,	O
MCPH1	O
(	O
86	O
)	O
,	O
SMAD4	O
(	O
63	O
)	O
,	O
and	O
MINPP1	O
(	O
51	O
)	O
,	O
which	O
may	O
represent	O
the	O
recurrent	O
driving	O
force	O
for	O
gene	O
expression	O
change	O
during	O
oncogenesis	O
.	O

The	O
congenital	B-Phenotype
myasthenic	I-Phenotype
syndromes	E-Phenotype
(	O
CMS	S-Phenotype
)	O
are	O
heterogeneous	S-Phenotype
disorders	O
in	O
which	O
the	O
safety	O
margin	O
of	O
neuromuscular	O
transmission	O
is	O
compromised	O
by	O
one	O
or	O
more	O
specific	O
mechanisms	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
relationship	O
between	O
ALDH5A1	O
and	O
the	O
prognosis	O
of	O
patients	O
with	O
ovarian	B-Phenotype
cancer	E-Phenotype
(	O
OC	S-Phenotype
)	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
tumor	S-Phenotype
necrosis	O
factor	O
(	O
TNF	O
)	O
receptor	O
-	O
associated	O
factor	O
5	O
(	O
TRAF5	O
)	O
and	O
TGF	O
-	O
b	O
activated	O
kinase	O
1	O
(	O
MAP3K7	O
)	O
binding	O
protein	O
1	O
(	O
TAB1	O
)	O
were	O
direct	O
targets	O
of	O
miR	O
-	O
873	O
in	O
CRC	O
cells	O
.	O

Whereas	O
Klf13	O
heterozygote	O
mice	O
have	O
no	O
detectable	O
cardiac	O
defects	O
,	O
loss	O
of	O
a	O
Klf13	O
allele	O
in	O
Tbx5	O
heterozygote	O
mice	O
significantly	O
increases	O
the	O
penetrance	O
of	O
TBX5	O
-	O
dependent	O
cardiac	B-Phenotype
abnormalities	E-Phenotype
including	O
atrial	B-Phenotype
,	I-Phenotype
atrial	I-Phenotype
-	I-Phenotype
ventricular	I-Phenotype
and	I-Phenotype
ventricular	I-Phenotype
septal	I-Phenotype
defects	E-Phenotype
.	O

We	O
further	O
demonstrated	O
that	O
genetic	O
loss	O
of	O
Fam13a	O
exacerbated	O
obesity	S-Phenotype
-	O
related	O
metabolic	O
disorders	O
,	O
while	O
targeted	O
activation	O
of	O
Fam13a	O
in	O
adipocytes	O
ameliorated	O
it	O
in	O
association	O
with	O
altered	O
adipose	O
tissue	O
insulin	O
sensitivity	O
in	O
mice	O
.	O

Subsequent	O
Sanger	O
sequencing	O
was	O
performed	O
on	O
a	O
panel	O
of	O
individuals	O
from	O
12	O
French	O
families	O
affected	O
by	O
microcephaly	S-Phenotype
and	O
ophthalmic	O
manifestations	O
,	O
and	O
one	O
other	O
individual	O
was	O
identified	O
with	O
compound	O
-	O
heterozygous	O
mutations	O
in	O
TUBGCP4	O
.	O

Our	O
results	O
demonstrated	O
that	O
the	O
overall	O
expression	O
of	O
NSUN2	O
significantly	O
correlated	O
with	O
clinical	O
stage	O
(	O
P=0.027	O
)	O
,	O
tumor	S-Phenotype
classification	O
(	O
P=0.012	O
)	O
,	O
pathological	O
differentiation	O
(	O
P=0.023	O
)	O
,	O
as	O
well	O
as	O
with	O
the	O
expression	O
levels	O
of	O
estrogen	O
receptor	O
(	O
PAAAA0.001	O
)	O
,	O
progesterone	O
receptor	O
(	O
P=0.001	O
)	O
,	O
and	O
Ki	O
-	O
67	O
(	O
PAAAA0.001	O
)	O
.	O

There	O
was	O
a	O
statistically	O
significant	O
difference	O
in	O
RASSF1	O
gene	O
methylation	O
between	O
SMARCB1	O
/	O
INI1	O
-	O
deficient	O
and	O
SMARCB1	O
/	O
INI1	O
-	O
positive	O
tumors	S-Phenotype
(	O
p=0.0095	O
)	O
.	O

EEF1A1	O
and	O
EEF1A2	O
,	O
in	O
most	O
of	O
the	O
cancer	S-Phenotype
types	O
.	O

In	O
a	O
meta	O
-	O
analysis	O
of	O
our	O
previous	O
GWAS	O
and	O
the	O
replication	O
studies	O
,	O
which	O
included	O
a	O
total	O
of	O
7,141	O
prostate	B-Phenotype
cancer	E-Phenotype
cases	O
and	O
11,804	O
controls	O
from	O
a	O
single	O
ancestry	O
group	O
,	O
three	O
new	O
loci	O
reached	O
genome	O
-	O
wide	O
significance	O
on	O
chromosomes	O
11q12	O
(	O
rs1938781	O
;	O
P	O
=	O
1.10	O
×	O
10	O
(	O
-	O
10	O
)	O
;	O
FAM111A	O
-	O
FAM111B	O
)	O
,	O
10q26	O
(	O
rs2252004	O
;	O
P	O
=	O
1.98	O
×	O
10	O
(	O
-	O
8	O
)	O
)	O
and	O
3p11.2	O
(	O
rs2055109	O
;	O
P	O
=	O
3.94	O
×	O
10	O
(	O
-	O
8	O
)	O
)	O
.	O

Recent	O
studies	O
identified	O
a	O
close	O
association	O
between	O
the	O
c.14576GAAAAA	O
(	O
p.R4859K	O
,	O
rs112735431	O
)	O
variant	O
of	O
the	O
ring	O
finger	O
protein	O
213	O
(	O
RNF213	O
)	O
gene	O
and	O
sporadic	B-Phenotype
intracranial	I-Phenotype
arterial	I-Phenotype
stenosis	E-Phenotype
(	O
ICAS	S-Phenotype
)	O
.	O

Systemic	B-Phenotype
lupus	I-Phenotype
erythematosus	E-Phenotype
(	O
SLE	S-Phenotype
)	O
is	O
a	O
heterogeneous	B-Phenotype
autoimmune	I-Phenotype
disease	E-Phenotype
with	O
a	O
strong	O
genetic	O
component	O
characterized	O
by	O
autoantibody	O
production	O
and	O
a	O
type	O
I	O
interferon	O
signature	O
.	O

This	O
study	O
aims	O
to	O
determine	O
the	O
association	O
between	O
FGF10	O
(	O
rs4415084	O
CAAAAT	O
)	O
,	O
FGFR2	O
(	O
rs2981582	O
CAAAAT	O
)	O
and	O
MAP3K1	O
(	O
rs889312	O
AAAAAC	O
)	O
gene	O
polymorphisms	O
and	O
breast	B-Phenotype
cancer	E-Phenotype
,	O
to	O
analyse	O
the	O
discriminative	O
ability	O
of	O
each	O
SNP	O
and	O
to	O
test	O
the	O
accuracy	O
of	O
the	O
predictive	O
breast	B-Phenotype
cancer	E-Phenotype
risk	O
model	O
which	O
includes	O
all	O
SNPs	O
.	O

MATERIAL	O
AND	O
METHODS	O
The	O
expression	O
of	O
ALG3	O
in	O
breast	B-Phenotype
carcinoma	E-Phenotype
tissues	O
was	O
determined	O
by	O
immunochemistry	O
.	O

However	O
,	O
the	O
expression	O
and	O
precise	O
role	O
of	O
SOX3	O
in	O
osteosarcoma	S-Phenotype
remain	O
unclear	O
.	O

This	O
similarity	O
was	O
revealed	O
by	O
the	O
same	O
number	O
of	O
passages	O
,	O
the	O
same	O
germ	O
cell	O
clusters	O
formation	O
and	O
similar	O
level	O
of	O
genes	O
expression	O
of	O
spermatogonial	O
markers	O
including	O
ubiquitin	O
carboxyl	O
-	O
terminal	O
esterase	O
L1	O
(	O
UCHL1	O
)	O
,	O
zinc	O
finger	O
and	O
BTB	O
domain	O
containing	O
16	O
(	O
ZBTB16	O
)	O
and	O
glial	O
cell	O
line	O
-	O
derived	O
neurotrophic	O
factor	O
family	O
receptor	O
alpha	O
1	O
(	O
GFRA1	O
)	O
,	O
as	O
well	O
as	O
germ	O
cell	O
differentiation	O
markers	O
including	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
(	O
STAT3	O
)	O
,	O
spermatogenesis	O
and	O
oogenesis	O
specific	O
basic	O
helix	O
-	O
loophelix	O
2	O
(	O
SOHLH2	O
)	O
,	O
v	O
-	O
kit	O
Hardy	O
-	O
Zuckerman	O
4	O
feline	O
sarcoma	S-Phenotype
viral	O
oncogene	O
homolog	O
(	O
KIT	O
)	O
and	O
synaptonemal	O
complex	O
protein	O
3	O
(	O
SYCP3	O
)	O
.	O

In	O
2016	O
,	O
two	O
research	O
groups	O
independently	O
identified	O
microdeletions	O
and	O
pathogenic	O
variants	O
in	O
the	O
lysine	O
-	O
specific	O
histone	O
methyltransferase	O
2B	O
gene	O
,	O
KMT2B	O
in	O
patients	O
with	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
progressive	I-Phenotype
dystonia	E-Phenotype
.	O

From	O
the	O
standpoint	O
of	O
the	O
phylogenetic	O
theory	O
of	O
general	O
pathology	O
,	O
atherosclerosis	S-Phenotype
and	O
atheromatosis	S-Phenotype
of	O
the	O
arteries	O
have	O
no	O
great	O
future	O
.	O

In	O
addition	O
,	O
splicing	O
variants	O
of	O
CIZ1	O
mRNA	O
is	O
associated	O
with	O
a	O
variety	O
of	O
cancers	S-Phenotype
and	O
Alzheimer	O
's	O
disease	O
,	O
and	O
mutations	O
of	O
the	O
CIZ1	O
gene	O
lead	O
to	O
cervical	B-Phenotype
dystonia	E-Phenotype
.	O

Salivary	B-Phenotype
gland	I-Phenotype
tumor	E-Phenotype
(	O
SGT	S-Phenotype
)	O
is	O
a	O
rare	O
tumor	S-Phenotype
type	O
,	O
which	O
exhibits	O
broad	O
-	O
spectrum	O
phenotypic	O
,	O
biological	O
,	O
and	O
clinical	O
heterogeneity	S-Phenotype
.	O

Oxidative	B-Phenotype
stress	E-Phenotype
,	O
which	O
is	O
induced	O
by	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
,	O
causes	O
cellular	O
damage	O
which	O
contributes	O
to	O
the	O
pathogenesis	O
of	O
neurodegenerative	B-Phenotype
diseases	E-Phenotype
.	O

The	O
genetic	O
study	O
by	O
panels	O
of	O
known	O
genes	O
associated	O
with	O
tubulointerstitial	O
disease	O
allowed	O
us	O
to	O
discover	O
autosomal	B-Phenotype
dominant	I-Phenotype
distal	I-Phenotype
renal	I-Phenotype
tubular	I-Phenotype
acidosis	E-Phenotype
associated	O
with	O
a	O
de	O
novo	O
mutation	O
in	O
exon	O
14	O
of	O
the	O
SLC4A1	O
gene	O
,	O
which	O
would	O
have	O
been	O
impossible	O
to	O
diagnose	O
clinically	O
due	O
to	O
the	O
advanced	O
nature	O
of	O
the	O
kidney	B-Phenotype
disease	E-Phenotype
when	O
it	O
was	O
discovered	O

Megaconial	B-Phenotype
congenital	I-Phenotype
muscular	I-Phenotype
dystrophy	E-Phenotype
is	O
a	O
disease	O
caused	O
by	O
pathogenic	O
mutations	O
in	O
the	O
gene	O
encoding	O
choline	O
kinase	O
beta	O
(	O
CHKB	O
)	O
.	O

These	O
fetal	O
structures	O
generate	O
regions	O
with	O
abnormal	O
activity	O
in	O
autism	S-Phenotype
,	O
including	O
the	O
dorsolateral	O
prefrontal	O
cortex	O
(	O
BA46	O
)	O
,	O
the	O
pars	O
opercularis	O
of	O
the	O
inferior	O
frontal	O
cortex	O
and	O
the	O
fusiform	O
gyrus	O
.	O

These	O
findings	O
demonstrate	O
that	O
SLC6A1	O
is	O
an	O
important	O
contributor	O
to	O
childhood	O
epilepsy	S-Phenotype
and	O
that	O
reduced	O
GAT	O
-	O
1	O
function	O
is	O
a	O
common	O
consequence	O
of	O
epilepsy	S-Phenotype
-	O
causing	O
SLC6A1	O
variants	O

The	O
newly	O
reported	O
myoclonus	S-Phenotype
-	O
dystonia	S-Phenotype
gene	O
,	O
RELN	O
,	O
plays	O
also	O
a	O
role	O
in	O
the	O
formation	O
of	O
brain	O
structures	O
.	O

She	O
developed	O
gastrointestinal	O
symptoms	O
,	O
dysarthria	S-Phenotype
,	O
dysphagia	S-Phenotype
and	O
weakness	S-Phenotype
,	O
and	O
MNGIE	O
was	O
considered	O
due	O
to	O
its	O
low	O
TP	O
levels	O
and	O
improvement	O
after	O
platelet	O
transfusions	O
.	O

Various	O
genes	O
(	O
eg	O
,	O
SPG7	O
,	O
SYNE1	O
,	O
PNPLA6	O
)	O
traditionally	O
rooted	O
in	O
either	O
the	O
ataxia	S-Phenotype
or	O
hereditary	B-Phenotype
spastic	I-Phenotype
paraplegia	E-Phenotype
classification	O
system	O
have	O
now	O
been	O
shown	O
to	O
cause	O
ataxia	S-Phenotype
on	O
the	O
one	O
end	O
of	O
the	O
disease	O
continuum	O
and	O
hereditary	B-Phenotype
spastic	I-Phenotype
paraplegia	E-Phenotype
on	O
the	O
other	O
.	O

Mutation	O
analysis	O
of	O
the	O
NDUFA11	O
is	O
warranted	O
in	O
isolated	O
complex	O
I	O
deficiency	O
presenting	O
with	O
infantile	B-Phenotype
lactic	I-Phenotype
acidemia	E-Phenotype
or	O
encephalocardiomyopathy	S-Phenotype

Using	O
gene	O
expression	O
profiles	O
,	O
we	O
established	O
a	O
gene	O
-	O
signature	O
(	O
CAV1	O
,	O
CD36	O
,	O
MLXIPL	O
,	O
CPT1C	O
,	O
CYP2E1	O
)	O
that	O
strongly	O
associated	O
with	O
epithelial	O
-	O
mesenchymal	O
program	O
across	O
multiple	O
cancers	S-Phenotype
.	O

Individuals	O
with	O
known	O
mutations	O
in	O
tumor	S-Phenotype
suppressor	O
genes	O
such	O
as	O
CDKN2A	O
and	O
BAP1	O
require	O
,	O
in	O
addition	O
,	O
follow	O
up	O
for	O
other	O
cancers	S-Phenotype

The	O
successful	O
therapeutic	O
use	O
of	O
anti	O
-	O
TNF	O
biological	O
agents	O
in	O
patients	O
with	O
ankylosing	B-Phenotype
spondylitis	E-Phenotype
(	O
AS	S-Phenotype
)	O
indicates	O
that	O
tumor	S-Phenotype
necrosis	O
factor	O
-	O
α	O
(	O
TNF	O
-	O
α	O
)	O
and	O
tumor	S-Phenotype
necrosis	O
factor	O
receptor	O
(	O
TNFR	O
)	O
genes	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
AS	O
.	O

Functional	O
studies	O
have	O
elucidated	O
the	O
role	O
of	O
the	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
pathway	O
in	O
breast	O
carcinogenesis	O
,	O
but	O
to	O
date	O
,	O
there	O
is	O
a	O
paucity	O
of	O
data	O
on	O
its	O
contribution	O
to	O
breast	B-Phenotype
cancer	E-Phenotype
risk	O
in	O
women	O
of	O
African	O
ancestry	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
incidence	O
of	O
SLC6A1	O
variants	O
in	O
460	O
unselected	O
epilepsy	S-Phenotype
patients	O
and	O
to	O
evaluate	O
the	O
impact	O
of	O
the	O
identified	O
variants	O
on	O
γ	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
)	O
transport	O
.	O

Mutations	O
in	O
the	O
DNAJB2	O
gene	O
lead	O
to	O
inherited	O
neuropathies	S-Phenotype
such	O
as	O
Charcot	O
-	O
Marie	O
-	O
Tooth	O
type	O
-	O
2	O
,	O
distal	O
hereditary	O
motor	O
neuropathies	S-Phenotype
,	O
spinal	B-Phenotype
muscular	I-Phenotype
atrophy	E-Phenotype
with	O
parkinsonism	S-Phenotype
and	O
the	O
later	O
stages	O
can	O
resemble	O
amyotrophic	B-Phenotype
lateral	I-Phenotype
sclerosis	E-Phenotype
.	O

In	O
families	O
severely	O
affected	O
with	O
breast	B-Phenotype
cancer	E-Phenotype
,	O
we	O
identified	O
inherited	O
BARD1	O
missense	O
mutations	O
Cys53Trp	O
,	O
Cys71Tyr	O
,	O
and	O
Cys83Arg	O
that	O
alter	O
three	O
zinc	O
-	O
binding	O
residues	O
of	O
the	O
BARD1	O
RING	O
domain	O
.	O

In	O
this	O
study	O
,	O
we	O
reported	O
that	O
SOX3	O
expression	O
was	O
upregulated	O
in	O
osteosarcoma	S-Phenotype
tissues	O
compared	O
with	O
non	B-Phenotype
-	I-Phenotype
cancerous	I-Phenotype
bone	I-Phenotype
cyst	E-Phenotype
tissues	O
.	O

Nogo	O
-	O
A	O
and	O
Nogo	O
-	O
C	O
are	O
potent	O
Nogos	O
that	O
are	O
predominantly	O
expressed	O
in	O
the	O
central	S-Phenotype
nervous	O
system	O
.	O

Primary	O
pigmented	O
nodular	O
adrenocortical	O
disease	O
(	O
PPNAD	O
)	O
is	O
the	O
rarest	O
form	O
of	O
ACTH	O
-	O
independent	O
CS	O
,	O
and	O
can	O
be	O
associated	O
with	O
endocrine	O
and	O
nonendocrine	O
tumors	S-Phenotype
,	O
forming	O
the	O
Carney	O
complex	O
(	O
CNC	O
)	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
increased	O
FAR2	O
expression	O
in	O
human	O
patients	O
is	O
associated	O
with	O
diabetic	B-Phenotype
nephropathy	E-Phenotype
,	O
lupus	B-Phenotype
nephritis	E-Phenotype
,	O
and	O
IgA	B-Phenotype
nephropathy	E-Phenotype
.	O

Recently	O
,	O
mutations	O
in	O
transmembrane	O
protein	O
240	O
(	O
TMEM240	O
)	O
were	O
identified	O
as	O
the	O
cause	O
of	O
spinocerebellar	B-Phenotype
ataxia	I-Phenotype
type	I-Phenotype
21	E-Phenotype
(	O
SCA21	S-Phenotype
)	O
in	O
several	O
French	O
families	O
.	O

Melanogenesis	O
genes	O
tyrosinase	O
,	O
tyrosinase	O
-	O
related	O
protein	O
1	O
,	O
Hermansky	O
-	O
Pudlak	O
Syndrome	O
3	O
,	O
premelanosome	O
protein	O
and	O
dopachrome	O
tautomerase	O
were	O
upregulated	O
,	O
as	O
was	O
the	O
melanogenesis	O
-	O
controlling	O
transcription	O
factor	O
,	O
microphthalmia	S-Phenotype
-	O
associated	O
transcription	O
factor	O
(	O
MITF	O
)	O
.	O

This	O
study	O
aims	O
to	O
determine	O
the	O
association	O
between	O
FGF10	O
(	O
rs4415084	O
CAAAAT	O
)	O
,	O
FGFR2	O
(	O
rs2981582	O
CAAAAT	O
)	O
and	O
MAP3K1	O
(	O
rs889312	O
AAAAAC	O
)	O
gene	O
polymorphisms	O
and	O
breast	B-Phenotype
cancer	E-Phenotype
,	O
to	O
analyse	O
the	O
discriminative	O
ability	O
of	O
each	O
SNP	O
and	O
to	O
test	O
the	O
accuracy	O
of	O
the	O
predictive	O
breast	B-Phenotype
cancer	E-Phenotype
risk	O
model	O
which	O
includes	O
all	O
SNPs	O
.	O

Variations	O
in	O
RNASEH2C	O
cause	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
form	O
of	O
AGS	O
.	O

Disorders	O
of	O
signalling	O
of	O
various	O
paracrine	O
factors	O
(	O
FGFs	O
,	O
BMPs	O
,	O
WNTs	O
,	O
PTHrP	O
/	O
IHH	O
,	O
and	O
CNP	O
/	O
NPR2	O
)	O
or	O
genetic	O
defects	O
affecting	O
cartilage	O
extracellular	O
matrix	O
usually	O
cause	O
disproportionate	B-Phenotype
short	I-Phenotype
stature	E-Phenotype
.	O

This	O
phenotype	O
is	O
associated	O
with	O
increased	O
cytosine	O
methylation	O
heterogeneity	S-Phenotype
,	O
but	O
not	O
with	O
increased	O
AICDA	O
-	O
mediated	O
somatic	B-Phenotype
mutation	E-Phenotype
burden	O
.	O

Here	O
we	O
show	O
that	O
the	O
transcription	O
factor	O
pleomorphic	O
adenoma	O
gene	O
1	O
(	O
PLAG1	O
)	O
is	O
a	O
microRNA	O
target	O
gene	O
that	O
is	O
overexpressed	O
in	O
Wilms	B-Phenotype
tumors	E-Phenotype
with	O
mutations	O
in	O
microRNA	O
processing	O
genes	O
.	O

Glutamine	O
:	O
fructose	O
-	O
6	O
-	O
phosphate	O
amidotransferase	O
(	O
GFAT1	O
)	O
is	O
the	O
rate	O
-	O
limiting	O
enzyme	O
of	O
the	O
HBP	O
;	O
nevertheless	O
,	O
the	O
prognostic	O
value	O
of	O
GFAT1	O
in	O
pancreatic	B-Phenotype
cancer	E-Phenotype
remains	O
elusive	O
.	O

The	O
high	O
levels	O
of	O
TNC	O
expression	O
in	O
gastric	O
GISTs	O
was	O
significantly	O
associated	O
with	O
tumor	S-Phenotype
size	O
(	O
P	O
AAAA	O
.001	O
)	O
,	O
multivisceral	O
resection	O
(	O
P	O
=	O
.006	O
)	O
,	O
metastasis	O
at	O
initial	O
diagnosis	O
(	O
P	O
=	O
.006	O
)	O
,	O
mitotic	O
count	O
(	O
P	O
=	O
.002	O
)	O
and	O
NIH	O
risk	O
classification	O
(	O
P	O
=	O
.015	O
)	O
.	O

Focusing	O
on	O
NOS1AP	O
,	O
we	O
observed	O
that	O
NOS1AP	O
colocalizes	O
with	O
both	O
SCRIB	O
and	O
VANGL1	O
along	O
cellular	O
protrusions	O
in	O
metastatic	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
,	O
but	O
does	O
not	O
colocalize	O
with	O
either	O
SCRIB	O
or	O
VANGL1	O
at	O
cell	O
junctions	O
in	O
normal	O
breast	O
cells	O
.	O

However	O
,	O
the	O
role	O
of	O
PNPO	O
and	O
its	O
regulatory	O
mechanism	O
in	O
epithelial	B-Phenotype
ovarian	I-Phenotype
cancer	E-Phenotype
(	O
EOC	S-Phenotype
)	O
are	O
unknown	O
.	O

Microfibrillar	O
-	O
associated	O
protein	O
5	O
(	O
MFAP5	O
)	O
is	O
a	O
component	O
of	O
extracellular	O
elastic	O
microfibril	O
which	O
has	O
been	O
confirmed	O
to	O
function	O
in	O
tissue	O
development	O
and	O
cancer	S-Phenotype
progression	O
.	O

RAD51C	O
and	O
RAD51D	O
have	O
been	O
defined	O
as	O
susceptibility	O
genes	O
for	O
hereditary	B-Phenotype
breast	I-Phenotype
and	I-Phenotype
ovarian	I-Phenotype
cancer	E-Phenotype
syndrome	O
in	O
several	O
studies	O
.	O

To	O
understand	O
how	O
mutant	O
PIK3CA	O
contributes	O
to	O
cancer	S-Phenotype
cell	O
proliferation	O
,	O
we	O
used	O
genome	O
scale	O
loss	O
-	O
of	O
-	O
function	O
screening	O
in	O
a	O
large	O
number	O
of	O
genomically	O
annotated	O
cancer	S-Phenotype
cell	O
lines	O
.	O

Furthermore	O
,	O
the	O
xenograft	O
study	O
confirmed	O
the	O
tumor	S-Phenotype
proliferation	O
-	O
promoting	O
role	O
of	O
SPRY4	O
-	O
IT1	O
in	O
PANC1	O
cells	O
.	O

Five	O
of	O
the	O
fifteen	O
SDH	O
-	O
deficient	O
GISTs	O
had	O
follow	O
-	O
up	O
data	O
:	O
one	O
patient	O
died	O
8	O
months	O
after	O
surgery	O
from	O
unknown	O
cause	O
,	O
four	O
had	O
no	O
recurrences	O
or	O
metastases	O
,	O
and	O
there	O
was	O
no	O
history	O
of	O
paraganglioma	S-Phenotype
and	O
pulmonary	B-Phenotype
chondroma	E-Phenotype
found	O
in	O
patients	O
and	O
their	O
families	O
.	O

Over	O
the	O
past	O
decade	O
,	O
the	O
genetic	O
basis	O
of	O
several	O
forms	O
of	O
autosomal	B-Phenotype
recessive	E-Phenotype
SCD	O
cases	O
has	O
been	O
solved	O
with	O
the	O
identification	O
of	O
four	O
causative	O
genes	O
(	O
DLL3	O
,	O
MESP2	O
,	O
LFNG	O
and	O
HES7	O
)	O
.	O

We	O
characterize	O
MYMK	O
-	O
CFZS	O
as	O
a	O
congenital	B-Phenotype
myopathy	E-Phenotype
with	O
marked	O
facial	B-Phenotype
weakness	E-Phenotype
and	O
additional	O
clinical	O
and	O
pathologic	O
features	O
that	O
distinguish	O
it	O
from	O
other	O
congenital	O
neuromuscular	O
syndromes	O
.	O

Recent	O
studies	O
have	O
suggested	O
possible	O
therapeutic	O
targets	O
for	O
some	O
patients	O
with	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
glaucoma	E-Phenotype
based	O
on	O
the	O
molecular	O
and	O
cellular	O
events	O
caused	O
by	O
MYOC	O
,	O
OPTN	O
and	O
TBK1	O
mutations	O
.	O

Epigenome	O
silencing	O
of	O
these	O
repeat	O
sites	O
does	O
not	O
affect	O
gene	O
expression	O
in	O
unrelated	O
cells	O
,	O
can	O
prevent	O
the	O
induction	O
of	O
gene	O
expression	O
by	O
EWS	O
-	O
FLI1	O
,	O
and	O
,	O
in	O
the	O
case	O
of	O
a	O
GGAA	O
repeat	O
that	O
controls	O
SOX2	O
expression	O
from	O
a	O
distance	O
of	O
470	O
kb	O
,	O
is	O
sufficient	O
to	O
impair	O
the	O
growth	O
of	O
Ewing	B-Phenotype
sarcoma	E-Phenotype
xenografts	O
.	O

Bardet	O
-	O
Biedl	O
syndrome	O
(	O
BBS	O
)	O
is	O
a	O
genetically	O
heterogeneous	O
disorder	O
characterized	O
by	O
retinal	B-Phenotype
dystrophy	E-Phenotype
,	O
polydactyly	S-Phenotype
,	O
obesity	S-Phenotype
,	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
and	O
renal	B-Phenotype
defects	E-Phenotype
.	O

To	O
test	O
whether	O
these	O
risk	O
SNPs	O
regulate	O
their	O
target	O
genes	O
through	O
long	O
-	O
range	O
chromatin	O
interactions	O
,	O
we	O
applied	O
capture	O
-	O
based	O
3C	O
sequencing	O
technology	O
to	O
investigate	O
possible	O
cis	O
-	O
interactions	O
at	O
ten	O
prostate	B-Phenotype
cancer	E-Phenotype
risk	O
loci	O
in	O
six	O
cell	O
lines	O
.	O

Ewing	B-Phenotype
's	I-Phenotype
sarcoma	E-Phenotype
is	O
an	O
aggressive	O
mesenchymal	O
tumor	S-Phenotype
characterized	O
by	O
the	O
presence	O
of	O
a	O
unique	O
EWSR1	O
-	O
FLI1	O
translocation	O
.	O

Furthermore	O
,	O
gene	O
ontology	O
(	O
GO	O
)	O
and	O
co	O
-	O
expression	O
analysis	O
of	O
these	O
differentially	O
expressed	O
genes	O
indicated	O
that	O
SPARCL1	O
may	O
play	O
a	O
core	O
role	O
in	O
cervical	B-Phenotype
cancer	E-Phenotype
development	O
.	O

This	O
similarity	O
was	O
revealed	O
by	O
the	O
same	O
number	O
of	O
passages	O
,	O
the	O
same	O
germ	O
cell	O
clusters	O
formation	O
and	O
similar	O
level	O
of	O
genes	O
expression	O
of	O
spermatogonial	O
markers	O
including	O
ubiquitin	O
carboxyl	O
-	O
terminal	O
esterase	O
L1	O
(	O
UCHL1	O
)	O
,	O
zinc	O
finger	O
and	O
BTB	O
domain	O
containing	O
16	O
(	O
ZBTB16	O
)	O
and	O
glial	O
cell	O
line	O
-	O
derived	O
neurotrophic	O
factor	O
family	O
receptor	O
alpha	O
1	O
(	O
GFRA1	O
)	O
,	O
as	O
well	O
as	O
germ	O
cell	O
differentiation	O
markers	O
including	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
(	O
STAT3	O
)	O
,	O
spermatogenesis	O
and	O
oogenesis	O
specific	O
basic	O
helix	O
-	O
loophelix	O
2	O
(	O
SOHLH2	O
)	O
,	O
v	O
-	O
kit	O
Hardy	O
-	O
Zuckerman	O
4	O
feline	O
sarcoma	S-Phenotype
viral	O
oncogene	O
homolog	O
(	O
KIT	O
)	O
and	O
synaptonemal	O
complex	O
protein	O
3	O
(	O
SYCP3	O
)	O
.	O

Five	O
genes	O
,	O
including	O
OTOGL	O
,	O
PLCB4	O
,	O
SCEL	O
,	O
THSD4	O
,	O
and	O
WWOX	O
,	O
have	O
CNVs	O
in	O
the	O
six	O
patients	O
with	O
sporadic	O
HBs	O
,	O
and	O
three	O
genes	O
,	O
including	O
ABCA6	O
,	O
CWC27	O
,	O
and	O
LAMA2	O
,	O
have	O
CNVs	O
in	O
the	O
five	O
patients	O
with	O
familial	O
HBs	O
.	O

Bardet	O
-	O
Biedl	O
Syndrome	O
(	O
BBS	O
)	O
is	O
a	O
rare	O
multi	O
-	O
systemic	O
disease	O
with	O
autosomal	B-Phenotype
recessive	E-Phenotype
transmission	O
.	O

Approximately	O
one	O
-	O
third	O
of	O
pediatric	O
malignant	O
rhabdoid	O
tumors	S-Phenotype
are	O
linked	O
to	O
germline	O
SWI	O
/	O
SNF	O
alterations	O
(	O
SMARCB1	O
/	O
INI1	O
,	O
rarely	O
SMARCA4	O
)	O
resulting	O
in	O
occasional	O
familial	O
clustering	O
of	O
these	O
highly	O
aggressive	O
malignancies	O
(	O
so	O
-	O
called	O
rhabdoid	O
tumor	S-Phenotype
predisposition	O
syndrome	O
,	O
RTPS	O
,	O
types	O
1	O
and	O
2	O
,	O
respectively	O
)	O
.	O

PurposeMonoallelic	O
germ	O
-	O
line	O
mutations	O
in	O
the	O
BRCA1	O
/	O
FANCS	O
,	O
BRCA2	O
/	O
FANCD1	O
and	O
PALB2	O
/	O
FANCN	O
genes	O
confer	O
high	O
risk	O
of	O
breast	B-Phenotype
cancer	E-Phenotype
.	O

Fanconi	B-Phenotype
anemia	E-Phenotype
(	O
FA	S-Phenotype
)	O
is	O
a	O
rare	O
disease	O
characterized	O
by	O
bone	B-Phenotype
marrow	I-Phenotype
failure	E-Phenotype
,	O
developmental	O
abnormalities	O
,	O
and	O
increased	O
cancer	S-Phenotype
risk	O
that	O
is	O
caused	O
by	O
defective	O
repair	O
of	O
DNA	O
interstrand	O
crosslinks	O
(	O
ICLs	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
MYH1	O
,	O
MYH2	O
,	O
MYH3	O
,	O
MYH7	O
,	O
MYH8	O
,	O
FOXO3	O
,	O
NFATC1	O
,	O
PTGS2	O
,	O
KAT6B	O
,	O
HDAC4	O
,	O
and	O
RUNX2	O
expression	O
is	O
suspected	O
to	O
be	O
involved	O
in	O
the	O
epigenetic	O
regulations	O
behind	O
the	O
mandibular	B-Phenotype
prognathism	E-Phenotype
phenotype	O

Although	O
disruption	O
of	O
the	O
CDKN2A	O
(	O
INK4A	O
/	O
ARF	O
)	O
locus	O
has	O
been	O
reported	O
in	O
end	O
-	O
stage	O
disease	O
,	O
information	O
is	O
lacking	O
on	O
the	O
status	O
of	O
this	O
key	O
tumor	S-Phenotype
suppressor	O
gene	O
in	O
pleural	O
lesions	O
preceding	O
mesothelioma	O
.	O

We	O
found	O
that	O
Smac	O
,	O
combined	O
with	O
DDP	O
greatly	O
inhibited	O
proliferation	O
of	O
subcutaneous	O
xenografts	O
of	O
ovarian	B-Phenotype
cancer	E-Phenotype
cell	O
line	O
SKOV3	O
/	O
DDP	O
without	O
side	O
effects	O
.	O

Global	O
gene	O
expression	O
profiling	O
studies	O
were	O
carried	O
out	O
using	O
cancer	S-Phenotype
cells	O
and	O
surrogate	O
tissues	O
,	O
such	O
as	O
whole	O
blood	O
and	O
skin	O
,	O
to	O
identify	O
genes	O
that	O
are	O
modulated	O
by	O
BET	O
family	O
proteins	O
.	O

We	O
also	O
functionally	O
characterized	O
two	O
CaBP4	O
mutants	O
that	O
are	O
associated	O
with	O
a	O
congenital	O
variant	O
of	O
human	O
night	B-Phenotype
blindness	E-Phenotype
and	O
other	O
closely	O
related	O
nonstationary	O
retinal	B-Phenotype
diseases	E-Phenotype
.	O

Several	O
putative	O
genes	O
associated	O
with	O
hallmarks	O
of	O
malignancy	O
that	O
may	O
have	O
an	O
important	O
role	O
in	O
predicting	O
the	O
progression	O
of	O
leukoplakia	O
and	O
erythroleukoplakia	O
to	O
squamous	B-Phenotype
cell	I-Phenotype
carcinoma	E-Phenotype
,	O
namely	O
gains	O
in	O
BNIPL	O
,	O
MCL1	O
,	O
STAG2	O
,	O
CSPP1	O
and	O
ZNRF3	O
genes	O
were	O
also	O
identified	O

Aberrant	O
expression	O
of	O
TRIM	O
-	O
containing	O
protein	O
44	O
(	O
TRIM44	O
)	O
acts	O
as	O
a	O
promoter	O
in	O
multiple	O
cancers	S-Phenotype
.	O

In	O
the	O
present	O
study	O
,	O
PNPO	O
expression	O
in	O
human	O
ovarian	B-Phenotype
tumour	E-Phenotype
tissue	O
and	O
its	O
association	O
with	O
the	O
clinicopathological	O
features	O
of	O
patients	O
with	O
EOC	O
were	O
examined	O
.	O

BACKGROUND	O
Latent	O
transforming	O
growth	O
factor	O
b	O
binding	O
protein	O
2	O
(	O
LTBP2	O
)	O
is	O
proven	O
to	O
be	O
associated	O
with	O
ECM	O
and	O
involved	O
in	O
the	O
advancement	O
of	O
several	O
kinds	O
of	O
cancer	S-Phenotype
.	O

RNASET2	O
deficiency	O
in	O
humans	O
is	O
associated	O
with	O
infant	B-Phenotype
cystic	I-Phenotype
leukoencephalopathy	E-Phenotype
,	O
which	O
causes	O
psychomotor	B-Phenotype
impairment	E-Phenotype
,	O
spasticity	S-Phenotype
and	O
epilepsy	S-Phenotype
.	O

Our	O
results	O
suggest	O
that	O
PPM1B	O
plays	O
a	O
negative	O
role	O
in	O
the	O
activation	O
of	O
the	O
p38	O
-	O
RB1	O
-	O
E2F1	O
pathway	O
and	O
that	O
targeting	O
PPM1B	O
could	O
be	O
useful	O
in	O
certain	O
types	O
of	O
cancer	S-Phenotype
by	O
stimulating	O
chemotherapy	O
-	O
induced	O
cell	O
death	O

Although	O
homozygous	O
inactivation	O
of	O
liCHEK2	O
/	O
i	O
in	O
mice	O
led	O
to	O
cancers	S-Phenotype
in	O
multiple	O
organs	O
,	O
accumulation	O
of	O
additional	O
human	O
cases	O
is	O
needed	O
to	O
establish	O
its	O
pathogenic	O
role	O
in	O
humans	O

We	O
identify	O
differentially	O
expressed	O
proteins	O
in	O
microdissected	O
GC	O
tumor	S-Phenotype
cells	O
relative	O
to	O
adjacent	O
nontumor	O
epithelia	O
by	O
isobaric	O
mass	O
tag	O
for	O
relative	O
and	O
absolute	O
quantitation	O
proteomics	O
analysis	O
.	O

The	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
pathway	O
is	O
overactivated	O
in	O
thyroid	B-Phenotype
cancer	E-Phenotype
(	O
TC	S-Phenotype
)	O
.	O

The	O
candidate	O
genes	O
located	O
within	O
the	O
new	O
loci	O
were	O
related	O
to	O
ocular	O
development	O
(	O
LMX1B	O
,	O
HMGA2	O
and	O
MAP3K1	O
)	O
and	O
glaucoma	S-Phenotype
-	O
related	O
phenotypes	O
(	O
FNDC3B	O
,	O
LMX1B	O
and	O
LOXL1	O
)	O
.	O

Treatment	O
should	O
be	O
considered	O
in	O
infertile	O
women	O
with	O
deeply	O
infiltrating	O
endometriosis	S-Phenotype
when	O
they	O
wish	O
to	O
conceive	O
.	O

Taking	O
advantage	O
of	O
the	O
homogeneous	O
and	O
heterogeneous	S-Phenotype
electrochemical	O
biosensors	O
,	O
a	O
simple	O
,	O
sensitive	O
,	O
and	O
selective	O
electrochemical	O
biosensor	O
is	O
constructed	O
by	O
combining	O
entropy	O
-	O
driven	O
amplification	O
(	O
EDA	O
)	O
with	O
DNA	O
walker	O
.	O

To	O
identify	O
other	O
possible	O
transcriptional	O
targets	O
of	O
PGC	O
-	O
1α	O
in	O
neural	O
tissue	O
,	O
we	O
conducted	O
a	O
microarray	O
on	O
neuroblastoma	S-Phenotype
cells	O
overexpressing	O
PGC	O
-	O
1α	O
,	O
mined	O
results	O
for	O
genes	O
with	O
physiological	O
relevance	O
to	O
interneurons	O
,	O
and	O
measured	O
cortical	O
gene	O
and	O
protein	O
expression	O
of	O
these	O
genes	O
in	O
mice	O
with	O
underexpression	O
and	O
overexpression	O
of	O
PGC	O
-	O
1α	O
.	O

Using	O
exome	O
sequencing	O
in	O
a	O
multiplex	O
family	O
and	O
three	O
simplex	O
case	O
subjects	O
with	O
an	O
atypical	O
association	O
of	O
LCA	O
with	O
early	B-Phenotype
-	I-Phenotype
onset	I-Phenotype
hearing	I-Phenotype
loss	E-Phenotype
,	O
we	O
identified	O
two	O
heterozygous	O
mutations	O
affecting	O
Arg391	O
in	O
β	O
-	O
tubulin	O
4B	O
isotype	O
-	O
encoding	O
(	O
TUBB4B	O
)	O
.	O

Low	O
LIFR	O
expression	O
correlated	O
with	O
a	O
poor	O
prognosis	O
and	O
an	O
aggressive	O
tumor	S-Phenotype
phenotype	O
.	O

Identification	O
of	O
miRNAs	O
related	O
to	O
metastasis	O
enables	O
us	O
to	O
obtain	O
better	O
insight	O
into	O
cancer	S-Phenotype
development	O
.	O

We	O
demonstrated	O
that	O
lilinc	O
-	O
ADAL	O
/	O
i	O
interacts	O
with	O
heterogeneous	S-Phenotype
nuclear	O
ribonucleoprotein	O
U	O
(	O
hnRNPU	O
)	O
and	O
insulin	O
-	O
like	O
growth	O
factor	O
2	O
mRNA	O
binding	O
protein	O
2	O
(	O
IGF2BP2	O
)	O
at	O
distinct	O
subcellular	O
locations	O
to	O
regulate	O
adipocyte	O
differentiation	O
and	O
lipogenesis	O

Renal	O
manifestations	O
of	O
multiple	B-Phenotype
myeloma	E-Phenotype
(	O
MM	S-Phenotype
)	O
including	O
cast	O
nephropathy	S-Phenotype
,	O
amyloidosis	S-Phenotype
,	O
and	O
renal	O
calcification	O
have	O
been	O
widely	O
recognized	O
.	O

We	O
found	O
sufficient	O
evidence	O
for	O
NTHL1	O
to	O
be	O
considered	O
a	O
CRC	O
predisposition	O
gene	O
-	O
members	O
of	O
3	O
unrelated	O
Dutch	O
families	O
were	O
homozygous	O
for	O
inactivating	O
p.Gln90Ter	O
mutations	O
;	O
a	O
Canadian	O
woman	O
with	O
polyposis	O
,	O
CRC	O
,	O
and	O
multiple	O
tumors	S-Phenotype
was	O
reported	O
to	O
be	O
heterozygous	O
for	O
the	O
inactivating	O
NTHL1	O
p.Gln90Ter	O
/	O
c.709+1GAAAAA	O
mutations	O
;	O
and	O
a	O
man	O
with	O
polyposis	O
was	O
reported	O
to	O
carry	O
p.Gln90Ter	O
/	O
p.Gln287Ter	O
;	O
whereas	O
no	O
inactivating	O
homozygous	O
or	O
compound	O
heterozygous	O
mutations	O
were	O
detected	O
in	O
controls	O
.	O

However	O
,	O
the	O
global	O
effects	O
of	O
DIO1	O
expression	O
in	O
various	O
tissues	O
affected	O
by	O
cancer	S-Phenotype
remain	O
unknown	O
.	O

Mabry	O
syndrome	O
,	O
hyperphosphatasia	B-Phenotype
mental	I-Phenotype
retardation	I-Phenotype
syndrome	E-Phenotype
(	O
HPMRS	S-Phenotype
)	O
,	O
is	O
an	O
autosomal	B-Phenotype
recessive	E-Phenotype
disease	O
characterized	O
by	O
increased	O
serum	O
levels	O
of	O
alkaline	O
phosphatase	O
(	O
ALP	O
)	O
,	O
severe	O
developmental	B-Phenotype
delay	E-Phenotype
,	O
intellectual	B-Phenotype
disability	E-Phenotype
,	O
and	O
seizures	S-Phenotype
.	O

We	O
identified	O
a	O
homozygous	O
missense	O
mutation	O
,	O
c.1308	O
G	O
-	O
A	O
(	O
p.V421M	O
)	O
in	O
FOXRED1	O
in	O
a	O
patient	O
who	O
presented	O
with	O
epilepsy	S-Phenotype
and	O
severe	O
psychomotor	B-Phenotype
retardation	E-Phenotype
.	O

Taken	O
together	O
,	O
these	O
data	O
reveal	O
that	O
CBX3	O
serves	O
as	O
a	O
positive	O
regulator	O
of	O
aerobic	O
glycolysis	O
via	O
suppressing	O
of	O
the	O
FBP1	O
in	O
pancreatic	B-Phenotype
cancer	E-Phenotype
cells	O
.	O

Carboxyl	O
terminus	O
of	O
Hsc	O
-	O
70	O
-	O
interacting	O
protein	O
(	O
CHIP	O
)	O
is	O
an	O
E3	O
ubiquitin	O
ligase	O
that	O
induces	O
the	O
ubiquitination	O
and	O
degradation	O
of	O
numerous	O
tumor	S-Phenotype
-	O
associated	O
proteins	O
and	O
serves	O
as	O
a	O
suppressor	O
or	O
promoter	O
in	O
tumor	S-Phenotype
progression	O
.	O

Accordingly	O
,	O
we	O
performed	O
a	O
study	O
to	O
examine	O
the	O
association	O
of	O
a	O
frequent	O
genetic	O
variation	O
in	O
WRAP53	O
,	O
rs2287499	O
(	O
C	O
/	O
G	O
)	O
,	O
with	O
breast	B-Phenotype
cancer	E-Phenotype
risk	O
and	O
prognosis	O
among	O
Iranian	O
-	O
Azeri	O
population	O
.	O

Activation	O
of	O
GPER	O
and	O
its	O
downstream	O
signaling	O
MAPK	O
/	O
ERK	O
,	O
not	O
PI3K	O
/	O
AKT	O
,	O
led	O
to	O
enhanced	O
TRIM2	O
protein	O
levels	O
and	O
affected	O
the	O
binding	O
between	O
TRIM2	O
and	O
Bim	O
which	O
resulted	O
in	O
a	O
reduced	O
Bim	O
in	O
TAM	O
-	O
resistant	O
breast	B-Phenotype
cancer	E-Phenotype
cells	O
.	O